



California State Board of Pharmacy

1625 N. Market Blvd, Suite N 219, Sacramento, CA 95834
Phone (916) 574-7900
Fax (916) 574-8618
www.pharmacy.ca.gov

STATE AND CONSUMERS SERVICES AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GOVERNOR EDMUND G. BROWN, JR.

Legislation and Regulation Committee

Shirley Wheat, Chair, Public Member
Ramón Castellblanch, Public Member
Deborah Veale, RPh
Tappan Zee, Public Member

LEGISLATION AND REGULATION COMMITTEE

The Legislation and Regulation Committee did not meet during the last quarter.

PART II: LEGISLATION REPORT

a. Board Sponsored Legislation

ATTACHMENT 1

SB 431 (Emmerson): Pharmacies - Regulation

In January 2010, the board voted to pursue legislation to improve the board's enforcement tools as well as to better define the return of medicine via reverse distributors. These provisions are incorporated in SB 431. Below are the specific code sections:

- a. **§4104 – Licensed Employee, Theft or Impairment, Pharmacy Procedure**
Amend to clarify that a pharmacy shall provide the board, within 14 days, evidence of a licensee's theft or impairment. Require a pharmacy to conduct an audit to determine the scope of a drug loss and to provide the board with a certified copy of the audit results.
- b. **§4105 – Retaining Records of Dangerous Drugs and Devices on Licensed Premises; Temporary Removal; Waivers; Access to Electronically Maintained Records**
Amend to specify the time period for which records shall be provided to the board when requested by an inspector or authorized representative of the board.
- c. **§4112 – Nonresident Pharmacy; Registration; Provision of Information to Board; Maintaining Records; Patient Consultation**
Require that a nonresident pharmacy cannot allow a pharmacist, whose license has been revoked in California, to provide pharmacist related services to Californians.
- d. **§4040.5 – Reverse Distributor**
Specifies that a reverse distributor may not accept previously dispensed medicine and that previously dispensed medicine returned to a pharmacy can only be handled by a licensed integrated waste hauler. Defines "dispensed" for purposes of this section only. This provision was approved in concept only by the board in January 2009.
- e. **§4081 – Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory**
Specifies that records documenting the return of drugs to a wholesaler or reverse distributor must include the quantity or weight of the drug being returned, the date returned and the name(s) to which the drugs were provided. Specifies that records documenting the return of drugs to a licensed integrated waste hauler shall include a list of the volume in weight and measurement, and the date and name of the hauler. Defines "licensed integrated waste hauler"

for purposes of this section only. This provision was approved in concept only by the board in January 2009.

f. §4126.5 – Furnishing Dangerous Drugs by a Pharmacy

Authorizes a pharmacy to furnish drugs to a licensed integrated waste hauler. Needs to authorize a pharmacy to accept returned product from a consumer in the event of a product recall.

This bill has been amended twice to address concerns. Board staff continues to advocate this legislation and is working with the author's office to address concerns raised.

Current Status: This bill passed out of Assembly Health Committee on July 6, 2011 and is scheduled to be heard in the Assembly Appropriations Committee August 17, 2011.

Senate Bill 943 (Senate Committee on Business, Professions and Economic Development) Omnibus

At the October 2010 Board Meeting, the board voted to pursue an omnibus provision to eliminate a reference to the previous pharmacists examination in Business and Professions Code section 4200. This provision is contained in Senate Bill 943.

Current Status: This measure passed out of the Assembly Business, Professions and Consumer Protection Committee on July 6 and is scheduled to be heard in the Assembly Appropriations Committee on August 17, 2011.

ATTACHMENT 1 contains a copy of SB 431 as well as relevant portions of SB 943.

b. Legislation Introduced Impacting the Practice of Pharmacy or the Board's Jurisdiction

1. Board of Pharmacy/Licensing

ATTACHMENT 2

AB 377 (Solorio) Pharmacy: Centralized Hospital Packaging

Version: As amended, April 14, 2011

Summary: This bill provides for centralized pharmacy packaging in a hospital, allowing the pharmacy to be located outside of a hospital on either the same premises or separate premises that is regulated under a hospital's license. The bill exempts from the definition of manufacturing, repackaging a drug for parenteral therapy, or oral therapy in a hospital for delivery to another pharmacy or hospital, as specified.

Board Position: Support If Amended

Recent Action: This bill is scheduled to be heard in the Senate Appropriations Committee on August 15, 2011.

Recent Update: Board staff was just advised by CSHP that this will be a two-year bill.

Attachment 2 contains a copy of the bill in its current form along with an analysis of the measure.

Currently Two-Year Bills

AB 847 (Lowenthal, Bonnie): Pharmacies: Clinics

Version: As Introduced March 10, 2011

Summary: Would expand these provisions to additionally authorize an outpatient setting or an ambulatory surgical center, as specified, to purchase drugs at wholesale for administration or dispensing, subject to the requirements applicable to surgical clinics. The bill would delete the requirement that a clinic operating under these provisions be licensed by the California State Board of Pharmacy and would make that licensure optional.

Board Position: None

SB 632 (Emmerson) Pharmacy

Version: As Amended March 24, 2011

Summary: Would prohibit a pharmacist from interchanging or substituting an opioid analgesic drug, as defined, for an opioid analgesic drug incorporating a tamper resistant technology, as defined, unless the opioid analgesic drug to be interchanged or substituted is described on a list to be prepared by the board. In those situations where the drug is not on the board's list, the bill would require the pharmacist to obtain consent from the prescriber prior to an interchange or substitution.

Board Position: None

2. Controlled Substances

ATTACHMENT 3

AB 507 (Hayashi): Pain Management

Version: As amended, July 1, 2011

Summary: In its current form, this measure would conform findings and declarations and other references to severe chronic intractable pain and to the California Intractable Pain Treatment Act.

History: As originally introduced, this measure repealed provisions in existing law which permit the Department of Justice (DOJ) to employ a physician to interview and examine any patient in connection with the prescription possession or use of a controlled substance, require the patient to submit to the interview and examination, and permit the physician to testify in prescribed administrative proceedings. Prior to the May Board Meeting, this measure has been amended twice since the committee reviewed it. The first amendments occurred on April 13, 2011 and removed the proposed changes to the board's unprofessional conduct statute, B&PC 4301. The bill was again amended on April 27, 2011 and again proposed a change to B&PC 4301(d).

Board Position: Oppose (April 27, 2011 version)

Recent Update: This measure has been amended again on June 20, 2011 and July 1, 2011 and proposed changes to the board's unprofessional conduct statute were removed.

Current Status: Hearing scheduled on August 15, 2011 in the Senate Appropriations Committee.

Attachment 3 contains a copy of the bill and an analysis of the measure.

3. Reporting Requirements/Records

ATTACHMENT 4

AB 1280 (Hill): Ephedrine - Retail Sale

Version: As amended, May 26, 2011

Summary: The bill contains provisions requiring the secure storage and monitoring of products containing any amount of ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine, as specified. This bill proposes a real-time tracking system beginning on or after July 1, 2012 through December 2018.

Board Position: Watch

Current Status: Hearing scheduled for August 15, 2011 in Senate Appropriations Committee.

Recent Update: This measure was amended twice since the May Board Meeting.

SB 360 (DeSaulnier): Controlled Substance Utilization Review and Evaluation System

Version: As amended, July 7, 2011

Summary: This bill would revise Schedule I and Schedule II to add additional opiates, revise Schedule III to add additional depressants, anabolic steroid products, and materials, compounds, mixtures, or preparations containing chorionic gonadotropin (a hormone), and Schedule IV to add additional depressants and stimulants.

Board Position: Watch

Recent Action: Hearing scheduled for August 17, 2011 in Senate Appropriations Committee.

Recent Update: This measure has been amended twice since the May Board Meeting. Most notably, this measure would specify reporting to the CURES system would be linked to the federal schedule of controlled drugs, not the state schedule. Board staff has identified the areas where the state and federal schedules vary. More information is included in the bill analysis for this measure.

SB 850 (Leno) Medical Records: Confidential Information

Version: As Amended, June 22, 2011

Summary: This bill would require an electronic health or medical record system to automatically record and preserve any change or deletion of electronically stored medical information, and would require the record to include, among other things, the identity of the person who accessed and changed the medical information and the change that was made to the medical information.

Board Position: None. The board has not previously discussed this measure.

Current Status: Hearing scheduled for August 17, 2011 in the Assembly Appropriations Committee.

Attachment 4 contains a copy of each of the above measures as well as an analysis.

Currently Two-Year Bills

SB 315 (Wright) Ephedrine and Pseudoephedrine

Version: As Introduced February 14, 2011

Summary: This bill would classify pseudoephedrine as a prescription drug.

Board Position: Support

4. Healing Arts/DCA

ATTACHMENT 5

SB 541 (Price) Regulatory boards: Expert Consultants

Version: As amended, June 21, 2011

Summary: This bill would authorize boards to enter into an agreement with an expert consultant, subject to the standards regarding personal service contracts described, to provide enforcement and examination assistance. The bill would require each board to establish policies and procedures for the selection and use of these consultants.

Board Position: Support (April 13, 2011 version)

Recent Action: This bill was amended June 21, 2011 to specify that the proposed change shall not be construed to expand the scope of service of an expert.

Current Status: Hearing scheduled for August 17, 2011 in the Assembly Appropriations Committee.

Attachment 5 contains a copy of this measure and a bill analysis.

Currently Two-Year bills

AB 675 (Hagman) Continuing Education

Version: As Amended April 5, 2011

Summary: This bill would specify that continuing education or competency courses that advance or promote labor organizing on behalf of a union, or that advance or promote statutory or regulatory changes, political candidates, political advocacy, or political strategy shall not be considered content relevant to the practice regulated by the board and shall not be acceptable for meeting requirements for licensure renewal.

Board Position: None

AB 958 (Berryhill) Regulatory boards: Limitation periods

Version: As introduced February 18, 2011

Summary: This bill would require the board to file an accusation within one year after the board discovers the violation.

Board Position: None

SB 544 (Price): Healing Arts

Version: As amended, April 14, 2011

Summary: The bill would require cooperation between state agencies and all boards within the department when investigating a licensee, and would require a state agency to provide to the board all licensee records in the custody of the state agency. The bill would require all local and state law enforcement agencies, state and local governments, state agencies, licensed health care facilities, and any employers of any licensee to provide licensee records to any board within the department upon request by that board, and would make an additional requirement specific to the Department of Justice.

Board Position: None

SB 667 (Wyland) Naturopathic Doctors

Version: As amended, March 31, 2011

Summary: This bill would provide that a naturopathic doctor is not prohibited from ordering, prescribing, or administering a nonprescription substance that becomes a substance requiring a prescription based solely on its route of administration.

Board Position: None

5. Other

ATTACHMENT 6

AB 389 (Mitchell): Bleeding disorders - blood clotting products

Version: As amended, March 30, 2011

Summary: This bill would impose specified requirements on providers of blood clotting products for home use for products used for the treatment and prevention of symptoms associated with bleeding disorders, including all forms of hemophilia.

Board Position: Watch

Current Status: Hearing scheduled for August 15, 2011 in the Senate Appropriations Committee.

AB 604 (Skinner): Needle Exchange Programs

Version: As amended, July 14, 2011

Summary: This bill would authorize, until January 1, 2019, the State Department of Public Health to approve certain entities to provide hypodermic needle and syringe exchange services in any location where the department determines that the conditions exist for the rapid spread of HIV, viral hepatitis, or any other potentially deadly or disabling infections that are spread through the sharing of used hypodermic needles and syringes.

Board Position: Support (April 5, 2011 version)

Recent Update: Recent amendments to this measure put a sunset date of January 1, 2019 on the authority of CDPH to NEP programs.

SB 41 (Yee): Disposal of Hypodermic Needles and Syringes

Version: As amended, June 28, 2011

Summary: This bill would allow, until January 1, 2015, a physician or pharmacist to furnish 30 or fewer hypodermic needles and syringes solely for personal use to a person 18 years of age or older. The bill addresses the storage of products to ensure they would be available only to authorized personnel, would require that disposal options are provided to consumers, and would require pharmacies to provide written information or verbal counseling at the time of furnishing on how to access drug treatment.

Board Position: Support If Amended

Recent Update: This measure has been amended three times since the May 2011 Board Meeting.

Current Status: Ordered to third reading in the Assembly.

SB 514 (Simitian): Dextromethorphan - sale to minors prohibited

Version: As amended, May 10, 2011

Summary: This bill would make it illegal to sell dextromethorphan to a person under the age of 18 without a prescription.

Board Position: Support

Recent Action: This measure was amended on May 10, 2011 to specify that an infraction of this provision may be punishable by a fine not to exceed \$250.00.

Current Status: Ordered to third reading in the Assembly.

A copy of each bill and an analysis are provided for each measure in **Attachment 6**.

6. Additional Legislation Impacting the Board or Its Regulatory Jurisdiction

Attachment 7

The board will have the opportunity to review additional legislation that affects the practice of pharmacy or the board's jurisdiction. One such measure was identified earlier this will and will be brought to the board for consideration. Additional items may be discussed at well if identified.

AB 1424 (Perea) Franchise Tax Board: Delinquent Tax Debt

Summary: This bill would require the State Board of Equalization and the Franchise Tax Board to each make available a list of the 500 largest tax delinquencies described above at least twice each calendar year. This bill would require the Franchise Tax Board to include additional information on the list with respect to each delinquency, including the type, status, and licence number of any occupational or professional license held by the person or persons liable for payment of the tax and the names and titles of the principal officers of the person liable for payment of the tax if that person is a limited liability company or corporation. This bill would specify that a license may be suspended for failure to pay tax delinquencies.

Current Status: Hearing scheduled for August 15, 2011 in Senate Appropriations Committee.

A copy of the bill and analysis are provided in **Attachment 7**.

AMENDED IN SENATE MAY 10, 2011

AMENDED IN SENATE APRIL 11, 2011

SENATE BILL

No. 431

Introduced by Senator Emmerson

February 16, 2011

An act to amend Sections 4081, 4104, 4105, ~~4112, and 4126.5 and 4112~~ of, and to add Section 4126.7 to, the Business and Professions Code, relating to pharmacies.

LEGISLATIVE COUNSEL'S DIGEST

SB 431, as amended, Emmerson. Pharmacies: regulation.

Existing law, the Pharmacy Law, creates the California State Board of Pharmacy and makes it responsible for administering and enforcing the provisions of that law, including the licensure of pharmacies, as defined, and nonresident pharmacies that ship, mail, or deliver controlled substances or dangerous drugs or devices, as defined, into this state. Under existing law, a reverse distributor is any person who acts as an agent for a pharmacy, drug wholesaler, manufacturer, or other entity by receiving, inventorying, and managing the disposition of outdated or nonsalable dangerous drugs. A knowing violation of the Pharmacy Law is a crime. ~~Existing law provides for the registration of hazardous waste haulers, as defined.~~

This bill would, *except as specified*, prohibit a reverse distributor from accepting the return of dangerous drugs that have been dispensed to a patient that are later returned by the patient or patient's agent to a pharmacy, as specified, ~~and would authorize only hazardous waste haulers to handle or dispose of those drugs.~~

Existing law requires that each pharmacy establish procedures for addressing the theft, diversion, or self-use of dangerous drugs by a

licensed individual employed by or with the pharmacy, and that every pharmacy report to the board within 30 days of the receipt or development of certain information affecting the ability of those individuals to practice the profession or occupation authorized by their license, as specified. Existing law requires an entity licensed by the board to retain records of the acquisition and disposition of dangerous drugs and devices in a specified manner. *Existing federal law requires registrants distributing specified controlled substances to conduct an inventory of controlled substances every 2 years.*

This bill would instead require a pharmacy to report and provide to the board, within 14 days of the receipt or development thereof, the information described above regarding the ability of licensed individuals employed by or with the pharmacy to practice the profession or occupation authorized by their license. The bill would require ~~a pharmacy to conduct an audit of the theft, diversion, or self-use of dangerous drugs by a licensed individual employed by or with the pharmacy and provide, as specified, the board with a copy of the audit and its results.~~ *the report to include specified detailed information, including the date of the last controlled substances inventory, and would require the pharmacy to prepare and submit an audit relating to the report upon the request of the board.* The bill would also require an entity licensed by the board to provide records to designated persons within ~~72 hours~~ *3 business days* of the time of the request, unless that timeframe is extended by the board, *as specified*. The bill would prohibit a pharmacist whose license was revoked by the board to perform pharmacy duties, as specified, for a nonresident pharmacy.

Existing law requires all records of manufacture and of sale, acquisition, or disposition of dangerous drugs or dangerous devices to be at all times during business hours open to inspection by authorized officers of the law and preserved at least 3 years from the date of making. Existing law requires every person or entity who maintains a stock of dangerous drugs or dangerous devices to keep a current inventory.

This bill would require that any record pertaining to the return of dangerous drugs to a wholesaler, reverse distributor, or hazardous waste hauler include specified information, including the quantity or weight of the drugs returned.

Because this bill would specify additional requirements under the Pharmacy Law, a violation of which is a crime, it would impose a state-mandated local program by creating additional crimes.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.

State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 4081 of the Business and Professions
2 Code is amended to read:

3 4081. (a) All records of manufacture and of sale, acquisition,
4 or disposition of dangerous drugs or dangerous devices shall be
5 at all times during business hours open to inspection by authorized
6 officers of the law, and shall be preserved for at least three years
7 from the date of making. A current inventory shall be kept by every
8 manufacturer, wholesaler, pharmacy, veterinary food-animal drug
9 retailer, physician, dentist, podiatrist, veterinarian, laboratory,
10 clinic, hospital, institution, or establishment holding a currently
11 valid and unrevoked certificate, license, permit, registration, or
12 exemption under Division 2 (commencing with Section 1200) of
13 the Health and Safety Code or under Part 4 (commencing with
14 Section 16000) of Division 9 of the Welfare and Institutions Code
15 who maintains a stock of dangerous drugs or dangerous devices.

16 (b) The owner, officer, and partner of a pharmacy, wholesaler,
17 or veterinary food-animal drug retailer shall be jointly responsible,
18 with the pharmacist-in-charge or designated
19 representative-in-charge, for maintaining the records and inventory
20 described in this section.

21 (c) The pharmacist-in-charge or designated
22 representative-in-charge shall not be criminally responsible for
23 acts of the owner, officer, partner, or employee that violate this
24 section and of which the pharmacist-in-charge or designated
25 representative-in-charge had no knowledge, or in which he or she
26 did not knowingly participate.

27 (d) Any record pertaining to the return of dangerous drugs to a
28 wholesaler or provided to a reverse distributor shall document the
29 quantity or weight of the drugs returned, the date the drugs were

1 returned, and the name of the reverse distributor or wholesaler to
2 whom the drugs were provided.

3 (e) Any record pertaining to the return of dangerous drugs to a
4 hazardous waste hauler, as described in Section 117660 of the
5 Health and Safety Code, shall list the volume in weight or
6 measurement of the pharmaceutical waste returned, the date the
7 waste was returned, and the name of the hazardous waste hauler
8 to whom the waste was provided.

9 SEC. 2. Section 4104 of the Business and Professions Code is
10 amended to read:

11 4104. (a) Every pharmacy shall have in place procedures for
12 taking action to protect the public when a licensed individual
13 employed by or with the pharmacy is discovered or known to be
14 chemically, mentally, or physically impaired to the extent it affects
15 his or her ability to practice the profession or occupation authorized
16 by his or her license, or is discovered or known to have engaged
17 in the theft, diversion, or self-use of dangerous drugs.

18 (b) Every pharmacy shall have written policies and procedures
19 for addressing chemical, mental, or physical impairment, as well
20 as theft, diversion, or self-use of dangerous drugs, among licensed
21 individuals employed by or with the pharmacy.

22 (c) Every pharmacy shall report and provide to the board, within
23 14 days of the receipt or development thereof, the following
24 information with regard to any licensed individual employed by
25 or with the pharmacy:

26 (1) Any admission by a licensed individual of chemical, mental,
27 or physical impairment affecting his or her ability to practice.

28 (2) Any admission by a licensed individual of theft, diversion,
29 or self-use of dangerous drugs.

30 (3) Any video or documentary evidence demonstrating chemical,
31 mental, or physical impairment of a licensed individual to the
32 extent it affects his or her ability to practice.

33 (4) Any video or documentary evidence demonstrating theft,
34 diversion, or self-use of dangerous drugs by a licensed individual.

35 (5) Any termination based on chemical, mental, or physical
36 impairment of a licensed individual to the extent it affects his or
37 her ability to practice.

38 (6) Any termination of a licensed individual based on theft,
39 diversion, or self-use of dangerous drugs.

1 ~~(d) The pharmacy shall conduct an audit to determine the~~
2 ~~quantity and type of dangerous drugs stolen, diverted, or used by~~
3 ~~a licensed individual employed by or with the pharmacy. The~~
4 ~~pharmacy shall submit to the board a copy of the audit within 30~~
5 ~~days of the initial report to the board regarding the evidence~~
6 ~~described in subdivision (c).~~

7 *(d) The report required in subdivision (c) shall include sufficient*
8 *detail to inform the board of the facts upon which the report is*
9 *based, including an estimate of the type and quantity of all*
10 *dangerous drugs involved, the timeframe over which the losses*
11 *are suspected, and the date of the last controlled substances*
12 *inventory. Upon request of the board, the pharmacy shall prepare*
13 *and submit an audit involving the dangerous drugs suspected to*
14 *be missing.*

15 (e) Anyone making a report authorized or required by this
16 section shall have immunity from any liability, civil or criminal,
17 that might otherwise arise from the making of the report. Any
18 participant shall have the same immunity with respect to
19 participation in any administrative or judicial proceeding resulting
20 from the report.

21 SEC. 3. Section 4105 of the Business and Professions Code is
22 amended to read:

23 4105. (a) All records or other documentation of the acquisition
24 and disposition of dangerous drugs and dangerous devices by any
25 entity licensed by the board shall be retained on the licensed
26 premises in a readily retrievable form.

27 (b) The licensee may remove the original records or
28 documentation from the licensed premises on a temporary basis
29 for license-related purposes. However, a duplicate set of those
30 records or other documentation shall be retained on the licensed
31 premises.

32 (c) The records required by this section shall be retained on the
33 licensed premises for a period of three years from the date of
34 making.

35 (d) Any records that are maintained electronically shall be
36 maintained so that the pharmacist-in-charge, the pharmacist on
37 duty if the pharmacist-in-charge is not on duty, or, in the case of
38 a veterinary food-animal drug retailer or wholesaler, the designated
39 representative on duty, shall, at all times during which the licensed
40 premises are open for business, be able to produce a hard copy

1 and electronic copy of all records of acquisition or disposition or
2 other drug or dispensing-related records maintained electronically.

3 (e) (1) Notwithstanding subdivisions (a), (b), and (c), the board,
4 may upon written request, grant to a licensee a waiver of the
5 requirements that the records described in subdivisions (a), (b),
6 and (c) be kept on the licensed premises.

7 (2) A waiver granted pursuant to this subdivision shall not affect
8 the board's authority under this section or any other provision of
9 this chapter.

10 (f) When requested by an authorized officer of the law or by an
11 authorized representative of the board, the owner, corporate officer,
12 or manager of an entity licensed by the board shall provide the
13 board with the requested records within ~~72 hours~~ *three business*
14 *days* of the time the request was made. The entity may request in
15 writing an extension of this timeframe for a period not to exceed
16 14 *calendar* days from the date the records were requested. A
17 request for an extension of time is subject to the approval of the
18 board. *An extension shall be deemed approved if the board fails*
19 *to deny the extension request within two business days of the time*
20 *the extension request was made directly to the board.*

21 SEC. 4. Section 4112 of the Business and Professions Code is
22 amended to read:

23 4112. (a) Any pharmacy located outside this state that ships,
24 mails, or delivers, in any manner, controlled substances, dangerous
25 drugs, or dangerous devices into this state shall be considered a
26 nonresident pharmacy.

27 (b) A person may not act as a nonresident pharmacy unless he
28 or she has obtained a license from the board. The board may
29 register a nonresident pharmacy that is organized as a limited
30 liability company in the state in which it is licensed.

31 (c) A nonresident pharmacy shall disclose to the board the
32 location, names, and titles of (1) its agent for service of process in
33 this state, (2) all principal corporate officers, if any, (3) all general
34 partners, if any, and (4) all pharmacists who are dispensing
35 controlled substances, dangerous drugs, or dangerous devices to
36 residents of this state. A report containing this information shall
37 be made on an annual basis and within 30 days after any change
38 of office, corporate officer, partner, or pharmacist.

39 (d) All nonresident pharmacies shall comply with all lawful
40 directions and requests for information from the regulatory or

1 licensing agency of the state in which it is licensed as well as with
2 all requests for information made by the board pursuant to this
3 section. The nonresident pharmacy shall maintain, at all times, a
4 valid unexpired license, permit, or registration to conduct the
5 pharmacy in compliance with the laws of the state in which it is a
6 resident. As a prerequisite to registering with the board, the
7 nonresident pharmacy shall submit a copy of the most recent
8 inspection report resulting from an inspection conducted by the
9 regulatory or licensing agency of the state in which it is located.

10 (e) All nonresident pharmacies shall maintain records of
11 controlled substances, dangerous drugs, or dangerous devices
12 dispensed to patients in this state so that the records are readily
13 retrievable from the records of other drugs dispensed.

14 (f) Any pharmacy subject to this section shall, during its regular
15 hours of operation, but not less than six days per week, and for a
16 minimum of 40 hours per week, provide a toll-free telephone
17 service to facilitate communication between patients in this state
18 and a pharmacist at the pharmacy who has access to the patient's
19 records. This toll-free telephone number shall be disclosed on a
20 label affixed to each container of drugs dispensed to patients in
21 this state.

22 (g) A nonresident pharmacy shall not permit a pharmacist whose
23 license has been revoked by the board to manufacture, compound,
24 furnish, sell, dispense, or initiate the prescription of a dangerous
25 drug or dangerous device, or to provide any pharmacy-related
26 service, to a person residing in California.

27 (h) The board shall adopt regulations that apply the same
28 requirements or standards for oral consultation to a nonresident
29 pharmacy that operates pursuant to this section and ships, mails,
30 or delivers any controlled substances, dangerous drugs, or
31 dangerous devices to residents of this state, as are applied to an
32 in-state pharmacy that operates pursuant to Section 4037 when the
33 pharmacy ships, mails, or delivers any controlled substances,
34 dangerous drugs, or dangerous devices to residents of this state.
35 The board shall not adopt any regulations that require face-to-face
36 consultation for a prescription that is shipped, mailed, or delivered
37 to the patient. The regulations adopted pursuant to this subdivision
38 shall not result in any unnecessary delay in patients receiving their
39 medication.

(i) The registration fee shall be the fee specified in subdivision (a) of Section 4400.

(j) The registration requirements of this section shall apply only to a nonresident pharmacy that ships, mails, or delivers controlled substances, dangerous drugs, and dangerous devices into this state pursuant to a prescription.

(k) Nothing in this section shall be construed to authorize the dispensing of contact lenses by nonresident pharmacists except as provided by Section 4124.

SEC. 5. ~~Section 4126.5 of the Business and Professions Code is amended to read:~~

~~4126.5. (a) A pharmacy may furnish dangerous drugs only to the following:~~

~~(1) A wholesaler owned or under common control by the wholesaler from whom the dangerous drug was acquired.~~

~~(2) The pharmaceutical manufacturer from whom the dangerous drug was acquired.~~

~~(3) A licensed wholesaler acting as a reverse distributor.~~

~~(4) Another pharmacy or wholesaler to alleviate a temporary shortage of a dangerous drug that could result in the denial of health care. A pharmacy furnishing dangerous drugs pursuant to this paragraph may only furnish a quantity sufficient to alleviate the temporary shortage.~~

~~(5) A patient or to another pharmacy pursuant to a prescription or as otherwise authorized by law.~~

~~(6) A health care provider that is not a pharmacy but that is authorized to purchase dangerous drugs.~~

~~(7) To another pharmacy under common control.~~

~~(8) A hazardous waste hauler, as described in Section 117660 of the Health and Safety Code, for the sole purpose of waste disposal of pharmaceutical waste returned to the pharmacy by a patient or patient's agent.~~

~~(b) Notwithstanding any other provision of law, a violation of this section may subject the person or persons who committed the violation to a fine not to exceed the amount specified in Section 125.9 for each occurrence pursuant to a citation issued by the board.~~

~~(c) Amounts due from any person under this section on or after January 1, 2005, shall be offset as provided under Section 12419.5 of the Government Code. Amounts received by the board under~~

1 this section shall be deposited into the Pharmacy Board Contingent
2 Fund.

3 ~~(d) For purposes of this section, “common control” means the~~
4 ~~power to direct or cause the direction of the management and~~
5 ~~policies of another person whether by ownership, by voting rights,~~
6 ~~by contract, or by other means.~~

7 ~~SEC. 6.~~

8 SEC. 5. Section 4126.7 is added to the Business and Professions
9 Code, to read:

10 4126.7. (a) A reverse distributor shall not accept the return of
11 dangerous drugs that have been dispensed to a patient ~~that are later~~
12 ~~returned by the patient or the patient’s agent to the pharmacy or~~
13 ~~another licensed entity. and returned to the pharmacy unless the~~
14 ~~dangerous drugs were dispensed in a sealed or tamper-evident~~
15 ~~package and there is no evidence that the package was opened,~~
16 ~~damaged, or otherwise tampered with prior to its return to the~~
17 ~~pharmacy. Records of these returned dangerous drugs shall be~~
18 ~~kept by the pharmacy.~~

19 ~~(b) Dangerous drugs returned by a patient or a patient’s agent~~
20 ~~to a pharmacy, if accepted by the pharmacy, may be picked up or~~
21 ~~handled only by a hazardous waste hauler, as described in Section~~
22 ~~117660 of the Health and Safety Code.~~

23 ~~(c)~~

24 (b) For purposes of this section, “dispensed” means that the
25 dangerous drugs have been provided to the patient or patient’s
26 agent and taken from a pharmacy.

27 ~~SEC. 7.~~

28 SEC. 6. No reimbursement is required by this act pursuant to
29 Section 6 of Article XIII B of the California Constitution because
30 the only costs that may be incurred by a local agency or school
31 district will be incurred because this act creates a new crime or
32 infraction, eliminates a crime or infraction, or changes the penalty
33 for a crime or infraction, within the meaning of Section 17556 of
34 the Government Code, or changes the definition of a crime within
35 the meaning of Section 6 of Article XIII B of the California
36 Constitution.

AMENDED IN ASSEMBLY JULY 12, 2011

AMENDED IN ASSEMBLY JUNE 13, 2011

AMENDED IN SENATE MAY 19, 2011

AMENDED IN SENATE MAY 11, 2011

SENATE BILL

No. 943

Introduced by Committee on Business, Professions and Economic Development (Senators Price (Chair), Corbett, Correa, Emmerson, Hernandez, Negrete McLeod, Vargas, Walters, and Wyland)

March 31, 2011

An act to amend Sections ~~1915~~, 1916, 1917, 1917.2, 1918, 1922, 1927, 1950, 1952, 1955, 1957, 1959, 1961, 1962, 1963, 1966.1, 2736.5, 2836.2, 2936, 3519, 3575, 4200, 4836.1, 4980.36, 4980.37, 4980.40.5, 4980.42, 4980.45, 4982.25, 4989.54, 4990.38, 4992.3, 4992.36, 4996.13, 4996.24, 4999.12, and 4999.90 of, to add Sections 1902.1, 4999.91, and 4999.455 to, and to repeal Section 1945 of, the Business and Professions Code, relating to healing arts.

LEGISLATIVE COUNSEL'S DIGEST

SB 943, as amended, Committee on Business, Professions and Economic Development. Healing arts.

Existing law provides for the licensure and regulation of various healing arts licensees by boards within the Department of Consumer Affairs.

(1) Existing law, the Dental Practice Act, provides for the licensure and regulation of registered dental hygienists, registered dental hygienists in alternative practice, and registered dental hygienists in extended functions by the Dental Hygiene Committee of California

within the Dental Board of California. ~~Existing law provides that no person other than those licensees or a licensed dentist may engage in the practice of dental hygiene or perform dental hygiene procedures on patients, including, but not limited to, supragingival and subgingival sealing, dental hygiene assessment, and treatment and planning.~~

~~This bill would add to that enumerated list periodontal record evaluation, administration of local anesthesia, nitrous oxide-oxygen analgesia, and gingival soft tissue curettage.~~

Existing law requires applicants for licensure to provide fingerprint images for submission to governmental agencies, in order to, among other things, establish the identity of the applicant.

This bill would require applicants to submit electronic fingerprint images.

Existing law requires the committee to license as a registered dental hygienist, a registered dental hygienist in extended functions, or a registered dental hygienist in alternative practice a person who meets certain educational, training, and examination requirements.

This bill would additionally require these applicants to complete an application and pay required application fees. ~~The bill would also require a registered dental hygienist to have completed committee-approved instruction in gingival soft tissue curettage, nitrous oxide-oxygen analgesia, and local anesthesia.~~

Existing law, until January 1, 2012, requires the committee to license as a registered dental hygienist a 3rd- or 4th-year dental student who is in good standing at an accredited California dental school, who satisfactorily performs on a clinical examination and an examination in California law and ethics as prescribed by the committee, and who satisfactorily completes a national written dental hygiene examination approved by the committee.

This bill would extend those provisions until January 1, 2014.

Under existing law, a licensee may have his or her license revoked or suspended, or may be reprimanded or placed on probation by the committee, for conviction of a crime substantially related to the licensee's qualifications, functions, or duties. Existing law authorizes the committee to order a license suspended or revoked or to decline to issue a license if certain procedural events occur.

This bill would additionally authorize the committee to reprimand a licensee or order a license placed on probation.

Under existing law, a licensee or health care facility that fails to comply with a specified request from the committee for a patient's

dental hygiene records is subject to a \$250 per day civil penalty for each day that the records have not been produced, as specified.

This bill would additionally require licensees and health care facilities to comply with a request for a patient's dental records and would make them subject to a civil or administrative penalty or fine up to a maximum of \$250 per day for each day that the records have not been produced, as specified.

(2) Existing law, the Nursing Practice Act, provides for the licensure and regulation of registered nurses by the Board of Registered Nursing.

Existing law requires applicants for licensure as a registered nurse to meet certain educational requirements, to have completed specified courses of instruction, and to not be subject to denial of licensure under specified circumstances. Existing law authorizes applicants who have served on active duty in the medical corps in the United States Armed Forces to submit a record of specified training to the board for evaluation in order to satisfy the courses of instruction requirement. Under existing law, if the applicant satisfies the other general licensure requirements and if the board determines that both education and experience establish competency to practice registered nursing, the applicant shall be granted a license upon passing a certain examination.

This bill would limit that board determination to be based on education only.

(3) Existing law, the Physician Assistant Practice Act, provides for the licensure and regulation of physician assistants by the Physician Assistant Committee. Existing law requires the committee to issue a license to a physician assistant applicant who, among other things, provides evidence of either successful completion of an approved program, as defined, or a resident course of professional instruction meeting certain requirements.

This bill would instead require applicants to provide evidence of successful completion of an approved program, as defined.

(4) Existing law provides for the registration and regulation of polysomnographic technologists by the Medical Board of California. Existing law requires the board to promulgate regulations relative to the qualifications for the registration of individuals as certified polysomnographic technologists. Existing law specifies that the qualifications for a certified polysomnographic technologist includes meeting certain educational requirements and the passage of a national certifying examination. Existing law authorizes, for a specified period, the examination requirement to be satisfied if the applicant submits

proof that he or she has been practicing polysomnography for at least 5 years, as specified.

This bill would authorize, for a specified period, all of these qualifications to be satisfied if the applicant submits proof that he or she has been practicing polysomnography for at least 5 years, as specified.

(5) Existing law, the Veterinary Medicine Practice Act, until January 1, 2012, authorizes a registered veterinary technician and an unregistered assistant to administer a drug, including, but not limited to, a drug that is a controlled substance, except for the induction of anesthesia, under the direct or indirect supervision of a licensed veterinarian when done pursuant to the order, control, and full professional responsibility of the veterinarian.

This bill would extend the operation of that provision to January 1, 2013.

(6) Under existing law, the Board of Behavioral Sciences is responsible for the licensure, registration, and regulation of, among others, marriage and family therapists, licensed clinical social workers, and licensed professional clinical counselors.

(A) Existing law, the Marriage and Family Therapist Act, provides for the licensure and regulation of marriage and family therapists and makes a violation of the act a crime. Existing law, with respect to marriage and family therapists and marriage and family therapist interns, requires an applicant to possess a doctoral or master's degree in any of various disciplines, including, but not limited to, marriage, family, and child counseling.

This bill would add couple and family therapy to that list of acceptable disciplines.

Existing law requires that degree to contain a specified number of units of instruction that includes practicum involving direct client contact of a specified number of hours of face-to-face experience counseling individuals, couples, families, or groups and authorizes a portion of those hours to be gained performing client centered advocacy, as defined.

This bill would revise and recast that requirement and would authorize that portion of hours to be gained performing either client centered advocacy or face-to-face experience counseling individuals, couples, families, or groups.

Existing law authorizes a licensed professional in private practice meeting certain requirements to supervise or employ no more than a

total of 2 individuals registered as either a marriage and family therapist intern or associate clinical social worker.

This bill would authorize such a licensed professional to supervise or employ no more than a total of 3 individuals and would add clinical counsel interns to that list. Because the bill would change the definition of a crime, it would thereby impose a state-mandated local program.

Under existing law, a marriage and family therapy corporation may employ no more than a total of 2 individuals registered as either a marriage and family therapist intern or associate clinical social worker for each employee. Existing law prohibits the corporation from employing more than 10 individuals registered as either a marriage and family therapist intern or associate clinical social worker.

This bill would authorize the corporation to employ no more than a total of 3 individuals and would add clinical counsel interns to that list. The bill would also authorize the corporation to employ no more than 15 registrants and would include clinical counsel interns.

(B) The Clinical Social Worker Practice Act provides for the licensure and regulation of social workers and makes a violation of the act a crime. Under existing law, qualified members of other professional groups may do work of a psychosocial nature consistent with the standards and ethics of their respective professions.

This bill would specify that licensed professional clinical counselors may do such work.

Existing law authorizes a licensee in private practice meeting certain requirements to supervise or employ no more than a total of 2 individuals registered as either a marriage and family therapist intern or associate clinical social worker.

This bill would authorize that licensed professional to supervise or employ no more than a total of 3 individuals and would add clinical counsel interns to that list.

Under existing law, a licensed clinical social workers' corporation may employ no more than a total of 2 individuals registered as either a marriage and family therapist intern or associate clinical social worker for each employee who has satisfied certain requirements. Existing law prohibits the corporation from employing more than 10 individuals registered as either a marriage and family therapist intern or associate clinical social worker.

This bill would authorize the corporation to employ no more than a total of 3 individuals and would add clinical counsel interns to that list.

The bill would also authorize the corporation to employ no more than 15 registrants and would include clinical counsel interns.

By changing the definition of crimes, the bill would impose a state-mandated local program.

(C) Existing law, the Licensed Professional Clinical Counselor Act, provides for the licensure and regulation of professional clinical counselors and makes a violation of the act a crime. Existing law generally authorizes the board to take certain enforcement actions against licensees for a violation of the act.

This bill would authorize the board to deny any application, or to suspend or revoke any license or registration, for specified reasons.

The bill would also authorize a licensee in private practice meeting certain requirements to supervise or employ no more than a total of 3 individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker. The bill would authorize professional clinical counselor corporation to employ no more than a total of 3 individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker for each employee. The bill would prohibit the corporation from employing more than 15 individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker. Because a violation of these requirements would constitute a crime, the bill would impose a state-mandated local program.

The bill would make other conforming and technical changes, including technical changes to the Psychology Licensing Law and the Pharmacy Law.

(7) The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

- 1 SECTION 1. Section 1902.1 is added to the Business and
- 2 Professions Code, to read:
- 3 1902.1. Protection of the public shall be the highest priority
- 4 for the committee in exercising its licensing, regulatory, and

1 disciplinary functions. Whenever the protection of the public is
2 inconsistent with other interests sought to be promoted, the
3 protection of the public shall be paramount.

4 ~~SEC. 2. Section 1915 of the Business and Professions Code is~~
5 ~~amended to read:~~

6 ~~1915. No person other than a registered dental hygienist,~~
7 ~~registered dental hygienist in alternative practice or registered~~
8 ~~dental hygienist in extended functions, or a licensed dentist may~~
9 ~~engage in the practice of dental hygiene or perform dental hygiene~~
10 ~~procedures on patients, including, but not limited to, supragingival~~
11 ~~and subgingival sealing, dental hygiene assessment, periodontal~~
12 ~~record evaluation, administration of local anesthesia, nitrous~~
13 ~~oxide-oxygen analgesia, gingival soft tissue curettage, and~~
14 ~~treatment planning, except for the following persons:~~

15 ~~(a) A student enrolled in a dental or a dental hygiene school~~
16 ~~who is performing procedures as part of the regular curriculum of~~
17 ~~that program under the supervision of the faculty of that program.~~

18 ~~(b) A dental assistant acting in accordance with the rules of the~~
19 ~~dental board in performing the following procedures:~~

20 ~~(1) Applying nonacrosol and noncaustic topical agents:~~

21 ~~(2) Applying topical fluoride.~~

22 ~~(3) Taking impressions for bleaching trays.~~

23 ~~(c) A registered dental assistant acting in accordance with the~~
24 ~~rules of the dental board in performing the following procedures:~~

25 ~~(1) Polishing the coronal surfaces of teeth.~~

26 ~~(2) Applying bleaching agents.~~

27 ~~(3) Activating bleaching agents with a nonlaser light-curing~~
28 ~~device.~~

29 ~~(4) Applying pit and fissure sealant.~~

30 ~~(d) A registered dental assistant in extended functions acting in~~
31 ~~accordance with the rules of the dental board in applying pit and~~
32 ~~fissure sealants.~~

33 ~~(e) A registered dental hygienist, registered dental hygienist in~~
34 ~~alternative practice, or registered dental hygienist in extended~~
35 ~~functions licensed in another jurisdiction, performing a clinical~~
36 ~~demonstration for educational purposes.~~

37 ~~SEC. 3.~~

38 ~~SEC. 2. Section 1916 of the Business and Professions Code is~~
39 ~~amended to read:~~

1 1916. (a) An applicant for licensure under this article shall
2 furnish electronic fingerprint images for submission to state and
3 federal criminal justice agencies, including, but not limited to, the
4 Federal Bureau of Investigation, in order to establish the identity
5 of the applicant and for the other purposes described in this section.

6 (b) The committee shall submit the fingerprint images to the
7 Department of Justice for the purposes of obtaining criminal
8 offender record information regarding state and federal level
9 convictions and arrests, including arrests for which the Department
10 of Justice establishes that the person is free on bail or on his or her
11 own recognizance pending trial or appeal.

12 (c) When received, the Department of Justice shall forward to
13 the Federal Bureau of Investigation requests for federal summary
14 criminal history information received pursuant to this section. The
15 Department of Justice shall review the information returned from
16 the Federal Bureau of Investigation and compile and disseminate
17 the response to the committee.

18 (d) The Department of Justice shall provide a response to the
19 committee pursuant to subdivision (p) of Section 11105 of the
20 Penal Code.

21 (e) The committee shall request from the Department of Justice
22 subsequent arrest notification service, as provided pursuant to
23 Section 11105.2 of the Penal Code.

24 (f) The information obtained as a result of the fingerprinting
25 shall be used in accordance with Section 11105 of the Penal Code,
26 and to determine whether the applicant is subject to denial of
27 licensure pursuant to Division 1.5 (commencing with Section 475)
28 or Section 1943.

29 (g) The Department of Justice shall charge a fee sufficient to
30 cover the cost of processing the request described in this section.

31 ~~SEC. 4.~~

32 SEC. 3. Section 1917 of the Business and Professions Code is
33 amended to read:

34 1917. The committee shall grant initial licensure as a registered
35 dental hygienist to a person who satisfies all of the following
36 requirements:

37 (a) Completion of an educational program for registered dental
38 hygienists, approved by the committee, accredited by the
39 Commission on Dental Accreditation, and conducted by a
40 degree-granting, postsecondary institution.

1 (b) Satisfactory performance on the state clinical examination,
2 or satisfactory completion of the dental hygiene examination given
3 by the Western Regional Examining Board or any other clinical
4 dental hygiene examination approved by the committee.

5 (c) Satisfactory completion of the National Dental Hygiene
6 Board examination.

7 (d) Satisfactory completion of the examination in California
8 law and ethics as prescribed by the committee.

9 (e) Submission of a completed application form and all fees
10 required by the committee.

11 ~~(f) Satisfactory completion of committee-approved instruction~~
12 ~~in gingival soft tissue curettage, nitrous oxide-oxygen analgesia,~~
13 ~~and local anesthesia.~~

14 ~~SEC. 5.~~

15 *SEC. 4.* Section 1917.2 of the Business and Professions Code
16 is amended to read:

17 1917.2. (a) The committee shall license as a registered dental
18 hygienist a third- or fourth-year dental student who is in good
19 standing at an accredited California dental school and who satisfies
20 the following requirements:

21 (1) Satisfactorily performs on a clinical examination and an
22 examination in California law and ethics as prescribed by the
23 committee.

24 (2) Satisfactorily completes a national written dental hygiene
25 examination approved by the committee.

26 (b) A dental student who is granted a registered dental hygienist
27 license pursuant to this section may only practice in a dental
28 practice that serves patients who are insured under Denti-Cal, the
29 Healthy Families Program, or other government programs, or a
30 dental practice that has a sliding scale fee system based on income.

31 (c) Upon receipt of a license to practice dentistry pursuant to
32 Section 1634, a registered dental hygienist license issued pursuant
33 to this subdivision is automatically revoked.

34 (d) The dental hygienist license is granted for two years upon
35 passage of the dental hygiene examination, without the ability for
36 renewal.

37 (e) Notwithstanding subdivision (d), if a dental student fails to
38 remain in good standing at an accredited California dental school,
39 or fails to graduate from the dental program, a registered dental
40 hygienist license issued pursuant to this section shall be revoked.

1 The student shall be responsible for submitting appropriate
2 verifying documentation to the committee.

3 (f) The provisions of this section shall be reviewed pursuant to
4 Division 1.2 (commencing with Section 473). However, the review
5 shall be limited to the fiscal feasibility and impact on the
6 committee.

7 (g) This section shall become inoperative as of January 1, 2014.

8 ~~SEC. 6.~~

9 *SEC. 5.* Section 1918 of the Business and Professions Code is
10 amended to read:

11 1918. The committee shall license as a registered dental
12 hygienist in extended functions a person who meets all of the
13 following requirements:

14 (a) Holds a current license as a registered dental hygienist in
15 California.

16 (b) Completes clinical training approved by the committee in a
17 facility affiliated with a dental school under the direct supervision
18 of the dental school faculty.

19 (c) Performs satisfactorily on an examination required by the
20 committee.

21 (d) Completes an application form and pays all application fees
22 required by the committee.

23 ~~SEC. 7.~~

24 *SEC. 6.* Section 1922 of the Business and Professions Code is
25 amended to read:

26 1922. The committee shall license as a registered dental
27 hygienist in alternative practice a person who demonstrates
28 satisfactory performance on an examination in California law and
29 ethics required by the committee and who completes an application
30 form and pays all application fees required by the committee and
31 meets either of the following requirements:

32 (a) Holds a current California license as a registered dental
33 hygienist and meets the following requirements:

34 (1) Has been engaged in the practice of dental hygiene, as
35 defined in Section 1908, as a registered dental hygienist in any
36 setting, including, but not limited to, educational settings and public
37 health settings, for a minimum of 2,000 hours during the
38 immediately preceding 36 months.

39 (2) Has successfully completed a bachelor's degree or its
40 equivalent from a college or institution of higher education that is

1 accredited by a national or regional accrediting agency recognized
2 by the United States Department of Education, and a minimum of
3 150 hours of additional educational requirements, as prescribed
4 by the committee by regulation, that are consistent with good dental
5 and dental hygiene practice, including, but not necessarily limited
6 to, dental hygiene technique and theory including gerontology and
7 medical emergencies, and business administration and practice
8 management.

9 (b) Has received a letter of acceptance into the employment
10 utilization phase of the Health Manpower Pilot Project No. 155
11 established by the Office of Statewide Health Planning and
12 Development pursuant to Article 1 (commencing with Section
13 128125) of Chapter 3 of Part 3 of Division 107 of the Health and
14 Safety Code.

15 ~~SEC. 8.~~

16 *SEC. 7.* Section 1927 of the Business and Professions Code is
17 amended to read:

18 1927. A registered dental hygienist in alternative practice shall
19 not do any of the following:

20 (a) Infer, purport, advertise, or imply that he or she is in any
21 way able to provide dental services or make any type of dental
22 diagnosis beyond evaluating a patient's dental hygiene status,
23 providing a dental hygiene treatment plan, and providing the
24 associated dental hygiene services.

25 (b) Hire a registered dental hygienist to provide direct patient
26 services other than a registered dental hygienist in alternative
27 practice.

28 ~~SEC. 9.~~

29 *SEC. 8.* Section 1945 of the Business and Professions Code is
30 repealed.

31 ~~SEC. 10.~~

32 *SEC. 9.* Section 1950 of the Business and Professions Code is
33 amended to read:

34 1950. (a) A licensee may have his or her license revoked or
35 suspended, or may be reprimanded or placed on probation by the
36 committee, for conviction of a crime substantially related to the
37 licensee's qualifications, functions, or duties. The record of
38 conviction or a copy certified by the clerk of the court or by the
39 judge in whose court the conviction occurred shall be conclusive
40 evidence of conviction.

(b) The committee shall undertake proceedings under this section upon the receipt of a certified copy of the record of conviction. A plea or verdict of guilty or a conviction following a plea of nolo contendere made to a charge of a felony or of any misdemeanor substantially related to the licensee's qualifications, functions, or duties is deemed to be a conviction within the meaning of this section.

(c) The committee may reprimand a licensee or order a license suspended or revoked, or placed on probation or may decline to issue a license, when any of the following occur:

- (1) The time for appeal has elapsed.
- (2) The judgment of conviction has been affirmed on appeal.
- (3) An order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under any provision of the Penal Code, including, but not limited to, Section 1203.4 of the Penal Code, allowing a person to withdraw his or her plea of guilty and to enter a plea of not guilty, or setting aside the verdict of guilty, or dismissing the accusation, information, or indictment.

~~SEC. 11.~~

SEC. 10. Section 1952 of the Business and Professions Code is amended to read:

1952. It is unprofessional conduct for a person licensed under this article to do any of the following:

(a) Obtain or possess in violation of law, or except as directed by a licensed physician and surgeon, dentist, or podiatrist, a controlled substance, as defined in Division 10 (commencing with Section 11000) of the Health and Safety Code, or any dangerous drug as defined in Section 4022.

(b) Use a controlled substance, as defined in Division 10 (commencing with Section 11000) of the Health and Safety Code, or a dangerous drug as defined in Section 4022, or alcoholic beverages or other intoxicating substances, to an extent or in a manner dangerous or injurious to himself or herself, to any person, or the public to the extent that the use impairs the licensee's ability to conduct with safety to the public the practice authorized by his or her license.

(c) Be convicted of a charge of violating any federal statute or rules, or any statute or rule of this state, regulating controlled substances, as defined in Division 10 (commencing with Section

1 11000) of the Health and Safety Code, or any dangerous drug, as
2 defined in Section 4022, or be convicted of more than one
3 misdemeanor, or any felony, involving the use or consumption of
4 alcohol or drugs, if the conviction is substantially related to the
5 practice authorized by his or her license.

6 (1) The record of conviction or a copy certified by the clerk of
7 the court or by the judge in whose court the conviction is had, shall
8 be conclusive evidence of a violation of this section. A plea or
9 verdict of guilty or a conviction following a plea of nolo contendere
10 is deemed to be a conviction within the meaning of this section.

11 (2) The committee may order the license suspended or revoked,
12 or may decline to issue a license, when the time for appeal has
13 elapsed or the judgment of conviction has been affirmed on appeal,
14 or when an order granting probation is made suspending imposition
15 of sentence, irrespective of a subsequent order under any provision
16 of the Penal Code, including, but not limited to, Section 1203.4
17 of the Penal Code, allowing a person to withdraw his or her plea
18 of guilty and to enter a plea of not guilty, or setting aside the verdict
19 of guilty, or dismissing the accusation, information, or indictment.

20 ~~SEC. 12.~~

21 *SEC. 11.* Section 1955 of the Business and Professions Code
22 is amended to read:

23 1955. (a) (1) A licensee who fails or refuses to comply with
24 a request for a patient's dental or dental hygiene records that is
25 accompanied by that patient's written authorization for release of
26 the records to the committee, within 15 days of receiving the
27 request and authorization, shall pay to the committee a civil or
28 administrative penalty or fine up to a maximum of two hundred
29 fifty dollars (\$250) per day for each day that the documents have
30 not been produced after the 15th day, up to a maximum of five
31 thousand dollars (\$5,000) unless the licensee is unable to provide
32 the documents within this time period for good cause.

33 (2) A health care facility shall comply with a request for the
34 dental or dental hygiene records of a patient that is accompanied
35 by that patient's written authorization for release of records to the
36 committee together with a notice citing this section and describing
37 the penalties for failure to comply with this section. Failure to
38 provide the authorizing patient's dental hygiene records to the
39 committee within 30 days of receiving this request, authorization,
40 and notice shall subject the health care facility to a civil or

1 administrative penalty or fine, payable to the committee, of up to
2 a maximum of two hundred fifty dollars (\$250) per day for each
3 day that the documents have not been produced after the 30th day,
4 up to a maximum of five thousand dollars (\$5,000), unless the
5 health care facility is unable to provide the documents within this
6 time period for good cause. This paragraph shall not require health
7 care facilities to assist the committee in obtaining the patient's
8 authorization. The committee shall pay the reasonable cost of
9 copying the dental hygiene records.

10 (b) (1) A licensee who fails or refuses to comply with a court
11 order issued in the enforcement of a subpoena mandating the
12 release of records to the committee shall pay to the committee a
13 civil penalty of one thousand dollars (\$1,000) per day for each day
14 that the documents have not been produced after the date by which
15 the court order requires the documents to be produced, unless it is
16 determined that the order is unlawful or invalid. Any statute of
17 limitations applicable to the filing of an accusation by the
18 committee shall be tolled during the period the licensee is out of
19 compliance with the court order and during any related appeals.

20 (2) A licensee who fails or refuses to comply with a court order
21 issued in the enforcement of a subpoena mandating the release of
22 records to the committee is guilty of a misdemeanor punishable
23 by a fine payable to the committee not to exceed five thousand
24 dollars (\$5,000). The fine shall be added to the licensee's renewal
25 fee if it is not paid by the next succeeding renewal date. Any statute
26 of limitations applicable to the filing of an accusation by the
27 committee shall be tolled during the period the licensee is out of
28 compliance with the court order and during any related appeals.

29 (3) A health care facility that fails or refuses to comply with a
30 court order issued in the enforcement of a subpoena mandating
31 the release of patient records to the committee, that is accompanied
32 by a notice citing this section and describing the penalties for
33 failure to comply with this section, shall pay to the committee a
34 civil penalty of up to one thousand dollars (\$1,000) per day for
35 each day that the documents have not been produced, up to ten
36 thousand dollars (\$10,000), after the date by which the court order
37 requires the documents to be produced, unless it is determined that
38 the order is unlawful or invalid. Any statute of limitations
39 applicable to the filing of an accusation by the committee against
40 a licensee shall be tolled during the period the health care facility

1 is out of compliance with the court order and during any related
2 appeals.

3 (4) A health care facility that fails or refuses to comply with a
4 court order, issued in the enforcement of a subpoena, mandating
5 the release of records to the committee is guilty of a misdemeanor
6 punishable by a fine payable to the committee not to exceed five
7 thousand dollars (\$5,000). Any statute of limitations applicable to
8 the filing of an accusation by the committee against a licensee
9 shall be tolled during the period the health care facility is out of
10 compliance with the court order and during any related appeals.

11 (c) Multiple acts by a licensee in violation of subdivision (b)
12 shall be punishable by a fine not to exceed five thousand dollars
13 (\$5,000) or by imprisonment in a county jail not exceeding six
14 months, or by both that fine and imprisonment. Multiple acts by
15 a health care facility in violation of subdivision (b) shall be
16 punishable by a fine not to exceed five thousand dollars (\$5,000)
17 and shall be reported to the State Department of Public Health and
18 shall be considered as grounds for disciplinary action with respect
19 to licensure, including suspension or revocation of the license or
20 permit.

21 (d) A failure or refusal to comply with a court order issued in
22 the enforcement of a subpoena mandating the release of records
23 to the committee constitutes unprofessional conduct and is grounds
24 for suspension or revocation of his or her license.

25 (e) Imposition of the civil or administrative penalties authorized
26 by this section shall be in accordance with the Administrative
27 Procedure Act (Chapter 5 (commencing with Section 11500) of
28 Division 3 of Title 2 of the Government Code).

29 (f) For the purposes of this section, a “health care facility” means
30 a clinic or health care facility licensed or exempt from licensure
31 pursuant to Division 2 (commencing with Section 1200) of the
32 Health and Safety Code.

33 ~~SEC. 13.~~

34 *SEC. 12.* Section 1957 of the Business and Professions Code
35 is amended to read:

36 1957. (a) A person whose license has been revoked or
37 suspended, who has been placed on probation, or whose license
38 was surrendered pursuant to a stipulated settlement as a condition
39 to avoid a disciplinary administrative hearing, may petition the
40 committee for reinstatement or modification of the penalty,

1 including modification or termination of probation, after a period
2 of not less than the following minimum periods have elapsed from
3 the effective date of the decision ordering disciplinary action:

4 (1) At least three years for reinstatement of a license revoked
5 for unprofessional conduct or surrendered pursuant to a stipulated
6 settlement as a condition to avoid an administrative disciplinary
7 hearing.

8 (2) At least two years for early termination, or modification of
9 a condition, of a probation of three years or more.

10 (3) At least one year for modification of a condition, or
11 reinstatement of a license revoked for mental or physical illness,
12 or termination, or modification of a condition, of a probation of
13 less than three years.

14 (b) The petition shall state any fact required by the committee.

15 (c) The petition may be heard by the committee, or the
16 committee may assign the petition to an administrative law judge
17 designated in Section 11371 of the Government Code.

18 (d) In considering reinstatement or modification or penalty, the
19 committee or the administrative law judge hearing the petition
20 may consider the following:

21 (1) All activities of the petitioner since the disciplinary action
22 was taken.

23 (2) The offense for which the petitioner was disciplined.

24 (3) The petitioner's activities during the time the license or
25 permit was in good standing.

26 (4) The petitioner's rehabilitative efforts, general reputation for
27 truth, and professional ability.

28 (e) The hearing may be continued from time to time as the
29 committee or the administrative law judge as designated in Section
30 11371 of the Government Code finds necessary.

31 (f) The committee or the administrative law judge may impose
32 necessary terms and conditions on the licensee in reinstating a
33 license or permit or modifying a penalty.

34 (g) A petition shall not be considered while the petitioner is
35 under sentence for any criminal offense, including any period
36 during which the petitioner is on court-imposed probation or parole.

37 (h) A petition shall not be considered while there is an
38 accusation or petition to revoke probation pending against the
39 person.

(i) The committee may deny without a hearing or argument any petition filed pursuant to this section within a period of two years from the effective date of the prior decision following a hearing under this section. Nothing in this section shall be deemed to alter Sections 822 and 823.

~~SEC. 14.~~

SEC. 13. Section 1959 of the Business and Professions Code is amended to read:

1959. A person who holds a valid, unrevoked, and unsuspended license as a registered dental hygienist, registered dental hygienist in alternative practice, or registered dental hygienist in extended functions under this article may append the letters “R.D.H.,” “R.D.H.A.P.,” or “R.D.H.E.F.,” respectively, to his or her name.

~~SEC. 15.~~

SEC. 14. Section 1961 of the Business and Professions Code is amended to read:

1961. A person who willfully, under circumstances that cause risk of bodily harm, serious physical or mental illness, or death, practices, attempts to practice, advertises, or holds himself or herself out as practicing dental hygiene without having at the time of so doing a valid, unrevoked, and unsuspended license as provided in this article, is guilty of a crime, punishable by imprisonment in a county jail for up to one year. The remedy provided in this section shall not preclude any other remedy provided by law.

~~SEC. 16.~~

SEC. 15. Section 1962 of the Business and Professions Code is amended to read:

1962. (a) An association, partnership, corporation, or group of three or more registered dental hygienists in alternative practice engaging in practice under a name that would otherwise be in violation of Section 1960 may practice under that name if the association, partnership, corporation, or group holds an unexpired, unsuspended, and unrevoked permit issued by the committee under this section.

(b) An individual registered dental hygienist in alternative practice or a pair of registered dental hygienists in alternative practice who practice dental hygiene under a name that would otherwise violate Section 1960 may practice under that name if the licensees hold a valid permit issued by the committee under

1 this section. The committee shall issue a written permit authorizing
2 the holder to use a name specified in the permit in connection with
3 the holder's practice if the committee finds all of the following:

4 (1) The applicant or applicants are duly licensed registered
5 dental hygienists in alternative practice.

6 (2) The place where the applicant or applicants practice is owned
7 or leased by the applicant or applicants, and the practice conducted
8 at the place is wholly owned and entirely controlled by the
9 applicant or applicants and is an approved area or practice setting
10 pursuant to Section 1926.

11 (3) The name under which the applicant or applicants propose
12 to operate contains at least one of the following designations:
13 "dental hygiene group," "dental hygiene practice," or "dental
14 hygiene office," contains the family name of one or more of the
15 past, present, or prospective associates, partners, shareholders, or
16 members of the group, and is in conformity with Section 651 and
17 not in violation of subdivisions (i) and (l) of Section 1950.5.

18 (4) All licensed persons practicing at the location designated in
19 the application hold valid licenses and no charges of unprofessional
20 conduct are pending against any person practicing at that location.

21 (c) A permit issued under this section shall expire and become
22 invalid unless renewed in the manner provided for in this article
23 for the renewal of permits issued under this article.

24 (d) A permit issued under this section may be revoked or
25 suspended if the committee finds that any requirement for original
26 issuance of a permit is no longer being fulfilled by the
27 permitholder. Proceedings for revocation or suspension shall be
28 governed by the Administrative Procedure Act.

29 (e) If charges of unprofessional conduct are filed against the
30 holder of a permit issued under this section, or a member of an
31 association, partnership, group, or corporation to whom a permit
32 has been issued under this section, proceedings shall not be
33 commenced for revocation or suspension of the permit until a final
34 determination of the charges of unprofessional conduct, unless the
35 charges have resulted in revocation or suspension of a license.

36 ~~SEC. 17.~~

37 *SEC. 16.* Section 1963 of the Business and Professions Code
38 is amended to read:

39 1963. The committee may file a complaint for violation of any
40 part of this article with any court of competent jurisdiction and

1 may, by its officers, counsel and agents, assist in presenting the
2 law or facts at the trial. The district attorney of each county in this
3 state shall prosecute all violations of this article in their respective
4 counties in which the violations occur.

5 ~~SEC. 18.~~

6 *SEC. 17.* Section 1966.1 of the Business and Professions Code
7 is amended to read:

8 1966.1. (a) The committee shall establish criteria for the
9 acceptance, denial, or termination of licensees in a diversion
10 program. Unless ordered by the committee as a condition of a
11 licensee's disciplinary probation, only those licensees who have
12 voluntarily requested diversion treatment and supervision by a
13 diversion evaluation committee shall participate in a diversion
14 program.

15 (b) A licensee who is not the subject of a current investigation
16 may self-refer to the diversion program on a confidential basis,
17 except as provided in subdivision (f).

18 (c) A licensee under current investigation by the committee may
19 also request entry into a diversion program by contacting the
20 committee. The committee may refer the licensee requesting
21 participation in the program to a diversion evaluation committee
22 for evaluation of eligibility. Prior to authorizing a licensee to enter
23 into the diversion program, the committee may require the licensee,
24 while under current investigation for any violations of this article
25 or other violations, to execute a statement of understanding that
26 states that the licensee understands that his or her violations of this
27 article or other statutes, that would otherwise be the basis for
28 discipline, may still be investigated and the subject of disciplinary
29 action.

30 (d) If the reasons for a current investigation of a licensee are
31 based primarily on the self-administration of any controlled
32 substance or dangerous drugs or alcohol under Section 1951, or
33 the illegal possession, prescription, or nonviolent procurement of
34 any controlled substance or dangerous drugs for self-administration
35 that does not involve actual, direct harm to the public, the
36 committee shall close the investigation without further action if
37 the licensee is accepted into the committee's diversion program
38 and successfully completes the requirements of the program. If
39 the licensee withdraws or is terminated from the program by a
40 diversion evaluation committee, the investigation shall be reopened

1 and disciplinary action imposed, if warranted, as determined by
2 the committee.

3 (e) Neither acceptance nor participation in the diversion program
4 shall preclude the committee from investigating or continuing to
5 investigate, or taking disciplinary action or continuing to take
6 disciplinary action against, any licensee for any unprofessional
7 conduct committed before, during, or after participation in the
8 diversion program.

9 (f) All licensees shall sign an agreement of understanding that
10 the withdrawal or termination from the diversion program at a time
11 when a diversion evaluation committee determines the licensee
12 presents a threat to the public's health and safety shall result in the
13 utilization by the committee of diversion treatment records in
14 disciplinary or criminal proceedings.

15 (g) Any licensee terminated from the diversion program for
16 failure to comply with program requirements is subject to
17 disciplinary action by the committee for acts committed before,
18 during, and after participation in the diversion program. A licensee
19 who has been under investigation by the committee and has been
20 terminated from the diversion program by a diversion evaluation
21 committee shall be reported by the diversion evaluation committee
22 to the committee.

23 ~~SEC. 19.~~

24 *SEC. 18.* Section 2736.5 of the Business and Professions Code
25 is amended to read:

26 2736.5. (a) Any person who has served on active duty in the
27 medical corps of any of the Armed Forces of the United States and
28 who has successfully completed the course of instruction required
29 to qualify him or her for rating as a medical service
30 technician—independent duty, or other equivalent rating in his
31 particular branch of the Armed Forces, and whose service in the
32 Armed Forces has been under honorable conditions, may submit
33 the record of such training to the board for evaluation.

34 (b) If such person meets the qualifications of paragraphs (1)
35 and (3) of subdivision (a) of Section 2736, and if the board
36 determines that his or her education would give reasonable
37 assurance of competence to practice as a registered nurse in this
38 state, he or she shall be granted a license upon passing the standard
39 examination for such licensure.

1 (c) The board shall, by regulation, establish criteria for
2 evaluating the education of applicants under this section.

3 (d) The board shall maintain records of the following categories
4 of applicants under this section:

5 (1) Applicants who are rejected for examination, and the areas
6 of such applicants' preparation which are the causes of rejection.

7 (2) Applicants who are qualified by their military education
8 alone to take the examination, and the results of their examinations.

9 (3) Applicants who are qualified to take the examination by
10 their military education plus supplementary education, and the
11 results of their examinations.

12 (e) The board shall attempt to contact by mail or other means
13 individuals meeting the requirements of subdivision (a) who have
14 been or will be discharged or separated from the Armed Forces of
15 the United States, in order to inform them of the application
16 procedure provided by this section. The board may enter into an
17 agreement with the federal government in order to secure the names
18 and addresses of such individuals.

19 ~~SEC. 20.~~

20 *SEC. 19.* Section 2836.2 of the Business and Professions Code
21 is amended to read:

22 2836.2. Furnishing or ordering of drugs or devices by nurse
23 practitioners is defined to mean the act of making a pharmaceutical
24 agent or agents available to the patient in strict accordance with a
25 standardized procedure. All nurse practitioners who are authorized
26 pursuant to Section 2836.1 to furnish or issue drug orders for
27 controlled substances shall register with the United States Drug
28 Enforcement Administration.

29 ~~SEC. 21.~~

30 *SEC. 20.* Section 2936 of the Business and Professions Code
31 is amended to read:

32 2936. The board shall adopt a program of consumer and
33 professional education in matters relevant to the ethical practice
34 of psychology. The board shall establish as its standards of ethical
35 conduct relating to the practice of psychology, the "Ethical
36 Principles and Code of Conduct" published by the American
37 Psychological Association (APA). Those standards shall be applied
38 by the board as the accepted standard of care in all licensing
39 examination development and in all board enforcement policies
40 and disciplinary case evaluations.

1 To facilitate consumers in receiving appropriate psychological
2 services, all licensees and registrants shall be required to post, in
3 a conspicuous location in their principal psychological business
4 office, a notice which reads as follows:

5
6 “NOTICE TO CONSUMERS: The Department of Consumer
7 Affair’s Board of Psychology receives and responds to questions
8 and complaints regarding the practice of psychology. If you have
9 questions or complaints, you may contact the board on the
10 Internet at www.psychboard.ca.gov, by calling 1-866-503-3221,
11 or by writing to the following address:

12 Board of Psychology
13 2005 Evergreen Street, Suite 1400
14 Sacramento, California 95815-3894”

15
16 ~~SEC. 22.~~

17 *SEC. 21.* Section 3519 of the Business and Professions Code
18 is amended to read:

19 3519. The committee shall issue under the name of the Medical
20 Board of California a license to all physician assistant applicants
21 who meet all of the following requirements:

22 (a) Provide evidence of successful completion of an approved
23 program.

24 (b) Pass any examination required under Section 3517.

25 (c) Not be subject to denial of licensure under Division 1.5
26 (commencing with Section 475) or Section 3527.

27 (d) Pay all fees required under Section 3521.1.

28 ~~SEC. 23.~~

29 *SEC. 22.* Section 3575 of the Business and Professions Code
30 is amended to read:

31 3575. (a) For the purposes of this chapter, the following
32 definitions shall apply:

33 (1) “Board” means the Medical Board of California.

34 (2) “Polysomnography” means the treatment, management,
35 diagnostic testing, control, education, and care of patients with
36 sleep and wake disorders. Polysomnography shall include, but not
37 be limited to, the process of analysis, monitoring, and recording
38 of physiologic data during sleep and wakefulness to assist in the
39 treatment of disorders, syndromes, and dysfunctions that are
40 sleep-related, manifest during sleep, or disrupt normal sleep

1 activities. Polysomnography shall also include, but not be limited
2 to, the therapeutic and diagnostic use of oxygen, the use of positive
3 airway pressure including continuous positive airway pressure
4 (CPAP) and bilevel modalities, adaptive servo-ventilation, and
5 maintenance of nasal and oral airways that do not extend into the
6 trachea.

7 (3) “Supervision” means that the supervising physician and
8 surgeon shall remain available, either in person or through
9 telephonic or electronic means, at the time that the
10 polysomnographic services are provided.

11 (b) (1) Within one year after the effective date of this chapter,
12 the board shall promulgate regulations relative to the qualifications
13 for the registration of individuals as certified polysomnographic
14 technologists, polysomnographic technicians, and
15 polysomnographic trainees. The qualifications for a certified
16 polysomnographic technologist shall include all of the following:

17 (A) He or she shall have valid, current credentials as a
18 polysomnographic technologist issued by a national accrediting
19 agency approved by the board.

20 (B) He or she shall have graduated from a polysomnographic
21 educational program that has been approved by the board.

22 (C) He or she shall have passed a national certifying examination
23 that has been approved by the board.

24 (2) An applicant for registration as a certified polysomnographic
25 technologist may satisfy the qualifications described in paragraph
26 (1) by submitting proof to the board that he or she has been
27 practicing polysomnography for at least five years in a manner
28 that is acceptable to the board. However, beginning three years
29 after the effective date of this chapter, all individuals seeking to
30 obtain certification as a polysomnographic technologist shall have
31 passed a national certifying examination that has been approved
32 by the board.

33 (c) In accordance with Section 144, any person seeking
34 registration from the board as a certified polysomnographic
35 technologist, a polysomnographic technician, or a
36 polysomnographic trainee shall be subject to a state and federal
37 level criminal offender record information search conducted
38 through the Department of Justice as specified in paragraphs (1)
39 to (5), inclusive, of this subdivision.

1 (1) The board shall submit to the Department of Justice
2 fingerprint images and related information required by the
3 Department of Justice of all polysomnographic technologist,
4 technician, or trainee certification candidates for the purposes of
5 obtaining information as to the existence and content of a record
6 of state or federal convictions and state or federal arrests and also
7 information as to the existence and content of a record of state or
8 federal arrests for which the Department of Justice establishes that
9 the person is free on bail or on his or her recognizance pending
10 trial or appeal.

11 (2) When received, the Department of Justice shall forward to
12 the Federal Bureau of Investigation requests for federal summary
13 criminal history information received pursuant to this subdivision.
14 The Department of Justice shall review the information returned
15 from the Federal Bureau of Investigation and compile and
16 disseminate a response to the board.

17 (3) The Department of Justice shall provide state and federal
18 responses to the board pursuant to paragraph (1) of subdivision
19 (p) of Section 11105 of the Penal Code.

20 (4) The board shall request from the Department of Justice
21 subsequent arrest notification service, pursuant to Section 11105.2
22 of the Penal Code, for persons described in this subdivision.

23 (5) The Department of Justice shall charge a fee sufficient to
24 cover the cost of processing the request described in this
25 subdivision. The individual seeking registration shall be responsible
26 for this cost.

27 (d) An individual may use the title “certified polysomnographic
28 technologist” and may engage in the practice of polysomnography
29 only under the following circumstances:

30 (1) He or she is registered with the board and has successfully
31 undergone a state and federal level criminal offender record
32 information search pursuant to subdivision (c).

33 (2) He or she works under the supervision and direction of a
34 licensed physician and surgeon.

35 (3) He or she meets the requirements of this chapter.

36 (e) Within one year after the effective date of this chapter, the
37 board shall adopt regulations that establish the means and
38 circumstances in which a licensed physician and surgeon may
39 employ polysomnographic technicians and polysomnographic
40 trainees. The board may also adopt regulations specifying the scope

1 of services that may be provided by a polysomnographic technician
2 or polysomnographic trainee. Any regulation adopted pursuant to
3 this section may specify the level of supervision that
4 polysomnographic technicians and trainees are required to have
5 when working under the supervision of a certified
6 polysomnographic technologist or licensed health care professional.

7 (f) This section shall not apply to California licensed allied
8 health professionals, including, but not limited to, respiratory care
9 practitioners, working within the scope of practice of their license.

10 (g) Nothing in this chapter shall be interpreted to authorize a
11 polysomnographic technologist, technician, or trainee to treat,
12 manage, control, educate, or care for patients other than those with
13 sleep disorders or to provide diagnostic testing for patients other
14 than those with suspected sleep disorders.

15 ~~SEC. 24.~~

16 *SEC. 23.* Section 4200 of the Business and Professions Code
17 is amended to read:

18 4200. (a) The board may license as a pharmacist an applicant
19 who meets all the following requirements:

20 (1) Is at least 18 years of age.

21 (2) (A) Has graduated from a college of pharmacy or
22 department of pharmacy of a university recognized by the board;
23 or

24 (B) If the applicant graduated from a foreign pharmacy school,
25 the foreign-educated applicant has been certified by the Foreign
26 Pharmacy Graduate Examination Committee.

27 (3) Has completed at least 150 semester units of collegiate study
28 in the United States, or the equivalent thereof in a foreign country.
29 No less than 90 of those semester units shall have been completed
30 while in resident attendance at a school or college of pharmacy.

31 (4) Has earned at least a baccalaureate degree in a course of
32 study devoted to the practice of pharmacy.

33 (5) Has completed 1,500 hours of pharmacy practice experience
34 or the equivalent in accordance with Section 4209.

35 (6) Has passed the North American Pharmacist Licensure
36 Examination and the California Practice Standards and
37 Jurisprudence Examination for Pharmacists on or after January 1,
38 2004.

39 (b) Proof of the qualifications of an applicant for licensure as a
40 pharmacist shall be made to the satisfaction of the board and shall

1 be substantiated by affidavits or other evidence as may be required
2 by the board.

3 (c) Each person, upon application for licensure as a pharmacist
4 under this chapter, shall pay to the executive officer of the board
5 the fees provided by this chapter. The fees shall be compensation
6 to the board for investigation or examination of the applicant.

7 ~~SEC. 25.~~

8 *SEC. 24.* Section 4836.1 of the Business and Professions Code
9 is amended to read:

10 4836.1. (a) Notwithstanding any other provision of law, a
11 registered veterinary technician or an unregistered assistant may
12 administer a drug, including, but not limited to, a drug that is a
13 controlled substance, under the direct or indirect supervision of a
14 licensed veterinarian when done pursuant to the order, control,
15 and full professional responsibility of a licensed veterinarian.
16 However, no person, other than a licensed veterinarian, may induce
17 anesthesia unless authorized by regulation of the board.

18 (b) For purposes of this section, the following definitions apply:

19 (1) “Controlled substance” has the same meaning as that term
20 is defined in Section 11007 of the Health and Safety Code.

21 (2) “Direct supervision” has the same meaning as that term is
22 defined in subdivision (e) of Section 2034 of Title 16 of the
23 California Code of Regulations.

24 (3) “Drug” has the same meaning as that term is defined in
25 Section 11014 of the Health and Safety Code.

26 (4) “Indirect supervision” has the same meaning as that term is
27 defined in subdivision (f) of Section 2034 of Title 16 of the
28 California Code of Regulations.

29 (c) This section shall remain in effect until January 1, 2013, and
30 as of that date is repealed, unless a later enacted statute, which is
31 enacted before January 1, 2013, deletes or extends that date.

32 ~~SEC. 26.~~

33 *SEC. 25.* Section 4980.36 of the Business and Professions Code
34 is amended to read:

35 4980.36. (a) This section shall apply to the following:

36 (1) Applicants for licensure or registration who begin graduate
37 study before August 1, 2012, and do not complete that study on
38 or before December 31, 2018.

1 (2) Applicants for licensure or registration who begin graduate
2 study before August 1, 2012, and who graduate from a degree
3 program that meets the requirements of this section.

4 (3) Applicants for licensure or registration who begin graduate
5 study on or after August 1, 2012.

6 (b) To qualify for a license or registration, applicants shall
7 possess a doctor's or master's degree meeting the requirements of
8 this section in marriage, family, and child counseling, marriage
9 and family therapy, couple and family therapy, psychology, clinical
10 psychology, counseling psychology, or counseling with an
11 emphasis in either marriage, family, and child counseling or
12 marriage and family therapy, obtained from a school, college, or
13 university approved by the Bureau for Private Postsecondary
14 Education or accredited by either the Commission on the
15 Accreditation of Marriage and Family Therapy Education or a
16 regional accrediting agency recognized by the United States
17 Department of Education. The board has the authority to make the
18 final determination as to whether a degree meets all requirements,
19 including, but not limited to, course requirements, regardless of
20 accreditation or approval.

21 (c) A doctor's or master's degree program that qualifies for
22 licensure or registration shall do the following:

23 (1) Integrate all of the following throughout its curriculum:

24 (A) Marriage and family therapy principles.

25 (B) The principles of mental health recovery-oriented care and
26 methods of service delivery in recovery-oriented practice
27 environments, among others.

28 (C) An understanding of various cultures and the social and
29 psychological implications of socioeconomic position, and an
30 understanding of how poverty and social stress impact an
31 individual's mental health and recovery.

32 (2) Allow for innovation and individuality in the education of
33 marriage and family therapists.

34 (3) Encourage students to develop the personal qualities that
35 are intimately related to effective practice, including, but not
36 limited to, integrity, sensitivity, flexibility, insight, compassion,
37 and personal presence.

38 (4) Permit an emphasis or specialization that may address any
39 one or more of the unique and complex array of human problems,

1 symptoms, and needs of Californians served by marriage and
2 family therapists.

3 (5) Provide students with the opportunity to meet with various
4 consumers and family members of consumers of mental health
5 services to enhance understanding of their experience of mental
6 illness, treatment, and recovery.

7 (d) The degree described in subdivision (b) shall contain no less
8 than 60 semester or 90 quarter units of instruction that includes,
9 but is not limited to, the following requirements:

10 (1) Both of the following:

11 (A) No less than 12 semester or 18 quarter units of coursework
12 in theories, principles, and methods of a variety of
13 psychotherapeutic orientations directly related to marriage and
14 family therapy and marital and family systems approaches to
15 treatment and how these theories can be applied therapeutically
16 with individuals, couples, families, adults, including elder adults,
17 children, adolescents, and groups to improve, restore, or maintain
18 healthy relationships.

19 (B) Practicum that involves direct client contact, as follows:

20 (i) A minimum of six semester or nine quarter units of practicum
21 in a supervised clinical placement that provides supervised
22 fieldwork experience.

23 (ii) A minimum of 150 hours of face-to-face experience
24 counseling individuals, couples, families, or groups.

25 (iii) A student must be enrolled in a practicum course while
26 counseling clients.

27 (iv) The practicum shall provide training in all of the following
28 areas:

29 (I) Applied use of theory and psychotherapeutic techniques.

30 (II) Assessment, diagnosis, and prognosis.

31 (III) Treatment of individuals and premarital, couple, family,
32 and child relationships, including trauma and abuse, dysfunctions,
33 healthy functioning, health promotion, illness prevention, and
34 working with families.

35 (IV) Professional writing, including documentation of services,
36 treatment plans, and progress notes.

37 (V) How to connect people with resources that deliver the
38 quality of services and support needed in the community.

39 (v) Educational institutions are encouraged to design the
40 practicum required by this subparagraph to include marriage and

1 family therapy experience in low-income and multicultural mental
2 health settings.

3 (vi) In addition to the 150 hours required in clause (ii), 75 hours
4 of either of the following:

5 (I) Client-centered advocacy, as defined in Section 4980.03.

6 (II) Face-to-face experience counseling individuals, couples,
7 families, or groups.

8 (2) Instruction in all of the following:

9 (A) Diagnosis, assessment, prognosis, and treatment of mental
10 disorders, including severe mental disorders, evidence-based
11 practices, psychological testing, psychopharmacology, and
12 promising mental health practices that are evaluated in peer
13 reviewed literature.

14 (B) Developmental issues from infancy to old age, including
15 instruction in all of the following areas:

16 (i) The effects of developmental issues on individuals, couples,
17 and family relationships.

18 (ii) The psychological, psychotherapeutic, and health
19 implications of developmental issues and their effects.

20 (iii) Aging and its biological, social, cognitive, and
21 psychological aspects.

22 (iv) A variety of cultural understandings of human development.

23 (v) The understanding of human behavior within the social
24 context of socioeconomic status and other contextual issues
25 affecting social position.

26 (vi) The understanding of human behavior within the social
27 context of a representative variety of the cultures found within
28 California.

29 (vii) The understanding of the impact that personal and social
30 insecurity, social stress, low educational levels, inadequate housing,
31 and malnutrition have on human development.

32 (C) The broad range of matters and life events that may arise
33 within marriage and family relationships and within a variety of
34 California cultures, including instruction in all of the following:

35 (i) Child and adult abuse assessment and reporting.

36 (ii) Spousal or partner abuse assessment, detection, intervention
37 strategies, and same-gender abuse dynamics.

38 (iii) Cultural factors relevant to abuse of partners and family
39 members.

40 (iv) Childbirth, child rearing, parenting, and stepparenting.

- 1 (v) Marriage, divorce, and blended families.
- 2 (vi) Long-term care.
- 3 (vii) End of life and grief.
- 4 (viii) Poverty and deprivation.
- 5 (ix) Financial and social stress.
- 6 (x) Effects of trauma.
- 7 (xi) The psychological, psychotherapeutic, community, and
- 8 health implications of the matters and life events described in
- 9 clauses (i) to (x), inclusive.
- 10 (D) Cultural competency and sensitivity, including a familiarity
- 11 with the racial, cultural, linguistic, and ethnic backgrounds of
- 12 persons living in California.
- 13 (E) Multicultural development and cross-cultural interaction,
- 14 including experiences of race, ethnicity, class, spirituality, sexual
- 15 orientation, gender, and disability, and their incorporation into the
- 16 psychotherapeutic process.
- 17 (F) The effects of socioeconomic status on treatment and
- 18 available resources.
- 19 (G) Resilience, including the personal and community qualities
- 20 that enable persons to cope with adversity, trauma, tragedy, threats,
- 21 or other stresses.
- 22 (H) Human sexuality, including the study of physiological,
- 23 psychological, and social cultural variables associated with sexual
- 24 behavior and gender identity, and the assessment and treatment of
- 25 psychosexual dysfunction.
- 26 (I) Substance use disorders, co-occurring disorders, and
- 27 addiction, including, but not limited to, instruction in all of the
- 28 following:
- 29 (i) The definition of substance use disorders, co-occurring
- 30 disorders, and addiction. For purposes of this subparagraph,
- 31 “co-occurring disorders” means a mental illness and substance
- 32 abuse diagnosis occurring simultaneously in an individual.
- 33 (ii) Medical aspects of substance use disorders and co-occurring
- 34 disorders.
- 35 (iii) The effects of psychoactive drug use.
- 36 (iv) Current theories of the etiology of substance abuse and
- 37 addiction.
- 38 (v) The role of persons and systems that support or compound
- 39 substance abuse and addiction.

1 (vi) Major approaches to identification, evaluation, and treatment
2 of substance use disorders, co-occurring disorders, and addiction,
3 including, but not limited to, best practices.

4 (vii) Legal aspects of substance abuse.

5 (viii) Populations at risk with regard to substance use disorders
6 and co-occurring disorders.

7 (ix) Community resources offering screening, assessment,
8 treatment, and followup for the affected person and family.

9 (x) Recognition of substance use disorders, co-occurring
10 disorders, and addiction, and appropriate referral.

11 (xi) The prevention of substance use disorders and addiction.

12 (J) California law and professional ethics for marriage and
13 family therapists, including instruction in all of the following areas
14 of study:

15 (i) Contemporary professional ethics and statutory, regulatory,
16 and decisional laws that delineate the scope of practice of marriage
17 and family therapy.

18 (ii) The therapeutic, clinical, and practical considerations
19 involved in the legal and ethical practice of marriage and family
20 therapy, including, but not limited to, family law.

21 (iii) The current legal patterns and trends in the mental health
22 professions.

23 (iv) The psychotherapist-patient privilege, confidentiality, the
24 patient dangerous to self or others, and the treatment of minors
25 with and without parental consent.

26 (v) A recognition and exploration of the relationship between
27 a practitioner's sense of self and human values and his or her
28 professional behavior and ethics.

29 (vi) Differences in legal and ethical standards for different types
30 of work settings.

31 (vii) Licensing law and licensing process.

32 (e) The degree described in subdivision (b) shall, in addition to
33 meeting the requirements of subdivision (d), include instruction
34 in case management, systems of care for the severely mentally ill,
35 public and private services and supports available for the severely
36 mentally ill, community resources for persons with mental illness
37 and for victims of abuse, disaster and trauma response, advocacy
38 for the severely mentally ill, and collaborative treatment. This
39 instruction may be provided either in credit level coursework or

1 through extension programs offered by the degree-granting
2 institution.

3 (f) The changes made to law by this section are intended to
4 improve the educational qualifications for licensure in order to
5 better prepare future licentiates for practice, and are not intended
6 to expand or restrict the scope of practice for marriage and family
7 therapists.

8 ~~SEC. 27.~~

9 *SEC. 26.* Section 4980.37 of the Business and Professions Code
10 is amended to read:

11 4980.37. (a) This section shall apply to applicants for licensure
12 or registration who begin graduate study before August 1, 2012,
13 and complete that study on or before December 31, 2018. Those
14 applicants may alternatively qualify under paragraph (2) of
15 subdivision (a) of Section 4980.36.

16 (b) To qualify for a license or registration, applicants shall
17 possess a doctor's or master's degree in marriage, family, and child
18 counseling, marriage and family therapy, couple and family
19 therapy, psychology, clinical psychology, counseling psychology,
20 or counseling with an emphasis in either marriage, family, and
21 child counseling or marriage and family therapy, obtained from a
22 school, college, or university accredited by a regional accrediting
23 agency recognized by the United States Department of Education
24 or approved by the Bureau for Private Postsecondary Education.
25 The board has the authority to make the final determination as to
26 whether a degree meets all requirements, including, but not limited
27 to, course requirements, regardless of accreditation or approval.
28 In order to qualify for licensure pursuant to this section, a doctor's
29 or master's degree program shall be a single, integrated program
30 primarily designed to train marriage and family therapists and shall
31 contain no less than 48 semester or 72 quarter units of instruction.
32 This instruction shall include no less than 12 semester units or 18
33 quarter units of coursework in the areas of marriage, family, and
34 child counseling, and marital and family systems approaches to
35 treatment. The coursework shall include all of the following areas:

36 (1) The salient theories of a variety of psychotherapeutic
37 orientations directly related to marriage and family therapy, and
38 marital and family systems approaches to treatment.

1 (2) Theories of marriage and family therapy and how they can
2 be utilized in order to intervene therapeutically with couples,
3 families, adults, children, and groups.

4 (3) Developmental issues and life events from infancy to old
5 age and their effect on individuals, couples, and family
6 relationships. This may include coursework that focuses on specific
7 family life events and the psychological, psychotherapeutic, and
8 health implications that arise within couples and families,
9 including, but not limited to, childbirth, child rearing, childhood,
10 adolescence, adulthood, marriage, divorce, blended families,
11 stepparenting, abuse and neglect of older and dependent adults,
12 and geropsychology.

13 (4) A variety of approaches to the treatment of children.

14 The board shall, by regulation, set forth the subjects of instruction
15 required in this subdivision.

16 (c) (1) In addition to the 12 semester or 18 quarter units of
17 coursework specified in subdivision (b), the doctor's or master's
18 degree program shall contain not less than six semester or nine
19 quarter units of supervised practicum in applied psychotherapeutic
20 technique, assessments, diagnosis, prognosis, and treatment of
21 premarital, couple, family, and child relationships, including
22 dysfunctions, healthy functioning, health promotion, and illness
23 prevention, in a supervised clinical placement that provides
24 supervised fieldwork experience within the scope of practice of a
25 marriage and family therapist.

26 (2) For applicants who enrolled in a degree program on or after
27 January 1, 1995, the practicum shall include a minimum of 150
28 hours of face-to-face experience counseling individuals, couples,
29 families, or groups.

30 (3) The practicum hours shall be considered as part of the 48
31 semester or 72 quarter unit requirement.

32 (d) As an alternative to meeting the qualifications specified in
33 subdivision (b), the board shall accept as equivalent degrees those
34 master's or doctor's degrees granted by educational institutions
35 whose degree program is approved by the Commission on
36 Accreditation for Marriage and Family Therapy Education.

37 (e) In order to provide an integrated course of study and
38 appropriate professional training, while allowing for innovation
39 and individuality in the education of marriage and family therapists,
40 a degree program that meets the educational qualifications for

1 licensure or registration under this section shall do all of the
2 following:

3 (1) Provide an integrated course of study that trains students
4 generally in the diagnosis, assessment, prognosis, and treatment
5 of mental disorders.

6 (2) Prepare students to be familiar with the broad range of
7 matters that may arise within marriage and family relationships.

8 (3) Train students specifically in the application of marriage
9 and family relationship counseling principles and methods.

10 (4) Encourage students to develop those personal qualities that
11 are intimately related to the counseling situation such as integrity,
12 sensitivity, flexibility, insight, compassion, and personal presence.

13 (5) Teach students a variety of effective psychotherapeutic
14 techniques and modalities that may be utilized to improve, restore,
15 or maintain healthy individual, couple, and family relationships.

16 (6) Permit an emphasis or specialization that may address any
17 one or more of the unique and complex array of human problems,
18 symptoms, and needs of Californians served by marriage and
19 family therapists.

20 (7) Prepare students to be familiar with cross-cultural mores
21 and values, including a familiarity with the wide range of racial
22 and ethnic backgrounds common among California's population,
23 including, but not limited to, Blacks, Hispanics, Asians, and Native
24 Americans.

25 (f) Educational institutions are encouraged to design the
26 practicum required by this section to include marriage and family
27 therapy experience in low-income and multicultural mental health
28 settings.

29 (g) This section shall remain in effect only until January 1, 2019,
30 and as of that date is repealed, unless a later enacted statute, that
31 is enacted before January 1, 2019, deletes or extends that date.

32 ~~SEC. 28:~~

33 *SEC. 27.* Section 4980.40.5 of the Business and Professions
34 Code is amended to read:

35 4980.40.5. (a) A doctoral or master's degree in marriage,
36 family, and child counseling, marital and family therapy, couple
37 and family therapy, psychology, clinical psychology, counseling
38 psychology, or counseling with an emphasis in either marriage,
39 family, and child counseling, or marriage and family therapy,
40 obtained from a school, college, or university approved by the

1 Bureau for Private Postsecondary Education as of June 30, 2007,
2 shall be considered by the board to meet the requirements necessary
3 for licensure as a marriage and family therapist and for registration
4 as a marriage and family therapist intern provided that the degree
5 is conferred on or before July 1, 2010.

6 (b) As an alternative to meeting the qualifications specified in
7 subdivision (a) of Section 4980.40, the board shall accept as
8 equivalent degrees those doctoral or master's degrees that otherwise
9 meet the requirements of this chapter and are conferred by
10 educational institutions accredited by any of the following
11 associations:

12 (1) Northwest Commission on Colleges and Universities.

13 (2) Middle States Association of Colleges and Secondary
14 Schools.

15 (3) New England Association of Schools and Colleges.

16 (4) North Central Association of Colleges and Secondary
17 Schools.

18 (5) Southern Association of Colleges and Schools.

19 ~~SEC. 29.~~

20 *SEC. 28.* Section 4980.42 of the Business and Professions Code
21 is amended to read:

22 4980.42. (a) Trainees performing services in any work setting
23 specified in subdivision (d) of Section 4980.43 may perform those
24 activities and services as a trainee, provided that the activities and
25 services constitute part of the trainee's supervised course of study
26 and that the person is designated by the title "trainee." Trainees
27 may gain hours of experience outside the required practicum. Those
28 hours shall be subject to the requirements of subdivision (b) and
29 to the other requirements of this chapter.

30 (b) On and after January 1, 1995, all hours of experience gained
31 as a trainee shall be coordinated between the school and the site
32 where the hours are being accrued. The school shall approve each
33 site and shall have a written agreement with each site that details
34 each party's responsibilities, including the methods by which
35 supervision shall be provided. The agreement shall provide for
36 regular progress reports and evaluations of the student's
37 performance at the site. If an applicant has gained hours of
38 experience while enrolled in an institution other than the one that
39 confers the qualifying degree, it shall be the applicant's
40 responsibility to provide to the board satisfactory evidence that

1 those hours of trainee experience were gained in compliance with
2 this section.

3 ~~SEC. 30.~~

4 *SEC. 29.* Section 4980.45 of the Business and Professions Code
5 is amended to read:

6 4980.45. (a) A licensed professional in private practice who
7 has satisfied the requirements of subdivision (g) of Section 4980.03
8 may supervise or employ, at any one time, no more than a total of
9 three individuals registered as a marriage and family therapist
10 intern, clinical counselor intern, or associate clinical social worker
11 in that private practice.

12 (b) A marriage and family therapy corporation may employ, at
13 any one time, no more than a total of three individuals registered
14 as a marriage and family therapist intern, clinical counselor intern,
15 or associate clinical social worker for each employee or shareholder
16 who has satisfied the requirements of subdivision (g) of Section
17 4980.03. In no event shall any marriage and family therapy
18 corporation employ, at any one time, more than a total of 15
19 individuals registered as a marriage and family therapist intern,
20 clinical counselor intern, or associate clinical social worker. In no
21 event shall any supervisor supervise, at any one time, more than
22 a total of three individuals registered as either a marriage and
23 family therapist intern, clinical counselor intern, or associate
24 clinical social worker. Persons who supervise individuals registered
25 as either a marriage and family therapist intern or associate clinical
26 social worker shall be employed full time by the marriage and
27 family therapy corporation and shall be actively engaged in
28 performing professional services at and for the marriage and family
29 therapy corporation. Employment and supervision within a
30 marriage and family therapy corporation shall be subject to all
31 laws and regulations governing experience and supervision gained
32 in a private practice setting.

33 ~~SEC. 31.~~

34 *SEC. 30.* Section 4982.25 of the Business and Professions Code
35 is amended to read:

36 4982.25. The board may deny an application, or may suspend
37 or revoke a license or registration issued under this chapter, for
38 any of the following:

39 (a) Denial of licensure, revocation, suspension, restriction, or
40 any other disciplinary action imposed by another state or territory

1 or possession of the United States, or by any other governmental
2 agency, on a license, certificate, or registration to practice marriage
3 and family therapy, or any other healing art, shall constitute
4 unprofessional conduct. A certified copy of the disciplinary action
5 decision or judgment shall be conclusive evidence of that action.

6 (b) Revocation, suspension, or restriction by the board of a
7 license, certificate, or registration to practice as a marriage and
8 family therapist, clinical social worker, professional clinical
9 counselor, or educational psychologist shall also constitute grounds
10 for disciplinary action for unprofessional conduct against the
11 licensee or registrant under this chapter.

12 ~~SEC. 32.~~

13 *SEC. 31.* Section 4989.54 of the Business and Professions Code
14 is amended to read:

15 4989.54. The board may deny a license or may suspend or
16 revoke the license of a licensee if he or she has been guilty of
17 unprofessional conduct. Unprofessional conduct includes, but is
18 not limited to, the following:

19 (a) Conviction of a crime substantially related to the
20 qualifications, functions, and duties of an educational psychologist.

21 (1) The record of conviction shall be conclusive evidence only
22 of the fact that the conviction occurred.

23 (2) The board may inquire into the circumstances surrounding
24 the commission of the crime in order to fix the degree of discipline
25 or to determine if the conviction is substantially related to the
26 qualifications, functions, or duties of a licensee under this chapter.

27 (3) A plea or verdict of guilty or a conviction following a plea
28 of nolo contendere made to a charge substantially related to the
29 qualifications, functions, or duties of a licensee under this chapter
30 shall be deemed to be a conviction within the meaning of this
31 section.

32 (4) The board may order a license suspended or revoked, or
33 may decline to issue a license when the time for appeal has elapsed,
34 or the judgment of conviction has been affirmed on appeal, or
35 when an order granting probation is made suspending the
36 imposition of sentence, irrespective of a subsequent order under
37 Section 1203.4 of the Penal Code allowing the person to withdraw
38 a plea of guilty and enter a plea of not guilty or setting aside the
39 verdict of guilty or dismissing the accusation, information, or
40 indictment.

1 (b) Securing a license by fraud, deceit, or misrepresentation on
2 an application for licensure submitted to the board, whether
3 engaged in by an applicant for a license or by a licensee in support
4 of an application for licensure.

5 (c) Administering to himself or herself a controlled substance
6 or using any of the dangerous drugs specified in Section 4022 or
7 an alcoholic beverage to the extent, or in a manner, as to be
8 dangerous or injurious to himself or herself or to any other person
9 or to the public or to the extent that the use impairs his or her ability
10 to safely perform the functions authorized by the license. The board
11 shall deny an application for a license or revoke the license of any
12 person, other than one who is licensed as a physician and surgeon,
13 who uses or offers to use drugs in the course of performing
14 educational psychology.

15 (d) Failure to comply with the consent provisions in Section
16 2290.5.

17 (e) Advertising in a manner that is false, fraudulent, misleading,
18 or deceptive, as defined in Section 651.

19 (f) Violating, attempting to violate, or conspiring to violate any
20 of the provisions of this chapter or any regulation adopted by the
21 board.

22 (g) Commission of any dishonest, corrupt, or fraudulent act
23 substantially related to the qualifications, functions, or duties of a
24 licensee.

25 (h) Denial of licensure, revocation, suspension, restriction, or
26 any other disciplinary action imposed by another state or territory
27 or possession of the United States or by any other governmental
28 agency, on a license, certificate, or registration to practice
29 educational psychology or any other healing art. A certified copy
30 of the disciplinary action, decision, or judgment shall be conclusive
31 evidence of that action.

32 (i) Revocation, suspension, or restriction by the board of a
33 license, certificate, or registration to practice as an educational
34 psychologist, a clinical social worker, professional clinical
35 counselor, or marriage and family therapist.

36 (j) Failure to keep records consistent with sound clinical
37 judgment, the standards of the profession, and the nature of the
38 services being rendered.

39 (k) Gross negligence or incompetence in the practice of
40 educational psychology.

1 (l) Misrepresentation as to the type or status of a license held
2 by the licensee or otherwise misrepresenting or permitting
3 misrepresentation of his or her education, professional
4 qualifications, or professional affiliations to any person or entity.

5 (m) Intentionally or recklessly causing physical or emotional
6 harm to any client.

7 (n) Engaging in sexual relations with a client or a former client
8 within two years following termination of professional services,
9 soliciting sexual relations with a client, or committing an act of
10 sexual abuse or sexual misconduct with a client or committing an
11 act punishable as a sexually related crime, if that act or solicitation
12 is substantially related to the qualifications, functions, or duties of
13 a licensed educational psychologist.

14 (o) Prior to the commencement of treatment, failing to disclose
15 to the client or prospective client the fee to be charged for the
16 professional services or the basis upon which that fee will be
17 computed.

18 (p) Paying, accepting, or soliciting any consideration,
19 compensation, or remuneration, whether monetary or otherwise,
20 for the referral of professional clients.

21 (q) Failing to maintain confidentiality, except as otherwise
22 required or permitted by law, of all information that has been
23 received from a client in confidence during the course of treatment
24 and all information about the client that is obtained from tests or
25 other means.

26 (r) Performing, holding himself or herself out as being able to
27 perform, or offering to perform any professional services beyond
28 the scope of the license authorized by this chapter or beyond his
29 or her field or fields of competence as established by his or her
30 education, training, or experience.

31 (s) Reproducing or describing in public, or in any publication
32 subject to general public distribution, any psychological test or
33 other assessment device the value of which depends in whole or
34 in part on the naivete of the subject in ways that might invalidate
35 the test or device. An educational psychologist shall limit access
36 to the test or device to persons with professional interests who can
37 be expected to safeguard its use.

38 (t) Aiding or abetting an unlicensed person to engage in conduct
39 requiring a license under this chapter.

1 (u) When employed by another person or agency, encouraging,
2 either orally or in writing, the employer's or agency's clientele to
3 utilize his or her private practice for further counseling without
4 the approval of the employing agency or administration.

5 (v) Failing to comply with the child abuse reporting
6 requirements of Section 11166 of the Penal Code.

7 (w) Failing to comply with the elder and adult dependent abuse
8 reporting requirements of Section 15630 of the Welfare and
9 Institutions Code.

10 (x) Willful violation of Chapter 1 (commencing with Section
11 123100) of Part 1 of Division 106 of the Health and Safety Code.

12 (y) (1) Engaging in an act described in Section 261, 286, 288a,
13 or 289 of the Penal Code with a minor or an act described in
14 Section 288 or 288.5 of the Penal Code regardless of whether the
15 act occurred prior to or after the time the registration or license
16 was issued by the board. An act described in this subdivision
17 occurring prior to the effective date of this subdivision shall
18 constitute unprofessional conduct and shall subject the licensee to
19 refusal, suspension, or revocation of a license under this section.

20 (2) The Legislature hereby finds and declares that protection of
21 the public, and in particular minors, from sexual misconduct by a
22 licensee is a compelling governmental interest, and that the ability
23 to suspend or revoke a license for sexual conduct with a minor
24 occurring prior to the effective date of this section is equally
25 important to protecting the public as is the ability to refuse a license
26 for sexual conduct with a minor occurring prior to the effective
27 date of this section.

28 (z) Engaging in any conduct that subverts or attempts to subvert
29 any licensing examination or the administration of the examination
30 as described in Section 123.

31 (aa) Impersonation of another by any licensee or applicant for
32 a license, or, in the case of a licensee, allowing any other person
33 to use his or her license.

34 (ab) Permitting a person under his or her supervision or control
35 to perform, or permitting that person to hold himself or herself out
36 as competent to perform, professional services beyond the level
37 of education, training, or experience of that person.

38 ~~SEC. 33.~~

39 *SEC. 32.* Section 4990.38 of the Business and Professions Code
40 is amended to read:

1 4990.38. The board may deny an application or may suspend
2 or revoke a license or registration issued under the chapters it
3 administers and enforces for any disciplinary action imposed by
4 this state or another state or territory or possession of the United
5 States, or by a governmental agency on a license, certificate or
6 registration to practice marriage and family therapy, clinical social
7 work, educational psychology, professional clinical counseling,
8 or any other healing art. The disciplinary action, which may include
9 denial of licensure or revocation or suspension of the license or
10 imposition of restrictions on it, constitutes unprofessional conduct.
11 A certified copy of the disciplinary action decision or judgment
12 shall be conclusive evidence of that action.

13 ~~SEC. 34.~~

14 SEC. 33. Section 4992.3 of the Business and Professions Code
15 is amended to read:

16 4992.3. The board may deny a license or a registration, or may
17 suspend or revoke the license or registration of a licensee or
18 registrant if he or she has been guilty of unprofessional conduct.
19 Unprofessional conduct includes, but is not limited to, the
20 following:

21 (a) The conviction of a crime substantially related to the
22 qualifications, functions, or duties of a licensee or registrant under
23 this chapter. The record of conviction shall be conclusive evidence
24 only of the fact that the conviction occurred. The board may inquire
25 into the circumstances surrounding the commission of the crime
26 in order to fix the degree of discipline or to determine if the
27 conviction is substantially related to the qualifications, functions,
28 or duties of a licensee or registrant under this chapter. A plea or
29 verdict of guilty or a conviction following a plea of nolo contendere
30 made to a charge substantially related to the qualifications,
31 functions, or duties of a licensee or registrant under this chapter
32 is a conviction within the meaning of this section. The board may
33 order any license or registration suspended or revoked, or may
34 decline to issue a license or registration when the time for appeal
35 has elapsed, or the judgment of conviction has been affirmed on
36 appeal, or, when an order granting probation is made suspending
37 the imposition of sentence, irrespective of a subsequent order under
38 Section 1203.4 of the Penal Code allowing the person to withdraw
39 a plea of guilty and enter a plea of not guilty, or setting aside the

1 verdict of guilty, or dismissing the accusation, information, or
2 indictment.

3 (b) Securing a license or registration by fraud, deceit, or
4 misrepresentation on any application for licensure or registration
5 submitted to the board, whether engaged in by an applicant for a
6 license or registration, or by a licensee in support of any application
7 for licensure or registration.

8 (c) Administering to himself or herself any controlled substance
9 or using any of the dangerous drugs specified in Section 4022 or
10 any alcoholic beverage to the extent, or in a manner, as to be
11 dangerous or injurious to the person applying for a registration or
12 license or holding a registration or license under this chapter, or
13 to any other person, or to the public, or, to the extent that the use
14 impairs the ability of the person applying for or holding a
15 registration or license to conduct with safety to the public the
16 practice authorized by the registration or license. The board shall
17 deny an application for a registration or license or revoke the
18 license or registration of any person who uses or offers to use drugs
19 in the course of performing clinical social work. This provision
20 does not apply to any person also licensed as a physician and
21 surgeon under Chapter 5 (commencing with Section 2000) or the
22 Osteopathic Act who lawfully prescribes drugs to a patient under
23 his or her care.

24 (d) Incompetence in the performance of clinical social work.

25 (e) An act or omission that falls sufficiently below the standard
26 of conduct of the profession as to constitute an act of gross
27 negligence.

28 (f) Violating, attempting to violate, or conspiring to violate this
29 chapter or any regulation adopted by the board.

30 (g) Misrepresentation as to the type or status of a license or
31 registration held by the person, or otherwise misrepresenting or
32 permitting misrepresentation of his or her education, professional
33 qualifications, or professional affiliations to any person or entity.
34 For purposes of this subdivision, this misrepresentation includes,
35 but is not limited to, misrepresentation of the person's
36 qualifications as an adoption service provider pursuant to Section
37 8502 of the Family Code.

38 (h) Impersonation of another by any licensee, registrant, or
39 applicant for a license or registration, or, in the case of a licensee,
40 allowing any other person to use his or her license or registration.

1 (i) Aiding or abetting any unlicensed or unregistered person to
2 engage in conduct for which a license or registration is required
3 under this chapter.

4 (j) Intentionally or recklessly causing physical or emotional
5 harm to any client.

6 (k) The commission of any dishonest, corrupt, or fraudulent act
7 substantially related to the qualifications, functions, or duties of a
8 licensee or registrant.

9 (l) Engaging in sexual relations with a client or with a former
10 client within two years from the termination date of therapy with
11 the client, soliciting sexual relations with a client, or committing
12 an act of sexual abuse, or sexual misconduct with a client, or
13 committing an act punishable as a sexually related crime, if that
14 act or solicitation is substantially related to the qualifications,
15 functions, or duties of a clinical social worker.

16 (m) Performing, or holding one's self out as being able to
17 perform, or offering to perform or permitting, any registered
18 associate clinical social worker or intern under supervision to
19 perform any professional services beyond the scope of one's
20 competence, as established by one's education, training, or
21 experience. This subdivision shall not be construed to expand the
22 scope of the license authorized by this chapter.

23 (n) Failure to maintain confidentiality, except as otherwise
24 required or permitted by law, of all information that has been
25 received from a client in confidence during the course of treatment
26 and all information about the client that is obtained from tests or
27 other means.

28 (o) Prior to the commencement of treatment, failing to disclose
29 to the client or prospective client the fee to be charged for the
30 professional services, or the basis upon which that fee will be
31 computed.

32 (p) Paying, accepting, or soliciting any consideration,
33 compensation, or remuneration, whether monetary or otherwise,
34 for the referral of professional clients. All consideration,
35 compensation, or remuneration shall be in relation to professional
36 counseling services actually provided by the licensee. Nothing in
37 this subdivision shall prevent collaboration among two or more
38 licensees in a case or cases. However, no fee shall be charged for
39 that collaboration, except when disclosure of the fee has been made
40 in compliance with subdivision (o).

1 (q) Advertising in a manner that is false, fraudulent, misleading,
2 or deceptive, as defined in Section 651.

3 (r) Reproduction or description in public, or in any publication
4 subject to general public distribution, of any psychological test or
5 other assessment device, the value of which depends in whole or
6 in part on the naivete of the subject, in ways that might invalidate
7 the test or device. A licensee shall limit access to that test or device
8 to persons with professional interest who are expected to safeguard
9 its use.

10 (s) Any conduct in the supervision of any registered associate
11 clinical social worker, intern, or trainee by any licensee that violates
12 this chapter or any rules or regulations adopted by the board.

13 (t) Failure to keep records consistent with sound clinical
14 judgment, the standards of the profession, and the nature of the
15 services being rendered.

16 (u) Failure to comply with the child abuse reporting
17 requirements of Section 11166 of the Penal Code.

18 (v) Failure to comply with the elder and dependent adult abuse
19 reporting requirements of Section 15630 of the Welfare and
20 Institutions Code.

21 (w) Willful violation of Chapter 1 (commencing with Section
22 123100) of Part 1 of Division 106 of the Health and Safety Code.

23 (x) Failure to comply with Section 2290.5.

24 (y) (1) Engaging in an act described in Section 261, 286, 288a,
25 or 289 of the Penal Code with a minor or an act described in
26 Section 288 or 288.5 of the Penal Code regardless of whether the
27 act occurred prior to or after the time the registration or license
28 was issued by the board. An act described in this subdivision
29 occurring prior to the effective date of this subdivision shall
30 constitute unprofessional conduct and shall subject the licensee to
31 refusal, suspension, or revocation of a license under this section.

32 (2) The Legislature hereby finds and declares that protection of
33 the public, and in particular minors, from sexual misconduct by a
34 licensee is a compelling governmental interest, and that the ability
35 to suspend or revoke a license for sexual conduct with a minor
36 occurring prior to the effective date of this section is equally
37 important to protecting the public as is the ability to refuse a license
38 for sexual conduct with a minor occurring prior to the effective
39 date of this section.

1 (z) Engaging in any conduct that subverts or attempts to subvert
2 any licensing examination or the administration of the examination
3 as described in Section 123.

4 ~~SEC. 35.~~

5 *SEC. 34.* Section 4992.36 of the Business and Professions Code
6 is amended to read:

7 4992.36. The board may deny an application, or may suspend
8 or revoke a license or registration issued under this chapter, for
9 any of the following:

10 (a) Denial of licensure, revocation, suspension, restriction, or
11 any other disciplinary action imposed by another state or territory
12 of the United States, or by any other governmental agency, on a
13 license, certificate, or registration to practice clinical social work
14 or any other healing art shall constitute grounds for disciplinary
15 action for unprofessional conduct. A certified copy of the
16 disciplinary action decision or judgment shall be conclusive
17 evidence of that action.

18 (b) Revocation, suspension, or restriction by the board of a
19 license, certificate, or registration to practice clinical social work,
20 marriage and family therapy, professional clinical counseling, or
21 educational psychology against a licensee or registrant shall also
22 constitute grounds for disciplinary action for unprofessional
23 conduct under this chapter.

24 ~~SEC. 36.~~

25 *SEC. 35.* Section 4996.13 of the Business and Professions Code
26 is amended to read:

27 4996.13. Nothing in this article shall prevent qualified members
28 of other professional groups from doing work of a psychosocial
29 nature consistent with the standards and ethics of their respective
30 professions. However, they shall not hold themselves out to the
31 public by any title or description of services incorporating the
32 words psychosocial, or clinical social worker, or that they shall
33 not state or imply that they are licensed to practice clinical social
34 work. These qualified members of other professional groups
35 include, but are not limited to, the following:

36 (a) A physician and surgeon certified pursuant to Chapter 5
37 (commencing with Section 2000).

38 (b) A psychologist licensed pursuant to Chapter 6.6
39 (commencing with Section 2900).

40 (c) Members of the State Bar of California.

(d) Marriage and family therapists licensed pursuant to Chapter 13 (commencing with Section 4980).

(e) Licensed professional clinical counselors pursuant to Chapter 16 (commencing with Section 4999.10).

(f) A priest, rabbi, or minister of the gospel of any religious denomination.

~~SEC. 37.~~

SEC. 36. Section 4996.24 of the Business and Professions Code is amended to read:

4996.24. (a) A licensee in private practice who has satisfied the requirements of Section 1870 of Title 16 of the California Code of Regulations may supervise or employ, at any one time, no more than a total of three individuals registered as either a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker in that private practice.

(b) A licensed clinical social workers' corporation may employ, at any one time, no more than a total of three individuals registered as either a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker for each employee or shareholder who has satisfied the requirements of Section 1870 of Title 16 of the California Code of Regulations.

(c) In no event shall any licensed clinical social workers' corporation employ, at any one time, more than a total of 15 individuals registered as either a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker. In no event shall any supervisor supervise, at any one time, more than a total of three individuals registered as either a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker. Persons who supervise individuals registered as either a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker shall be employed full time by the licensed clinical social workers' corporation and shall be actively engaged in performing professional services at and for the licensed clinical social workers' corporation. Employment and supervision within the licensed clinical social workers' corporation shall be subject to all laws and regulations governing experience and supervision gained in a private practice setting.

~~SEC. 38.~~

SEC. 37. Section 4999.12 of the Business and Professions Code is amended to read:

1 4999.12. For purposes of this chapter, the following terms have
2 the following meanings:

3 (a) “Board” means the Board of Behavioral Sciences.

4 (b) “Accredited” means a school, college, or university
5 accredited by the Western Association of Schools and Colleges,
6 or its equivalent regional accrediting association.

7 (c) “Approved” means a school, college, or university that
8 possessed unconditional approval by the Bureau for Private
9 Postsecondary Education at the time of the applicant’s graduation
10 from the school, college, or university.

11 (d) “Applicant” means an unlicensed person who has completed
12 a master’s or doctoral degree program, as specified in Section
13 4999.32 or 4999.33, as applicable, and whose application for
14 registration as an intern is pending or who has applied for
15 examination eligibility, or an unlicensed person who has completed
16 the requirements for licensure specified in this chapter and is no
17 longer registered with the board as an intern.

18 (e) “Licensed professional clinical counselor” or “LPCC” means
19 a person licensed under this chapter to practice professional clinical
20 counseling, as defined in Section 4999.20.

21 (f) “Intern” means an unlicensed person who meets the
22 requirements of Section 4999.42 and is registered with the board.

23 (g) “Clinical counselor trainee” means an unlicensed person
24 who is currently enrolled in a master’s or doctoral degree program,
25 as specified in Section 4999.32 or 4999.33, as applicable, that is
26 designed to qualify him or her for licensure under this chapter, and
27 who has completed no less than 12 semester units or 18 quarter
28 units of coursework in any qualifying degree program.

29 (h) “Approved supervisor” means an individual who meets the
30 following requirements:

31 (1) Has documented two years of clinical experience as a
32 licensed professional clinical counselor, licensed marriage and
33 family therapist, licensed clinical psychologist, licensed clinical
34 social worker, or licensed physician and surgeon who is certified
35 in psychiatry by the American Board of Psychiatry and Neurology.

36 (2) Has received professional training in supervision.

37 (3) Has not provided therapeutic services to the clinical
38 counselor trainee or intern.

39 (4) Has a current and valid license that is not under suspension
40 or probation.

1 (i) “Client centered advocacy” includes, but is not limited to,
2 researching, identifying, and accessing resources, or other activities,
3 related to obtaining or providing services and supports for clients
4 or groups of clients receiving psychotherapy or counseling services.

5 (j) “Advertising” or “advertise” includes, but is not limited to,
6 the issuance of any card, sign, or device to any person, or the
7 causing, permitting, or allowing of any sign or marking on, or in,
8 any building or structure, or in any newspaper or magazine or in
9 any directory, or any printed matter whatsoever, with or without
10 any limiting qualification. It also includes business solicitations
11 communicated by radio or television broadcasting. Signs within
12 church buildings or notices in church bulletins mailed to a
13 congregation shall not be construed as advertising within the
14 meaning of this chapter.

15 (k) “Referral” means evaluating and identifying the needs of a
16 client to determine whether it is advisable to refer the client to
17 other specialists, informing the client of that judgment, and
18 communicating that determination as requested or deemed
19 appropriate to referral sources.

20 (l) “Research” means a systematic effort to collect, analyze, and
21 interpret quantitative and qualitative data that describes how social
22 characteristics, behavior, emotion, cognitions, disabilities, mental
23 disorders, and interpersonal transactions among individuals and
24 organizations interact.

25 (m) “Supervision” includes the following:

26 (1) Ensuring that the extent, kind, and quality of counseling
27 performed is consistent with the education, training, and experience
28 of the person being supervised.

29 (2) Reviewing client or patient records, monitoring and
30 evaluating assessment, diagnosis, and treatment decisions of the
31 clinical counselor trainee.

32 (3) Monitoring and evaluating the ability of the intern or clinical
33 counselor trainee to provide services to the particular clientele at
34 the site or sites where he or she will be practicing.

35 (4) Ensuring compliance with laws and regulations governing
36 the practice of licensed professional clinical counseling.

37 (5) That amount of direct observation, or review of audio or
38 videotapes of counseling or therapy, as deemed appropriate by the
39 supervisor.

1 ~~SEC. 39.~~

2 *SEC. 38.* Section 4999.90 of the Business and Professions Code
3 is amended to read:

4 4999.90. The board may refuse to issue any registration or
5 license, or may suspend or revoke the registration or license of
6 any intern or licensed professional clinical counselor, if the
7 applicant, licensee, or registrant has been guilty of unprofessional
8 conduct. Unprofessional conduct includes, but is not limited to,
9 the following:

10 (a) The conviction of a crime substantially related to the
11 qualifications, functions, or duties of a licensee or registrant under
12 this chapter. The record of conviction shall be conclusive evidence
13 only of the fact that the conviction occurred. The board may inquire
14 into the circumstances surrounding the commission of the crime
15 in order to fix the degree of discipline or to determine if the
16 conviction is substantially related to the qualifications, functions,
17 or duties of a licensee or registrant under this chapter. A plea or
18 verdict of guilty or a conviction following a plea of nolo contendere
19 made to a charge substantially related to the qualifications,
20 functions, or duties of a licensee or registrant under this chapter
21 shall be deemed to be a conviction within the meaning of this
22 section. The board may order any license or registration suspended
23 or revoked, or may decline to issue a license or registration when
24 the time for appeal has elapsed, or the judgment of conviction has
25 been affirmed on appeal, or, when an order granting probation is
26 made suspending the imposition of sentence, irrespective of a
27 subsequent order under Section 1203.4 of the Penal Code allowing
28 the person to withdraw a plea of guilty and enter a plea of not
29 guilty, or setting aside the verdict of guilty, or dismissing the
30 accusation, information, or indictment.

31 (b) Securing a license or registration by fraud, deceit, or
32 misrepresentation on any application for licensure or registration
33 submitted to the board, whether engaged in by an applicant for a
34 license or registration, or by a licensee in support of any application
35 for licensure or registration.

36 (c) Administering to himself or herself any controlled substance
37 or using any of the dangerous drugs specified in Section 4022, or
38 any alcoholic beverage to the extent, or in a manner, as to be
39 dangerous or injurious to the person applying for a registration or
40 license or holding a registration or license under this chapter, or

1 to any other person, or to the public, or, to the extent that the use
2 impairs the ability of the person applying for or holding a
3 registration or license to conduct with safety to the public the
4 practice authorized by the registration or license, or the conviction
5 of more than one misdemeanor or any felony involving the use,
6 consumption, or self-administration of any of the substances
7 referred to in this subdivision, or any combination thereof. The
8 board shall deny an application for a registration or license or
9 revoke the license or registration of any person, other than one
10 who is licensed as a physician and surgeon, who uses or offers to
11 use drugs in the course of performing licensed professional clinical
12 counseling services.

13 (d) Gross negligence or incompetence in the performance of
14 licensed professional clinical counseling services.

15 (e) Violating, attempting to violate, or conspiring to violate any
16 of the provisions of this chapter or any regulation adopted by the
17 board.

18 (f) Misrepresentation as to the type or status of a license or
19 registration held by the person, or otherwise misrepresenting or
20 permitting misrepresentation of his or her education, professional
21 qualifications, or professional affiliations to any person or entity.

22 (g) Impersonation of another by any licensee, registrant, or
23 applicant for a license or registration, or, in the case of a licensee
24 or registrant, allowing any other person to use his or her license
25 or registration.

26 (h) Aiding or abetting, or employing, directly or indirectly, any
27 unlicensed or unregistered person to engage in conduct for which
28 a license or registration is required under this chapter.

29 (i) Intentionally or recklessly causing physical or emotional
30 harm to any client.

31 (j) The commission of any dishonest, corrupt, or fraudulent act
32 substantially related to the qualifications, functions, or duties of a
33 licensee or registrant.

34 (k) Engaging in sexual relations with a client, or a former client
35 within two years following termination of therapy, soliciting sexual
36 relations with a client, or committing an act of sexual abuse, or
37 sexual misconduct with a client, or committing an act punishable
38 as a sexually related crime, if that act or solicitation is substantially
39 related to the qualifications, functions, or duties of a licensed
40 professional clinical counselor.

1 (l) Performing, or holding oneself out as being able to perform,
2 or offering to perform, or permitting any clinical counselor trainee
3 or intern under supervision to perform, any professional services
4 beyond the scope of the license authorized by this chapter.

5 (m) Failure to maintain confidentiality, except as otherwise
6 required or permitted by law, of all information that has been
7 received from a client in confidence during the course of treatment
8 and all information about the client which is obtained from tests
9 or other means.

10 (n) Prior to the commencement of treatment, failing to disclose
11 to the client or prospective client the fee to be charged for the
12 professional services, or the basis upon which that fee will be
13 computed.

14 (o) Paying, accepting, or soliciting any consideration,
15 compensation, or remuneration, whether monetary or otherwise,
16 for the referral of professional clients. All consideration,
17 compensation, or remuneration shall be in relation to professional
18 clinical counseling services actually provided by the licensee.
19 Nothing in this subdivision shall prevent collaboration among two
20 or more licensees in a case or cases. However, no fee shall be
21 charged for that collaboration, except when disclosure of the fee
22 has been made in compliance with subdivision (n).

23 (p) Advertising in a manner that is false, fraudulent, misleading,
24 or deceptive, as defined in Section 651.

25 (q) Reproduction or description in public, or in any publication
26 subject to general public distribution, of any psychological test or
27 other assessment device, the value of which depends in whole or
28 in part on the naivete of the subject, in ways that might invalidate
29 the test or device.

30 (r) Any conduct in the supervision of a registered intern,
31 associate clinical social worker, or clinical counselor trainee by
32 any licensee that violates this chapter or any rules or regulations
33 adopted by the board.

34 (s) Performing or holding oneself out as being able to perform
35 professional services beyond the scope of one's competence, as
36 established by one's education, training, or experience. This
37 subdivision shall not be construed to expand the scope of the
38 license authorized by this chapter.

39 (t) Permitting a clinical counselor trainee or intern under one's
40 supervision or control to perform, or permitting the clinical

1 counselor trainee or intern to hold himself or herself out as
2 competent to perform, professional services beyond the clinical
3 counselor trainee's or intern's level of education, training, or
4 experience.

5 (u) The violation of any statute or regulation of the standards
6 of the profession, and the nature of the services being rendered,
7 governing the gaining and supervision of experience required by
8 this chapter.

9 (v) Failure to keep records consistent with sound clinical
10 judgment, the standards of the profession, and the nature of the
11 services being rendered.

12 (w) Failure to comply with the child abuse reporting
13 requirements of Section 11166 of the Penal Code.

14 (x) Failing to comply with the elder and dependent adult abuse
15 reporting requirements of Section 15630 of the Welfare and
16 Institutions Code.

17 (y) Repeated acts of negligence.

18 (z) (1) Engaging in an act described in Section 261, 286, 288a,
19 or 289 of the Penal Code with a minor or an act described in
20 Section 288 or 288.5 of the Penal Code regardless of whether the
21 act occurred prior to or after the time the registration or license
22 was issued by the board. An act described in this subdivision
23 occurring prior to the effective date of this subdivision shall
24 constitute unprofessional conduct and shall subject the licensee to
25 refusal, suspension, or revocation of a license under this section.

26 (2) The Legislature hereby finds and declares that protection of
27 the public, and in particular minors, from sexual misconduct by a
28 licensee is a compelling governmental interest, and that the ability
29 to suspend or revoke a license for sexual conduct with a minor
30 occurring prior to the effective date of this section is equally
31 important to protecting the public as is the ability to refuse a license
32 for sexual conduct with a minor occurring prior to the effective
33 date of this section.

34 (aa) Engaging in any conduct that subverts or attempts to subvert
35 any licensing examination or the administration of an examination
36 as described in Section 123.

37 (ab) Revocation, suspension, or restriction by the board of a
38 license, certificate, or registration to practice as a professional
39 clinical counselor, clinical social worker, educational psychologist,
40 or marriage and family therapist.

(ac) Failing to comply with the procedures set forth in Section 2290.5 when delivering health care via telemedicine.

~~SEC. 40.~~

SEC. 39. Section 4999.91 is added to the Business and Professions Code, to read:

4999.91. The board may deny any application, or may suspend or revoke any license or registration issued under this chapter, for any of the following:

(a) Denial of licensure, revocation, suspension, restriction, or any other disciplinary action imposed by this state or another state or territory of the United States, or by any other governmental agency, on a license, certificate, or registration to practice professional clinical counseling or any other healing art shall constitute grounds for disciplinary action for unprofessional conduct. A certified copy of the disciplinary action decision or judgment shall be conclusive evidence of that action.

(b) Revocation, suspension, or restriction by the board of a license, certificate, or registration to practice clinical counseling, clinical social work, professional clinical counseling, marriage and family therapy, or educational psychology shall also constitute grounds for disciplinary action for unprofessional conduct under this chapter.

~~SEC. 41.~~

SEC. 40. Section 4999.455 is added to the Business and Professions Code, to read:

4999.455. (a) A licensed professional in private practice who has satisfied the requirements of subdivision (h) of Section 4999.12 may supervise or employ, at any one time, no more than a total of three individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker in that private practice.

(b) A professional clinical counselor corporation may employ, at any one time, no more than three individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker for each employee or shareholder who has satisfied the requirements of subdivision (h) of Section 4999.12. In no event shall any professional clinical counselor corporation employ, at any one time, more than 15 individuals registered as a marriage and family therapist intern, clinical counselor intern, or associate clinical social worker. In no event

1 shall any supervisor supervise, at any one time, more than three
2 individuals registered as a marriage and family therapist intern,
3 clinical counselor intern, or associate clinical social worker.
4 Persons who supervise individuals registered as a marriage and
5 family therapist intern, clinical counselor intern, or associate
6 clinical social worker shall be employed full time by the
7 professional clinical counselor corporation and shall be actively
8 engaged in performing professional services at and for the
9 professional clinical counselor corporation. Employment and
10 supervision within a professional clinical counselor corporation
11 shall be subject to all laws and regulations governing experience
12 and supervision gained in a private practice setting.

13 ~~SEC. 42.~~

14 *SEC. 41.* No reimbursement is required by this act pursuant to
15 Section 6 of Article XIII B of the California Constitution because
16 the only costs that may be incurred by a local agency or school
17 district will be incurred because this act creates a new crime or
18 infraction, eliminates a crime or infraction, or changes the penalty
19 for a crime or infraction, within the meaning of Section 17556 of
20 the Government Code, or changes the definition of a crime within
21 the meaning of Section 6 of Article XIII B of the California
22 Constitution.

AMENDED IN ASSEMBLY APRIL 14, 2011

CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 377

Introduced by Assembly Member Solorio

February 14, 2011

An act to amend Sections 4029 and 4033 of the Business and Professions Code, relating to pharmacy.

LEGISLATIVE COUNSEL'S DIGEST

AB 377, as amended, Solorio. Pharmacy.

Existing law, the Pharmacy Law, provides for the licensure and regulation of pharmacies, including hospital pharmacies, by the California State Board of Pharmacy, and makes a knowing violation of that law a crime. Existing law prohibits the operation of a pharmacy without a license and a separate license is required for each pharmacy location. Under existing law, a hospital pharmacy, as defined, includes a pharmacy located outside of the hospital in another physical plant. However, as a condition of licensure by the board for these pharmacies, pharmaceutical services may only be provided to registered hospital patients who are on the premises of the same physical plant in which the pharmacy is located and those services must be directly related to the services or treatment plan administered in the physical plant. Existing law imposes various requirements on manufacturers, as defined, and states that a manufacturer does not mean a pharmacy compounding a drug for parenteral therapy, pursuant to a prescription, for delivery to another pharmacy for the purpose of delivering or administering the drug to the patient or patients, provided that neither the components for the drug nor the drug are compounded, fabricated, packaged, or otherwise prepared prior to receipt of the prescription.

This bill would provide that a hospital pharmacy also includes a pharmacy, licensed by the board, that may be located outside of the hospital in either another physical plant on the same premises or on a separate premises, located within a 100-mile radius of the hospital, that is regulated under a hospital's license, *but would impose limitations on the services provided by a centralized hospital pharmacy*. The bill would eliminate the conditions of licensure by the board that limit the services provided by the pharmacy in the other physical plant, but would require that any unit-dose medication produced by a hospital pharmacy under common ownership be barcoded to be readable at the patient's bedside. The bill would authorize a hospital pharmacy to prepare and store a limited quantity of unit-dose medications in advance of a patient-specific prescription under certain circumstances. The bill would also provide that a "manufacturer" does not mean a pharmacy compounding or repackaging a drug for parenteral therapy or oral therapy in a hospital for delivery to another pharmacy or hospital under common ownership in order to dispense or administer the drug to the patient or patients pursuant to a prescription or order. The bill would require a pharmacy compounding or repackaging a drug pursuant to this provision to notify the board of the location of the compounding or repackaging within a specified period of time. Because a knowing violation of the bill's requirements would be a crime, the bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

- 1 SECTION 1. Section 4029 of the Business and Professions
- 2 Code is amended to read:
- 3 4029. (a) "Hospital pharmacy" means and includes a pharmacy,
- 4 licensed by the board, located within any licensed hospital,
- 5 institution, or establishment that maintains and operates organized
- 6 facilities for the diagnosis, care, and treatment of human illnesses
- 7 to which persons may be admitted for overnight stay and that meets

1 all of the requirements of this chapter and the rules and regulations
2 of the board.

3 (b) A hospital pharmacy also includes a pharmacy, licensed by
4 the board, that may be located outside of the hospital, in either
5 another physical plant on the same premises or on a separate
6 premises, located within a ~~100-mile~~ 100-mile radius of the hospital,
7 that is regulated under a hospital's license. *A centralized hospital*
8 *pharmacy may only provide pharmaceutical services to its own*
9 *patients who are either admitted or registered patients of a hospital*
10 *within the same health care system.* Nothing in this subdivision
11 shall be construed to restrict or expand the services that a hospital
12 pharmacy may provide.

13 (c) Any unit-dose medication produced by a hospital pharmacy
14 under common ownership, as described in Section 4033, shall be
15 barcoded to be readable at the patient's bedside.

16 (d) A hospital pharmacy may prepare and store a limited quantity
17 of unit-dose medications in advance of receipt of a patient-specific
18 prescription in a quantity as is necessary to ensure continuity of
19 care for an identified population of patients of the hospital based
20 on a documented history of prescriptions for that patient population.

21 (e) Nothing in this section shall limit the obligation of a hospital
22 pharmacy, hospital, or pharmacist to comply with all applicable
23 federal and state laws.

24 SEC. 2. Section 4033 of the Business and Professions Code is
25 amended to read:

26 4033. (a) (1) "Manufacturer" means and includes every person
27 who prepares, derives, produces, compounds, or repackages any
28 drug or device except a pharmacy that manufactures on the
29 immediate premises where the drug or device is sold to the ultimate
30 consumer.

31 (2) Notwithstanding paragraph (1), "manufacturer" shall not
32 mean a pharmacy compounding or repackaging a drug for
33 parenteral therapy or oral therapy in a hospital for delivery to
34 another pharmacy or hospital under common ownership for the
35 purpose of dispensing or administering the drug, pursuant to a
36 prescription or order, to the patient or patients named in the
37 prescription or order. A pharmacy compounding or repackaging
38 a drug as described in this paragraph shall notify the board in
39 writing of the location where the compounding or repackaging is
40 being performed within 30 days of initiating the compounding or

1 repackaging. The pharmacy shall report any change in that
2 information to the board in writing within 30 days of the change.

3 (3) Notwithstanding paragraph (1), “manufacturer” shall not
4 mean a pharmacy that, at a patient’s request, repackages a drug
5 previously dispensed to the patient, or to the patient’s agent,
6 pursuant to a prescription.

7 (b) Notwithstanding subdivision (a), as used in Sections 4034,
8 4163, 4163.1, 4163.2, 4163.3, 4163.4, and 4163.5, “manufacturer”
9 means a person who prepares, derives, manufactures, produces,
10 or repackages a dangerous drug, as defined in Section 4022, device,
11 or cosmetic. Manufacturer also means the holder or holders of a
12 New Drug Application (NDA), an Abbreviated New Drug
13 Application (ANDA), or a Biologics License Application (BLA),
14 provided that such application has been approved; a manufacturer’s
15 third-party logistics provider; a private label distributor (including
16 colicensed partners) for whom the private label distributor’s
17 prescription drugs are originally manufactured and labeled for the
18 distributor and have not been repackaged; or the distributor agent
19 for the manufacturer, contract manufacturer, or private label
20 distributor, whether the establishment is a member of the
21 manufacturer’s affiliated group (regardless of whether the member
22 takes title to the drug) or is a contract distributor site.

23 SEC. 3. No reimbursement is required by this act pursuant to
24 Section 6 of Article XIII B of the California Constitution because
25 the only costs that may be incurred by a local agency or school
26 district will be incurred because this act creates a new crime or
27 infraction, eliminates a crime or infraction, or changes the penalty
28 for a crime or infraction, within the meaning of Section 17556 of
29 the Government Code, or changes the definition of a crime within
30 the meaning of Section 6 of Article XIII B of the California
31 Constitution.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: AB 377

VERSION: As Amended April 14, 2011

AUTHOR: Solorio

SPONSOR: California Hospital Association &
California Society of Health Systems Pharmacists

BOARD POSITION: Support if Amended

SUBJECT: Pharmacies: Centralized Hospital Packaging

AFFECTED SECTIONS: Amend Sections 4029 and 4033 of the Business and Professions Code

CURRENT STATUS: Senate Appropriations Committee hearing scheduled for August 15, 2011.

EXISTING LAW:

1. Defines a hospital pharmacy as a pharmacy licensed by the board that is located inside a hospital as specified.
2. Allows a hospital pharmacy to be located outside of the hospital building if the hospital pharmacy is on the California Department of Public Health's consolidated license and if the pharmacy is only providing pharmacy services to inpatients of the hospital.
3. Defines "manufacturer" and exempts compounding, as specified from the definition.

THIS BILL WOULD:

1. Specify a hospital pharmacy may be located outside of a hospital on either the same premises or separate premises, located within 100 mile radius, which is regulated under a hospital's license.
2. Specify that these services can only be provided to its own patients who are either admitted or registered patients of a hospital within the same health care system.
3. Specify that unit-dose medication produced from a centralized pharmacy location for hospitals under common ownership must be bar-coded to be readable at the patient's bedside.
4. Allow for anticipatory unit-dose packaging as specified to ensure continuity of patient care.
5. Exempt from the definition of manufacturing, repackaging of a drug for parenteral therapy, or oral therapy in a hospital for delivery to another pharmacy or hospital under common ownership for purposes of administering medication pursuant to a prescription order.
6. Require a pharmacy performing such services to notify the board in writing within 30 days of initiating prepackaging or compounding from a centralized location, as well as within 30 days of any change in the information.

AUTHOR'S INTENT:

According to the author, "technology is now capable of providing hospitals with a method to deliver barcoded unit-doses to in-patients' bedsides. However, the cost of this technology renders it virtually impossible for hospitals to do within the structures of the current hospital pharmacy. In addition, because the new central pharmacy would serve multiple hospitals (though the hospitals are under common ownership), currently lawful hospital pharmacy activities might run afoul of the manufacturing law." The author notes that the potential to finally and effectively address in-patient medication errors is greatly expanded by this proposal.

FISCAL IMPACT:

Any minor fiscal impact could be absorbed within existing resources.

COMMENTS:

Amendments to this measure clarify that the centralized pharmacy services can only be provided to its own patients who are either admitted or registered patients of a hospital within the same health care system.

This proposal appears consistent with the board's mission statement, "The Board of Pharmacy protects and promotes the health and safety of Californians by pursuing the highest quality of pharmacist's care and the appropriate use of pharmaceuticals through education, communication, licensing, legislation, regulation, and enforcement." This proposal would allow a hospital to leverage existing technology to prepare unit-dose medications that include bar-coding technology that must be readable at the patient's bedside.

Over the years the board has evaluated the issue of medication errors and reviewed materials and heard presentations from experts on what can be done to reduce such errors. Bar-coding technology has been identified as one tool that can be used to reduce medication errors. In 2004, the FDA established bar code label requirements for human drug and biological products (21 CFR Parts 201, 606, et al.) The FDA included in its guidance document, "Bar codes will allow health care professionals to use bar code scanning equipment to verify that the right drug (in the right dose and right route of administration) is being given to the right patient at the right time. This new system is intended to help reduce the number of medication errors that occur in hospitals and health care settings." (Hospitals are exempt from the FDA requirement to barcode unit-dose packages.) In 2004, the FDA also noted that hospitals that were using bar-coding at that time avoided 50% of the adverse drug events caused by errors in the distribution and administration of prescriptions.

A summary from a study published in 2006, "Medication Dispensing Errors and Potential Adverse Drug Events before and after Implementing Bar Code Technology in the Pharmacy, Poon et. Al," included:

"...our study results suggest that bar code technology in a hospital pharmacy may substantially reduce serious dispensing errors. In particular, it may target several types of dispensing errors that may frequently harm patients, including wrong medication, wrong dose, or wrong formulation errors. However, the scanning technology should be

configured to ensure that all doses are scanned at least once during the dispensing process. If optimally configured, this technology may be an important addition to the medication safety armamentarium.”

Further, a portion of the discussion from this study also included:

“The rates of target dispensing errors and potential ADEs substantially decreased after the implementation of bar code technology: The target dispensing error rate decreased by 85%, and the rate of all dispensing-related potential ADEs decreased by more than 60%.”

As this measure does not currently specify the requirements of the bar-coding, the board may want to consider offering an amendment to clarify what information should be contained within bar-code. The board may want to consider the FDA requirement elements established in 21 CFR Parts 201, 606, et al.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board spoke in support of this measure. Technical issues were raised by counsel during this discussion about some clarity issues. As a result, the board voted to establish a Support if Amended position. Following the meeting, board staff conveyed the board’s position to CSHP and discussed the changes being sought. Subsequent discussions with CSHP revealed that the board’s request for amendments may present some challenges to the bill moving forward. However, CSHP has confirmed their commitment to working with the board to clarify these items, but has informally requested that this could perhaps be accomplished as clean-up legislation next year if these changes cannot be accommodated this year.

Board staff was recently advised that this will be a two-year bill.

PREVIOUS LEGISLATION:

The board previously supported AB 1370 (Solorio, 2009) which contained provisions similar to this bill.

The board previously supported AB 2077 (Solorio, 2010) which contained provisions similar to this bill. This bill was vetoed by the governor.

“This bill potentially places vulnerable patients at risk of medication error or exposure to adulterated or misbranded drugs. Without maintaining strict adherence to federal Food and Drug Administration requirements, there is a greater likelihood of product mix-up, loss of product identity, contamination and cross-contamination, and lack of adequate control systems. Current law clearly outlines the regulatory oversight functions for the Department of Public Health and the Board of Pharmacy. I see no reason to change these well-defined regulatory roles in California.”

SUPPORT/OPPOSITION:

Support:

California Hospital Association (sponsor)
California Pharmacists Association
Antelope Valley Hospital

California Society of Health-System Pharmacists
Mercy General Hospital
Sharp
St. Joseph's Medical Center, Pharmacy Department
Touro University, College of Pharmacy
Individual Pharmacists

Opposition:

None of file

HISTORY:

Date	Action
July 5	In committee: Set, second hearing. Hearing canceled at the request of author.
June 21	In committee: Set, first hearing. Hearing canceled at the request of author.
June 14	From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (June 13). Re-referred to Com. on APPR.
May 26	Referred to Com. on B., P. & E.D.
May 12	In Senate. Read first time. To Com. on RLS. for assignment.
May 12	Read third time. Passed. Ordered to the Senate. (Ayes 70. Noes 0. Page 1356.)
May 9	Read second time. Ordered to consent calendar.
May 5	From committee: Do pass. To consent calendar. (Ayes 17. Noes 0.) (May 4).
Apr. 26	From committee: Do pass and re-refer to Com. on APPR. With recommendation: to consent calendar. (Ayes 9. Noes 0.) (April 26). Re-referred to Com. on APPR.
Apr. 25	Re-referred to Com. on B., P. & C.P.
Apr. 14	From committee chair, with author's amendments: Amend, and re-refer to Com. on B., P. & C.P. Read second time and amended.
Apr. 12	From committee: Do pass and re-refer to Com. on B., P. & C.P. (Ayes 19. Noes 0.) (April 12). Re-referred to Com. on B., P. & C.P.
Mar. 7	Referred to Coms. on HEALTH and B., P. & C.P.
Feb. 15	From printer. May be heard in committee March 17.
Feb. 14	Read first time. To print.

AMENDED IN SENATE JULY 1, 2011
AMENDED IN SENATE JUNE 20, 2011
AMENDED IN ASSEMBLY APRIL 27, 2011
AMENDED IN ASSEMBLY APRIL 13, 2011
AMENDED IN ASSEMBLY MARCH 21, 2011
CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 507

Introduced by Assembly Member Hayashi

February 15, 2011

An act to amend Sections 124960 and 124961 of, and to repeal Section 11453 of, the Health and Safety Code, relating to public health.

LEGISLATIVE COUNSEL'S DIGEST

AB 507, as amended, Hayashi. Pain management.

(1) Existing law authorizes the Department of Justice to employ a physician to interview and examine any patient in connection with the prescription, possession, or use of a controlled substance, requires the patient to submit to the interview and examination, and authorizes the physician to testify in prescribed administrative proceedings.

This bill would repeal that provision.

(2) Existing law, the Medical Practice Act, provides for the licensing and regulation of physicians and surgeons by the Medical Board of California, and the. *The* violation of specified provisions of the act is a crime. Existing law authorizes a physician and surgeon to prescribe for, or dispense or administer to, a person under his or her treatment for a medical condition, drugs or prescription controlled substances for the

treatment of pain or a condition causing pain, including, but not limited to, intractable pain.

This bill would conform findings and declarations and other references to severe chronic intractable pain and to the California Intractable Pain Treatment Act.

Vote: majority. Appropriation: no. Fiscal committee: yes.

State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. Section 11453 of the Health and Safety Code is
2 repealed.

3 SEC. 2. Section 124960 of the Health and Safety Code is
4 amended to read:

5 124960. The Legislature finds and declares all of the following:

6 (a) The state has a right and duty to control the illegal use of
7 opiate drugs.

8 (b) Inadequate treatment of acute and chronic pain originating
9 from cancer or noncancerous conditions is a significant health
10 problem.

11 (c) For some patients, pain management is the single most
12 important treatment a physician can provide.

13 (d) A patient suffering from pain or a condition causing pain,
14 including, but not limited to, intractable pain should have access
15 to proper treatment of his or her pain.

16 (e) Due to the complexity of their problems, many patients
17 suffering from pain or a condition causing pain, including, but not
18 limited to, intractable pain may require referral to a physician with
19 expertise in the treatment of pain or a condition causing pain,
20 including, but not limited to, intractable pain. In some cases, pain
21 or a condition causing pain, including, but not limited to, intractable
22 pain is best treated by a team of clinicians in order to address the
23 associated physical, psychological, social, and vocational issues.

24 (f) In the hands of knowledgeable, ethical, and experienced pain
25 management practitioners, opiates administered for pain or a
26 condition causing pain, including, but not limited to, intractable
27 pain can be safe.

28 (g) Opiates can be an accepted treatment for patients in pain or
29 a condition causing pain, including, but not limited to, intractable

1 pain who have not obtained relief from any other means of
2 treatment.

3 (h) A patient suffering from pain or a condition causing pain,
4 including, but not limited to, intractable pain has the option to
5 request or reject the use of any or all modalities to relieve his or
6 her pain.

7 (i) A physician treating a patient who suffers from pain or a
8 condition causing pain, including, but not limited to, intractable
9 pain may prescribe a dosage deemed medically necessary to relieve
10 pain as long as the prescribing is in conformance with Section
11 2241.5 of the Business and Professions Code.

12 (j) A patient who suffers from pain or a condition causing pain,
13 including, but not limited to, intractable pain, has the option to
14 choose opiate medication for the treatment of the severe chronic
15 intractable pain as long as the prescribing is in conformance with
16 the provisions of Section 2241.5 of the Business and Professions
17 Code.

18 (k) The patient's physician may refuse to prescribe opiate
19 medication for a patient who requests the treatment for pain or a
20 condition causing pain, including, but not limited to, intractable
21 pain. However, that physician shall ~~refer the patient to~~ *inform the*
22 *patient that there are* physicians who treat pain or a condition
23 causing pain, including, but not limited to, intractable pain with
24 methods that include the use of opiates.

25 SEC. 3. Section 124961 of the Health and Safety Code is
26 amended to read:

27 124961. Nothing in this section shall be construed to alter any
28 of the provisions set forth in Section 2241.5 of the Business and
29 Professions Code. This section shall be known as the Pain Patient's
30 Bill of Rights.

31 (a) A patient suffering from pain or a condition causing pain,
32 including, but not limited to, intractable pain has the option to
33 request or reject the use of any or all modalities in order to relieve
34 his or her pain.

35 (b) A patient who suffers from pain or a condition causing pain,
36 including, but not limited to, intractable pain has the option to
37 choose opiate medications to relieve that pain without first having
38 to submit to an invasive medical procedure, which is defined as
39 surgery, destruction of a nerve or other body tissue by
40 manipulation, or the implantation of a drug delivery system or

1 device, as long as the prescribing physician acts in conformance
2 with the provisions of the California Intractable Pain Treatment
3 Act, Section 2241.5 of the Business and Professions Code.

4 (c) The patient's physician may refuse to prescribe opiate
5 medication for the patient who requests a treatment for pain or a
6 condition causing pain, including, but not limited to, intractable
7 pain. However, that physician shall inform the patient that there
8 are physicians who treat pain and whose methods include the use
9 of opiates.

10 (d) A physician who uses opiate therapy to relieve pain or a
11 condition causing pain, including, but not limited to, intractable
12 pain may prescribe a dosage deemed medically necessary to relieve
13 the patient's pain, as long as that prescribing is in conformance
14 with Section 2241.5 of the Business and Professions Code.

15 (e) A patient may voluntarily request that his or her physician
16 provide an identifying notice of the prescription for purposes of
17 emergency treatment or law enforcement identification.

18 (f) Nothing in this section shall do either of the following:

19 (1) Limit any reporting or disciplinary provisions applicable to
20 licensed physicians and surgeons who violate prescribing practices
21 or other provisions set forth in the Medical Practice Act, Chapter
22 5 (commencing with Section 2000) of Division 2 of the Business
23 and Professions Code, or the regulations adopted thereunder.

24 (2) Limit the applicability of any federal statute or federal
25 regulation or any of the other statutes or regulations of this state
26 that regulate dangerous drugs or controlled substances.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: AB 507

VERSION: As Amended July 1, 2011

AUTHOR: Hayashi

SPONSOR: American Cancer Society

BOARD POSITION: Oppose (April 27, 2011 version)

SUBJECT: Pain Management

Affected Sections: Amend Sections 124960 and 124961 of the Health and Safety Code and repeal Section 11453 of the Health and Safety Code.

CURRENT STATUS: Senate Appropriations Committee hearing scheduled for August 15, 2011.

EXISTING LAW:

1. Business and Professions Code section 4301 authorizes the board to take action against any holder of a license that is guilty of unprofessional conduct as specified. Unprofessional conduct includes several elements including the clearly excessive furnishing of controlled substances in violation of Health and Safety Code section 11153(a).
2. Health and Safety Code section 11453 authorizes the Department of Justice to employ a physician to interview and examine any patient for whom any Scheduled I – III controlled substance has been furnished as specified.
3. Health and Safety Code section 124960 sets forth legislative findings and declarations including the state's right and duty to control the illegal use of opiates, inadequate treatment of acute and chronic pain is a significant health program, patients that suffer from severe chronic intractable pain should have access to proper treatment of his or her pain, many patients suffering require referral to a physician with expertise, opiates can be an accepted treatment for patients in severe chronic intractable pain and provides that a patient's physician may refuse to prescribe opiate medication however the physician shall inform that patient about physicians that specialize in such treatment.
4. Establishes the Pain Patient's Bill of Rights that includes:
 - a. A patient suffering from severe chronic intractable pain has the option to request or reject the use of any or all modalities in order to relieve his or her pain.

- b. A patient has the option to choose opiate medications to relieve the pain as specified.
- c. A physician's right to refuse to prescribe opiate medication, however requires the physician to inform the patient about physicians that specialize in such treatment.
- d. A physician who uses opiate therapy may prescribe dosage deemed medically necessary consistent with Section 2241.5 of the Business and Professions Code.
- e. A patient may request that the physician provide an identifying notice of the prescription for purposes of emergency treatment or law information.
- f. Nothing in the section limits any reporting or disciplinary provisions against those who violate prescribing practices or applicability of federal and state laws that regulate dangerous drugs or controlled substances.

AS AMENDED THIS BILL WOULD:

- 1. Repeals the provisions authorizing the DOJ to employ a physician to interview and examine any patient for whom any Scheduled I – III controlled substance has been furnished as specified.
- 2. Replaces the clause “severe chronic intractable pain” with “pain or a condition causing pain, including, but not limited to, intractable pain.”

AUTHOR'S INTENT:

According to the author's office, this bill eliminates ambiguities and inconsistencies in the Intractable Pain Treatment Act that negatively affect appropriate clinical interpretation.

COMMENTS:

As originally introduced this bill could have limited the board's ability to discipline a pharmacist's license when they fail to exercise their professional judgment.

In the past three calendar years, the board has initiated 36 investigations alleging violations of Health and Safety Code section 11153. This code establishes the corresponding responsibility that rests with a pharmacist who fills a prescription for a controlled substance and the board relies upon B&PC 4301(d) to establish such action as unprofessional conduct for purposes of discipline.

The bill in its current form removes the condition that the furnishing of the controlled substances must be clearly excessive to constitute unprofessional conduct and would instead provide that unprofessional conduct includes any furnishing of controlled

substances in violation of those prescribed provisions relating to the prescription of controlled substances by a practitioner.

PREVIOUS BOARD DISCUSSION and ACTION

During the board meeting, members discussed the measure and the challenges that were presented with the amendments to the board's unprofessional conduct provisions. After discussion, the board voted to establish an "oppose" position on the measure because the proposed amendments compromised the board's consumer protection mandate and conflicted with existing case law. Board staff conveyed the board's position both verbally and in writing. The board's Executive Officer and Board President also met with Assembly Member Hayashi as well as staff and representatives of the sponsor of this measure. As a result, the provisions amending the board's unprofessional conduct statute were removed.

FISCAL IMPACT:

In its current form board staff does not anticipate any significant impact to the board. Any minor impact could be absorbed within existing resources.

SUPPORT/OPPOSITION:

Support

American Cancer Society (Sponsor)
American Chronic Pain Association
American Society for Pain Management Nursing
California Academy of Physician Assistants
Feinberg Medical Group
For Grace
Hollywood Presbyterian Medical Center
Medical Board of California
Southern California Cancer Pain Initiative
USC/Keck School of Medicine CARE Team/Palliative Medicine Department

Opposition

None on file

HISTORY:

Date	Action
July 1	Read second time and amended. Re-referred to Com. on APPR.
June 30	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 8. Noes 1.) (June 27).
June 20	From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D.
June 2	Referred to Com. on B., P. & E.D.
May 19	In Senate. Read first time. To Com. on RLS. for assignment.
May 19	Read third time. Passed. Ordered to the Senate. (Ayes 55. Noes 20. Page 1470.)
May 16	Read second time. Ordered to third reading.
May 12	From committee: Do pass. (Ayes 13. Noes 3.) (May 11).
May 4	From committee: Do pass and re-refer to Com. on APPR. (Ayes 6. Noes 0.) (May 3). Re-referred to Com. on APPR.

Apr. 28 Re-referred to Com. on B., P. & C.P.
Apr. 27 From committee: Do pass and re-refer to Com. on B., P. & C.P. (Ayes 13. Noes 4.) (April 26).
Re-referred to Com. on B., P. & C.P. From committee chair, with author's amendments:
Amend, and re-refer to Com. on B., P. & C.P. Read second time and amended.
Apr. 14 Re-referred to Com. on HEALTH.
Apr. 13 From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH.
Read second time and amended.
Apr. 5 In committee: Hearing postponed by committee.
Mar. 22 Re-referred to Com. on HEALTH.
Mar. 21 From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH.
Read second time and amended.
Mar. 3 Referred to Coms. on HEALTH and B., P. & C.P.
Feb. 16 From printer. May be heard in committee March 18.
Feb. 15 Read first time. To print.

AMENDED IN ASSEMBLY MAY 26, 2011

AMENDED IN ASSEMBLY MAY 11, 2011

AMENDED IN ASSEMBLY MARCH 25, 2011

CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 1280

**Introduced by Assembly Member Hill
(Coauthor: Assembly Member Hagman)**

February 18, 2011

An act to amend, repeal, and add Section 11100 of, and to add and repeal Section 11100.02 of, the Health and Safety Code, relating to controlled substances.

LEGISLATIVE COUNSEL'S DIGEST

AB 1280, as amended, Hill. Ephedrine: retail sale.

(1) Existing law classifies controlled substances into 5 schedules, with the most restrictive limitations placed on controlled substances classified in Schedule I, and the least restrictive limitations placed on controlled substances classified in Schedule V. A controlled substance in any of the schedules may be possessed or dispensed only upon a lawful prescription, as specified. Existing law does not classify ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine within any of these 5 schedules, but provides that it is a crime, punishable as specified, for a person in this state who engages in specified transactions involving those drugs to fail to submit a report to the Department of Justice of all of those transactions, or to fail to submit an application to, and obtain a permit for the conduct of that business from, the Department of Justice, as specified. Existing law prohibits the sale of more than 3 packages or 9 grams of a

nonprescription product containing ephedrine or the other drugs, as specified.

This bill would instead provide that it is a misdemeanor, punishable as specified, for any retail distributor, except pursuant to a valid prescription from a licensed practitioner with prescriptive authority, to sell or distribute to a person specified amounts of nonprescription products containing ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine within specified time limits, to sell or distribute any of those substances to a person whose information has generated an alert, or, except under specified conditions, to sell or distribute to any purchaser a nonprescription product containing any amount of those substances. The bill would contain provisions requiring the secure storage and monitoring of products containing any amount of ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine, as specified.

The bill would require retail distributors to transmit, *on and after July 1, 2012*, sale information to the National Precursor Log Exchange (NPLEx) for purposes of determining whether the sale would violate these provisions. The bill would require the Department of Justice to enter into a memorandum of understanding with the National Association of Drug Diversion Investigators regarding the transaction records in NPLEx, as specified. The bill would provide that the information in the system may not be used for any purpose other than to meet the requirements of, or comply with, this act or a certain federal act, as specified. The bill would specify legislative findings and intent. The bill's provisions would remain in effect only until January 1, 2018. By creating a new crime, this bill would impose a state-mandated local program.

(2) The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 11100 of the Health and Safety Code is
2 amended to read:

1 11100. (a) Any manufacturer, wholesaler, retailer, or other
2 person or entity in this state that sells, transfers, or otherwise
3 furnishes any of the following substances to any person or entity
4 in this state or any other state shall submit a report to the
5 Department of Justice of all of those transactions:

- 6 (1) Phenyl-2-propanone.
- 7 (2) Methylamine.
- 8 (3) Ethylamine.
- 9 (4) D-lysergic acid.
- 10 (5) Ergotamine tartrate.
- 11 (6) Diethyl malonate.
- 12 (7) Malonic acid.
- 13 (8) Ethyl malonate.
- 14 (9) Barbituric acid.
- 15 (10) Piperidine.
- 16 (11) N-acetylanthranilic acid.
- 17 (12) Pyrrolidine.
- 18 (13) Phenylacetic acid.
- 19 (14) Anthranilic acid.
- 20 (15) Morpholine.
- 21 (16) Ephedrine.
- 22 (17) Pseudoephedrine.
- 23 (18) Norpseudoephedrine.
- 24 (19) Phenylpropanolamine.
- 25 (20) Propionic anhydride.
- 26 (21) Isosafrole.
- 27 (22) Safrole.
- 28 (23) Piperonal.
- 29 (24) Thionylchloride.
- 30 (25) Benzyl cyanide.
- 31 (26) Ergonovine maleate.
- 32 (27) N-methylephedrine.
- 33 (28) N-ethylephedrine.
- 34 (29) N-methylpseudoephedrine.
- 35 (30) N-ethylpseudoephedrine.
- 36 (31) Chloroephedrine.
- 37 (32) Chloropseudoephedrine.
- 38 (33) Hydriodic acid.
- 39 (34) Gamma-butyrolactone, including butyrolactone;
40 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro;

1 dihydro-2(3H)-furanone; tetrahydro-2-furanone; 1,2-butanolide;
2 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone;
3 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone
4 with Chemical Abstract Service number (96-48-0).

5 (35) 1,4-butanediol, including butanediol; butane-1,4-diol;
6 1,4-butylene glycol; butylene glycol; 1,4-dihydroxybutane;
7 1,4-tetramethylene glycol; tetramethylene glycol; tetramethylene
8 1,4-diol with Chemical Abstract Service number (110-63-4).

9 (36) Red phosphorus, including white phosphorus,
10 hypophosphorous acid and its salts, ammonium hypophosphite,
11 calcium hypophosphite, iron hypophosphite, potassium
12 hypophosphite, manganese hypophosphite, magnesium
13 hypophosphite, sodium hypophosphite, and phosphorous acid and
14 its salts.

15 (37) Iodine or tincture of iodine.

16 (38) Any of the substances listed by the Department of Justice
17 in regulations promulgated pursuant to subdivision (b).

18 (b) The Department of Justice may adopt rules and regulations
19 in accordance with Chapter 3.5 (commencing with Section 11340)
20 of Part 1 of Division 3 of Title 2 of the Government Code that add
21 substances to subdivision (a) if the substance is a precursor to a
22 controlled substance and delete substances from subdivision (a).
23 However, no regulation adding or deleting a substance shall have
24 any effect beyond March 1 of the year following the calendar year
25 during which the regulation was adopted.

26 (c) (1) (A) Any manufacturer, wholesaler, retailer, or other
27 person or entity in this state, prior to selling, transferring, or
28 otherwise furnishing any substance specified in subdivision (a) to
29 any person or business entity in this state or any other state, shall
30 require (i) a letter of authorization from that person or business
31 entity that includes the currently valid business license number or
32 federal Drug Enforcement Administration (DEA) registration
33 number, the address of the business, and a full description of how
34 the substance is to be used, and (ii) proper identification from the
35 purchaser. The manufacturer, wholesaler, retailer, or other person
36 or entity in this state shall retain this information in a readily
37 available manner for three years. The requirement for a full
38 description of how the substance is to be used does not require the
39 person or business entity to reveal their chemical processes that
40 are typically considered trade secrets and proprietary information.

(B) For the purposes of this paragraph, “proper identification” for in-state or out-of-state purchasers includes two or more of the following: federal tax identification number; seller’s permit identification number; city or county business license number; license issued by the State Department of Public Health; registration number issued by the federal Drug Enforcement Administration; precursor business permit number issued by the Bureau of Narcotic Enforcement of the Department of Justice; driver’s license; or other identification issued by a state.

(2) (A) Any manufacturer, wholesaler, retailer, or other person or entity in this state that exports a substance specified in subdivision (a) to any person or business entity located in a foreign country shall, on or before the date of exportation, submit to the Department of Justice a notification of that transaction, which notification shall include the name and quantity of the substance to be exported and the name, address, and, if assigned by the foreign country or subdivision thereof, business identification number of the person or business entity located in a foreign country importing the substance.

(B) The department may authorize the submission of the notification on a monthly basis with respect to repeated, regular transactions between an exporter and an importer involving a substance specified in subdivision (a), if the department determines that a pattern of regular supply of the substance exists between the exporter and importer and that the importer has established a record of utilization of the substance for lawful purposes.

(d) (1) Any manufacturer, wholesaler, retailer, or other person or entity in this state that sells, transfers, or otherwise furnishes a substance specified in subdivision (a) to a person or business entity in this state or any other state shall, not less than 21 days prior to delivery of the substance, submit a report of the transaction, which includes the identification information specified in subdivision (c), to the Department of Justice. The Department of Justice may authorize the submission of the reports on a monthly basis with respect to repeated, regular transactions between the furnisher and the recipient involving the substance or substances if the Department of Justice determines that a pattern of regular supply of the substance or substances exists between the manufacturer, wholesaler, retailer, or other person or entity that sells, transfers, or otherwise furnishes the substance or substances and the recipient

1 of the substance or substances, and the recipient has established a
2 record of utilization of the substance or substances for lawful
3 purposes.

4 (2) The person selling, transferring, or otherwise furnishing any
5 substance specified in subdivision (a) shall affix his or her signature
6 or otherwise identify himself or herself as a witness to the
7 identification of the purchaser or purchasing individual, and shall,
8 if a common carrier is used, maintain a manifest of the delivery
9 to the purchaser for three years.

10 (e) This section shall not apply to any of the following:

11 (1) Any pharmacist or other authorized person who sells or
12 furnishes a substance upon the prescription of a physician, dentist,
13 podiatrist, or veterinarian.

14 (2) Any physician, dentist, podiatrist, or veterinarian who
15 administers or furnishes a substance to his or her patients.

16 (3) Any manufacturer or wholesaler licensed by the California
17 State Board of Pharmacy that sells, transfers, or otherwise furnishes
18 a substance to a licensed pharmacy, physician, dentist, podiatrist,
19 or veterinarian, or a retail distributor as defined in subdivision (h),
20 provided that the manufacturer or wholesaler submits records of
21 any suspicious sales or transfers as determined by the Department
22 of Justice.

23 (4) Any analytical research facility that is registered with the
24 federal Drug Enforcement Administration of the United States
25 Department of Justice.

26 (5) A state-licensed health care facility that administers or
27 furnishes a substance to its patients.

28 (6) (A) Any sale, transfer, furnishing, or receipt of any product
29 that contains ephedrine, pseudoephedrine, norpseudoephedrine,
30 or phenylpropanolamine and which is lawfully sold, transferred,
31 or furnished over the counter without a prescription pursuant to
32 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et
33 seq.) or regulations adopted thereunder. However, this section
34 shall apply to preparations in solid or liquid dosage form, except
35 pediatric liquid forms, as defined, containing ephedrine,
36 pseudoephedrine, norpseudoephedrine, or phenylpropanolamine
37 where the individual transaction involves more than three packages
38 or nine grams of ephedrine, pseudoephedrine, norpseudoephedrine,
39 or phenylpropanolamine.

1 (B) Any ephedrine, pseudoephedrine, norpseudoephedrine, or
2 phenylpropanolamine product subsequently removed from
3 exemption pursuant to Section 814 of Title 21 of the United States
4 Code shall similarly no longer be exempt from any state reporting
5 or permitting requirement, unless otherwise reinstated pursuant to
6 subsection (d) of Section 814 of Title 21 of the United States Code
7 as an exempt product.

8 (7) The sale, transfer, furnishing, or receipt of any betadine or
9 povidone solution with an iodine content not exceeding 1 percent
10 in containers of eight ounces or less, or any tincture of iodine not
11 exceeding 2 percent in containers of one ounce or less, that is sold
12 over the counter.

13 (8) Any transfer of a substance specified in subdivision (a) for
14 purposes of lawful disposal as waste.

15 (f) (1) Any person specified in subdivision (a) or (d) who does
16 not submit a report as required by that subdivision or who
17 knowingly submits a report with false or fictitious information
18 shall be punished by imprisonment in a county jail not exceeding
19 six months, by a fine not exceeding five thousand dollars (\$5,000),
20 or by both the fine and imprisonment.

21 (2) Any person specified in subdivision (a) or (d) who has
22 previously been convicted of a violation of paragraph (1) shall,
23 upon a subsequent conviction thereof, be punished by
24 imprisonment in the state prison, or by imprisonment in a county
25 jail not exceeding one year, by a fine not exceeding one hundred
26 thousand dollars (\$100,000), or by both the fine and imprisonment.

27 (g) (1) Except as otherwise provided in subparagraph (A) of
28 paragraph (6) of subdivision (e), it is unlawful for any
29 manufacturer, wholesaler, retailer, or other person to sell, transfer,
30 or otherwise furnish a substance specified in subdivision (a) to a
31 person under 18 years of age.

32 (2) Except as otherwise provided in subparagraph (A) of
33 paragraph (6) of subdivision (e), it is unlawful for any person under
34 18 years of age to possess a substance specified in subdivision (a).

35 (3) (A) A first violation of this subdivision is a misdemeanor.

36 (B) Any person who has previously been convicted of a violation
37 of this subdivision shall, upon a subsequent conviction thereof, be
38 punished by imprisonment in a county jail not exceeding one year,
39 by a fine not exceeding ten thousand dollars (\$10,000), or by both
40 the fine and imprisonment.

(h) This section shall remain in effect only until January 1, 2018, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2018, deletes or extends that date.

SEC. 2. Section 11100 is added to the Health and Safety Code, to read:

11100. (a) Any manufacturer, wholesaler, retailer, or other person or entity in this state that sells, transfers, or otherwise furnishes any of the following substances to any person or entity in this state or any other state shall submit a report to the Department of Justice of all of those transactions:

- (1) Phenyl-2-propanone.
- (2) Methylamine.
- (3) Ethylamine.
- (4) D-lysergic acid.
- (5) Ergotamine tartrate.
- (6) Diethyl malonate.
- (7) Malonic acid.
- (8) Ethyl malonate.
- (9) Barbituric acid.
- (10) Piperidine.
- (11) N-acetylanthranilic acid.
- (12) Pyrrolidine.
- (13) Phenylacetic acid.
- (14) Anthranilic acid.
- (15) Morpholine.
- (16) Ephedrine.
- (17) Pseudoephedrine.
- (18) Norpseudoephedrine.
- (19) Phenylpropanolamine.
- (20) Propionic anhydride.
- (21) Isosafrole.
- (22) Safrole.
- (23) Piperonal.
- (24) Thionylchloride.
- (25) Benzyl cyanide.
- (26) Ergonovine maleate.
- (27) N-methylephedrine.
- (28) N-ethylephedrine.
- (29) N-methylpseudoephedrine.
- (30) N-ethylpseudoephedrine.

(31) Chloroephedrine.

(32) Chloropseudoephedrine.

(33) Hydriodic acid.

(34) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)-furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number (96-48-0).

(35) 1,4-butanediol, including butanediol; butane-1,4-diol; 1,4-butylene glycol; butylene glycol; 1,4-dihydroxybutane; 1,4-tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4-diol with Chemical Abstract Service number (110-63-4).

(36) Red phosphorus, including white phosphorus, hypophosphorous acid and its salts, ammonium hypophosphite, calcium hypophosphite, iron hypophosphite, potassium hypophosphite, manganese hypophosphite, magnesium hypophosphite, sodium hypophosphite, and phosphorous acid and its salts.

(37) Iodine or tincture of iodine.

(38) Any of the substances listed by the Department of Justice in regulations promulgated pursuant to subdivision (b).

(b) The Department of Justice may adopt rules and regulations in accordance with Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code that add substances to subdivision (a) if the substance is a precursor to a controlled substance and delete substances from subdivision (a). However, no regulation adding or deleting a substance shall have any effect beyond March 1 of the year following the calendar year during which the regulation was adopted.

(c) (1) (A) Any manufacturer, wholesaler, retailer, or other person or entity in this state, prior to selling, transferring, or otherwise furnishing any substance specified in subdivision (a) to any person or business entity in this state or any other state, shall require (i) a letter of authorization from that person or business entity that includes the currently valid business license number or federal Drug Enforcement Administration (DEA) registration number, the address of the business, and a full description of how the substance is to be used, and (ii) proper identification from the purchaser. The manufacturer, wholesaler, retailer, or other person

1 or entity in this state shall retain this information in a readily
2 available manner for three years. The requirement for a full
3 description of how the substance is to be used does not require the
4 person or business entity to reveal their chemical processes that
5 are typically considered trade secrets and proprietary information.

6 (B) For the purposes of this paragraph, “proper identification”
7 for in-state or out-of-state purchasers includes two or more of the
8 following: federal tax identification number; seller’s permit
9 identification number; city or county business license number;
10 license issued by the State Department of Public Health;
11 registration number issued by the federal Drug Enforcement
12 Administration; precursor business permit number issued by the
13 Bureau of Narcotic Enforcement of the Department of Justice;
14 driver’s license; or other identification issued by a state.

15 (2) (A) Any manufacturer, wholesaler, retailer, or other person
16 or entity in this state that exports a substance specified in
17 subdivision (a) to any person or business entity located in a foreign
18 country shall, on or before the date of exportation, submit to the
19 Department of Justice a notification of that transaction, which
20 notification shall include the name and quantity of the substance
21 to be exported and the name, address, and, if assigned by the
22 foreign country or subdivision thereof, business identification
23 number of the person or business entity located in a foreign country
24 importing the substance.

25 (B) The department may authorize the submission of the
26 notification on a monthly basis with respect to repeated, regular
27 transactions between an exporter and an importer involving a
28 substance specified in subdivision (a), if the department determines
29 that a pattern of regular supply of the substance exists between the
30 exporter and importer and that the importer has established a record
31 of utilization of the substance for lawful purposes.

32 (d) (1) Any manufacturer, wholesaler, retailer, or other person
33 or entity in this state that sells, transfers, or otherwise furnishes a
34 substance specified in subdivision (a) to a person or business entity
35 in this state or any other state shall, not less than 21 days prior to
36 delivery of the substance, submit a report of the transaction, which
37 includes the identification information specified in subdivision
38 (c), to the Department of Justice. The Department of Justice may
39 authorize the submission of the reports on a monthly basis with
40 respect to repeated, regular transactions between the furnisher and

1 the recipient involving the substance or substances if the
2 Department of Justice determines that a pattern of regular supply
3 of the substance or substances exists between the manufacturer,
4 wholesaler, retailer, or other person or entity that sells, transfers,
5 or otherwise furnishes the substance or substances and the recipient
6 of the substance or substances, and the recipient has established a
7 record of utilization of the substance or substances for lawful
8 purposes.

9 (2) The person selling, transferring, or otherwise furnishing any
10 substance specified in subdivision (a) shall affix his or her signature
11 or otherwise identify himself or herself as a witness to the
12 identification of the purchaser or purchasing individual, and shall,
13 if a common carrier is used, maintain a manifest of the delivery
14 to the purchaser for three years.

15 (e) This section shall not apply to any of the following:

16 (1) Any pharmacist or other authorized person who sells or
17 furnishes a substance upon the prescription of a physician, dentist,
18 podiatrist, or veterinarian.

19 (2) Any physician, dentist, podiatrist, or veterinarian who
20 administers or furnishes a substance to his or her patients.

21 (3) Any manufacturer or wholesaler licensed by the California
22 State Board of Pharmacy that sells, transfers, or otherwise furnishes
23 a substance to a licensed pharmacy, physician, dentist, podiatrist,
24 or veterinarian, or a retail distributor as defined in subdivision (h),
25 provided that the manufacturer or wholesaler submits records of
26 any suspicious sales or transfers as determined by the Department
27 of Justice.

28 (4) Any analytical research facility that is registered with the
29 federal Drug Enforcement Administration of the United States
30 Department of Justice.

31 (5) A state-licensed health care facility that administers or
32 furnishes a substance to its patients.

33 (6) (A) Any sale, transfer, furnishing, or receipt of any product
34 that contains ephedrine, pseudoephedrine, norpseudoephedrine,
35 or phenylpropanolamine and which is lawfully sold, transferred,
36 or furnished over the counter without a prescription pursuant to
37 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et
38 seq.) or regulations adopted thereunder. However, this section
39 shall apply to preparations in solid or liquid dosage form, except
40 pediatric liquid forms, as defined, containing ephedrine,

1 pseudoephedrine, norpseudoephedrine, or phenylpropanolamine
2 where the individual transaction involves more than three packages
3 or nine grams of ephedrine, pseudoephedrine, norpseudoephedrine,
4 or phenylpropanolamine.

5 (B) Any ephedrine, pseudoephedrine, norpseudoephedrine, or
6 phenylpropanolamine product subsequently removed from
7 exemption pursuant to Section 814 of Title 21 of the United States
8 Code shall similarly no longer be exempt from any state reporting
9 or permitting requirement, unless otherwise reinstated pursuant to
10 subsection (d) of Section 814 of Title 21 of the United States Code
11 as an exempt product.

12 (7) The sale, transfer, furnishing, or receipt of any betadine or
13 povidone solution with an iodine content not exceeding 1 percent
14 in containers of eight ounces or less, or any tincture of iodine not
15 exceeding 2 percent in containers of one ounce or less, that is sold
16 over the counter.

17 (8) Any transfer of a substance specified in subdivision (a) for
18 purposes of lawful disposal as waste.

19 (f) (1) Any person specified in subdivision (a) or (d) who does
20 not submit a report as required by that subdivision or who
21 knowingly submits a report with false or fictitious information
22 shall be punished by imprisonment in a county jail not exceeding
23 six months, by a fine not exceeding five thousand dollars (\$5,000),
24 or by both the fine and imprisonment.

25 (2) Any person specified in subdivision (a) or (d) who has
26 previously been convicted of a violation of paragraph (1) shall,
27 upon a subsequent conviction thereof, be punished by
28 imprisonment in the state prison, or by imprisonment in a county
29 jail not exceeding one year, by a fine not exceeding one hundred
30 thousand dollars (\$100,000), or by both the fine and imprisonment.

31 (g) (1) Except as otherwise provided in subparagraph (A) of
32 paragraph (6) of subdivision (e), it is unlawful for any
33 manufacturer, wholesaler, retailer, or other person to sell, transfer,
34 or otherwise furnish a substance specified in subdivision (a) to a
35 person under 18 years of age.

36 (2) Except as otherwise provided in subparagraph (A) of
37 paragraph (6) of subdivision (e), it is unlawful for any person under
38 18 years of age to possess a substance specified in subdivision (a).

39 (3) Notwithstanding any other law, it is unlawful for any retail
40 distributor to (A) sell in a single transaction more than three

1 packages of a product that he or she knows to contain ephedrine,
2 pseudoephedrine, norpseudoephedrine, or phenylpropanolamine,
3 or (B) knowingly sell more than nine grams of ephedrine,
4 pseudoephedrine, norpseudoephedrine, or phenylpropanolamine,
5 other than pediatric liquids as defined. Except as otherwise
6 provided in this section, the three package per transaction limitation
7 or nine gram per transaction limitation imposed by this paragraph
8 shall apply to any product that is lawfully sold, transferred, or
9 furnished over the counter without a prescription pursuant to the
10 Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et
11 seq.), or regulations adopted thereunder, unless exempted from
12 the requirements of the federal Controlled Substances Act (21
13 U.S.C. Sec. 801 et seq.) by the federal Drug Enforcement
14 Administration pursuant to Section 814 of Title 21 of the United
15 States Code.

16 (4) (A) A first violation of this subdivision is a misdemeanor.

17 (B) Any person who has previously been convicted of a violation
18 of this subdivision shall, upon a subsequent conviction thereof, be
19 punished by imprisonment in a county jail not exceeding one year,
20 by a fine not exceeding ten thousand dollars (\$10,000), or by both
21 the fine and imprisonment.

22 (h) For the purposes of this article, the following terms have
23 the following meanings:

24 (1) "Drug store" is any entity described in Code 5912 of the
25 Standard Industrial Classification (SIC) Manual published by the
26 United States Office of Management and Budget, 1987 edition.

27 (2) "General merchandise store" is any entity described in Codes
28 5311 to 5399, inclusive, and Code 5499 of the Standard Industrial
29 Classification (SIC) Manual published by the United States Office
30 of Management and Budget, 1987 edition.

31 (3) "Grocery store" is any entity described in Code 5411 of the
32 Standard Industrial Classification (SIC) Manual published by the
33 United States Office of Management and Budget, 1987 edition.

34 (4) "Pediatric liquid" means a nonencapsulated liquid whose
35 unit measure according to product labeling is stated in milligrams,
36 ounces, or other similar measure. In no instance shall the dosage
37 units exceed 15 milligrams of phenylpropanolamine or
38 pseudoephedrine per five milliliters of liquid product, except for
39 liquid products primarily intended for administration to children
40 under two years of age for which the recommended dosage unit

1 does not exceed two milliliters and the total package content does
2 not exceed one fluid ounce.

3 (5) “Retail distributor” means a grocery store, general
4 merchandise store, drugstore, or other related entity, the activities
5 of which, as a distributor of ephedrine, pseudoephedrine,
6 norpseudoephedrine, or phenylpropanolamine products, are limited
7 exclusively to the sale of ephedrine, pseudoephedrine,
8 norpseudoephedrine, or phenylpropanolamine products for personal
9 use both in number of sales and volume of sales, either directly to
10 walk-in customers or in face-to-face transactions by direct sales.
11 “Retail distributor” includes an entity that makes a direct sale, but
12 does not include the parent company of that entity if the company
13 is not involved in direct sales regulated by this article.

14 (6) “Sale for personal use” means the sale in a single transaction
15 to an individual customer for a legitimate medical use of a product
16 containing ephedrine, pseudoephedrine, norpseudoephedrine, or
17 phenylpropanolamine in dosages at or below that specified in
18 paragraph (3) of subdivision (g). “Sale for personal use” also
19 includes the sale of those products to employers to be dispensed
20 to employees from first aid kits or medicine chests.

21 (i) It is the intent of the Legislature that this section shall
22 preempt all local ordinances or regulations governing the sale by
23 a retail distributor of over-the-counter products containing
24 ephedrine, pseudoephedrine, norpseudoephedrine, or
25 phenylpropanolamine.

26 (j) This section shall become operative on January 1, 2018.

27 SEC. 3. Section 11100.02 is added to the Health and Safety
28 Code, to read:

29 11100.02. (a) Notwithstanding any other law, it is unlawful
30 for any retail distributor to knowingly do the following, except
31 pursuant to a valid prescription from a licensed practitioner with
32 prescriptive authority:

33 (1) To sell or distribute to the same purchaser within any 30-day
34 period more than nine grams, or within any day more than 3.6
35 grams, of ephedrine base, pseudoephedrine base,
36 norpseudoephedrine base, or phenylpropanolamine base contained
37 in any product that is lawfully sold, transferred, or furnished over
38 the counter without a prescription pursuant to the Federal Food,
39 Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et seq.), or regulations
40 adopted thereunder, unless exempted from the requirements of the

1 federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) by
2 the federal Drug Enforcement Administration pursuant to Section
3 814 of Title 21 of the United States Code.

4 (2) To sell or distribute any ephedrine, pseudoephedrine,
5 norpseudoephedrine, or phenylpropanolamine to a person whose
6 information has generated an alert as described in paragraph (3)
7 of subdivision (d) regarding that sale.

8 (3) To sell or distribute to any purchaser a nonprescription
9 product containing any amount of ephedrine, pseudoephedrine,
10 norpseudoephedrine, or phenylpropanolamine, except under the
11 following conditions:

12 (A) The purchaser shall produce valid government-issued photo
13 identification.

14 (B) The purchaser shall sign a written or electronic log showing
15 the following:

16 (i) The date and time of the transaction.

17 (ii) The identification number presented.

18 (iii) The agency issuing the identification and the type of
19 identification issued.

20 (iv) The name, date of birth, and address of the purchaser.

21 (v) The amount of ephedrine base, pseudoephedrine base,
22 norpseudoephedrine base, or phenylpropanolamine base contained
23 in the material, compound, mixture, or preparation sold.

24 (b) The retail distributor shall store any product containing any
25 amount of ephedrine, pseudoephedrine, norpseudoephedrine, or
26 phenylpropanolamine either behind the counter or in a locked
27 cabinet so that the customer does not have access to the product.

28 (c) (1) To facilitate the monitoring of the sales of
29 nonprescription products containing ephedrine, pseudoephedrine,
30 norpseudoephedrine, or phenylpropanolamine, the retail distributor
31 shall record all of the following information at the point of sale
32 regarding the proposed transaction for the purpose of complying
33 with this section or the federal Combat Methamphetamine
34 Epidemic Act of 2005, or any regulation adopted pursuant to this
35 section or that act, and for no other purpose:

36 (A) The date and time of the transaction.

37 (B) The identification number of the purchaser, issuing agency
38 of the identification, and the type of identification used.

39 (C) The name, date of birth, and address of the purchaser
40 verified through a photo identification of the purchaser.

1 (D) The name, quantity of packages, and total gram weight of
2 ephedrine base, pseudoephedrine base, norpseudoephedrine base,
3 or phenylpropanolamine base contained in a product or products
4 purchased, received, or otherwise acquired.

5 (E) The name or initials of the person making the sale.

6 (2) ~~Beginning January 1, 2013~~ *On and after July 1, 2012*, the
7 retail distributor shall transmit the information immediately to the
8 National Precursor Log Exchange (NPLEx) administered by the
9 National Association of Drug Diversion Investigators (NADDI)
10 for purposes of determining whether the proposed sale would
11 violate this section and therefore may not proceed, provided that
12 the NPLEx system is available to retailers in the state without a
13 charge for accessing the system. The transaction information shall
14 not be accessed, stored, or used by the retail distributor for any
15 purpose other than to meet the requirements set forth in this section
16 or to comply with the provisions of the federal Combat
17 Methamphetamine Epidemic Act of 2005, or any regulation
18 adopted pursuant to this section or that act. The retail distributor
19 shall not maintain a separate copy of the transaction information
20 except as required by the federal Combat Methamphetamine
21 Epidemic Act of 2005.

22 (3) (A) A retail distributor shall provide notice electronically,
23 in writing, or by signage to purchasers that the information
24 collected pursuant to the federal Combat Methamphetamine
25 Epidemic Act of 2005 and this section shall be provided to law
26 enforcement for purposes of determining the legality of a proposed
27 sale.

28 (B) The Legislature finds that it is necessary for probable cause
29 to be demonstrated to trigger an investigation in connection with
30 an individual whose requested purchase is denied by the system a
31 single time.

32 (4) This subdivision shall not be construed to require a retail
33 distributor to maintain state-required records relating to the sale
34 of products containing ephedrine, pseudoephedrine,
35 norpseudoephedrine, or phenylpropanolamine in a separate location
36 or log from records required by federal law to be kept with respect
37 to those products.

38 (5) The recording requirements specified in this subdivision
39 shall not apply to the sale of a single package containing not more

1 than 60 milligrams of pseudoephedrine, consistent with the federal
2 Combat Methamphetamine Epidemic Act of 2005.

3 (6) If a retail distributor experiences mechanical or electronic
4 failure of the system and is unable to comply with the recording
5 requirements of this subdivision, the retail distributor shall maintain
6 the required records in a written log or an alternative electronic
7 recordkeeping mechanism until the retail distributor is able to
8 comply with the recording requirements of this subdivision.

9 (d) (1) Provided that the department executes a memorandum
10 of understanding (MOU) with NADDI governing access, pursuant
11 to this subdivision, NADDI shall forward California transaction
12 records in NPLeX to the Department of Justice weekly and provide
13 real-time access to NPLeX information through the NPLeX online
14 portal to law enforcement in the state as authorized by the
15 department.

16 (2) The system shall allow retail distributors of products
17 containing ephedrine, pseudoephedrine, norpseudoephedrine, or
18 phenylpropanolamine to enter into the database the information
19 specified in subdivision ~~(d)~~ (c) regarding the proposed sale of those
20 products.

21 (3) The system shall be capable of providing the retail distributor
22 with an immediate real-time alert any time any provision of this
23 section is being violated by a proposed sale.

24 (4) The MOU shall state that no party to the MOU nor any entity
25 under contract to provide the electronic authorization and
26 monitoring system shall be authorized to use the information
27 contained in the system for any purpose other than those set forth
28 in this section, the federal Combat Methamphetamine Epidemic
29 Act of 2005, or any regulation adopted pursuant to this section or
30 that act. However, the system operator shall be authorized to
31 analyze the information for the sole purpose of assessing and
32 improving the performance and efficacy of the system. In addition,
33 the MOU shall require that any retail distributor's access to the
34 electronic authorization and monitoring system's database is
35 limited solely to records of sales transactions made by that retail
36 distributor, which access shall be solely for purposes of complying
37 with the federal Combat Methamphetamine Epidemic Act of 2005
38 or this section, or to respond to a duly authorized law enforcement
39 request or court order for information collected under that act or
40 this section.

(5) The system's security program shall comply with the security standards for the Criminal Justice Information System of the Federal Bureau of Investigation and may be audited once a year by the department.

(6) A retail distributor's use of the system shall be subject to Section ~~56.10~~ 56.101 of the Civil Code. A retail distributor shall not maintain any records collected under this system for longer than two years, or as otherwise required by the federal Combat Methamphetamine Epidemic Act of 2005.

(7) Law enforcement access to the system shall be recorded by means of a unique access code for each individual accessing the system. Each user's history shall be maintained and may be audited by the department.

(8) The department may submit recommendations to NADDI regarding system changes to assist in identifying false identification cards.

(e) The State Board of Equalization shall notify all retailers about the requirement to submit transactions to NPLeX no later than ~~September~~ April 1, 2012.

(f) This section shall not apply to a health care practitioner with prescriptive authority who is currently licensed in this state.

(g) (1) A first violation of this section is a misdemeanor.

(2) Any person who has previously been convicted of a violation of this section shall, upon a subsequent conviction thereof, be punished by imprisonment in a county jail not exceeding one year, by a fine not exceeding ten thousand dollars (\$10,000), or by both the fine and imprisonment.

(h) For the purposes of this section, the following terms have the following meanings:

(1) "Department" means the Department of Justice.

(2) "Drug store" is any entity described in Code 5912 of the Standard Industrial Classification (SIC) Manual published by the United States Office of Management and Budget, 1987 edition.

(3) "General merchandise store" is any entity described in Codes 5311 to 5399, inclusive, and Code 5499 of the Standard Industrial Classification (SIC) Manual published by the United States Office of Management and Budget, 1987 edition.

(4) "Grocery store" is any entity described in Code 5411 of the Standard Industrial Classification (SIC) Manual published by the United States Office of Management and Budget, 1987 edition.

(5) “Retail distributor” means a grocery store, general merchandise store, drugstore, or other related entity, the activities of which, as a distributor of ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine products, are limited exclusively to the sale of ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine products for personal use both in number of sales and volume of sales, either directly to walk-in customers or in face-to-face transactions by direct sales. “Retail distributor” includes an entity that makes a direct sale, but does not include the parent company of that entity if the company is not involved in direct sales regulated by this article.

(6) “Sale for personal use” means the sale in a single transaction to an individual customer for a legitimate medical use of a product containing ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine in amounts at or below that specified in subdivision (a). “Sale for personal use” also includes the sale of those products to employers to be dispensed to employees from first aid kits or medicine chests.

(i) It is the intent of the Legislature that this section shall preempt all local ordinances or regulations governing the sale by a retail distributor of over-the-counter products containing ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine.

(j) This section shall remain in effect only until January 1, 2018, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2018, deletes or extends that date.

SEC. 4. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: AB 1280

VERSION: As Amended May 26, 2011

AUTHOR: Hill

SPONSOR: Author

BOARD POSITION: Watch

SUBJECT: Ephedrine: Retail Sale

AFFECTED SECTIONS: An act to amend, repeal, and add Section 11100 of, and to add and repeal Section 11100.02 of, the Health and Safety Code

CURRENT STATUS: Assembly Public Safety Hearing scheduled for May 3, 2011.

EXISTING LAW:

Health and Safety Code section 11100:

1. Requires any manufacturer, wholesaler, retailer or other person or entity in this state that sells, transfers or otherwise furnishes specified substances, to report to the Department of Justice (DOJ). These substances are controlled substances and/or chemical precursors for manufacture of illicit drugs.
2. Specifies that such entities, prior to selling, transferring or otherwise furnishing any specified substance shall require a letter of authorization that includes the current valid business license or DEA registration, and the address of the business and proper identification of the purchaser. Information collected must also include how the substance is to be used, and specifies that this information shall be maintained for three years.
3. Defines proper identification to include two of the following:
 - a. Federal tax identification number
 - b. Seller's permit identification number
 - c. City or county business license number
 - d. State Department of Public Health License
 - e. Registration issued by federal Drug Enforcement Administration
 - f. Precursor business permit number issued by the Bureau of Narcotic Enforcement
 - g. Driver's license
 - h. Other identification issued by a state.
4. Requires any entity that exports a substance, as provided in this section, to any person or business located in a foreign country to notify the DOJ of the transaction and specifies that the notification shall include the name and quantity of the substance, the name, address and business identification number (if assigned by the foreign country).
5. Specifies that the DOJ may require such reports on a monthly basis.
6. Requires reporting not less than 21 days in advance of a transaction to any entity in the US or on a monthly basis as determined by the DOJ.
7. Requires the seller to affix his or her signature or provide other identification to the purchaser and specifies requirement for the use of a common carrier.

8. Specifies exemptions to these provisions for the following:
 - a. Pharmacist or other authorized person who sells or furnishes a substance pursuant to a prescription.
 - b. Any physician, dentist, podiatrist or veterinarian who administers or furnishes a substance to his or her patients.
 - c. Manufacturers and board licensed wholesalers from these provisions as specified, but requires records of suspicious sales and transfers as determined by the DOJ.
 - d. Any analytical research facility that is registered with the federal DEA.
 - e. A state-licensed health care facility that administers or furnishes a substance to its patients.
 - f. Specified products that are sold over the counter without a prescription, unless the individual transaction involves more than three packages or nine grams of the substance.
 - g. Any transfer or a substance for lawful disposal as waste.
9. Creates penalties for non-compliance, including jail time and fines as specified.
10. Specifies the conditions under which it is unlawful to sell, transfer or otherwise furnish a substance to a person under 18 years of age.
11. Provides that it is unlawful for a retailer to sell more than three packages of ephedrine containing products in a single transaction or sell more than nine grams of ephedrine containing products as specified.
12. Defines several terms for purposes of this article.
13. Specifies that these provisions preempt all local ordinances or regulations governing the sale of specified products.

THIS BILL WOULD:

Until January 1, 2018 amend Section 11100 of the Health and Safety Code to move some provisions into Section 11100.02.

Until January 1, 2018 add Section 11100.02 of the Health and Safety Code:

1. Specify it is unlawful for a retailers to:
 - a. Sell to the same purchaser within 30-days, more than nine grams or within any day more than 3.6 grams of ephedrine containing products
 - b. Sell ephedrine containing products to a person whose information has generated an alert, as specified
 - c. Sell ephedrine containing products without collecting proper identification as specified
2. Require a retail distributor to store ephedrine containing products behind the counter or in a locked cabinet.
3. Establish recordkeeping elements including:
 - a. Date and time of transaction
 - b. Purchaser identification information - name, date of birth and address
 - c. Name, quantity of packages and total gram weight of ephedrine containing products
 - d. Initial of person making the sale
4. Beginning on or after July 1, 2010, require the retailer to immediately transmit the information required above to the National Precursor Log Exchange (NPLEx) to determine if the proposed sale would violate the transaction limits for ephedrine containing products.
Further it would:

- a. Prohibit the retailer from using this information for any other purpose
 - b. Require the retailer to post a notice regarding the collection of this information
 - c. Specify that a separate record of this information shall not also be required to maintain state-required records in a separate location
 - d. Exempt from this requirement the sale of a single package containing not more than 60 milligrams of an ephedrine product
 - e. Establish system requirements and implementation options.
5. Require the State Board of Equalization to notify retailers of this requirement
 6. Exempt CA licensed health care practitioners with prescriptive authority.
 7. Define various terms for purposes of this section.

Effective January 1, 2018

1. Restore Section 11100 to its current form.
2. Repeal Section 11100.02.

FISCAL IMPACT:

Enforcement of these provisions would reside primarily with the Department of Justice. The board does not anticipate any significant fiscal impact. Any minor impact could be absorbed within existing resources.

COMMENTS:

The federal government passed The Combat Methamphetamine Act of 2005 to establish restrictions on the sale of over-the-counter (nonprescription) products containing ephedrine (EPH), pseudoephedrine (PSE), or phenylpropanolamine (PPA) - classified under the federal Controlled Substances Act as "scheduled listed chemical products." The act changed the limit amount of product that could be sold by a retailer to an individual and the amount that can be purchased by an individual. The requirements of this Act include blister packaging for nonliquid dosages, buyer's proof of identification, recordkeeping by the seller, and penalties for violators of the new restrictions.

Arguments in support of this measure indicate that the proposed solution leverages and existing database (NPLeX) that is used by 13 other states is funded by manufacturers. Arguments in opposition to this proposed solution include privacy concerns about patient information and who would have access to the information as well as if a California specific database, similar to CURES would be a viable option.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board discussed the provisions of this measure and established a "Watch" position on the measure. Since that time the bill has been amended twice, updating a reference to the Civil Code and to change in effective date for the reporting requirement from "January 1, 2013" to "on or after July 1, 2012."

PREVIOUS/RELATED LEGISLATION:

Previous

AB 1455 (Hill, 2009) contained similar provisions but stalled in policy committee. The board did not have a position on this measure.

Related

SB 315 (Wright, 2011) contains provisions that are also intended to reduce the sales of ephedrine products, however it takes a much different approach. Generally, SB 315 would prohibit the sale of ephedrine product to an individual except pursuant to a prescription. SB 315 is a two-year bill.

SUPPORT/OPPOSITION:

Support

Alameda County Sheriff's Office	Marin Medical Society
Alliance for Patient Access, California Chapter	Napa County Medical Society
Alameda Health Consortium	National Association of Chain Drug Stores
Bayer Health Care	National Federation of Independent Business
BIOCOM	Orange County Business Council
Calaveras County Sheriffs' Department	Orange County Sheriff-Coroner Department
California Alliance for Retired Americans	Peace Officers Research Association of California
California Black Health Network	Pfizer, Inc.
California Chamber of Commerce	Reckitt Benckiser
California District Attorneys Association	Rite Aid
California Healthcare Institute	Sacramento County Sheriff's Department
California Hispanic Chamber of Commerce	San Francisco Chamber of Commerce
California Manufacturers and Technology Association	San Joaquin County Sheriff
California Medical Association	Sanofi-Aventis
California Pharmacists Association	Santa Clara County Medical Association
California Primary Care Association	Santa Cruz County Sheriff-Coroner
California Retailers Association	Shasta County Sheriff
California State Sheriffs' Association	Siskiyou County Sheriff's Department
Community Clinic Association of LA County	Solano County Medical Society
Consumer Healthcare Products Association	Sonoma County Medical Association
Johnson and Johnson	Valley Industry & Commerce Association (VICA)
Healthy African American Families II	Walgreens
Kern County Sheriff	Yolo County Sheriff's Department
Lassen County Sheriff's Office	
Los Angeles County Medical Association	
Los Angeles Society of Allergy, Asthma & Clinical Immunology, Inc.	

Opposition

American Civil Liberties Union
California Department of Justice
California Narcotics Officers' Association
California Public Defenders Association
Electronic Frontier Foundation
Los Angeles County District Attorney
National Narcotics Officers Association Coalition
Privacy Rights Clearinghouse

HISTORY:**Date Action**

July 6 From committee: Do pass and re-refer to Com. on APPR. (Ayes 4. Noes 1.) (July 5). Re-referred to Com. on APPR.
June 21 From committee: Do pass and re-refer to Com. on JUD. (Ayes 6. Noes 0.) (June 21). Re-referred to Com. on JUD.
June 8 Referred to Coms. on PUB. S. and JUD.
May 31 In Senate. Read first time. To Com. on RLS. for assignment.
May 31 Read third time. Passed. Ordered to the Senate. (Ayes 79. Noes 0. Page 1636.)
May 26 Read third time and amended. Ordered to third reading. (Page 1558.)
May 19 Read second time. Ordered to third reading.
May 18 From committee: Do pass. (Ayes 16. Noes 0.) (May 18).
May 12 Re-referred to Com. on APPR.
May 11 Read second time and amended.
May 10 From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (May 3).
Mar. 29 Re-referred to Com. on PUB. S.
Mar. 25 Referred to Com. on PUB. S. From committee chair, with author's amendments: Amend, and re-refer to Com. on PUB. S. Read second time and amended.
Feb. 20 From printer. May be heard in committee March 22.
Feb. 18 Read first time. To print.

AMENDED IN ASSEMBLY JULY 7, 2011

AMENDED IN SENATE MAY 10, 2011

AMENDED IN SENATE APRIL 14, 2011

AMENDED IN SENATE MARCH 22, 2011

SENATE BILL

No. 360

Introduced by Senator DeSaulnier

February 15, 2011

An act to amend Sections 11161.5, 11162.1, 11165, *and* 11165.1, ~~and 11212~~ of, and to add Sections 11165.2 and 11165.3 to, the Health and Safety Code, relating to controlled substances.

LEGISLATIVE COUNSEL'S DIGEST

SB 360, as amended, DeSaulnier. Controlled Substance Utilization Review and Evaluation System.

Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice, contingent upon the availability of adequate funds from various funds related to health care, as specified, to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe or dispense these controlled substances.

Existing law defines a security printer as a person approved to produce controlled substance prescription forms. Existing law requires that prescription forms for controlled substance prescriptions be obtained from security printers approved by the Department of Justice. These provisions authorize the department to approve a security printer who provides specified information to the department, including the location,

names, and titles of the applicant's agent for service of process, all principal corporate officers, if any, and all managing general partners, if any. Existing law also requires those persons to provide a signed statement indicating whether they have ever been convicted of, or pled no contest to, a violation of any law or ordinance. Existing law authorizes the department to revoke its approval of a security printer for a violation of these provisions or action that would permit a denial.

This bill would expand those requirements imposed on an applicant for approval as a security printer to additionally require the applicant to provide the location, names, and titles of any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms and require those persons to submit the signed statement described above. The bill would also make conforming and related changes. In addition, the bill would require that controlled substance prescription forms provided in person be restricted to established customers. The bill would require security printers to obtain photo identification from the customer and maintain a log of the information, and to report any theft or loss of controlled substance prescription forms to the department via fax or e-mail within 24 hours of the incident. The bill would also require that controlled substance prescription forms be shipped only to the prescriber's address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California. The bill would specify penalties for certain violations, including, among others, failure to comply with security printer guidelines, failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms, and theft or fraudulent use of a prescriber's identity in order to obtain security prescription forms. By creating new crimes, this bill would impose a state-mandated local program.

Existing law governs the prescription forms for controlled substances. Among other things, the forms are required to include the preprinted name, category of licensure, license number, and federal controlled substance registration number of the prescribing practitioner.

This bill would also require the forms to include the address of the prescribing practitioner. The bill would make an additional change relating to forms ordered for use by prescribers when treating patients in licensed health care facilities or certain clinics that are exempt from other requirements governing these forms. The bill would provide that

prescription forms that are not in compliance with these provisions shall not be accepted after July 1, 2012.

The bill would establish a specified process by which a licensed health care practitioner or a pharmacist may obtain approval to access information stored on the Internet regarding the controlled substance history of a patient, as specified.

The bill would require that the theft or loss of prescription forms be reported immediately to the department, as specified. The bill would also require the department to conduct audits of the CURES prescription drug monitoring system and authorize the department to establish a system for issuing citations, and for assessing and imposing administrative fines, not to exceed \$2,500 for each violation, that would be deposited in the CURES Program Special Fund, for violations of the program, as specified.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.

State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 11161.5 of the Health and Safety Code
2 is amended to read:
3 11161.5. (a) Prescription forms for controlled substance
4 prescriptions shall be obtained from security printers approved by
5 the Department of Justice.
6 (b) The department may approve security printer applications
7 after the applicant has provided the following information:
8 (1) Name, address, and telephone number of the applicant.
9 (2) Policies and procedures of the applicant for verifying the
10 identity of the prescriber ordering controlled substance prescription
11 forms.
12 (3) Policies and procedures of the applicant for verifying
13 delivery of controlled substance prescription forms to prescribers.
14 (4) (A) The location, names, and titles of the applicant's agent
15 for service of process in this state; all principal corporate officers,
16 if any; all managing general partners, if any; and any individual

1 owner, partner, corporate officer, manager, agent, representative,
2 employee, or subcontractor of the applicant who has direct access
3 to, or management or control of, controlled substance prescription
4 forms.

5 (B) A report containing this information shall be made on an
6 annual basis and within 30 days after any change of office,
7 principal corporate officers, managing general partner, or of any
8 person described in subparagraph (A).

9 (5) (A) A signed statement indicating whether the applicant,
10 any principal corporate officer, any managing general partner, or
11 any individual owner, partner, corporate officer, manager, agent,
12 representative, employee, or subcontractor of the applicant who
13 has direct access to, or management or control of, controlled
14 substance prescription forms, has ever been convicted of, or pled
15 no contest to, a violation of any law of a foreign country, the United
16 States, or any state, or of any local ordinance.

17 (B) The department shall provide the applicant and any
18 individual owner, partner, corporate officer, manager, agent,
19 representative, employee, or subcontractor of the applicant who
20 has direct access to, or management or control of, controlled
21 substance prescription forms, with the means and direction to
22 provide fingerprints and related information, in a manner specified
23 by the department, for the purpose of completing state, federal, or
24 foreign criminal background checks.

25 (C) Any applicant described in subdivision (b) shall submit his
26 or her fingerprint images and related information to the department,
27 for the purpose of the department obtaining information as to the
28 existence and nature of a record of state, federal, or foreign level
29 convictions and state, federal, or foreign level arrests for which
30 the department establishes that the applicant was released on bail
31 or on his or her own recognizance pending trial, as described in
32 subdivision (l) of Section 11105 of the Penal Code. Requests for
33 federal level criminal offender record information received by the
34 department pursuant to this section shall be forwarded to the
35 Federal Bureau of Investigation by the department.

36 (D) The department shall assess against each security printer
37 applicant a fee determined by the department to be sufficient to
38 cover all processing, maintenance, and investigative costs generated
39 from or associated with completing state, federal, or foreign
40 background checks and inspections of security printers pursuant

1 to this section with respect to that applicant; the fee shall be paid
2 by the applicant at the time he or she submits the security printer
3 application, fingerprints, and related information to the department.

4 (E) The department shall retain fingerprint impressions and
5 related information for subsequent arrest notification pursuant to
6 Section 11105.2 of the Penal Code for all applicants.

7 (c) The department may, within 60 calendar days of receipt of
8 the application from the applicant, deny the security printer
9 application.

10 (d) The department may deny a security printer application on
11 any of the following grounds:

12 (1) The applicant, any individual owner, partner, corporate
13 officer, manager, agent, representative, employee, or subcontractor
14 for the applicant, who has direct access, management, or control
15 of controlled substance prescription forms, has been convicted of
16 a crime. A conviction within the meaning of this paragraph means
17 a plea or verdict of guilty or a conviction following a plea of nolo
18 contendere. Any action which a board is permitted to take
19 following the establishment of a conviction may be taken when
20 the time for appeal has elapsed, the judgment of conviction has
21 been affirmed on appeal, or when an order granting probation is
22 made suspending the imposition of sentence, irrespective of a
23 subsequent order under the provisions of Section 1203.4 of the
24 Penal Code.

25 (2) The applicant committed any act involving dishonesty, fraud,
26 or deceit with the intent to substantially benefit himself, herself,
27 or another, or substantially injure another.

28 (3) The applicant committed any act that would constitute a
29 violation of this division.

30 (4) The applicant knowingly made a false statement of fact
31 required to be revealed in the application to produce controlled
32 substance prescription forms.

33 (5) The department determines that the applicant failed to
34 demonstrate adequate security procedures relating to the production
35 and distribution of controlled substance prescription forms.

36 (6) The department determines that the applicant has submitted
37 an incomplete application.

38 (7) As a condition for its approval as a security printer, an
39 applicant shall authorize the Department of Justice to make any
40 examination of the books and records of the applicant, or to visit

1 and inspect the applicant during business hours, to the extent
2 deemed necessary by the board or department to properly enforce
3 this section.

4 (e) An approved applicant shall submit an exemplar of a
5 controlled substance prescription form, with all security features,
6 to the Department of Justice within 30 days of initial production.

7 (f) The department shall maintain a list of approved security
8 printers and the department shall make this information available
9 to prescribers and other appropriate government agencies, including
10 the Board of Pharmacy.

11 (g) Before printing any controlled substance prescription forms,
12 a security printer shall verify with the appropriate licensing board
13 that the prescriber possesses a license and current prescribing
14 privileges which permits the prescribing of controlled substances
15 with the federal Drug Enforcement Administration (DEA).

16 (h) Controlled substance prescription forms shall be provided
17 directly to the prescriber either in person, by certified mail, or by
18 a means that requires a signature signifying receipt of the package
19 and provision of that signature to the security printer. Controlled
20 substance prescription forms provided in person shall be restricted
21 to established customers. Security printers shall obtain a photo
22 identification from the customer and maintain a log of this
23 information. Controlled substance prescription forms shall be
24 shipped only to the prescriber's address on file and verified with
25 the federal Drug Enforcement Administration or the Medical Board
26 of California.

27 (i) Security printers shall retain ordering and delivery records
28 in a readily retrievable manner for individual prescribers for three
29 years.

30 (j) Security printers shall produce ordering and delivery records
31 upon request by an authorized officer of the law as defined in
32 Section 4017 of the Business and Professions Code.

33 (k) Security printers shall report any theft or loss of controlled
34 substance prescription forms to the Department of Justice via fax
35 or e-mail within 24 hours of the theft or loss.

36 (l) (1) The department shall impose restrictions, sanctions, or
37 penalties, subject to subdivisions (m) and (n), against security
38 printers who are not in compliance with this division pursuant to
39 regulations implemented pursuant to this division and shall revoke
40 its approval of a security printer for a violation of this division or

1 action that would permit a denial pursuant to subdivision (d) of
2 this section.

3 (2) When the department revokes its approval, it shall notify
4 the appropriate licensing boards and remove the security printer
5 from the list of approved security printers.

6 (m) The following violations by security printers shall be
7 punishable pursuant to subdivision (n):

8 (1) Failure to comply with the Security Printer Guidelines
9 established by the Security Printer Program as a condition of
10 approval.

11 (2) Failure to take reasonable precautions to prevent any
12 dishonest act or illegal activity related to the access and control of
13 security prescription forms.

14 (3) Theft or fraudulent use of a prescriber's identity in order to
15 obtain security prescription forms.

16 (n) A security printer approved pursuant to subdivision (b) shall
17 be subject to the following penalties for actions leading to the
18 denial of a security printer application specified in subdivision (d)
19 or for a violation specified in subdivision (m):

20 (1) For a first violation, a fine not to exceed one thousand dollars
21 (\$1,000).

22 (2) For a second or subsequent violation, a fine not to exceed
23 two thousand five hundred dollars (\$2,500) for each violation.

24 (3) For a third or subsequent violation, a filing of an
25 administrative disciplinary action seeking to suspend or revoke
26 security printer approval.

27 SEC. 2. Section 11162.1 of the Health and Safety Code is
28 amended to read:

29 11162.1. (a) The prescription forms for controlled substances
30 shall be printed with the following features:

31 (1) A latent, repetitive "void" pattern shall be printed across the
32 entire front of the prescription blank; if a prescription is scanned
33 or photocopied, the word "void" shall appear in a pattern across
34 the entire front of the prescription.

35 (2) A watermark shall be printed on the backside of the
36 prescription blank; the watermark shall consist of the words
37 "California Security Prescription."

38 (3) A chemical void protection that prevents alteration by
39 chemical washing.

40 (4) A feature printed in thermochromic ink.

1 (5) An area of opaque writing so that the writing disappears if
2 the prescription is lightened.

3 (6) A description of the security features included on each
4 prescription form.

5 (7) (A) Six quantity check off boxes shall be printed on the
6 form so that the prescriber may indicate the quantity by checking
7 the applicable box where the following quantities shall appear:

8 1–24

9 25–49

10 50–74

11 75–100

12 101–150

13 151 and over.

14 (B) In conjunction with the quantity boxes, a space shall be
15 provided to designate the units referenced in the quantity boxes
16 when the drug is not in tablet or capsule form.

17 (8) Prescription blanks shall contain a statement printed on the
18 bottom of the prescription blank that the “Prescription is void if
19 the number of drugs prescribed is not noted.”

20 (9) The preprinted name, category of licensure, license number,
21 federal controlled substance registration number, and address of
22 the prescribing practitioner.

23 (10) Check boxes shall be printed on the form so that the
24 prescriber may indicate the number of refills ordered.

25 (11) The date of origin of the prescription.

26 (12) A check box indicating the prescriber’s order not to
27 substitute.

28 (13) An identifying number assigned to the approved security
29 printer by the Department of Justice.

30 (14) (A) A check box by the name of each prescriber when a
31 prescription form lists multiple prescribers.

32 (B) Each prescriber who signs the prescription form shall
33 identify himself or herself as the prescriber by checking the box
34 by his or her name.

35 (b) Each batch of controlled substance prescription forms shall
36 have the lot number printed on the form and each form within that
37 batch shall be numbered sequentially beginning with the numeral
38 one.

39 (c) (1) A prescriber designated by a licensed health care facility,
40 a clinic specified in Section 1200, or a clinic specified in

1 subdivision (a) of Section 1206 that has 25 or more physicians or
2 surgeons may order controlled substance prescription forms for
3 use by prescribers when treating patients in that facility without
4 the information required in paragraph (9) of subdivision (a) or
5 paragraph (3) of this subdivision.

6 (2) Forms ordered pursuant to this subdivision shall have the
7 name, category of licensure, license number, and federal controlled
8 substance registration number of the designated prescriber and the
9 name, address, category of licensure, and license number of the
10 licensed health care facility the clinic specified in Section 1200,
11 or the clinic specified in Section 1206 that has 25 or more
12 physicians or surgeons preprinted on the form. Licensed health
13 care facilities or clinics exempt under Section 1206 are not required
14 to preprint the category of licensure and license number of their
15 facility or clinic.

16 (3) Forms ordered pursuant to this section shall not be valid
17 prescriptions without the name, category of licensure, license
18 number, and federal controlled substance registration number of
19 the prescriber on the form.

20 (4) (A) Except as provided in subparagraph (B), the designated
21 prescriber shall maintain a record of the prescribers to whom the
22 controlled substance prescription forms are issued, that shall
23 include the name, category of licensure, license number, federal
24 controlled substance registration number, and quantity of controlled
25 substance prescription forms issued to each prescriber. The record
26 shall be maintained in the health facility for three years.

27 (B) Forms ordered pursuant to this subdivision that are printed
28 by a computerized prescription generation system shall not be
29 subject to subparagraph (A) or paragraph (7) of subdivision (a).
30 Forms printed pursuant to this subdivision that are printed by a
31 computerized prescription generation system may contain the
32 prescriber's name, category of professional licensure, license
33 number, federal controlled substance registration number, and the
34 date of the prescription.

35 (d) This section shall become operative on January 1, 2012.
36 Prescription forms not in compliance with this division shall not
37 be valid or accepted after July 1, 2012.

38 SEC. 3. Section 11165 of the Health and Safety Code is
39 amended to read:

1 11165. (a) To assist law enforcement and regulatory agencies
2 in their efforts to control the diversion and resultant abuse of
3 Schedule II, Schedule III, and Schedule IV controlled substances,
4 and for statistical analysis, education, and research, the Department
5 of Justice shall, contingent upon the availability of adequate funds
6 from the Contingent Fund of the Medical Board of California, the
7 Pharmacy Board Contingent Fund, the State Dentistry Fund, the
8 Board of Registered Nursing Fund, and the Osteopathic Medical
9 Board of California Contingent Fund, maintain the Controlled
10 Substance Utilization Review and Evaluation System (CURES)
11 for the electronic monitoring of, and Internet access to information
12 regarding, the prescribing and dispensing of Schedule II, Schedule
13 III, and Schedule IV controlled substances by all practitioners
14 authorized to prescribe or dispense these controlled substances.

15 (b) The reporting of Schedule III and Schedule IV controlled
16 substance prescriptions to CURES shall be contingent upon the
17 availability of adequate funds from the Department of Justice. The
18 department may seek and use grant funds to pay the costs incurred
19 from the reporting of controlled substance prescriptions to CURES.
20 Funds shall not be appropriated from the Contingent Fund of the
21 Medical Board of California, the Pharmacy Board Contingent
22 Fund, the State Dentistry Fund, the Board of Registered Nursing
23 Fund, the Naturopathic Doctor's Fund, or the Osteopathic Medical
24 Board of California Contingent Fund to pay the costs of reporting
25 Schedule III and Schedule IV controlled substance prescriptions
26 to CURES.

27 (c) CURES shall operate under existing provisions of law to
28 safeguard the privacy and confidentiality of patients. Data obtained
29 from CURES shall only be provided to appropriate state, local,
30 and federal persons or public agencies for disciplinary, civil, or
31 criminal purposes and to other agencies or entities, as determined
32 by the Department of Justice, for the purpose of educating
33 practitioners and others in lieu of disciplinary, civil, or criminal
34 actions. Data may be provided to public or private entities, as
35 approved by the Department of Justice, for educational, peer
36 review, statistical, or research purposes, provided that patient
37 information, including any information that may identify the
38 patient, is not compromised. Further, data disclosed to any
39 individual or agency as described in this subdivision shall not be
40 disclosed, sold, or transferred to any third party.

(d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy or clinic shall provide the following information to the Department of Justice on a weekly basis and in a format specified by the Department of Justice:

(1) Full name, address, and the telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.

(2) The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.

(3) Pharmacy prescription number, license number, and federal controlled substance registration number.

(4) NDC (National Drug Code) number of the controlled substance dispensed.

(5) Quantity of the controlled substance dispensed.

(6) ICD-9 (diagnosis code), if available.

(7) Number of refills ordered.

(8) Whether the drug was dispensed as a refill of a prescription or as a first-time request.

(9) Date of origin of the prescription.

(10) Date of dispensing of the prescription.

(e) This section shall become operative on January 1, 2005.

SEC. 4. Section 11165.1 of the Health and Safety Code is amended to read:

11165.1. (a) (1) A licensed health care practitioner eligible to prescribe Schedule II, Schedule III, or Schedule IV controlled substances or a pharmacist may provide a notarized application developed by the Department of Justice to obtain approval to access information stored on the Internet regarding the controlled substance history of a patient maintained within the Department of Justice, and the department may release to that practitioner or pharmacist, the electronic history of controlled substances dispensed to an individual under his or her care based on data

1 contained in the CURES Prescription Drug Monitoring Program
2 (PDMP).

3 (A) An application may be denied, or a subscriber may be
4 suspended, for reasons which include, but are not limited to, the
5 following:

6 (i) Materially falsifying an application for a subscriber.

7 (ii) Failure to maintain effective controls for access to the patient
8 activity report.

9 (iii) Suspended or revoked federal Drug Enforcement
10 Administration (DEA) registration.

11 (iv) Any subscriber who is arrested for a violation of law
12 governing controlled substances or any other law for which the
13 possession or use of a controlled substance is an element of the
14 crime.

15 (v) Any subscriber accessing information for any other reason
16 than caring for his or her patients.

17 (B) Any authorized subscriber shall notify the Department of
18 Justice within 10 days of any changes to the subscriber account.

19 (2) To allow sufficient time for licensed health care practitioners
20 eligible to prescribe Schedule II, Schedule III, or Schedule IV
21 controlled substances and a pharmacist to apply and receive access
22 to PDMP, a written request may be made, until July 1, 2012, and
23 the Department of Justice may release to that practitioner or
24 pharmacist the history of controlled substances dispensed to an
25 individual under his or her care based on data contained in CURES.

26 (b) Any request for, or release of, a controlled substance history
27 pursuant to this section shall be made in accordance with guidelines
28 developed by the Department of Justice.

29 (c) In order to prevent the inappropriate, improper, or illegal
30 use of Schedule II, Schedule III, or Schedule IV controlled
31 substances, the Department of Justice may initiate the referral of
32 the history of controlled substances dispensed to an individual
33 based on data contained in CURES to licensed health care
34 practitioners, pharmacists, or both, providing care or services to
35 the individual.

36 (d) The history of controlled substances dispensed to an
37 individual based on data contained in CURES that is received by
38 a practitioner or pharmacist from the Department of Justice
39 pursuant to this section shall be considered medical information
40 subject to the provisions of the Confidentiality of Medical

1 Information Act contained in Part 2.6 (commencing with Section
2 56) of Division 1 of the Civil Code.

3 (e) Information concerning a patient's controlled substance
4 history provided to a prescriber or pharmacist pursuant to this
5 section shall include prescriptions for controlled substances listed
6 in Sections 1308.12, 1308.13, and 1308.14 of Title 21 of the Code
7 of Federal Regulations.

8 SEC. 5. Section 11165.2 is added to the Health and Safety
9 Code, to read:

10 11165.2. (a) The Department of Justice may conduct audits
11 of the CURES Prescription Drug Monitoring Program system and
12 its users.

13 (b) The Department of Justice may establish, by regulation, a
14 system for the issuance to a CURES Prescription Drug Monitoring
15 Program subscriber of a citation which may contain an order of
16 abatement, or an order to pay an administrative fine assessed by
17 the Department of Justice if the subscriber is in violation of any
18 provision of this chapter or any regulation adopted by the
19 Department of Justice pursuant to this chapter.

20 (c) The system shall contain the following provisions:

21 (1) Citations shall be in writing and shall describe with
22 particularity the nature of the violation, including specific reference
23 to the provision of law or regulation of the department determined
24 to have been violated.

25 (2) Whenever appropriate, the citation shall contain an order of
26 abatement establishing a reasonable time for abatement of the
27 violation.

28 (3) In no event shall the administrative fine assessed by the
29 department exceed two thousand five hundred dollars (\$2,500) for
30 each violation. In assessing a fine, due consideration shall be given
31 to the appropriateness of the amount of the fine with respect to
32 such factors as the gravity of the violation, the good faith of the
33 subscribers, and the history of previous violations.

34 (4) An order of abatement or a fine assessment issued pursuant
35 to a citation shall inform the subscriber that if the subscriber desires
36 a hearing to contest the finding of a violation, a hearing shall be
37 requested by written notice to the CURES Prescription Drug
38 Monitoring Program within 30 days of the date of issuance of the
39 citation or assessment. Hearings shall be held pursuant to Chapter

1 5 (commencing with Section 11500) of Part 1 of Division 3 of
2 Title 2 of the Government Code.

3 (5) In addition to requesting a hearing, the subscriber may,
4 within 10 days after service of the citation, request in writing an
5 opportunity for an informal conference with the department
6 regarding the citation. At the conclusion of the informal conference,
7 the department may affirm, modify, or dismiss the citation,
8 including any fine levied or order of abatement issued. The decision
9 shall be deemed to be a final order with regard to the citation
10 issued, including the fine levied or the order of abatement which
11 could include permanent suspension to the system, a monetary
12 fine, or both, depending on the gravity of the violation. However,
13 the subscriber does not waive its right to request a hearing to
14 contest a citation by requesting an informal conference. If the
15 citation is affirmed, a formal hearing may be requested within 30
16 days of the date the citation was affirmed. If the citation is
17 dismissed after the informal conference, the request for a hearing
18 on the matter of the citation shall be deemed to be withdrawn. If
19 the citation, including any fine levied or order of abatement, is
20 modified, the citation originally issued shall be considered
21 withdrawn and a new citation issued. If a hearing is requested for
22 a subsequent citation, it shall be requested within 30 days of service
23 of that subsequent citation.

24 (6) Failure of a subscriber to pay a fine within 30 days of the
25 date of assessment or comply with an order of abatement within
26 the fixed time, unless the citation is being appealed, may result in
27 disciplinary action taken by the department. If a citation is not
28 contested and a fine is not paid, the subscriber account will be
29 terminated:

30 (A) A citation may be issued without the assessment of an
31 administrative fine.

32 (B) Assessment of administrative fines may be limited to only
33 particular violations of law or department regulations.

34 (d) Notwithstanding any other provision of law, if a fine is paid
35 to satisfy an assessment based on the finding of a violation,
36 payment of the fine shall be represented as a satisfactory resolution
37 of the matter for purposes of public disclosure.

38 (e) Administrative fines collected pursuant to this section shall
39 be deposited in the CURES Program Special Fund, available upon
40 appropriation by the Legislature. These special funds shall provide

1 support for costs associated with informal and formal hearings,
2 maintenance, and updates to the CURES Prescription Drug
3 Monitoring Program.

4 (f) The sanctions authorized under this section shall be separate
5 from, and in addition to, any other administrative, civil, or criminal
6 remedies; however, a criminal action may not be initiated for a
7 specific offense if a citation has been issued pursuant to this section
8 for that offense, and a citation may not be issued pursuant to this
9 section for a specific offense if a criminal action for that offense
10 has been filed.

11 (g) Nothing in this section shall be deemed to prevent the
12 department from serving and prosecuting an accusation to suspend
13 or revoke a subscriber if grounds for that suspension or revocation
14 exist.

15 SEC. 6. Section 11165.3 is added to the Health and Safety
16 Code, to read:

17 11165.3. The theft or loss of prescription forms shall be
18 reported immediately *by the security printer or affected prescriber*
19 to the CURES Prescription Drug Monitoring Program, but no later
20 than three days after the discovery of the theft or loss. This
21 notification may be done in writing utilizing the Bureau of Narcotic
22 Enforcement 1175 Reporting Theft/Loss Form or may be reported
23 by the authorized subscriber through the CURES Prescription Drug
24 Monitoring Program.

25 ~~SEC. 7. Section 11212 of the Health and Safety Code is~~
26 ~~amended to read:~~

27 ~~11212. (a) Persons who, under applicable federal laws or~~
28 ~~regulations, are lawfully entitled to use controlled substances for~~
29 ~~the purpose of research, instruction, or analysis, may lawfully~~
30 ~~obtain and use for such purposes those substances classified in~~
31 ~~paragraphs (81) and (82) of subdivision (b) of Section 11054 of~~
32 ~~the Health and Safety Code, upon registration with and approval~~
33 ~~by the Department of Justice for use of those substances in bona~~
34 ~~fide research, instruction, or analysis.~~

35 ~~(b) That research, instruction, or analysis shall be carried on~~
36 ~~only under the auspices of the individual identified by the registrant~~
37 ~~as responsible for the research. Complete records of receipts, stocks~~
38 ~~at hand, and use of these controlled substances shall be kept.~~

39 ~~(c) The Department of Justice may withdraw approval of the~~
40 ~~use of such substances at any time. The department may obtain~~

1 and inspect at any time the records required to be maintained by
2 this section.

3 ~~SEC. 8.~~

4 *SEC. 7.* No reimbursement is required by this act pursuant to
5 Section 6 of Article XIII B of the California Constitution because
6 the only costs that may be incurred by a local agency or school
7 district will be incurred because this act creates a new crime or
8 infraction, eliminates a crime or infraction, or changes the penalty
9 for a crime or infraction, within the meaning of Section 17556 of
10 the Government Code, or changes the definition of a crime within
11 the meaning of Section 6 of Article XIII B of the California
12 Constitution.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: SB 360

VERSION: As Amended July 7, 2011

AUTHOR: DeSaulnier

SPONSOR: Attorney General

BOARD POSITION: Watch

SUBJECT: Controlled Substance Utilization Review and Evaluation System (CURES)

Affected Sections: Amend Sections 11161.5, 11162.1, 11165, 11165.1, and add 11165.2 and 11165.3 to the Health and Safety Code

CURRENT STATUS: Assembly Appropriations Committee hearing scheduled for August 17, 2011

EXISTING LAW:

The Uniform Controlled Substances Act places controlled substances into four schedules, found in Health and Safety Code sections 11054 through 11057.

Health and Safety Code sections 11161.5 – 11162.1 establish guidelines for the printing of controlled substance security prescription forms, which is managed by the California Department of Justice (DOJ) California Security Prescription Printer Program. These provisions provide for the approval (or denial) of applicants who wish to be approved printers of security controlled substances prescription forms and requires approved printers to verify prescribers with the appropriate licensing board prior to printing; delivery of controlled substance prescription forms; and maintenance of records. These provisions also specify the content required to be printed on a security prescription form.

Health and Safety Code sections 11165 – 11165.1 provides for the Controlled Substances Utilization Review and Evaluation System (CURES), administered by the DOJ, to provide for monitoring of the prescribing and dispensing of Schedule II, III and IV controlled substances. Upon dispensing of a controlled substance in Schedules II – IV, the dispensing pharmacy or clinic must provide dispensing information to the DOJ within a specified time frame. CURES data is utilized by those approved to have access through the DOJ. This data can assist a prescriber or pharmacist to make informed decisions and detect those patients who may be attempting to abuse controlled substances by obtaining multiple prescriptions through various practitioners. The board pays approximately \$92,000 annually to help fund the CURES system.

THIS BILL WOULD:

Amend Health and Safety Code sections 11161.5 – 11162.1 to specify additional information that is required of a security printer applicant, to include all levels of persons (i.e., managers, employees, contractors, etc.) that may have access to the controlled substances security forms. Amendments also specify that the fee the DOJ may assess would be sufficient to cover inspection of security printers. The amendments further specify that a security prescription form that is not in compliance with the section shall not be valid after July 1, 2012.

Amend Health and Safety Code section 11165 to specify that only those prescriptions for a schedule II – IV controlled substance, as defined by federal law, will be required to be reported to CURES.

Amend Health and Safety Code section 11165.1 to allow a licensed health care practitioner, who is eligible to prescribe Schedule II, III or IV controlled substances, to apply to the DOJ to obtain approval to electronically access data in the Prescription Drug Monitoring Program and specifies that authorized health care practitioners will only have access to schedule II – IV controlled substances, as defined by federal law.

This bill adds Section 11165.2 to the Health and Safety Code to provide for sanctions and/or penalties of those found to have violated any provision of Chapter 4 of the Health and Safety Code. This section specifies provisions for citations, the assessment and payment of administrative fines, orders of abatement, etc. The provisions allow for a subscriber to request an informal conference regarding any citation or fine; and provides for disciplinary action if fines are not paid within specified time frames.

This bill also adds Section 11165.3 to the Health and Safety Code to specify that the theft or loss of prescription information or forms shall be reported immediately to CURES, no later than three days after the discovery of the loss or theft. The section requires the theft or loss to be reported via (1) the Bureau of Narcotic Enforcement 1175 Reporting Theft/Loss Form or (2) through the CURES PDMP electronic system.

AUTHOR'S INTENT:

According to the author, SB 360 will update the CURES to allow electronic access to the Prescription Drug Monitoring Program (PDMP) launched in 2009. The PDMP provides authorized users, or “*subscribers*” (prescribers, pharmacists, etc.), access to patient controlled substance prescription information in real-time at the point of care – allowing a prescriber or a pharmacist to detect those who may be abusing controlled substances by obtaining multiple prescriptions. Also, this bill would provide safeguards against the theft and fraudulent use of controlled substance prescription pads.

COMMENTS:

Board staff notes some possible challenges with the bill in its current form, most notably the proposed changes to section 11165(d) which would in effect no longer require a pharmacy to transmit data to CURES for items that are only scheduled in California and not at the federal level. The ramification is compromised information available to conduct CA specific schedule narcotic enforcement activity due to a lack of available dispensing data from now on and into the future. (Sometimes items are scheduled at the state level to address a specific issue that is either not an issue at the federal level, or are necessary to address an enforcement issue at the state level.) Similarly, health care practitioners would also only have information on those products as scheduled at the federal level.

The board may wish to considering offering amended language that would require reporting of those prescriptions that are scheduled either at the state or federal level. (A brief review of the CURES data appears that this may be what is occurring currently.) This amendment could address the concerns stated above.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board briefly discussed this measure and established a “Watch” position. The bill has been amended twice since that time.

This bill was originally intended to add substances that were scheduled at the federal level, but included in the state schedules including:

Amend Health and Safety Code section 11054 – 11057 for the purpose of adding substances to Schedules I through IV, as follows:

Schedules I and II – adds Opiates

Schedule III – Adds depressants, and anabolic steroids and chorionic gonadotropin

Schedule IV – Adds depressants, stimulants

Previous versions of the the bill would also have the following conforming changes (update references) in the following sections:

1. Family Code section 6929 - Defines various terms, including “LAAM.” This bill makes a conforming change to a reference to Section 11055 of the Health and Safety Code.
2. Health and Safety Code section 11212 - Cross references substances in Schedule I for the purpose of research, instruction, or analysis.
3. Health and Safety Code section 11350 – 11355 - Updates references to Schedule III, regarding possession / punishment.
4. a. Health and Safety Code section 11377 – Punishment for possession. Updates references to Schedule II related to Ketamine, Cathine and norpseudoephedrine; and
b. Amends subdivision (a) of HSC 11377 to reference Pharmacy Law (commencing with 4110, not 4211)
5. Health and Safety Code section 11378 – Cross reference to Schedule III updated

6. Health and Safety Code section 11379-11379.2 – Updates cross references to Pharmacy Law section 4110 and updates cross references to Schedule III. Punishment.
7. Health and Safety Code section 11839.2, 11875 – Updates cross reference to LAAM in Schedule II.

PREVIOUS/RELATED LEGISLATION:

Prior to recent amendments, SB 260 (2011, Cannella) contained similar provisions. SB 260 was amended and now addresses provisions related to the reporting of transactions of ephedrine and other specified substances to the Department of Justice.

SB 734 (Torlakson) – Chapter 487, Statutes of 2005. This bill provided clean-up changes to facilitate the effective operation of the CURES, and the program duties of the Bureau of Narcotic Enforcement. The board had a “Oppose unless amended” position on the measure.

SB 1071 (DeSaulnier). 2010. This bill would have imposed a tax on every manufacturer and importer of a controlled substance specified in Schedules II, III or IV to secure funding for providing Patient Activity Reports (CURES data) to all practitioners and those who dispense controlled substances. The board did not take a position on the bill, which died in committee.

FISCAL IMPACT:

The enforcement of these provisions resides primarily with the Department of Justice. The board does not anticipate any significant impact. Minor impact to board operations could be absorbed within existing resources.

SUPPORT/OPPOSITION:

Support

Department of Justice (Sponsor)
California Narcotic Officers' Association
California Peace Officers' Association
California Police Chiefs Association
California State Sheriffs' Association
California Statewide Law Enforcement Association
Consumer Attorneys of California
Peace Officers Research Association of California

Opposition

None

HISTORY:

Date	Action
July 7	Read second time and amended. Re-referred to Com. on APPR.
July 6	From committee: Do pass as amended and re-refer to Com. on APPR.with recommendation: To consent calendar. (Ayes 7. Noes 0.) (July 5).
June 13	Referred to Com. on PUB. S.
June 2	In Assembly. Read first time. Held at Desk.
June 2	Read third time. Passed. (Ayes 39. Noes 0. Page 1282.) Ordered to the Assembly.
May 31	Ordered to special consent calendar.
May 27	Read second time. Ordered to third reading.
May 26	From committee: Do pass. (Ayes 9. Noes 0. Page 1115.) (May 26).
May 25	Set for hearing May 26.
May 23	Placed on APPR. suspense file.
May 13	Set for hearing May 23.
May 10	Read second time and amended. Re-referred to Com. on APPR.
May 9	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 7. Noes 0. Page 862.) (May 3).
Apr. 26	Set for hearing May 3.
Apr. 14	From committee with author's amendments. Read second time and amended. Re-referred to Com. on PUB. S.
Mar. 31	Re-referred to Com. on PUB. S.
Mar. 22	From committee with author's amendments. Read second time and amended. Re-referred to Com. on RLS.
Feb. 24	Referred to Com. on RLS.
Feb. 16	From printer. May be acted upon on or after March 18.
Feb. 15	Introduced. Read first time. To Com. on RLS. for assignment. To print.

AMENDED IN ASSEMBLY JUNE 22, 2011

AMENDED IN SENATE MAY 2, 2011

SENATE BILL

No. 850

Introduced by Senator Leno

February 18, 2011

An act to amend Section 56.101 of the Civil Code, relating to medical records.

LEGISLATIVE COUNSEL'S DIGEST

SB 850, as amended, Leno. Medical records: confidential information.

The Confidentiality of Medical Information Act requires that every provider of health care, health care service plan, pharmaceutical company, and contractor who creates, maintains, preserves, stores, abandons, destroys, or disposes of medical records do so in a manner that preserves the confidentiality of the information contained in the record, and provides that negligence in conducting these activities may result in damages or an administrative fine or civil penalty, as specified.

This bill would require an electronic health or medical record system to automatically record *and preserve* any change or deletion of electronically stored medical information, and would require the record to include, among other things, the identity of the person who accessed and changed the medical information and the change that was made to the medical information.

Vote: majority. Appropriation: no. Fiscal committee: no.
State-mandated local program: no.

The people of the State of California do enact as follows:

SECTION 1. Section 56.101 of the Civil Code is amended to read:

56.101. (a) Every provider of health care, health care service plan, pharmaceutical company, or contractor who creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information shall do so in a manner that preserves the confidentiality of the information contained therein. Any provider of health care, health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of medical information shall be subject to the remedies and penalties provided under subdivisions (b) and (c) of Section 56.36.

(b) (1) An electronic health record system or electronic medical record system shall ~~automatically record~~ *do the following:*

(A) *Protect and preserve the integrity of electronic medical information.*

(B) *Automatically record and preserve any change or deletion of any electronically stored medical information. The record of any change or deletion shall include the identity of the person who accessed and changed the medical information, the date and time the medical information was accessed, and the change that was made to the medical information. ~~The record of the change or deletion shall be made part of the patient's medical information, and shall be accessible upon request of a patient or his or her representative to review the medical information.~~*

(2) *A patient's right to access or receive a copy of his or her electronic medical records upon request shall be consistent with current applicable state and federal laws governing patient access to, and the use and disclosures of, medical information.*

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: SB 850

VERSION: As amended June 22, 2011

AUTHOR: Leno

SPONSOR: Consumer Attorneys of California

BOARD POSITION: None

SUBJECT: Medical Records: Confidential Information

Affected Sections: Amend Section 56.101 of the Civil Code

CURRENT STATUS: Assembly Appropriations Committee hearing scheduled for August 17, 2011

EXISTING LAW:

1. Requires every provider of health care, health care service plan, pharmaceutical company, or contractor who creates, maintains, preserves, stores, abandons, destroys, or disposes of medical records to do so in a manner that preserves the confidentiality of the information contained therein.
2. Further it specifies that any provider of health care, health care service plan, pharmaceutical company, or contractor who negligently creates, maintains, preserves, stores, abandons, destroys, or disposes of medical records shall be subject to the remedies and penalties provided under subdivisions (b) and (c) of Section 56.36.

THIS BILL WOULD:

In addition to the above, specify that an electronic medical record system shall do the following:

- Protect and preserve the integrity of the information
- Automatically record and preserve any changes to the record, including the person that made the change as specified
- Clarify that a patient's access to electronic medical records is consistent with current state and federal law.

AUTHOR'S INTENT:

The sponsor of this bill states that this bill will help to prevent medical errors and improve the quality of patient care "by ensuring that electronic medical records accurately reflect a patient's medical treatment and history, by preserving a record of any modification or deletion made to a patient's medical record."

FISCAL IMPACT:

The board does not anticipate any significant impact to board operations. Any minimal impact could be addressed within existing resources.

SUPPORT/OPPOSITION:Support

Consumer Attorneys of California (sponsor)
California Association of Health Underwriters
Consumer Federation of California

Opposition

None

HISTORY:**Date Action**

June 28	From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 2.) (June 27). Re-referred to Com. on APPR.
June 22	From committee with author's amendments. Read second time and amended. Re-referred to Com. on JUD.
June 22	From committee: Do pass and re-refer to Com. on JUD. (Ayes 14. Noes 0.) (June 21). Re-referred to Com. on JUD.
June 9	Referred to Coms. on HEALTH and JUD.
June 1	In Assembly. Read first time. Held at Desk.
May 31	Read third time. Passed. (Ayes 21. Noes 15. Page 1178.) Ordered to the Assembly.
May 12	Read second time. Ordered to third reading.
May 11	From committee: Do pass. (Ayes 3. Noes 2. Page 951.) (May 10).
May 2	From committee with author's amendments. Read second time and amended. Re-referred to Com. on JUD.
Apr. 29	Set for hearing May 10.
Mar. 10	Referred to Com. on JUD.
Feb. 20	From printer. May be acted upon on or after March 22.
Feb. 18	Introduced. Read first time. To Com. on RLS. for assignment. To print.

AMENDED IN ASSEMBLY JUNE 21, 2011

AMENDED IN SENATE APRIL 13, 2011

SENATE BILL

No. 541

Introduced by Senator Price

February 17, 2011

An act to add Section 40 to the Business and Professions Code, relating to ~~profession~~ *professions* and vocations, and declaring the urgency thereof, to take effect immediately.

LEGISLATIVE COUNSEL'S DIGEST

SB 541, as amended, Price. ~~Contractors' State License Regulatory boards: expert consultants.~~

Existing law provides for the licensure and regulation of various professions and vocations by boards within the Department of Consumer Affairs. Existing law, the Chiropractic Act, enacted by initiative, provides for the licensure and regulation of chiropractors by the State Board of Chiropractic Examiners. Existing law, the Osteopathic Act, requires the Osteopathic Medical Board of California to regulate osteopathic physicians and surgeons. Existing law generally requires applicants for a license to pass an examination and authorizes boards to take disciplinary action against licensees for violations of law. Existing law establishes standards relating to personal service contracts in state employment.

This bill would authorize these boards to enter into an agreement with an expert consultant, subject to the standards regarding personal service contracts described above, to provide enforcement and examination assistance. The bill would require each board to establish policies and procedures for the selection and use of these consultants.

This bill would declare that it is to take effect immediately as an urgency statute.

Vote: $\frac{2}{3}$. Appropriation: no. Fiscal committee: yes.

State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. Section 40 is added to the Business and
2 Professions Code, to read:

3 40. (a) Subject to the standards described in Section 19130 of
4 the Government Code, any board, as defined in Section 22, the
5 State Board of Chiropractic Examiners, or the Osteopathic Medical
6 Board of California may enter into an agreement with an expert
7 consultant to do any of the following:

8 (1) Provide an expert opinion on enforcement-related matters,
9 including providing testimony at an administrative hearing.

10 (2) Assist the board as a subject matter expert in examination
11 development, examination validation, or occupational analyses.

12 (3) Evaluate the mental or physical health of a licensee or an
13 applicant for a license as may be necessary to protect the public
14 health and safety.

15 (b) An executed contract between a board and an expert
16 consultant shall be exempt from the provisions of Part 2
17 (commencing with Section 10100) of Division 2 of the Public
18 Contract Code.

19 (c) Each board shall establish policies and procedures for the
20 selection and use of expert consultants.

21 (d) *Nothing in this section shall be construed to expand the*
22 *scope of practice of an expert consultant providing services*
23 *pursuant to this section.*

24 SEC. 2. This act is an urgency statute necessary for the
25 immediate preservation of the public peace, health, or safety within
26 the meaning of Article IV of the Constitution and shall go into
27 immediate effect. The facts constituting the necessity are:

28 To ensure that licensees engaging in certain professions and
29 vocations are adequately regulated at the earliest possible time in
30 order to protect and safeguard consumers and the public in this
31 state, it is necessary that this act take effect immediately.

O

CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS



BILL NUMBER: SB 541

VERSION: As Amended June 21, 2011

AUTHOR: Price

SPONSOR: Author

BOARD POSITION: Support

SUBJECT: Regulatory Boards: Expert Consultants

Affected Sections: Add Section 40 to the Business and Professions Code

Current Status: Assembly Appropriations Committee hearing scheduled for August 17, 2011

EXISTING LAW:

1. Business and Professions Code section 157 allows the director, at the request of and with the consent of a board, to enter into a contract on behalf of the board.
2. Business and Professions Code section 307 allows the director to contract for services of experts and consultants where necessary.

THIS BILL WOULD:

1. Authorize the board to enter into an agreement with an expert consultant and would specify that an executed contract between the board and an expert is exempt from the Public Contract Code.
2. Require the board to establish policies and procedures for the selection of experts.
3. Specify that nothing in these provisions are intended to expand the scope of practice of an expert performing a service.

AUTHOR'S INTENT:

This measure will ensure that licensees engaging in certain professions and vocations are adequately regulated at the earliest possible time in order to protect and safeguard consumers and the public in this state.

COMMENTS:

This bill contains an urgency provision which will allow this measure to take effect immediately.

This proposal will aid the board in meeting its consumer protection mandate by ensuring the board has the ability to quickly enter into an agreement with an expert in disciplinary matters. Further, this proposal will ensure that the board can timely and efficiently contract with experts whose services are needed to develop the pharmacist licensure exam.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board discussed this measure and its benefits. The board established a “Support” position on this measure. Board staff advised the author’s office verbally and in writing.

This measure was amended since the board meeting to specify that the scope of practice of the expert cannot be expanded.

FISCAL/ECONOMIC IMPACT:

Board staff does not anticipate any significant impact to board operations or funds.

SUPPORT/OPPOSITION:

Support

Medical Board of California (co-sponsor)
Contractors State License Board (co-sponsor)
Board of Barbering and Cosmetology
Board of Behavioral Sciences
Board of Optometry
Board of Pharmacy
Board of Podiatric Medicine
Board of Psychology
Board of Registered Nursing
Board of Vocational Nursing and Psychiatric Technicians
California Board of Accountancy
California State Pipe Trades Council
Court Reporters Board of California
Dental Board of California
International Brotherhood of Electrical Workers
Physician Assistant Committee
Respiratory Care Board of California
State Board of Guide Dogs for the Blind
Western States Council of Sheet Metal Workers

Opposition

None of file

HISTORY:

Date	Action
June 28	From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (June 28). Re-referred to Com. on APPR.
June 21	From committee with author's amendments. Read second time and amended. Re-referred to Com. on B., P. & C.P.
June 2	Referred to Com. on B., P. & C.P.
May 23	In Assembly. Read first time. Held at Desk.
May 23	Read third time. Urgency clause adopted. Passed. (Ayes 39. Noes 0. Page 1065.) Ordered to the Assembly.
May 18	Read second time. Ordered to third reading. Ordered to special consent calendar.
May 17	From committee: Be placed on second reading file pursuant to Senate Rule 28.8.
May 6	Set for hearing May 16.
May 3	From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0. Page 848.) (May 2). Re-referred to Com. on APPR.
Apr. 13	From committee with author's amendments. Read second time and amended. Re-referred to Com. on B., P. & E.D.
Apr. 12	Set for hearing May 2.
Apr. 11	Hearing postponed by committee.
Apr. 4	Set for hearing April 25.
Mar. 3	Referred to Com. on B., P. & E.D.
Feb. 18	From printer. May be acted upon on or after March 20.
Feb. 17	Introduced. Read first time. To Com. on RLS. for assignment. To print.

AMENDED IN ASSEMBLY MARCH 30, 2011

AMENDED IN ASSEMBLY MARCH 15, 2011

AMENDED IN ASSEMBLY MARCH 7, 2011

CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 389

Introduced by Assembly Member Mitchell
(Principal coauthor: Senator Pavley)

February 14, 2011

~~An act to amend Section 2191 of the Business and Professions Code;~~
~~and~~ *An act* to add Article 5 (commencing with Section 125286.10) to
Chapter 2 of Part 5 of Division 106 of the Health and Safety Code,
relating to genetic diseases.

LEGISLATIVE COUNSEL'S DIGEST

AB 389, as amended, Mitchell. Bleeding disorders.

Existing law, the Holden-Moscone-Garamendi Genetically Handicapped Person's Program, requires the Director of Health Care Services to establish and administer a program for the medical care of persons with genetically handicapping conditions, including hemophilia.

This bill would impose specified requirements on providers of blood clotting products for home use, as described, whose products are used for the treatment and prevention of symptoms associated with bleeding disorders, including all forms of hemophilia. This bill would require the California State Board of Pharmacy to administer and enforce these provisions.

~~Existing law requires the Division of Licensing of the Medical Board of California to establish continuing education requirements for physicians and surgeons.~~

This bill would require the division to consider including a course on bleeding disorders, as specified, in determining its continuing education requirements.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

1 ~~SECTION 1. Section 2191 of the Business and Professions~~
2 ~~Code is amended to read:~~
3 ~~2191. (a) In determining its continuing education requirements,~~
4 ~~the Division of Licensing shall consider including a course in~~
5 ~~human sexuality as defined in Section 2090 and nutrition to be~~
6 ~~taken by those licensees whose practices may require knowledge~~
7 ~~in those areas.~~
8 ~~(b) The division shall consider including a course in child abuse~~
9 ~~detection and treatment to be taken by those licensees whose~~
10 ~~practices are of a nature that there is a likelihood of contact with~~
11 ~~abused or neglected children.~~
12 ~~(c) The division shall consider including a course in acupuncture~~
13 ~~to be taken by those licensees whose practices may require~~
14 ~~knowledge in the area of acupuncture and whose education has~~
15 ~~not included instruction in acupuncture.~~
16 ~~(d) The division shall encourage every physician and surgeon~~
17 ~~to take nutrition as part of his or her continuing education,~~
18 ~~particularly a physician and surgeon involved in primary care.~~
19 ~~(e) The division shall consider including a course in elder abuse~~
20 ~~detection and treatment to be taken by those licensees whose~~
21 ~~practices are of a nature that there is a likelihood of contact with~~
22 ~~abused or neglected persons 65 years of age and older.~~
23 ~~(f) In determining its continuing education requirements, the~~
24 ~~division shall consider including a course in the early detection~~
25 ~~and treatment of substance abusing pregnant women to be taken~~
26 ~~by those licensees whose practices are of a nature that there is a~~
27 ~~likelihood of contact with these women.~~
28 ~~(g) In determining its continuing education requirements, the~~
29 ~~division shall consider including a course in the special care needs~~
30 ~~of drug addicted infants to be taken by those licensees whose~~
31 ~~practices are of a nature that there is a likelihood of contact with~~
32 ~~these infants.~~

1 ~~(h) In determining its continuing education requirements, the~~
2 ~~division shall consider including a course providing training and~~
3 ~~guidelines on how to routinely screen for signs exhibited by abused~~
4 ~~women, particularly for physicians and surgeons in emergency,~~
5 ~~surgical, primary care, pediatric, prenatal, and mental health~~
6 ~~settings. In the event the division establishes a requirement for~~
7 ~~continuing education coursework in spousal or partner abuse~~
8 ~~detection or treatment, that requirement shall be met by each~~
9 ~~licensee within no more than four years from the date the~~
10 ~~requirement is imposed.~~

11 ~~(i) In determining its continuing education requirements, the~~
12 ~~division shall consider including a course in the special care needs~~
13 ~~of individuals and their families facing end-of-life issues, including,~~
14 ~~but not limited to, all of the following:~~

15 ~~(1) Pain and symptom management.~~

16 ~~(2) The psychosocial dynamics of death.~~

17 ~~(3) Dying and bereavement.~~

18 ~~(4) Hospice care.~~

19 ~~(j) In determining its continuation education requirements, the~~
20 ~~division shall give its highest priority to considering a course on~~
21 ~~pain management.~~

22 ~~(k) In determining its continuing education requirements, the~~
23 ~~division shall consider including a course on bleeding disorders,~~
24 ~~with particular emphasis on von Willebrand disease using the latest~~
25 ~~treatment guidelines adopted by the National Heart, Lung, and~~
26 ~~Blood Institute.~~

27 ~~SEC. 2.~~

28 ~~SECTION 1.~~ Article 5 (commencing with Section 125286.10)
29 ~~is added to Chapter 2 of Part 5 of Division 106 of the Health and~~
30 ~~Safety Code, to read:~~

31
32 Article 5. Standards of Service for Providers of Blood Clotting
33 Products for Home Use Act

34
35 125286.10. This article shall be known, and may be cited, as
36 the Standards of Service for Providers of Blood Clotting Products
37 for Home Use Act.

38 125286.15. The Legislature hereby finds and declares all of
39 the following:

1 (a) Hemophilia is a rare, hereditary, bleeding disorder affecting
2 at least 4,000 persons in California and is a chronic, lifelong, and
3 incurable, but treatable, disease.

4 (b) Von Willebrand disease is a human bleeding disorder caused
5 by a hereditary deficiency or abnormality of the von Willebrand
6 factor in human blood, which is a protein that helps clot blood.
7 Von Willebrand disease is a chronic, lifelong, incurable, but
8 treatable, disease affecting at least 360,000 Californians.

9 (c) Until the 1970s, people with severe hemophilia suffered
10 from uncontrollable internal bleeding, crippling orthopedic
11 deformities, and a shortened lifespan. More recently, the production
12 of highly purified blood clotting factors has provided people with
13 hemophilia and other bleeding disorders the opportunity to lead
14 normal lives, free of pain and crippling arthritis.

15 (d) The preferred method of treatment of hemophilia today is
16 intravenous injection, or infusion, of prescription blood clotting
17 products several times per week, along with case management and
18 specialized medical care at a federally designated regional
19 hemophilia treatment center.

20 (e) Pharmacies and other entities specializing in the delivery of
21 blood clotting products and related equipment, supplies, and
22 services for home use form a growing enterprise in California.

23 (f) Timely access to federally designated regional hemophilia
24 centers and appropriate products and services in the home,
25 including infusion of blood clotting products and related
26 equipment, and supplies and services for persons with hemophilia
27 and other bleeding disorders, reduces mortality and bleeding-related
28 hospitalizations according to the federal Centers for Disease
29 Control and Prevention and the Medical and Scientific Advisory
30 Council of the National Hemophilia Foundation.

31 (g) Eligible persons with hemophilia or other bleeding disorders
32 may receive treatment through the Genetically Handicapped
33 Persons Program, the California Children's Services Program, and
34 the Medi-Cal program.

35 (h) For the benefit of persons with hemophilia or other bleeding
36 disorders, the purposes of this article are to do the following:

37 (1) Establish standards of service for entities that deliver blood
38 clotting products and related equipment, supplies, and services for
39 home use.

1 (2) Promote access to a full range of essential, cost-effective,
2 lifesaving, blood clotting products and related equipment, supplies,
3 and high-quality services for home use for persons with hemophilia
4 and other bleeding disorders.

5 125286.20. Unless the context otherwise requires, the following
6 definitions shall apply for purposes of this article:

7 (a) "Assay" means the amount of a particular constituent of a
8 mixture or of the biological or pharmacological potency of a drug.

9 (b) "Ancillary infusion equipment and supplies" means the
10 equipment and supplies required to infuse a blood clotting product
11 into a human vein, including, but not limited to, syringes, needles,
12 sterile gauze, field pads, gloves, alcohol swabs, numbing creams,
13 tourniquets, medical tape, sharps or equivalent biohazard waste
14 containers, and cold compression packs.

15 (c) "Bleeding disorder" means a medical condition characterized
16 by a deficiency or absence of one or more essential blood clotting
17 proteins in the human blood, often called "factors," including all
18 forms of hemophilia and other bleeding disorders that, without
19 treatment, result in uncontrollable bleeding or abnormal blood
20 clotting.

21 (d) "Blood clotting product" means an intravenously
22 administered medicine manufactured from human plasma or
23 recombinant biotechnology techniques, approved for distribution
24 by the federal Food and Drug Administration, that is used for the
25 treatment and prevention of symptoms associated with bleeding
26 disorders. Blood clotting products include, but are not limited to,
27 Factor VII, Factor VIIa, Factor VIII, and Factor IX products, von
28 Willebrand Factor products, bypass products for patients with
29 inhibitors, and activated prothrombin complex concentrates.

30 (e) "Emergency" means care as defined in Section 1317.1.

31 (f) "Hemophilia" means a human bleeding disorder caused by
32 a hereditary deficiency of the Factors I, II, V, VIII, IX, XI, XII,
33 or XIII blood clotting protein in human blood.

34 (g) "Hemophilia treatment center" means a facility for the
35 treatment of bleeding disorders, including, but not limited to,
36 hemophilia, that receives funding specifically for the treatment of
37 patients with bleeding disorders from federal government sources,
38 including, but not limited to, the federal Centers for Disease
39 Control and Prevention and the federal Health Resources and

1 Services Administration (HRSA) of the United States Department
2 of Health and Human Services.

3 (h) “Home nursing services” means specialized nursing care
4 provided in the home setting to assist a patient in the reconstitution
5 and administration of blood clotting products.

6 (i) “Home use” means infusion or other use of a blood clotting
7 product in a place other than a state-recognized hemophilia
8 treatment center or other clinical setting. Places where home use
9 occurs include, without limitation, a home or other nonclinical
10 setting.

11 (j) “Patient” means a person needing a blood clotting product
12 for home use.

13 (k) (1) “Provider of blood clotting products for home use”
14 means all the following pharmacies, except as described in Section
15 125286.35, that dispense blood clotting factors for home use:

16 (A) Hospital pharmacies.

17 (B) Health system pharmacies.

18 (C) Pharmacies affiliated with hemophilia treatment centers.

19 (D) Specialty home care pharmacies.

20 (E) Retail pharmacies.

21 (2) The providers described in this subdivision may also provide
22 home nursing services for persons with bleeding disorders.

23 (3) The providers described in this subdivision shall include a
24 health care service plan and all its affiliated providers if the health
25 care service plan exclusively contracts with a single medical group
26 in a specified geographic area to provide professional services to
27 its enrollees.

28 125286.25. Each provider of blood clotting products for home
29 use shall meet all of the following requirements:

30 (a) Have sufficient knowledge and understanding of bleeding
31 disorders to accurately follow the instructions of the prescribing
32 physician and ensure high-quality service for the patient and the
33 medical and psychosocial management thereof, including, but not
34 limited to, home therapy.

35 (b) Have access to a provider with sufficient clinical experience
36 providing services to persons with bleeding disorders that enables
37 the provider to know when patients have an appropriate supply of
38 clotting factor on hand and about proper storage and refrigeration
39 of clotting factors.

1 (c) Maintain 24-hour on-call service seven days a week for
2 every day of the year, adequately screen telephone calls for
3 emergencies, acknowledge all telephone calls within one hour or
4 less, and have access to knowledgeable pharmacy staffing on call
5 24 hours a day, to initiate emergency requests for clotting factors.

6 (d) Have the ability to obtain all brands of blood clotting
7 products approved by the federal Food and Drug Administration
8 in multiple assay ranges (low, medium, and high, as applicable)
9 and vial sizes, including products manufactured from human
10 plasma and those manufactured with recombinant biotechnology
11 techniques, provided manufacturer supply exists and payer
12 authorization is obtained.

13 (e) Supply all necessary ancillary infusion equipment and
14 supplies with each prescription, as needed.

15 (f) Store and ship, or otherwise deliver, all blood clotting
16 products in conformity with all state and federally mandated
17 standards, including, but not limited to, the standards set forth in
18 the product's approved package insert (PI).

19 (g) When home nursing services are necessary, as determined
20 by the treating physician, provide these services either directly or
21 through a qualified third party with experience in treating bleeding
22 disorders and coordinate pharmacy services with the third party
23 when one is used to provide home nursing services.

24 (h) Upon receiving approved authorization for a nonemergency
25 prescription, provided manufacturer supply exists, ship the
26 prescribed blood clotting products and ancillary infusion equipment
27 and supplies to the patient within two business days or less for
28 established and new patients.

29 (i) Upon receiving approved authorization to dispense a
30 prescription for an emergency situation, provided manufacturer
31 supply exists, deliver prescribed blood products, ancillary infusion
32 equipment and supplies, medications, and home nursing services
33 to the patient within 12 hours for patients living within 100 miles
34 of a major metropolitan airport, and within one day for patients
35 living more than 100 miles from a major metropolitan airport.

36 (j) Provide patients who have ordered their products with a
37 designated contact telephone number for reporting problems with
38 a delivery and respond to these calls within a reasonable time
39 period.

1 (k) Provide patients with notification of Class 1 and Class 2
2 recalls and withdrawals of blood clotting products and ancillary
3 infusion equipment within 24 hours of the provider of blood
4 clotting products for home use receiving notification and participate
5 in the National Patient Notification System for blood clotting
6 product recalls.

7 (l) Provide language interpretive services over the telephone or
8 in person, as needed by the patient.

9 (m) Have a detailed plan for meeting the requirements of this
10 article in the event of a natural or manmade disaster or other
11 disruption of normal business operations.

12 (n) Provide appropriate and necessary recordkeeping and
13 documentation as required by state and federal law and retain
14 copies of the patient's prescriptions.

15 (o) Comply with the privacy and confidentiality requirements
16 of the federal Health Insurance Portability and Accountability Act
17 of 1996 (HIPAA).

18 125286.30. The California State Board of Pharmacy shall
19 administer and enforce this article.

20 125286.35. Nothing in this article shall apply to either hospital
21 pharmacies or health system pharmacies that dispense blood
22 clotting products due only to emergency, urgent care, or inpatient
23 encounters, or if an inpatient is discharged with a supply of blood
24 clotting products for home use.

CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS



BILL NUMBER: AB 389

VERSION: As Amended March 30, 2011

AUTHOR: Mitchell

SPONSOR: Hemophilia Council of California

BOARD POSITION: Watch

SUBJECT: Bleeding disorders: Blood Clotting Products

Affected Sections: Amend Section 2191 of the Business and Professions Code and Add Article 5 (commencing with Section 125286.10) to Chapter 2 or Part 5 of Division 106 of the Health and Safety Code

Current Status: Senate Appropriation Committee hearing scheduled for August 15, 2011

EXISTING LAW:

1. Establishes the Holden-Moscone-Garamendi Genetically Handicapped Person's Program within the Department of Health Care Services. [HSC §125125]
2. Requires the Director of Health Care Services to establish and administer a program for the medical care of persons with genetically disabling conditions, including hemophilia. [HSC §125130]
3. Requires the Division of Licensing of the Medical Board of California to establish continuing education requirements for physicians and surgeons as specified and sets forth the criteria that the division shall use in considering courses. [B&PC §2191]

THIS BILL WOULD:

1. Require the division to consider including a course on bleeding disorders with particular emphasis on von Willebrand disease using the latest treatment guidelines adopted by the National Heart, Lung and Blood Institute.
2. Add Article 5. Standards of Service for Providers of Blood Clotting Products for Home Use Act that includes the following:
 - a. Findings and declarations about bleeding disorders, history of and treatment of such disorders, pharmacies role in the delivery of products, identification of persons eligible for treatment through various programs, and states that this article is necessary for the benefit of persons with bleeding disorders to establish standards of service and to promote cost effective, life saving products for home use.
 - b. Defines various terms for purposes of this article including:

- i. “home nursing services” means specialized nursing care provided in the home setting to assist a patient in the reconstitution and administration of blood clotting products.
 - ii. “provider of blood clotting products for home use” means hospital pharmacies, health systems pharmacies, pharmacies affiliated with treatment centers, specialty home care pharmacies and retail pharmacies. These providers are allowed to provide home nursing services and are required to include a health care service plan and all its affiliated providers if the plan exclusively contracts with a single medication group in a specified areas to provide professional services to enrollees.
- c. Requires that each provider, as defined above, meet the following requirements:
 - i. Have sufficient knowledge and understanding of bleeding disorders to accurately follow the instructions of the prescriber and ensure quality care.
 - ii. Have access to a provider with sufficient clinical experience providing services to persons with bleeding disorders that enables the provider to know when patients have an appropriate supply of product on hand as well and understanding about proper storage and refrigeration.
 - iii. Maintain 24-hour on-call service seven days a week, 365 days a years.
 - iv. Have the ability to obtain all brands of the products approved by the FDA in multiple assay ranges as specified.
 - v. Supply all necessary ancillary infusion equipment and supplies as needed.
 - vi. Store, ship, or otherwise deliver, all products in conformity with state and federally mandated standards.
 - vii. Provide home nursing services either directly or via a third party, when determined necessary by the physician.
 - viii. Ship product within two business days to a patient for a nonemergency prescription.
 - ix. For emergencies, deliver products, equipment, medications and home nursing services within 12 hours, for patients living within 100 miles of a major metropolitan airport, or within one days for patients living outside that area.
 - x. Provide contact information to a patient to report problems with delivery.
 - xi. Provide patient with product recall and withdrawal notifications within 24 hours.
 - xii. Provide language interpretive service via phone or in person, as needed.
 - xiii. Have a detailed plan in the event of a natural or manmade disaster.
 - xiv. Provide appropriate record keeping.
 - xv. Comply with HIPAA requirements.
- d. Requires the California Board of Pharmacy to administer and enforce this article.

AUTHOR'S INTENT:

According to the author's office, "AB 389 will establish standards of service for pharmacies that deliver blood clotting products and related equipment, supplies, and services for home use and would promote access to a full range of essential, cost effective, life-saving, blood clotting products and related equipment, supplies for home use for people who have hemophilia, von Willebrand disease and other bleeding disorders."

COMMENTS:

Many of these provisions are currently the standard of practice, but are not mandated anywhere. This measure specifies that the Board of Pharmacy will enforce the provisions of this bill. The board could fulfill this mandate through routine inspections of pharmacies and others under the board's jurisdiction as well as investigation of consumer complaints received. The board would already have jurisdiction to investigate consumer complaints involving poor service or product delivery that resulted in either patient harm or the potential for harm. We are unaware of any such complaints received by the board.

There are potential challenges in enforcing some of these provisions. Specifically, the board may not be in a position to assess the clinical experience of the provider to ensure they have sufficient experience to know when patients have an appropriate supply of clotting factor on hand as required. Further, it is unclear if the board would have jurisdiction over the home nursing services and the quality of the care provided.

The previous version of this bill contained a provision requiring the Licensing Division of the Medical Board to consider requiring a continuing education course on bleeding disorders. This provision was amended out of the measure on March 30, 2011.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board briefly discussed this measure and established a "watch" position on the measure.

FISCAL/ECONOMIC IMPACT:

We anticipate a portion of an inspector PY will be necessary to ensure compliance with these provisions. This workload could possibly be absorbed if the board is able to fill all authorized inspector positions. However, because of the bill's specificity and the need for close monitoring of these provisions, the board would need to do frequent inspections. Because the specialty pharmacies are not required to have a separate license, nor are they required to notify the board that they provide such services, performing inspection on all pharmacies that provide these services would be a challenge.

PREVIOUS/RELATED LEGISLATION

SB 1594 (Steinberg, 2007) would have established standards for providers of blood clotting products. The board had a “Watch” position on the bill. The measure later died after being placed on the Senate Appropriations Suspense File and never passed out of the house of origin.

SB 971 (Pavely, 2010) introduced legislation similar to this proposal. The board did not have a position on this bill. This bill was vetoed by the governor.

“I am returning Senate Bill 971 without my signature. This bill is unnecessary and attempts to create additional standards that are already being adequately enforced through other regulatory and administrative mechanisms. Since the current standards of practice for blood clotting products and service are already being met through state and federal pharmacy laws, voluntary compliance and existing state contract provisions, it is unclear what problem this bill seeks to address. For these reasons, I am unable to sign this bill.”

SUPPORT/OPPOSITION:**Support**

Baxter Healthcare
California Medical Association
California Pharmacists Association
Community Healthcare Services
CSL Behring
Federal Hemophilia Treatment Centers, Region IX
Grifols Inc.
Hemophilia Council of California
Hemophilia Foundation of Northern California
Herndon Pharmacy
Hueneme Family Pharmacy
Meyer Family Cellars
National Cornerstone Healthcare Services Inc.
Pfizer Inc.
Plasma Protein Therapeutics Association
Talecris Biotherapeutics
UCD Hemophilia Treatment Center
Walgreens
Two individuals

Oppose

None

HISTORY:

July 6 From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (July 6). Re-referred to Com. on APPR.

June 23 From committee: Do pass and re-refer to Com. on B., P. & E.D. with recommendation: to consent calendar. (Ayes 8. Noes 0.) (June 22). Re-referred to Com. on B.,P. & E.D.
 June 8 In committee: Hearing postponed by committee.
 May 12 Referred to Coms. on HEALTH and B., P. & E.D.
 Apr. 28 In Senate. Read first time. To Com. on RLS. for assignment.
 Apr. 28 Read third time. Passed. Ordered to the Senate. (Ayes 78. Noes 0. Page 1127.)
 Apr. 14 Read second time. Ordered to third reading.
 Apr. 13 From committee: Do pass. (Ayes 12. Noes 3.) (April 13).
 Apr. 6 From committee: Do pass and re-refer to Com. on APPR. (Ayes 15. Noes 3.) (April 5). Re-referred to Com. on APPR.
 Mar. 31 Re-referred to Com. on HEALTH.
 Mar. 30 From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
 Mar. 22 From committee: Do pass and re-refer to Com. on HEALTH. (Ayes 9. Noes 0.) (March 22). Re-referred to Com. on HEALTH.
 Mar. 16 Re-referred to Com. on B., P. & C.P.
 Mar. 15 From committee chair, with author's amendments: Amend, and re-refer to Com. on B., P. & C.P. Read second time and amended.
 Mar. 8 Re-referred to Com. on B., P. & C.P.
 Mar. 7 From committee chair, with author's amendments: Amend, and re-refer to Com. on B., P. & C.P. Read second time and amended.
 Feb. 24 Referred to Com. on B., P. & C.P.
 Feb. 15 From printer. May be heard in committee March 17.
 Feb. 14 Read first time. To print.

AMENDED IN SENATE JULY 14, 2011

AMENDED IN ASSEMBLY APRIL 5, 2011

AMENDED IN ASSEMBLY MARCH 17, 2011

CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 604

**Introduced by Assembly Member Skinner
(Coauthor: Assembly Member Blumenfield)**

February 16, 2011

An act to amend, *repeal, and add* Sections 121349, 121349.1, 121349.2, and 121349.3 of the Health and Safety Code, relating to public health.

LEGISLATIVE COUNSEL'S DIGEST

AB 604, as amended, Skinner. Needle exchange programs.

Existing law, with certain exceptions, makes it a misdemeanor for a person to deliver, furnish, or transfer, or possess with intent to deliver, furnish, or transfer drug paraphernalia, knowing, or under circumstances where one reasonably should know, that it will be used to introduce into the human body a controlled substance. Existing law provides an exception to this general rule by authorizing a city, county, or city and county to conduct a clean needle and syringe exchange project authorized by the public entity to combat the spread of HIV and bloodborne hepatitis. Existing law exempts providers participating in an exchange project from criminal prosecution for possession of needles or syringes during participation in the project. Existing law also provides a specified annual comment and reporting process relating to the needle and syringe exchange projects.

This bill would, *until January 1, 2019*, authorize the State Department of Public Health to authorize, as specified, certain entities to provide hypodermic needle and syringe exchange services in any location where the department determines that the conditions exist for the rapid spread of HIV, viral hepatitis, or any other potentially deadly or disabling infections that are spread through the sharing of used hypodermic needles and syringes. The bill would, *until January 1, 2019*, require the department to establish and maintain on its Internet Web site the address and contact information of these programs.

This bill would, *until January 1, 2019*, exempt staff and volunteers participating in an authorized exchange project from criminal prosecution for violation of any law related to the possession, furnishing, or transfer of hypodermic needles or syringes during participation in an exchange project and would exempt program participants from criminal prosecution for possession of needles and syringes acquired from an authorized exchange project entity. The bill would also, *until January 1, 2019*, make the comment and reporting process for the projects biennial.

This bill would make additional technical and nonsubstantive changes.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. Section 121349 of the Health and Safety Code
2 is amended to read:
3 121349. (a) The Legislature finds and declares that scientific
4 data from needle exchange programs in the United States and in
5 Europe have shown that the exchange of used hypodermic needles
6 and syringes for clean hypodermic needles and syringes does not
7 increase drug use in the population, can serve as an important
8 bridge to treatment and recovery from drug abuse, and can curtail
9 the spread of human immunodeficiency virus (HIV) infection
10 among the intravenous drug user population.
11 (b) In order to reduce the spread of HIV infection and
12 bloodborne hepatitis among the intravenous drug user population
13 within California, the Legislature hereby authorizes a clean needle
14 and syringe exchange project pursuant to this chapter in any city,
15 county, or city and county upon the action of a county board of
16 supervisors and the local health officer or health commission of

1 that county, or upon the action of the city council, the mayor, and
2 the local health officer of a city with a health department, or upon
3 the action of the city council and the mayor of a city without a
4 health department.

5 (c) In order to reduce the spread of HIV infection, viral hepatitis,
6 and other potentially deadly bloodborne infections, the State
7 Department of Public Health may, notwithstanding any other law,
8 authorize entities that provide services set forth in paragraph (1)
9 of subdivision (d), and that have sufficient staff and capacity to
10 provide the services described in Section 121349.1, as determined
11 by the department, to apply for authorization under this chapter to
12 provide hypodermic needle and syringe exchange services
13 consistent with state and federal standards, including those of the
14 United States Public Health Service, in any location where the
15 department determines that the conditions exist for the rapid spread
16 of HIV, viral hepatitis, or any other potentially deadly or disabling
17 infections that are spread through the sharing of used hypodermic
18 needles and syringes.

19 (d) In order for an entity to be authorized to conduct a project
20 pursuant to this chapter, its application to the department shall
21 demonstrate that the entity complies with all of the following
22 minimum standards:

23 (1) The entity provides, directly or through referral, all of the
24 following services:

- 25 (A) Drug abuse treatment services.
- 26 (B) HIV or hepatitis screening.
- 27 (C) Hepatitis A and hepatitis B vaccination.
- 28 (D) Screening for sexually transmitted infections.
- 29 (E) Housing services for the homeless, for victims of domestic
30 violence, or other similar housing services.
- 31 (F) Services related to provision of education and materials for
32 the reduction of sexual risk behaviors, including, but not limited
33 to, the distribution of condoms.

34 (2) The entity has the capacity to commence needle and syringe
35 exchange services within three months of authorization.

36 (3) The entity has adequate funding to do all of the following
37 at reasonably projected program participation levels:

38 (A) Provide needles and syringe exchange services for all of its
39 participants.

1 (B) Provide HIV and viral hepatitis prevention education
2 services for all of its participants.

3 (C) Provide for the safe recovery and disposal of used syringes
4 and sharps waste from all of its participants.

5 (4) The entity has the capacity, and an established plan, to collect
6 evaluative data in order to assess program impact, including, but
7 not limited to, all of the following:

8 (A) The total number of persons served.

9 (B) The total number of syringes and needles distributed,
10 recovered, and disposed of.

11 (C) The total numbers and types of referrals to drug treatment
12 and other services.

13 (5) If the application is provisionally deemed appropriate by
14 the department, the department shall, at least 45 days prior to
15 approval of the application, provide for a period of public comment
16 as follows:

17 (A) Post on the department's Internet Web site the name of the
18 applicant, the nature of the services, and the location where the
19 applying entity will provide the services.

20 (B) Send a written and an e-mail notice to the local health officer
21 of the affected jurisdiction.

22 (e) The department shall establish and maintain on its Internet
23 Web site the address and contact information of programs
24 providing hypodermic needle and syringe exchange services
25 pursuant to this chapter.

26 (f) The authorization provided under this section shall only be
27 for a clean needle and syringe exchange project as described in
28 Section 121349.1.

29 (g) *This section shall become inoperative on January 1, 2019,*
30 *and as of that date is repealed.*

31 *SEC. 1.5. Section 121349 is added to the Health and Safety*
32 *Code, to read:*

33 *121349. (a) The Legislature finds and declares that scientific*
34 *data from needle exchange programs in the United States and in*
35 *Europe have shown that the exchange of used hypodermic needles*
36 *and syringes for clean hypodermic needles and syringes does not*
37 *increase drug use in the population, can serve as an important*
38 *bridge to treatment and recovery from drug abuse, and can curtail*
39 *the spread of human immunodeficiency virus (HIV) infection among*
40 *the intravenous drug user population.*

1 ***(b) In order to reduce the spread of HIV infection and***
2 ***bloodborne hepatitis among the intravenous drug user population***
3 ***within California, the Legislature hereby authorizes a clean needle***
4 ***and syringe exchange project pursuant to this chapter in any city,***
5 ***county, or city and county upon the action of a county board of***
6 ***supervisors and the local health officer or health commission of***
7 ***that county, or upon the action of the city council, the mayor, and***
8 ***the local health officer of a city with a health department, or upon***
9 ***the action of the city council and the mayor of a city without a***
10 ***health department.***

11 ***(c) The authorization provided under this section shall only be***
12 ***for a clean needle and syringe exchange project as described in***
13 ***Section 121349.1.***

14 ***(d) This section shall become operative on January 1, 2019.***

15 **SEC. 2.** Section 121349.1 of the Health and Safety Code is
16 amended to read:

17 121349.1. ***(a)*** The State Department of Public Health or a city,
18 county, or a city and county with or without a health department,
19 that acts to authorize a clean needle and syringe exchange project
20 pursuant to this chapter shall, in consultation with the State
21 Department of Public Health, authorize the exchange of clean
22 hypodermic needles and syringes, as recommended by the United
23 States Public Health Service, subject to the availability of funding,
24 as part of a network of comprehensive services, including treatment
25 services, to combat the spread of HIV and bloodborne hepatitis
26 infection among injection drug users. Staff and volunteers
27 participating in an exchange project authorized by the state, county,
28 city, or city and county pursuant to this chapter shall not be subject
29 to criminal prosecution for violation of any law related to the
30 possession, furnishing, or transfer of hypodermic needles or
31 syringes during participation in an exchange project. Program
32 participants shall not be subject to criminal prosecution for
33 possession of needles or syringes acquired from an authorized
34 needle and syringe exchange project entity.

35 ***(b) This section shall become inoperative on January 1, 2019,***
36 ***and as of that date is repealed***

37 **SEC. 2.5.** Section 121349.1 is added to the Health and Safety
38 Code, to read:

39 121349.1. ***(a)*** A city, county, or a city and county, with or
40 without a health department, that acts to authorize a clean needle

1 *and syringe exchange project pursuant to this chapter shall, in*
2 *consultation with the State Department of Public Health, authorize*
3 *the exchange of clean hypodermic needles and syringes, as*
4 *recommended by the United States Public Health Service, subject*
5 *to the availability of funding, as part of a network of comprehensive*
6 *services, including treatment services, to combat the spread of*
7 *HIV and bloodborne hepatitis infection among injection drug*
8 *users. Providers participating in an exchange project authorized*
9 *by the county, city, or city and county pursuant to this chapter*
10 *shall not be subject to criminal prosecution for possession of*
11 *needles or syringes during participation in an exchange project.*

12 *(b) This section shall become operative on January 1, 2019.*

13 SEC. 3. Section 121349.2 of the Health and Safety Code is
14 amended to read:

15 121349.2. (a) Local government, local health officials, and
16 law enforcement shall be given the opportunity to comment on
17 clean needle and syringe exchange programs on a biennial basis.
18 The public shall be given the opportunity to provide input to local
19 leaders to ensure that any potential adverse impacts on the public
20 welfare of clean needle and syringe exchange programs are
21 addressed and mitigated.

22 *(b) This section shall become inoperative on January 1, 2019,*
23 *and as of that date is repealed.*

24 SEC. 3.5. Section 121349.2 is added to the Health and Safety
25 Code, to read:

26 121349.2. (a) Local government, local public health officials,
27 and law enforcement shall be given the opportunity to comment
28 on clean needle and syringe exchange programs on an annual
29 basis. The public shall be given the opportunity to provide input
30 to local leaders to ensure that any potential adverse impacts on
31 the public welfare of clean needle and syringe exchange programs
32 are addressed and mitigated.

33 *(b) This section shall become operative on January 1, 2019.*

34 SEC. 4. Section 121349.3 of the Health and Safety Code is
35 amended to read:

36 121349.3. (a) The health officer of the participating jurisdiction
37 shall present biennially at an open meeting of the board of
38 supervisors or city council a report detailing the status of clean
39 needle and syringe exchange programs, including, but not limited
40 to, relevant statistics on bloodborne infections associated with

1 needle sharing activity and the use of public funds for these
2 programs. Law enforcement, administrators of alcohol and drug
3 treatment programs, other stakeholders, and the public shall be
4 afforded ample opportunity to comment at this biennial meeting.
5 The notice to the public shall be sufficient to ensure adequate
6 participation in the meeting by the public. This meeting shall be
7 noticed in accordance with all state and local open meeting laws
8 and ordinances, and as local officials deem appropriate. For
9 hypodermic needle and syringe exchange services authorized by
10 the State Department of Public Health, a biennial report shall be
11 provided by the department to the local health officer based on the
12 reports to the department from service providers within the
13 jurisdiction of that local health officer.

14 *(b) This section shall become inoperative on January 1, 2019,*
15 *and as of that date is repealed.*

16 *SEC. 5. Section 121349.3 is added to the Health and Safety*
17 *Code, to read:*

18 *121349.3. (a) The health officer of the participating*
19 *jurisdiction shall present annually at an open meeting of the board*
20 *of supervisors or city council a report detailing the status of clean*
21 *needle and syringe exchange programs, including, but not limited*
22 *to, relevant statistics on bloodborne infections associated with*
23 *needle sharing activity and the use of public funds for these*
24 *programs. Law enforcement, administrators of alcohol and drug*
25 *treatment programs, other stakeholders, and the public shall be*
26 *afforded ample opportunity to comment at this annual meeting.*
27 *The notice to the public shall be sufficient to ensure adequate*
28 *participation in the meeting by the public. This meeting shall be*
29 *noticed in accordance with all state and local open meeting laws*
30 *and ordinances, and as local officials deem appropriate.*

31 *(b) This section shall become operative on January 1, 2019.*

CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS



BILL NUMBER: AB 604

VERSION: As Amended July 14, 2011

AUTHOR: Skinner

SPONSOR: Drug Policy Alliance

BOARD POSITION: Support

SUBJECT: Needle exchange programs.

Affected Sections: An act to amend Sections 121349, 121349.1, 121349.2, and 121349.3 of the Health and Safety Code

CURRENT STATUS: Assembly Third Reading

EXISTING LAW:

Health and Safety Code Section 121349

1. Sets for legislative findings and declarations about needle exchange programs (NEPs).
2. Authorizes a clean needle and syringe exchange project in any city and county as specified.

Health and Safety Code Section 121349.1

Requires a city or county that approves such a project shall, in consultation with the State Department of Public Health, authorize the exchange of clean needles and syringes under conditions as specified.

Health and Safety Code Section 121349.2

Provides for an opportunity to comment on such a program on an annual basis.

Health and Safety Code Section 121349.3

1. Requires that the health officer of the participating jurisdiction shall present annually at an open meeting of the board of supervisors or city council a report detailing the program including, relevant statistics on blood-borne infections associated with needle sharing activity and the use of public funds for these programs.
2. Specifies that law enforcement, other stakeholders and the public be provided ample opportunity to provide comment during this meeting.

THIS BILL WOULD:

1. Allow the California Department of Public Health, until January 1, 2019, to also authorize NEPs, consistent with state and federal standards, and set for the application criteria.
2. Require the department to hold a public meeting at least 45 days prior to approving the program, as specified.
3. Clarify that the California Department of Public Health, a city, county or a city and county, with or without a department of public health department, may provide an NEP pursuant to appropriate authorizations. Also specifies that program participants shall not be subject to criminal prosecution for possession.
4. Would require an opportunity for public comment on any city or county program on a biennial basis.
5. Would require the health officer to present on a biennial basis, a report detailing the program relevant statistics on *bloodborne* infections associated with needle sharing activity and the use of public funds for these programs, either to the city or county, or to the department.

AUTHOR'S INTENT:

The author notes that the state lacks the authority to respond to urgent public health and fiscal concerns in parts of the state. Counties without a syringe exchange are amongst the counties with the highest number of AIDS cases related to syringe sharing, and with the highest per capita rate of AIDS from syringe sharing.

PRIOR BOARD DISCUSSION and ACTION

During the May Board Meeting, the board discussed the measure and established a "Support" position. Board staff provided a letter of support following the meeting.

This bill was amended to include a December 18, 2018 sunset date on its provisions. After that time, the law would return to its current form.

FISCAL/ECONOMIC IMPACT:

The bill does not have any significant fiscal impact to the board.

PREVIOUS/RELATED LEGISLATION:

SB 1159 (Vasconcellos) Chapter 608, Statutes of 2004 - Furnishing Hypodermic Needles and Syringes Without Prescription authorized until December 31, 2010, a pharmacist to sell or furnish 10 or fewer hypodermic needles or syringes to a person for human use without a prescription if the pharmacy is registered with a local health department in the Disease Prevention Demonstration Project, which would be created to evaluate the long-term

desirability of allowing licensed pharmacies to sell or furnish nonprescription hypodermic needles or syringes to prevent the spread of blood-borne pathogens, including HIV and hepatitis C. Detailed records of nonprescription sales of hypodermic needles and syringes are no longer required. The board had a support position on this bill.

SB 774 (Vasconcellos, 2005) would have authorized a licensed pharmacist to sell or furnish 30 or fewer hypodermic needles or syringes to a person for human use without a prescription as specified. The board supported this bill; however it was vetoed by the governor.

SB 1305 (Figueroa) Chapter 64, Statutes of 2006, prohibited a person from knowingly placing home-generated sharps waste in commercial and residential solid waste collection containers after September 1, 2008.

AB 110 (Laird), Chapter 707, Statutes of 2007, permits a public entity that receives General Fund money from the Department of Health Services (now DPH) for HIV prevention and education to use that money to support needle exchange programs. The board had a support position on this bill.

AB 1701 (Chesbro, Chapter 667, Statutes of 2010), extended the Disease Prevention Demonstration Project (DPDP) until December 31, 2018, which permits cities or counties to authorize licensed pharmacists to sell or furnish 10 or fewer hypodermic needles or syringes to a person for use without a prescription, as specified. This bill was signed by the governor.

AB 1858 (Blumenfield, 2010) would have allowed the California Department of Public Health to authorize entities to provide hypodermic needle and syringe exchange programs in any location where the department determines conditions exist for the rapid spread of deadly or disabling disease spread through the sharing of unclean hypodermic needles and syringes. This bill was vetoed by the governor.

“I am returning Assembly Bill 1858 without my signature. I signed legislation in 2005 that reflected a careful balance between good public health policy and local decision-making authority. I remain comfortable with that original decision and do not believe it is appropriate to change this balance and instead give authority to the state Department of Public Health to overrule local decisions regarding syringe exchange programs. For this reason, I am unwilling to sign this bill.”

SB 1029 (Yee, 2010) contained many of the same provisions. The governor vetoed this measure.

“I am returning Senate Bill 1029 without my signature. When I signed legislation my first year in office allowing for a pilot program to allow the sale of syringes through participating counties and registered pharmacies, I was seeking to balance the competing public health, law enforcement and local control issues that this issue requires. I believe this balance was achieved and SB 1029 would remove the ability of local officials to best determine policies in their jurisdiction. Some counties have not

sought to implement this pilot program, citing competing priorities, lack of pharmacy interest and law enforcement opposition. I respect these local decisions and while I appreciate the author's hard work and dedication to this issue, I cannot sign this bill.”

SUPPORT/OPPOSITION:

Support

Drug Policy Alliance (sponsor)
AIDS Project Los Angeles
American Civil Liberties Union
American Nurses Association California
California Association of Alcohol and Drug Program Executives, Inc.
California Hepatitis Alliance
California Nurses Association
California Opioid Maintenance Providers
California Society of Addiction Medicine
California State Board of Pharmacy
California Syringe Exchange Provider Network
Center for Health Justice
Clinica Monsenor Oscar A. Romero
Common Ground: The Westside HIV Community Center
County Alcohol and Drug Program Administrators Association of California
Harm Reduction Coalition
L.A. Gay and Lesbian Center
National Association of Social Workers
Redwood AIDS Information Network and Services
Saint James Infirmary
San Francisco AIDS Foundation
San Francisco Hepatitis C Task Force
Santa Clara County Board of Supervisors
Waste Management

Oppose

California Narcotic Officers' Association
California Police Chiefs Association
International Faith Based Coalition
League of California Cities
Los Angeles Division, League of California Cities

HISTORY:

Date	Action
July 14	Read second time and amended. Ordered to third reading.
July 13	From committee: Do pass as amended. (Ayes 6. Noes 3.) (July 11).

June 23 From committee: Do pass and re-refer to Com. on APPR. (Ayes 5. Noes 3.) (June 22). Re-referred to Com. on APPR.
 June 8 In committee: Hearing postponed by committee.
 May 26 Referred to Com. on HEALTH.
 May 16 In Senate. Read first time. To Com. on RLS. for assignment.
 May 16 Read third time. Passed. Ordered to the Senate. (Ayes 52. Noes 26. Page 1386.)
 Apr. 14 Read second time. Ordered to third reading.
 Apr. 13 From committee: Do pass. (Ayes 12. Noes 3.) (April 13).
 Apr. 6 Re-referred to Com. on APPR.
 Apr. 5 Read second time and amended.
 Apr. 4 From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 13. Noes 6.) (March 29).
 Mar. 21 Re-referred to Com. on HEALTH.
 Mar. 17 Referred to Com. on HEALTH. From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
 Feb. 17 From printer. May be heard in committee March 19.
 Feb. 16 Read first time. To print.

AMENDED IN ASSEMBLY JUNE 28, 2011

AMENDED IN SENATE MAY 24, 2011

AMENDED IN SENATE MAY 9, 2011

SENATE BILL

No. 41

Introduced by Senator Yee

December 7, 2010

An act to add and repeal Sections 4144.5, 4145.5, and 4148.5 of, and to repeal Section 4140 of, the Business and Professions Code, and to add Section 121281 to, and to add and repeal Section ~~11364.5~~ *11364.1* of, the Health and Safety Code, relating to public health.

LEGISLATIVE COUNSEL'S DIGEST

SB 41, as amended, Yee. Hypodermic needles and syringes.

Existing law regulates the sale, possession, and disposal of hypodermic needles and syringes, and requires, with certain exceptions, a prescription to purchase a hypodermic needle or syringe for human use. Existing law prohibits any person from possessing or having under his or her control any hypodermic needle or syringe, except in accordance with those regulatory provisions.

This bill would delete the prohibition against any person possessing or having under his or her control any hypodermic needle or syringe, except in accordance with the aforementioned regulatory provisions.

Existing law, beginning January 1, 2011, and ending December 31, 2018, authorizes a county or city to authorize a licensed pharmacist to sell or furnish 10 or fewer hypodermic needles or syringes to a person 18 years of age or older for human use without a prescription if the pharmacist works for a pharmacy that is registered with a local health department in the Disease Prevention Demonstration Project, established

by law to evaluate the long-term desirability of allowing licensed pharmacies to sell or furnish nonprescription hypodermic needles or syringes to prevent the spread of bloodborne pathogens, including HIV and hepatitis C.

Under existing law, it is unlawful to possess an opium pipe or any device, contrivance, instrument, or paraphernalia used for unlawfully injecting or smoking specified controlled substances.

Existing law, beginning January 1, 2011, and ending December 31, 2018, provides that the above-described provisions, pursuant to authorization from a city or county, shall not apply to the possession solely for personal use of 10 or fewer hypodermic needles or syringes.

This bill would, until January 1, 2015, make these provisions, including any local authorization, inoperative, and would in the interim, authorize a physician or pharmacist, without a prescription or a permit, to furnish 30 or fewer hypodermic needles and syringes for human use to a person 18 years of age or older and would authorize a person 18 years of age or older, without a prescription or license, to obtain 30 or fewer hypodermic needles and syringes solely for personal use from a physician or pharmacist.

This bill would, until January 1, 2015, provide that the above-described provisions making it unlawful to possess an opium pipe or any device, contrivance, instrument, or paraphernalia for unlawfully injecting or smoking certain controlled substances shall not apply to possession solely for personal use of 30 or fewer hypodermic needles or syringes if acquired from a physician, pharmacist, hypodermic needle and syringe exchange program, or any other source that is authorized by law to provide sterile syringes or hypodermic needles without a prescription.

This bill would require the state Office of AIDS to develop and maintain information on its Internet Web site to educate consumers at risk of bloodborne infections of opportunities to improve and protect their health, and to protect the public health and would also require the California State Board of Pharmacy to post, or post a link to, this information on its Internet Web site.

The Pharmacy Law requires a pharmacist to keep detailed records of nonprescription sales of hypodermic needles and syringes. Existing law makes it a crime to knowingly violate any provision relating to the Pharmacy Law.

This bill would, until January 1, 2015, require pharmacies that furnish nonprescription hypodermic needles and syringes to store the

hypodermic needles and syringes in a manner that ensures that they are not accessible to unauthorized persons, and would require pharmacies or hypodermic needle and syringe exchange programs to provide consumers with prescribed options for consumer disposal of hypodermic needles and syringes. This bill would also, until January 1, 2015, require the pharmacies to provide prescribed written information or verbal counseling at the time of furnishing or sale of nonprescription hypodermic needles or syringes. By changing the definition of an existing crime, this bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. It is the intent of the Legislature to improve access
2 to syringes and hypodermic needles so as to remove significant
3 barriers for persons seeking to protect their health and the health
4 of other persons, and to remove barriers for programs or businesses
5 to provide sterile injection equipment and education to adults,
6 thereby reducing the spread of communicable diseases and
7 protecting the public health.

8 SEC. 2. Section 4140 of the Business and Professions Code is
9 repealed.

10 SEC. 3. Section 4144.5 is added to the Business and Professions
11 Code, to read:

12 4144.5. (a) A person may sell or obtain hypodermic needles
13 and hypodermic syringes without a prescription or permit, for uses
14 that the board determines are industrial, and that person shall not
15 be required to comply with Section 4145.5 or 4146.

16 (b) This section shall remain in effect only until January 1, 2015,
17 and as of that date is repealed, unless a later enacted statute, that
18 is enacted before January 1, 2015, deletes or extends that date.

19 SEC. 4. Section 4145.5 is added to the Business and Professions
20 Code, to read:

1 4145.5. (a) Notwithstanding any other provision of law, a
2 pharmacist or physician may, without a prescription or a permit,
3 furnish hypodermic needles and syringes for human use, and a
4 person may, without a prescription or license, obtain hypodermic
5 needles and syringes from a pharmacist or physician for human
6 use, if the person is known to the furnisher and the furnisher has
7 previously been provided a prescription or other proof of a
8 legitimate medical need requiring a hypodermic needle or syringe
9 to administer a medicine or treatment.

10 (b) Notwithstanding any other provision of law, as a public
11 health measure intended to prevent the transmission of HIV, viral
12 hepatitis, and other bloodborne diseases among persons who use
13 syringes and hypodermic needles, and to prevent subsequent
14 infection of sexual partners, newborn children, or other persons,
15 a physician or pharmacist may, without a prescription or a permit,
16 furnish 30 or fewer hypodermic needles and syringes for human
17 use to a person 18 years of age or older, and a person 18 years of
18 age or older may, without a prescription or license, obtain 30 or
19 fewer hypodermic needles and syringes solely for personal use
20 from a physician or pharmacist.

21 (c) Notwithstanding any other provision of law, a pharmacist,
22 veterinarian, or person licensed pursuant to Section 4141 may,
23 without a prescription or license, furnish hypodermic needles and
24 syringes for use on animals, and a person may, without a
25 prescription or license, obtain hypodermic needles and syringes
26 from a pharmacist, veterinarian, or person licensed pursuant to
27 Section 4141 for use on animals, providing that no needle or
28 syringe shall be furnished to a person who is unknown to the
29 furnisher and unable to properly establish his or her identity.

30 (d) A pharmacy that furnishes nonprescription hypodermic
31 needles and syringes shall store hypodermic needles and syringes
32 in a manner that ensures that they are available only to authorized
33 personnel, and are not accessible to other persons.

34 (e) In order to provide for the safe disposal of hypodermic
35 needles and syringes, a pharmacy or hypodermic needle and syringe
36 exchange program that furnishes nonprescription hypodermic
37 needles and syringes shall provide consumers with one or more
38 of the following disposal options:

39 (1) It shall establish an onsite, safe, hypodermic needle and
40 syringe collection and disposal program.

(2) It shall furnish, or make available, mail-back sharps disposal containers authorized by the United States Postal Service that meet applicable state and federal requirements, and shall provide tracking forms to verify destruction at a certified disposal facility.

(3) It shall furnish, or make available, a personal medical sharps disposal container that meets applicable state and federal standards for disposal of medical sharps waste.

(f) A pharmacy that furnishes nonprescription syringes shall provide written information or verbal counseling to consumers at the time of furnishing or sale of nonprescription hypodermic needles or syringes on how to do the following:

(1) Access drug treatment.

(2) Access testing and treatment for HIV and hepatitis C.

(3) Safely dispose of sharps waste.

(g) This section shall remain in effect only until January 1, 2015, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2015, deletes or extends that date.

SEC. 5. Section 4148.5 is added to the Business and Professions Code, to read:

4148.5. (a) All stocks of hypodermic needles or syringes shall be confiscated if found outside the licensed premises of any person holding a permit under Section 4141 and found not in the possession or under the control of a person entitled to an exemption under Section 4143, 4144, or 4145.5, or under Section 11364.5, 121349, or 121349.1 of the Health and Safety Code.

(b) This section shall remain in effect only until January 1, 2015, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2015, deletes or extends that date.

SEC. 6. Section ~~41364.5~~ *11364.1* is added to the Health and Safety Code, to read:

~~41364.5.~~

11364.1. (a) It is unlawful to possess an opium pipe or any device, contrivance, instrument, or paraphernalia used for unlawfully injecting or smoking (1) a controlled substance specified in subdivision (b), (c), or (e), or paragraph (1) of subdivision (f) of Section 11054, specified in paragraph (14), (15), or (20) of subdivision (d) of Section 11054, specified in subdivision (b) or (c) of Section 11055, or specified in paragraph (2) of subdivision (d) of Section 11055, or (2) a controlled substance which is a narcotic drug classified in Schedule III, IV, or V.

(b) This section shall not apply to hypodermic needles or syringes that have been containerized for safe disposal in a container that meets state and federal standards for disposal of sharps waste.

(c) As a public health measure intended to prevent the transmission of HIV, viral hepatitis, and other bloodborne diseases among persons who use syringes and hypodermic needles, and to prevent subsequent infection of sexual partners, newborn children, or other persons, this section shall not apply to the possession solely for personal use of 30 or fewer hypodermic needles or syringes if acquired from a physician, pharmacist, hypodermic needle and syringe exchange program, or any other source that is authorized by law to provide sterile syringes or hypodermic needles without a prescription.

(d) This section shall remain in effect only until January 1, 2015, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2015, deletes or extends that date.

SEC. 7. Section 121281 is added to the Health and Safety Code, to read:

121281. In order to assist pharmacists and pharmacy personnel in the education of consumers who are at risk of bloodborne infections regarding methods and opportunities for improving and protecting their health, and thereby protect the public health, the Office of AIDS shall develop and maintain all of the following information, on its Internet Web site, and the California State Board of Pharmacy shall also post, or maintain a link to, the information on its Internet Web site:

(a) How consumers can access testing and treatment for HIV and viral hepatitis.

(b) How consumers can safely dispose of syringes and hypodermic needles or other sharps waste.

(c) How consumers can access drug treatment.

SEC. 8. (a) Sections 4144, 4145, and 4148 of the Business and Professions Code, and Sections 11364 and 121285 of the Health and Safety Code, including related local authorizations, shall become inoperative until January 1, 2015.

(b) On and after January 1, 2015, Sections 4144, 4145, and 4148 of the Business and Professions Code, and Sections 11364 and 121285 of the Health and Safety Code, shall be operative, including

1 related local authorization unless the county or city acts to remove
2 the authorization.

3 SEC. 9. No reimbursement is required by this act pursuant to
4 Section 6 of Article XIII B of the California Constitution because
5 the only costs that may be incurred by a local agency or school
6 district will be incurred because this act creates a new crime or
7 infraction, eliminates a crime or infraction, or changes the penalty
8 for a crime or infraction, within the meaning of Section 17556 of
9 the Government Code, or changes the definition of a crime within
10 the meaning of Section 6 of Article XIII B of the California
11 Constitution.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: SB 41

VERSION: As Amended June 28, 2011

AUTHOR: Yee

SPONSOR: San Francisco Aids Foundation
Drug Policy Alliance

BOARD POSITION: Support If Amended

SUBJECT: Hypodermic Needles and Syringes

Affected Sections: Add and repeal Sections 4144.5, 4145.5, 4148.5 and repeal Section 4140 of the Business and Professions Code and add Section 121218 to and add and repeal Section 11364.1 of the Health and Safety Code

CURRENT STATUS: Senate Health Committee Hearing April 6, 2011

EXISTING LAW:

1. Allows a pharmacist, if authorized by a county or city, to furnish or sell 10 or fewer hypodermic needles or syringes at any one time as specified.
2. Establishes a December 31, 2018 sunset date for this provision.
3. Specified that no person shall possess a hypodermic needle or syringe except when acquired in accordance with specified provisions of the law.
4. Allows a pharmacist or physician to furnish hypodermic needles or syringes for human use without a prescription or permit if the person is known to the furnisher and the furnisher has been previously provided with a prescription or proof of legitimate medical need.
5. Establishes the Disease Prevention Demonstration Project (DPDP) as collaboration between pharmacies and local and state health officials for the purpose of evaluating the long-term desirability of allowing licensed pharmacists to furnish or sell nonprescription hypodermic needles or syringes to prevent the spread of blood-borne pathogens, including HIV and hepatitis C.
6. Allows for a person to possess, for personal use, 10 or fewer hypodermic needles and syringes if acquired from an authorized source.
7. Allows local governments, local health officers, and law enforcement, the opportunity to comment on needle exchange programs (NEPs) on an annual basis.

THIS BILL WOULD:

1. Repeal the section prohibiting a person from possessing a hypodermic needle or syringe except as provided in Article 9 (Hypodermic Needles and Syringes).

Would authorize the following until January 1, 2015:

2. Allow a physician or pharmacist to furnish hypodermic needles and syringes, without a prescription, if the person is known to the furnisher and the furnisher has previously been provided a prescription or other proof of the legitimate medical need to administer a medicine or treatment.
3. Allow a physician or pharmacist to furnish 30 or fewer hypodermic needles and syringes for human use to a person 18 years of age or older for personal use.
4. Specify that pharmacies shall furnish such products in a manner to ensure that they are only available to authorized personnel.
5. Shall provide consumers with disposal options including an onsite collection program or make available mail-back sharps containers or personal medical sharps disposal containers.
6. Shall provide written information or verbal counseling to patients about access to drug treatment, testing and treatment for HIV and hepatitis C and safe disposal of sharps waste.
7. Specify that all stocks of needles and syringes shall be confiscated if found outside the licensed premises or found not in the possession or control of a person entitled under these provisions.
8. Require Office of Aids to develop and maintain information on its website about accessing drug treatment, accessing HIV and hepatitis screenings and safe disposal of syringe and sharps waste; require the Board to either post or maintain a link to the same information on its Web site.
9. Specifies that it is unlawful to possess an opium pipe or any device as specified, used for unlawfully injecting or smoking controlled substances as specified. Further indicates that this does not apply to the possession for personal use of 30 or few hypodermic needle and syringes obtained consistent with legal requirements.

AUTHOR'S INTENT:

According to the author, the intent of the bill is to improve access to hypodermic needles and syringes in order to remove significant barriers for persons seeking to protect their health and the health of other persons. The author also seeks to remove barriers for programs or businesses to provide sterile injection equipment and education to adults.

FISCAL IMPACT:

The bill does not have any significant fiscal impact to the board. As the measure may impact a licensee or entity under the board's jurisdiction, it is possible that the board may exercise regulatory authority over any related activities within a licensee's scope of

practice or authority. The board could likely utilize existing resources to comply with the posting requirements.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting, the board discussed this measure as well as the potential unintended consequences if the repeal of the section prohibiting a person from possessing a hypodermic needle or syringe remained in the bill. After discussion the board established a "Support If Amended" position and requested that board staff advise the author's office. Following the meeting board staff conveyed the board's concerns to the author's office.

This measure has been amended three times since the board meeting. In its current form, this measure does include provisions about the unlawful possession of needles unless it is consistent with the provisions. This is established in the Health and Safety Code, not in the Business and Professions Code.

PREVIOUS/CURRENT LEGISLATION:

SB 1159 (Vasconcellos) Chapter 608, Statutes of 2004 - Furnishing Hypodermic Needles and Syringes Without Prescription authorized until December 31, 2010, a pharmacist to sell or furnish 10 or fewer hypodermic needles or syringes to a person for human use without a prescription if the pharmacy is registered with a local health department in the Disease Prevention Demonstration Project, which would be created to evaluate the long-term desirability of allowing licensed pharmacies to sell or furnish nonprescription hypodermic needles or syringes to prevent the spread of blood-borne pathogens, including HIV and hepatitis C. Detailed records of nonprescription sales of hypodermic needles and syringes are no longer required. The board had a support position on this bill.

SB 774 (Vasconcellos, 2005) would have authorized a licensed pharmacist to sell or furnish 30 or fewer hypodermic needles or syringes to a person for human use without a prescription as specified. The board supported this bill; however it was vetoed by the governor.

SB 1305 (Figueroa) Chapter 64, Statutes of 2006, prohibited a person from knowingly placing home-generated sharps waste in commercial and residential solid waste collection containers after September 1, 2008.

AB 110 (Laird), Chapter 707, Statutes of 2007, permits a public entity that receives General Fund money from the Department of Health Services (now DPH) for HIV prevention and education to use that money to support needle exchange programs. The board had a support position on this bill.

AB 1701 (Chesbro, Chapter 667, Statutes of 2010), extended the Disease Prevention Demonstration Project (DPDP) until December 31, 2018, which permits cities or counties to authorize licensed pharmacists to sell or furnish 10 or fewer hypodermic needles or syringes to a person for use without a prescription, as specified. This bill was signed by the governor.

AB 1858 (Blumenfield, 2010) would have allowed the California Department of Public Health to authorize entities to provide hypodermic needle and syringe exchange programs in any location where the department determines conditions exist for the rapid spread of deadly or disabling disease spread through the sharing of unclean hypodermic needles and syringes. This bill was vetoed by the governor.

“I am returning Assembly Bill 1858 without my signature. I signed legislation in 2005 that reflected a careful balance between good public health policy and local decision-making authority. I remain comfortable with that original decision and do not believe it is appropriate to change this balance and instead give authority to the state Department of Public Health to overrule local decisions regarding syringe exchange programs. For this reason, I am unwilling to sign this bill.”

SB 1029 (Yee, 2010) contained many of the same provisions. The governor vetoed this measure.

“I am returning Senate Bill 1029 without my signature. When I signed legislation my first year in office allowing for a pilot program to allow the sale of syringes through participating counties and registered pharmacies, I was seeking to balance the competing public health, law enforcement and local control issues that this issue requires. I believe this balance was achieved and SB 1029 would remove the ability of local officials to best determine policies in their jurisdiction. Some counties have not sought to implement this pilot program, citing competing priorities, lack of pharmacy interest and law enforcement opposition. I respect these local decisions and while I appreciate the author's hard work and dedication to this issue, I cannot sign this bill.”

SUPPORT and OPPOSITION:

Support

Drug Policy Alliance (sponsor)
San Francisco AIDS Foundation (co-sponsor)
ACLU
AFSCME
AIDS Project Los Angeles
Alameda County Board of Supervisors
California Hepatitis Alliance
California Medical Association
California Nurses Association

California Opioid Maintenance Providers
 California Pharmacists Association
 California Psychiatric Association
 California Retailers Association
 County Alcohol and Drug Program Administrators Association of California
 CVS/Caremark
 Drug Policy Alliance
 Friends Committee on Legislation of California
 Health Officers Association of California
 Rite Aid
 San Francisco Hepatitis C Task Force
 Santa Clara County Board of Supervisors
 Walgreens

Oppose

Association of Los Angeles Deputy Sheriffs
 California District Attorneys Association

HISTORY:

Date	Action
July 14	Read second time. Ordered to third reading.
July 13	From committee: Do pass. (Ayes 11. Noes 4.) (July 13).
June 28	Read second time and amended. Re-referred to Com. on APPR.
June 27	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 12. Noes 6.) (June 21).
June 9	Referred to Com. on HEALTH.
June 1	In Assembly. Read first time. Held at Desk.
May 31	Read third time. Passed. (Ayes 24. Noes 13. Page 1187.) Ordered to the Assembly.
May 24	Read second time and amended. Ordered to third reading.
May 23	From committee: Be placed on second reading file pursuant to Senate Rule 28.8 and be amended.
May 13	Set for hearing May 23.
May 9	Read second time and amended. Re-referred to Com. on APPR.
May 5	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 5. Noes 1. Page 741.) (April 26).
Apr. 14	Set for hearing April 26.
Apr. 7	From committee: Do pass and re-refer to Com. on PUB. S. (Ayes 5. Noes 3. Page 580.) (April 6). Re-referred to Com. on PUB. S.
Mar. 15	Set for hearing April 6.
Mar. 14	Set, first hearing. Hearing canceled at the request of author.
Mar. 4	Set for hearing March 23.
Jan. 20	Referred to Coms. on HEALTH and PUB. S.
Jan. 3	Read first time.
2010	
Dec. 8	From printer. May be acted upon on or after January 7.
Dec. 7	Introduced. To Com. on RLS. for assignment. To print.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: SB 514

VERSION: As Amended May 10, 2011

AUTHOR: Simitian

SPONSOR: Author

BOARD POSITION: SUPPORT

SUBJECT: Dextromethorphan: sale to minors prohibited

Affected Sections: Add Sections 11110 and 11111 to the Health and Safety Code

CURRENT STATUS: Ordered to Third Reading in the Assembly

EXISTING LAW:

1. Health and Safety Code section 11100 establishes the conditions and reporting requirements for the sale of ephedrine and pseudoephedrine to a person under 18 years of age.
2. Regulates the sale of nonprescription drugs.

THIS BILL WOULD:

1. State that it shall be an infraction (punishable by a fine of up to \$250) to sell willfully and knowingly to a person under 18 years of age, an over-the-counter drug, material, compound, mixture, preparation or substance containing dextromethorphan without a prescription.
2. State it shall be prima facie evidence of a violation if the person making the sale does not require and obtain "proof of age" from anyone presumably younger than 25.
 - a. Defines "proof of age" as any document issued by a government agency that contains a description or photo and provides the person's date of birth.
3. State it shall be affirmative defense to a violation if the defendant can prove all of the following:
 - a. Proof of age was obtained as required
 - b. The purchaser provided false representation of his or her age
 - c. The appearance of the purchaser would lead an ordinary person to believe the purchaser was at least 18 years old.
 - d. The sale was made in good faith based on the information provided.
4. Specify that a retail clerk that fails to obtain proof of age is not guilty of an infraction, subject to civil penalties.

- a. State that this does not apply to a retail clerk that is willfully participating in an ongoing criminal conspiracy to violate these provisions.
5. Specify, that if feasible, the retailer selling the product, use a cash register that is equipped with an age-verification feature to monitor age-restricted items which shall be programmed to direct the clerk to request verification of age prior to the sale.

AUTHOR'S INTENT:

The intent of this legislation is to restrict access to dextromethorphan by minors. According to the author's office, Poison Control reports an 850% increase in the number of calls it has received over the last ten years resulting from dextromethorphan. The author's office also stated that one in ten high school students has abused this drug.

FISCAL IMPACT:

The board does not anticipate any significant impact to board operations.

COMMENTS:

The author's office indicated that there are conversations at the federal level about whether to classify dextromethorphan as a scheduled substance.

As amended, the provisions that prohibited an employer to taking action against a clerk that unlawfully sold this product have been removed, and provisions were added regarding the use of a cash register that is equipped with an age-verification feature to monitor age-restricted items if feasible.

PRIOR BOARD DISCUSSION and ACTION:

During the May Board Meeting the board discussed this bill as well as the effects of dextromethorphan and the prevalence of abuse. Based on this discussion the board established a "Support" position which was conveyed to the author's office.

This bill was amended to specify that an infraction of this provision could result in a fine of up to \$250.

RELATED/PREVIOUS LEGISLATION:

AB 1853 (Simitian, 2003) would have prohibited the sale, without a prescription, of a nonprescription drug containing dextromethorphan to a minor. This bill died on the inactive file.

SB 307 (Simitian, 2005) contained the same general provisions. This bill was never heard in committee.

SUPPORT/OPPOSITION:Support

California Chapter of American College of Emergency Physicians
California Peace Officers' Association
California Police Chiefs Association, Inc.
California State Board of Pharmacy
City of Palo Alto Police Department
Consumer Healthcare Products Association
Full Circle Treatment Center
Junior Leagues of California
Palo Alto Police Officers' Association
Rady Children's Hospital of San Diego

Opposition

California Grocers Association

HISTORY:

Date	Action
Apr. 25	From committee with author's amendments. Read second time and amended. Re-referred to Com. on PUB. S.
Apr. 21	Set for hearing May 3.
Mar. 17	Hearing postponed by committee.
Mar. 9	Set for hearing March 22.
Mar. 3	Referred to Com. on PUB. S.
Feb. 18	From printer. May be acted upon on or after March 20.
Feb. 17	Introduced. Read first time. To Com. on RLS. for assignment. To print.

AMENDED IN SENATE MAY 10, 2011

AMENDED IN SENATE APRIL 25, 2011

SENATE BILL

No. 514

Introduced by Senator Simitian

February 17, 2011

An act to add Sections 11110 and 11111 to the Health and Safety Code, relating to nonprescription drugs.

LEGISLATIVE COUNSEL'S DIGEST

SB 514, as amended, Simitian. Dextromethorphan: sale to minors prohibited.

Existing law prohibits a manufacturer, wholesaler, retailer, or other person from selling, transferring, or otherwise furnishing a specified substance, including ephedrine and pseudoephedrine, to a person under 18 years of age, except as specified. A first violation of this provision is a misdemeanor. Existing law further regulates the sale of nonprescription drugs, as specified.

This bill would, in addition, make it an infraction, *punishable by a fine not exceeding \$250*, for any person, corporation, or retail distributor, in an over-the-counter sale to, without a prescription, to willfully and knowingly supply, deliver, or give possession of a nonprescription drug containing dextromethorphan to a person under 18 years of age. The bill would provide that proof that bona fide evidence of majority and identity was demanded and shown shall be a defense to any criminal prosecution.

The bill would further provide that a retail clerk who fails to require and obtain proof of age from the purchaser shall not be guilty of an infraction or subject to any civil penalties, unless the retail clerk is a willful participant in an ongoing criminal conspiracy to violate the

provisions prohibiting the sale of dextromethorphan to minors. By creating new crimes, this bill would impose a state-mandated local program.

The bill would require a person, corporation, or retail distributor that sells a product containing dextromethorphan to use a cash register that is equipped with an age-verification feature that directs the retail clerk to request identification before the product may be purchased, as provided.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 11110 is added to the Health and Safety
2 Code, to read:

3 11110. (a) It shall be an infraction, *punishable by a fine not*
4 *exceeding two hundred fifty dollars (\$250)*, for any person,
5 corporation, or retail distributor to willfully and knowingly supply,
6 deliver, or give possession of a drug, material, compound, mixture,
7 preparation, or substance containing any quantity of
8 dextromethorphan (the dextrorotatory isomer of
9 3-methoxy-N-methylmorphinan, including its salts, but not
10 including its racemic or levorotatory forms) to a person under 18
11 years of age in an over-the-counter sale without a prescription.

12 (b) It shall be prima facie evidence of a violation of this section
13 if the person, corporation, or retail distributor making the sale does
14 not require and obtain bona fide evidence of majority and identity
15 from the purchaser, unless from the purchaser's outward
16 appearance the person making the sale would reasonably presume
17 the purchaser to be 25 years of age or older.

18 (c) Proof that a person, corporation, or retail distributor, or his
19 or her agent or employee, demanded, was shown, and acted in
20 reasonable reliance upon, bona fide evidence of majority and
21 identity shall be a defense to any criminal prosecution under this
22 section. As used in this section, "bona fide evidence of majority

1 and identity” means a document issued by a federal, state, county,
2 or municipal government, or subdivision or agency thereof,
3 including, but not limited to, a motor vehicle operator’s license,
4 California state identification card, identification card issued to a
5 member of the Armed Forces, or other form of identification that
6 bears the name, date of birth, description, and picture of the person.

7 (d) (1) Notwithstanding any other provision of this section, a
8 retail clerk who fails to require and obtain proof of age from the
9 purchaser shall not be guilty of an infraction pursuant to
10 subdivision (a) or subject to any civil penalties.

11 (2) This subdivision shall not apply to a retail clerk who is a
12 willful participant in an ongoing criminal conspiracy to violate
13 this section.

14 SEC. 2. Section 11111 is added to the Health and Safety Code,
15 to read:

16 11111. A person, corporation, or retail distributor that sells or
17 makes available products containing dextromethorphan, as defined
18 in subdivision (a) of Section 11110, in an over-the-counter sale
19 without a prescription shall, if feasible, use a cash register that is
20 equipped with an age-verification feature to monitor age-restricted
21 items. The cash register shall be programmed to direct the retail
22 clerk making the sale to request bona fide evidence of majority
23 and identity, as described in subdivision (c) of Section 11110,
24 before a product containing dextromethorphan may be purchased.

25 SEC. 3. No reimbursement is required by this act pursuant to
26 Section 6 of Article XIII B of the California Constitution because
27 the only costs that may be incurred by a local agency or school
28 district will be incurred because this act creates a new crime or
29 infraction, eliminates a crime or infraction, or changes the penalty
30 for a crime or infraction, within the meaning of Section 17556 of
31 the Government Code, or changes the definition of a crime within
32 the meaning of Section 6 of Article XIII B of the California
33 Constitution.

AMENDED IN SENATE JULY 12, 2011

AMENDED IN SENATE JUNE 7, 2011

AMENDED IN SENATE JUNE 6, 2011

AMENDED IN ASSEMBLY MAY 4, 2011

CALIFORNIA LEGISLATURE—2011–12 REGULAR SESSION

ASSEMBLY BILL

No. 1424

Introduced by Assembly Member Perea

March 22, 2011

An act to amend Sections 31, 476, and 7145.5 of, and to add Section 494.5 to, the Business and Professions Code, to add Section ~~12419~~ *12419.13* to the Government Code, to add Section 10295.4 to the Public Contract Code, and to amend ~~Section Sections~~ *Sections 7063 and* 19195 of, to add Sections 6834, 6835, 7057, 19265, 19377.5, and 19571 to, *to add Article 9 (commencing with Section 6850) to Chapter 6 of Part 1 of Division 2 of*, and to add Article 7 (commencing with Section 19291) to Chapter 5 of Part 10.2 of Division 2 of, the Revenue and Taxation Code, relating to taxation.

LEGISLATIVE COUNSEL'S DIGEST

AB 1424, as amended, Perea. Franchise Tax Board: delinquent tax debt.

The Personal Income Tax Law and the Corporation Tax Law impose taxes on, or measured by, income. Existing law requires the Franchise Tax Board to make available as a matter of public record each calendar year a list of the 250 largest tax delinquencies in excess of \$100,000, and requires the list to include specified information with respect to each delinquency. Existing law requires every board, as defined, and

the Department of Insurance, upon request of the Franchise Tax Board, to furnish to the Franchise Tax Board certain information with respect to every licensee.

This bill would require the *State Board of Equalization and the Franchise Tax Board* to *each* make available a list of the ~~250~~ 500 largest tax delinquencies described above at least twice each calendar year. This bill would require the Franchise Tax Board to include additional information on the list with respect to each delinquency, including the type, status, and licence number of any occupational or professional license held by the person or persons liable for payment of the tax and the names and titles of the principal officers of the person liable for payment of the tax if that person is a limited liability company or corporation. This bill would require a person whose delinquency appeared on ~~the~~ *either* list and whose name has been removed, as provided, to comply with the terms of the arranged resolution, and would authorize *the State Board of Equalization and the Franchise Tax Board*, if the person fails to comply with the terms of the arranged resolution, to add the person's name to the list without providing prior written notice, as provided.

This bill would permit a state governmental licensing entity, that issues professional or occupational licenses, certificates, registrations, or permits, to suspend, revoke, or refuse to issue a license if the licensee's name is included on ~~the~~ *either* list of the ~~250~~ 500 largest tax delinquencies described above. This bill would also require those licensing entities to provide to *the State Board of Equalization and the Franchise Tax Board* the name and social security number or federal taxpayer identification number of each individual licensee of that entity, and would require each application for a new license or renewal of a license to indicate on the application that the law allows *the State Board of Equalization and the Franchise Tax Board* to share taxpayer information with a board and requires the licensee to pay his or her state ~~income~~ tax obligation and that his or her license may be suspended if the state ~~income~~ tax obligation is not paid. The bill would require *the State Board of Equalization and the Franchise Tax Board*, if an individual licensee appears on ~~the~~ *either* list of the ~~250~~ 500 largest tax delinquencies described above, and the specified licensing entity has not made a decision regarding suspension or revocation of the license, to send a notice of suspension to the licensee. The bill would provide that the license of a licensee who fails to satisfy the unpaid taxes by a certain date shall be automatically suspended, except as specified, and

would require *the State Board of Equalization or* the Franchise Tax Board to mail a notice of suspension to the applicable state governmental licensing entity and to the licensee, and would provide that the suspension be canceled upon compliance with the tax obligation. The bill would require *the State Board of Equalization and* the Franchise Tax Board to meet certain requirements and would make related changes.

The bill would provide that the release or other use of information received by a state governmental licensing entity pursuant to these provisions, except as authorized, is punishable as a misdemeanor. By creating a new crime, the bill would impose a state-mandated local program.

This bill would also prohibit a state agency from entering into any contract for the acquisition of goods or services with a contractor whose name appears on ~~the~~ *either* list of the ~~250~~ 500 largest tax delinquencies described above.

Existing law authorizes the Franchise Tax Board to collect specified amounts for the Department of Industrial Relations and specified amounts imposed by a court pursuant to specified procedures.

This bill would authorize *the State Board of Equalization and* the Franchise Tax Board to enter into an agreement to collect any delinquent tax debt due to the Internal Revenue Service or any other state imposing an income tax or tax measured by income pursuant to specified procedures, provided that the Internal Revenue Service or that state has entered into an agreement to collect delinquent tax debts due to *the State Board of Equalization or* the Franchise Tax Board, and the agreements do not cause the net displacement of civil service employees, as specified. This bill would require the Controller, upon execution of a reciprocal agreement between *the State Board of Equalization*, the Franchise Tax Board, and any other state imposing *a sales and use tax, a tax similar to a sales and use tax*, an income tax, or tax measured by income, to offset any delinquent tax debt due to that other state from a person or entity, against any refund under the Personal Income Tax Law or the Corporation Tax Law owed to that person or entity, as provided.

This bill would incorporate additional changes to Section 7145.5 of the Business and Professions Code, proposed by AB 1307, to be operative as specified.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.

State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 31 of the Business and Professions Code
2 is amended to read:

3 31. (a) As used in this section, “board” means any entity listed
4 in Section 101, the entities referred to in Sections 1000 and 3600,
5 the State Bar, the Department of Real Estate, and any other state
6 agency that issues a license, certificate, or registration authorizing
7 a person to engage in a business or profession.

8 (b) Each applicant for the issuance or renewal of a license,
9 certificate, registration, or other means to engage in a business or
10 profession regulated by a board who is not in compliance with a
11 judgment or order for support shall be subject to Section 17520 of
12 the Family Code.

13 (c) “Compliance with a judgment or order for support” has the
14 meaning given in paragraph (4) of subdivision (a) of Section 17520
15 of the Family Code.

16 (d) Each licensee whose name appears on a list of the ~~250~~ 500
17 largest tax delinquencies pursuant to Section ~~7063~~ or 19195 of the
18 Revenue and Taxation Code shall be subject to Section 494.5 or
19 7145.5 or to Section ~~6834~~ or 19265 of the Revenue and Taxation
20 Code.

21 (e) Each application for a new license or renewal of a license
22 shall indicate on the application that the law allows *the State Board*
23 *of Equalization and* the Franchise Tax Board to share taxpayer
24 information with a board and requires the licensee to pay his or
25 her state ~~income~~ tax obligation and that his or her license may be
26 suspended if the state ~~income~~ tax obligation is not paid.

27 (f) *For purposes of this section, “tax obligation” means the tax*
28 *imposed under, or in accordance with, Part 1 (commencing with*
29 *Section 6001), Part 1.5 (commencing with Section 7200), Part 1.6*
30 *(commencing with Section 7251), Part 1.7 (commencing with*

1 *Section 7285), Part 10 (commencing with Section 17001), and*
2 *Part 11 (commencing with Section 23001) of Division 2 of the*
3 *Revenue and Taxation Code.*

4 SEC. 2. Section 476 of the Business and Professions Code is
5 amended to read:

6 476. (a) Except as provided in subdivision (b), nothing in this
7 division shall apply to the licensure or registration of persons
8 pursuant to Chapter 4 (commencing with Section 6000) of Division
9 3, or pursuant to Division 9 (commencing with Section 23000) or
10 pursuant to Chapter 5 (commencing with Section 19800) of
11 Division 8.

12 (b) Section 494.5 shall apply to the licensure of persons
13 authorized to practice law pursuant to Chapter 4 (commencing
14 with Section 6000) of Division 3, and the licensure or registration
15 of persons pursuant to Chapter 5 (commencing with Section 19800)
16 of Division 8 or pursuant to Division 9 (commencing with Section
17 23000).

18 SEC. 3. Section 494.5 is added to the Business and Professions
19 Code, to read:

20 494.5. (a) A state governmental licensing entity may refuse
21 to issue, reactivate, reinstate, or renew a license or may suspend
22 a license if a licensee's name is included on a certified list.

23 (1) Until the liabilities covered by this section are satisfied, the
24 qualifying person and any other personnel of record named on a
25 license who have been suspended under this section shall be
26 prohibited from serving in any capacity that is subject to licensure,
27 but shall be permitted to act in the capacity of a nonsupervising
28 bona fide employee.

29 (2) The license of any other renewable licensed entity with any
30 of the same personnel of record who have been assessed an
31 outstanding liability covered by this section shall be suspended
32 until the liability has been satisfied or until the same personnel of
33 record disassociate themselves from the renewable licensed entity.

34 (b) For purposes of this section:

35 (1) "Certified list" means ~~a~~ *either* list provided by the *State*
36 *Board of Equalization or the* Franchise Tax Board of persons
37 whose names appear on ~~a list~~ *the lists* of the ~~250~~ 500 largest tax
38 delinquencies pursuant to Section 7063 *or* 19195 of the Revenue
39 and Taxation Code.

(2) “License” includes a certificate, registration, or any other authorization to engage in a profession or occupation issued by a state governmental licensing entity. “License” includes a driver’s license issued pursuant to Chapter 1 (commencing with Section 12500) of Division 6 of the Vehicle Code.

(3) “Licensee” means an individual authorized by a license to drive a motor vehicle or authorized by a license, certificate, registration, or other authorization to engage in a profession or occupation issued by a state governmental licensing entity.

(4) (A) “State governmental licensing entity” means any entity listed in Section 101, 1000, or 19420, the office of the Attorney General, the Department of Insurance, the Department of Motor Vehicles, the State Bar of California, the Department of Real Estate, and any other state agency, board, or commission that issues a license, certificate, or registration authorizing an individual to engage in a profession or occupation, including any certificate, business or occupational license, or permit or license issued by the Department of Motor Vehicles or the Department of the California Highway Patrol.

(B) “State governmental licensing entity” shall not include any entity described in subparagraph (A) that has elected to decline to exercise the authority provided by this section to suspend or refuse to issue, reinstate, reactivate, or renew the license of a licensee for failure to pay the taxes described in subdivision (a). An election under this subparagraph shall not be valid unless notification of that election has been provided to *the State Board of Equalization and the Franchise Tax Board* at the time and in the manner prescribed by *the State Board of Equalization and the Franchise Tax Board*.

(c) The *State Board of Equalization and the Franchise Tax Board* shall ~~submit a~~ *each submit its respective* certified list to state governmental licensing entities.

(d) Notwithstanding any other law, all state governmental licensing entities shall collect the social security number or the federal taxpayer identification number from all applicants for the purposes of matching the names of the certified ~~list~~ *lists* provided by *the State Board of Equalization and the Franchise Tax Board* to applicants and licensees.

(e) (1) Each state governmental licensing entity shall determine whether an applicant or licensee is on the most recent certified list

1 provided by *the State Board of Equalization and the Franchise*
2 *Tax Board*. The state governmental licensing entity shall have the
3 authority to withhold issuance or renewal of the license of any
4 applicant ~~on the either~~ list or to suspend the license of any licensee
5 ~~on the either~~ list.

6 (2) If an applicant or licensee is ~~on a certified list~~ *either of the*
7 *certified lists*, the state governmental licensing entity shall
8 immediately provide a preliminary notice to the applicant or
9 licensee of the entity's intent to suspend or withhold issuance or
10 renewal of the license. The preliminary notice shall be delivered
11 personally or by mail to the applicant's or licensee's last known
12 mailing address on file with the state governmental licensing entity
13 within 30 days of receipt of the certified list. Service by mail shall
14 be completed in accordance with Section 1013 of the Code of Civil
15 Procedure.

16 (A) The state governmental licensing entity shall issue a
17 temporary license valid for a period of 90 days to any applicant
18 whose name is on a certified list if the applicant is otherwise
19 eligible for a license.

20 (B) The 90-day time period for a temporary license shall not be
21 extended. Only one temporary license shall be issued during a
22 regular license term and the term of the temporary license shall
23 coincide with the first 90 days of the regular license term. A license
24 for the full term or the remainder of the license term may be issued
25 or renewed only upon compliance with this section.

26 (C) In the event that a license is suspended or an application for
27 a license or the renewal of a license is denied pursuant to this
28 section, any funds paid by the applicant or licensee shall not be
29 refunded by the state governmental licensing entity.

30 (f) A state governmental licensing entity shall make a final
31 determination to refuse to issue or to suspend a license pursuant
32 to this section no sooner than 30 days and no later than 90 days of
33 the mailing of the preliminary notice described in paragraph (2)
34 of subdivision (e). The procedures in the administrative
35 adjudication provisions of the Administrative Procedure Act
36 (Chapter 4.5 (commencing with Section 11400) and Chapter 5
37 (commencing with Section 11500) of Part 1 of Division 3 of Title
38 2 of the Government Code) shall not apply to the revocation or
39 suspension of a license pursuant to this section.

1 (g) Notices shall be developed by each state governmental
2 licensing entity. ~~The~~ *For an applicant or licensee on the State*
3 *Board of Equalization's certified list, the notice shall include the*
4 *address and telephone number of the State Board of Equalization,*
5 *and shall emphasize the necessity of obtaining a release from the*
6 *State Board of Equalization as a condition for the issuance,*
7 *renewal, or continued valid status of a license or licenses. For an*
8 *applicant or licensee on the Franchise Tax Board's certified list,*
9 *the notice shall include the address and telephone number of the*
10 Franchise Tax Board, and shall emphasize the necessity of
11 obtaining a release from the Franchise Tax Board as a condition
12 for the issuance, renewal, or continued valid status of a license or
13 licenses.

14 (1) The notice shall inform the applicant that the state
15 governmental licensing entity shall issue a temporary license, as
16 provided in subparagraph (A) of paragraph (2) of subdivision (e),
17 for 90 calendar days if the applicant is otherwise eligible and that
18 upon expiration of that time period, the license will be denied
19 unless the state governmental licensing entity has received a release
20 from *the State Board of Equalization and* the Franchise Tax Board.

21 (2) The notice shall inform the licensee that any license
22 suspended under this section will remain suspended unless the
23 state governmental licensing entity receives a release along with
24 applications and fees, if applicable, to reinstate the license.

25 (3) The notice shall also inform the applicant or licensee that if
26 an application is denied or a license is suspended pursuant to this
27 section, any moneys paid by the applicant or licensee shall not be
28 refunded by the state governmental licensing entity. The state
29 governmental licensing entity shall also develop a form that the
30 applicant or licensee shall use to request a release by *the State*
31 *Board of Equalization and* the Franchise Tax Board. A copy of
32 this form shall be included with every notice sent pursuant to this
33 subdivision.

34 (h) If the applicant or licensee wishes to challenge the
35 submission of his or her name on a certified list, the applicant or
36 licensee shall make a timely written request for release to *the State*
37 *Board of Equalization or* the Franchise Tax ~~Board~~ Board,
38 *whichever is applicable.* The *State Board of Equalization or the*
39 Franchise Tax Board shall immediately send a release to the

1 appropriate state governmental licensing entity and the applicant
2 or licensee, if any of the following conditions are met:

3 (1) The applicant or licensee has complied with the tax
4 obligation, either by payment of the unpaid taxes or entry into an
5 installment payment agreement, as described in Section 6832 or
6 19008 of the Revenue and Taxation Code, to satisfy the unpaid
7 taxes.

8 (2) The applicant or licensee has submitted a request for release
9 not later than 45 days after the applicant's or licensee's receipt of
10 a preliminary notice described in paragraph (2) of subdivision (e),
11 but *the State Board of Equalization or the Franchise Tax Board,*
12 *whichever is applicable,* will be unable to complete the release
13 review and send notice of its findings to the applicant or licensee
14 and state governmental licensing entity within 45 days after *the*
15 *State Board of Equalization's or the Franchise Tax Board's* receipt
16 of the applicant's or licensee's request for release. Whenever a
17 release is granted under this paragraph, and, notwithstanding that
18 release, the applicable license or licenses have been suspended
19 erroneously, the state governmental licensing entity shall reinstate
20 the applicable licenses with retroactive effect back to the date of
21 the erroneous suspension and that suspension shall not be reflected
22 on any license record.

23 (3) The applicant or licensee *that is on the certified list provided*
24 *by the Franchise Tax Board* is unable to pay the outstanding
25 liability due to a current financial hardship, as determined by the
26 Franchise Tax Board.

27 (i) An applicant or licensee is required to act with diligence in
28 responding to notices from the state governmental licensing entity
29 and *the State Board of Equalization or the Franchise Tax Board*
30 with the recognition that the temporary license will lapse or the
31 license suspension will go into effect after 90 days and that *the*
32 *State Board of Equalization or the Franchise Tax Board* must have
33 time to act within that period. An applicant's or licensee's delay
34 in acting, without good cause, which directly results in the inability
35 of *the State Board of Equalization or the Franchise Tax Board,*
36 *whichever is applicable,* to complete a review of the applicant's
37 or licensee's request for release shall not constitute the diligence
38 required under this section which would justify the issuance of a
39 release. An applicant or licensee shall have the burden of
40 establishing that he or she diligently responded to notices from the

1 state governmental licensing entity or *the State Board of*
2 *Equalization* or the Franchise Tax Board and that any delay was
3 not without good cause.

4 (j) The *State Board of Equalization* or the Franchise Tax Board
5 shall create release forms for use pursuant to this section. When
6 the applicant or licensee has complied with the tax obligation,
7 either by payment of the unpaid taxes or entry into an installment
8 payment agreement, *the State Board of Equalization* or the
9 Franchise Tax Board, *whichever is applicable*, shall mail a release
10 form to the applicant or licensee and provide a release to the
11 appropriate state governmental licensing entity. Any state
12 governmental licensing entity that has received a release from *the*
13 *State Board of Equalization* and the Franchise Tax Board pursuant
14 to this subdivision shall process the release within five business
15 days of its receipt. If *the State Board of Equalization* or the
16 Franchise Tax Board determines subsequent to the issuance of a
17 release that the licensee has not complied with their installment
18 payment agreement, *the State Board of Equalization* or the
19 Franchise Tax Board, *whichever is applicable*, may notify the state
20 governmental licensing entity and the licensee in a format
21 prescribed by *the State Board of Equalization* and the Franchise
22 Tax Board that the licensee is not in compliance and the release
23 shall be rescinded. The *State Board of Equalization* and the
24 Franchise Tax Board may, when it is economically feasible for
25 the state governmental licensing entity to develop an automated
26 process for complying with this subdivision, notify the state
27 governmental licensing entity in a manner prescribed by *the State*
28 *Board of Equalization* and the Franchise Tax Board, that the
29 licensee has not complied with the installment payment agreement.
30 Upon receipt of this notice, the state governmental licensing entity
31 shall immediately notify the licensee on a form prescribed by the
32 state governmental licensing entity that the licensee's license will
33 be suspended on a specific date, and this date shall be no longer
34 than 30 days from the date the form is mailed. The licensee shall
35 be further notified that the license will remain suspended until a
36 new release is issued in accordance with subdivision (h).

37 (k) The *State Board of Equalization* and the Franchise Tax
38 Board may enter into interagency agreements with the state
39 governmental licensing entities necessary to implement this section,
40 to the extent that it is cost effective to implement this section.

1 (l) Notwithstanding any other law, a state governmental
2 licensing entity, with the approval of the appropriate department
3 director or governing body, may impose a fee on a licensee whose
4 license has been suspended pursuant to this section. The fee shall
5 not exceed the amount necessary for the state governmental
6 licensing entity to cover its costs in carrying out the provisions of
7 this section. Fees imposed pursuant to this section shall be
8 deposited in the fund in which other fees imposed by the state
9 governmental licensing entity are deposited and shall be available
10 to that entity upon appropriation in the annual Budget Act.

11 (m) The process described in subdivision (h) shall constitute
12 the sole administrative remedy for contesting the issuance of a
13 temporary license or the denial or suspension of a license under
14 this section. The procedures specified in the administrative
15 adjudication provisions of the Administrative Procedure Act
16 (Chapter 4.5 (commencing with Section 11400) and Chapter 5
17 (commencing with Section 11500) of Part 1 of Division 3 of Title
18 2 of the Government Code) shall not apply to the denial,
19 suspension, or failure to issue or renew a license or the issuance
20 of a temporary license pursuant to this section.

21 (n) Any state governmental licensing entity receiving an inquiry
22 as to the licensed status of an applicant or licensee who has had a
23 license denied or suspended under this section or who has been
24 granted a temporary license under this section shall respond only
25 that the license was denied or suspended or the temporary license
26 was issued pursuant to this section. Information collected pursuant
27 to this section by any state agency, board, or department shall be
28 subject to the Information Practices Act of 1977 (Chapter 1
29 (commencing with Section 1798) of Title 1.8 of Part 4 of Division
30 3 of the Civil Code).

31 (o) Any rules and regulations issued pursuant to this section by
32 any state agency, board, or department may be adopted as
33 emergency regulations in accordance with the rulemaking
34 provisions of the Administrative Procedure Act (Chapter 3.5
35 (commencing with Section 11340) of Part 1 of Division 3 of Title
36 2 of the Government Code). The adoption of these regulations
37 shall be deemed an emergency and necessary for the immediate
38 preservation of the public peace, health, and safety, or general
39 welfare. The regulations shall become effective immediately upon
40 filing with the Secretary of State.

1 (p) The *State Board of Equalization*, the Franchise Tax Board,
2 and state governmental licensing entities, as appropriate, shall
3 adopt regulations as necessary to implement this section.

4 (q) (1) Neither the state governmental licensing entity, nor any
5 officer, employee, or agent, or former officer, employee, or agent
6 of a state governmental licensing entity, may disclose or use any
7 information obtained from *the State Board of Equalization* or the
8 Franchise Tax Board, pursuant to this section, except to inform
9 the public of the suspension of a license pursuant to this section.
10 The release or other use of information received by a state
11 governmental licensing entity pursuant to this section, except as
12 authorized by this section, is punishable as a misdemeanor. This
13 subdivision may not be interpreted to prevent the State Bar of
14 California from filing a request with the Supreme Court of
15 California to suspend a member of the bar pursuant to this section.

16 (2) To the extent permitted under federal law, a suspension or
17 revocation of a license pursuant to this section shall not be reported
18 to the National Practitioner Data Bank.

19 (r) If any provision of this section or the application thereof to
20 any person or circumstance is held invalid, that invalidity shall not
21 affect other provisions or applications of this section that can be
22 given effect without the invalid provision or application, and to
23 this end the provisions of this section are severable.

24 (s) All rights to review afforded by this section to an applicant
25 shall also be afforded to a licensee.

26 (t) (1) If the state governmental licensing entity, as defined in
27 Section 6834 or 19265 of the Revenue and Taxation Code, does
28 not suspend, revoke, or deny renewal of a license within 90 days
29 of the mailing of preliminary notice as described in subdivision
30 (f), *the State Board of Equalization* or the Franchise Tax Board,
31 *whichever is applicable*, is authorized to suspend the license
32 pursuant to Section 6834 or 19265 of the Revenue and Taxation
33 Code.

34 (2) If the state governmental licensing entity has not suspended,
35 revoked, or denied the renewal of a license within 90 days of the
36 mailing of the preliminary notice as described in subdivision (e),
37 the state governmental licensing entity shall promptly notify *the*
38 *State Board of Equalization* or the Franchise Tax Board, *whichever*
39 *is applicable*, and the licensee. The notification shall include the

1 reason why no action was taken by the state governmental licensing
2 entity.

3 (3) If the election described in subparagraph (B) of paragraph
4 (4) of subdivision (b) has been made, *the State Board of*
5 *Equalization or the Franchise Tax Board, whichever is applicable,*
6 is authorized to suspend, pursuant to Section 6834 or 19265 of the
7 Revenue and Taxation Code, the license of a licensee subject to
8 the jurisdiction of the entity that made that election.

9 (u) Unless otherwise provided in this section, the policies,
10 practices, and procedures of a state governmental licensing entity
11 with respect to license suspensions under this section shall be the
12 same as those applicable with respect to suspensions pursuant to
13 Section 17520 of the Family Code.

14 (v) No provision of this section shall be interpreted to allow a
15 court to review and prevent the collection of ~~income~~ taxes prior
16 to the payment of those taxes in violation of the California
17 Constitution.

18 (w) This section shall apply to any licensee whose name appears
19 ~~on a list~~ *the lists* of the ~~250~~ 500 largest tax delinquencies pursuant
20 to ~~Section~~ Sections 7063 and 19195 of the Revenue and Taxation
21 Code on or after January 1, 2012.

22 SEC. 4. Section 7145.5 of the Business and Professions Code
23 is amended to read:

24 7145.5. (a) The registrar may refuse to issue, reinstate,
25 reactivate, or renew a license or may suspend a license for the
26 failure of a licensee to resolve all outstanding final liabilities, which
27 include taxes, additions to tax, penalties, interest, and any fees that
28 may be assessed by the board, the Department of Industrial
29 Relations, the Employment Development Department, or the
30 Franchise Tax Board.

31 (1) Until the debts covered by this section are satisfied, the
32 qualifying person and any other personnel of record named on a
33 license that has been suspended under this section shall be
34 prohibited from serving in any capacity that is subject to licensure
35 under this chapter, but shall be permitted to act in the capacity of
36 a nonsupervising bona fide employee.

37 (2) The license of any other renewable licensed entity with any
38 of the same personnel of record that have been assessed an
39 outstanding liability covered by this section shall be suspended

1 until the debt has been satisfied or until the same personnel of
2 record disassociate themselves from the renewable licensed entity.

3 (b) The refusal to issue a license or the suspension of a license
4 as provided by this section shall be applicable only if the registrar
5 has mailed a notice preliminary to the refusal or suspension that
6 indicates that the license will be refused or suspended by a date
7 certain. This preliminary notice shall be mailed to the licensee at
8 least 60 days before the date certain.

9 (c) In the case of outstanding final liabilities assessed by the
10 Franchise Tax Board, this section shall be operative within 60 days
11 after the Contractors' State License Board has provided the
12 Franchise Tax Board with the information required under Section
13 30, relating to licensing information that includes the federal
14 employee identification number or social security number.

15 (d) All versions of the application for contractors' licenses shall
16 include, as part of the application, an authorization by the applicant,
17 in the form and manner mutually agreeable to the Franchise Tax
18 Board and the board, for the Franchise Tax Board to disclose the
19 tax information that is required for the registrar to administer this
20 section. The Franchise Tax Board may from time to time audit
21 these authorizations.

22 (e) This section shall not be interpreted to conflict with the
23 suspension of a license pursuant to Section 494.5 of this code or
24 Section 19265 of the Revenue and Taxation Code.

25 *SEC. 4.5. Section 7145.5 of the Business and Professions Code*
26 *is amended to read:*

27 7145.5. (a) The registrar may refuse to issue, reinstate,
28 reactivate, or renew a license or may suspend a license for the
29 failure of a licensee to resolve all outstanding final liabilities, which
30 include taxes, additions to tax, penalties, interest, and any fees that
31 may be assessed by the board, the Department of Industrial
32 Relations, the Employment Development Department, ~~or the~~
33 Franchise Tax Board, *or the State Board of Equalization.*

34 (1) Until the debts covered by this section are satisfied, the
35 qualifying person and any other personnel of record named on a
36 license that has been suspended under this section shall be
37 prohibited from serving in any capacity that is subject to licensure
38 under this chapter, but shall be permitted to act in the capacity of
39 a nonsupervising bona fide employee.

1 (2) The license of any other renewable licensed entity with any
2 of the same personnel of record that have been assessed an
3 outstanding liability covered by this section shall be suspended
4 until the debt has been satisfied or until the same personnel of
5 record disassociate themselves from the renewable licensed entity.

6 (b) The refusal to issue a license or the suspension of a license
7 as provided by this section shall be applicable only if the registrar
8 has mailed a notice preliminary to the refusal or suspension that
9 indicates that the license will be refused or suspended by a date
10 certain. This preliminary notice shall be mailed to the licensee at
11 least 60 days before the date certain.

12 (c) In the case of outstanding final liabilities assessed by the
13 Franchise Tax Board, this section shall be operative within 60 days
14 after the Contractors' State License Board has provided the
15 Franchise Tax Board with the information required under Section
16 30, relating to licensing information that includes the federal
17 employee identification number or social security number.

18 (d) All versions of the application for contractors' licenses shall
19 include, as part of the application, an authorization by the applicant,
20 in the form and manner mutually agreeable to the Franchise Tax
21 Board and the board, for the Franchise Tax Board to disclose the
22 tax information that is required for the registrar to administer this
23 section. The Franchise Tax Board may from time to time audit
24 these authorizations.

25 (e) *In the case of outstanding final liabilities assessed by the*
26 *State Board of Equalization, this section shall not apply to any*
27 *outstanding final liability if the licensee has entered into an*
28 *installment payment agreement for that liability with the State*
29 *Board of Equalization and is in compliance with the terms of that*
30 *agreement.*

31 (f) *This section shall not be interpreted to conflict with the*
32 *suspension of a license pursuant to Section 494.5 of this code or*
33 *Section 6834 or 19265 of the Revenue and Taxation Code.*

34 SEC. 5. Section 12419.13 is added to the Government Code,
35 to read:

36 12419.13. (a) (1) The Controller shall, upon execution of a
37 reciprocal agreement between *the State Board of Equalization or*
38 *the Franchise Tax Board, and any other state imposing a sales and*
39 *use tax, an income tax, or tax measured by income, offset any*
40 *delinquent tax debt due to that other state from a person or entity,*

1 against any refund under *the Sales and Use Tax Law*, the Personal
2 Income Tax Law, or the Corporation Tax Law owed to that person
3 or entity.

4 (2) Standards and procedures for submission of requests for
5 offsets shall be as prescribed by the Controller.

6 (3) Payment of the offset amount shall occur only after other
7 offset requests for debts owed by a person or entity to this state or
8 the federal government have been satisfied in accordance with the
9 priority established under Section 12419.3.

10 (b) The reciprocal agreement identified in subdivision (a) shall
11 prescribe the manner in which the administrative costs of the
12 Controller, *the State Board of Equalization*, and the Franchise Tax
13 Board shall be reimbursed.

14 SEC. 6. Section 10295.4 is added to the Public Contract Code,
15 to read:

16 10295.4. (a) Notwithstanding any other law, a state agency
17 shall not enter into any contract for the acquisition of goods or
18 services with a contractor whose name appears on ~~the~~ *either* list
19 of the ~~250~~ 500 largest tax delinquencies pursuant to Section 7063
20 or 19195 of the Revenue and Taxation Code. Any contract entered
21 into in violation of this subdivision is void and unenforceable.

22 (b) This section shall apply to any contract executed on or after
23 January 1, 2012.

24 SEC. 7. Section 6834 is added to the Revenue and Taxation
25 Code, to read:

26 6834. (a) (1) All state governmental licensing entities issuing
27 professional or occupational licenses, certificates, registrations,
28 or permits shall provide to the board the name and social security
29 number or federal taxpayer identification number, as applicable,
30 of each licensee of that state governmental licensing entity.

31 (2) If any licensee appears on a list of the 500 largest tax
32 delinquencies pursuant to Section 7063, and the license of that
33 licensee has not been suspended, revoked, or denied by the
34 applicable state governmental licensing entity pursuant to Section
35 494.5 of the Business and Professions Code, then the board shall
36 mail a preliminary notice of suspension to the licensee indicating
37 that the license will be suspended by a date certain, which shall
38 be at least 60 days after the mailing of the preliminary notice,
39 unless prior to the date certain the licensee pays the unpaid taxes
40 or enters into an installment payment agreement, as described in

1 *Section 6832, to satisfy the unpaid taxes. The preliminary notice*
2 *shall also advise the licensee of the opportunity to request deferral*
3 *or cancellation of a suspension pursuant to subdivision (b).*

4 *(3) If any licensee subject to paragraph (2) fails to pay the*
5 *unpaid taxes or to enter into an installment payment agreement,*
6 *as described in Section 6832, to satisfy the unpaid taxes prior to*
7 *the date certain listed in the preliminary notice of suspension, his*
8 *or her license shall be automatically suspended by operation of*
9 *this section, except as provided in subdivision (b), and the board*
10 *shall provide a notice of suspension to the applicable state*
11 *governmental licensing entity and shall mail a notice of suspension*
12 *to the licensee. The rights, powers, and privileges of any licensee*
13 *whose license to drive a motor vehicle, professional or*
14 *occupational license, certificate, registration, or permit has been*
15 *suspended pursuant to this section shall be subject to the same*
16 *prohibitions, limitations, and restrictions as if the license to drive*
17 *a motor vehicle, professional or occupational license, certificate,*
18 *registration, or permit were suspended by the state governmental*
19 *licensing entity that issued the professional or occupational license,*
20 *certificate, registration, or permit.*

21 *(4) (A) Upon compliance by the licensee with the tax obligation,*
22 *either by payment of the unpaid taxes or entry into an installment*
23 *payment agreement, as described in Section 6832, to satisfy the*
24 *unpaid taxes, a suspension pursuant to this subdivision shall be*
25 *canceled. The board shall, within 10 business days of compliance*
26 *by the licensee with the tax obligation, notify both the state*
27 *governmental licensing entity and the licensee that the unpaid*
28 *taxes have been paid or that an installment payment agreement,*
29 *as described in Section 6832, has been entered into to satisfy the*
30 *unpaid taxes and that the suspension has been canceled.*

31 *(B) Whenever a suspension is canceled under this paragraph*
32 *and the applicable license or licenses have been suspended in*
33 *error, the board shall notify the state governmental licensing entity*
34 *to reinstate all applicable licenses back to the date of suspension*
35 *and expunge any notation of that suspension from the licensee's*
36 *record.*

37 *(5) If a license is not suspended, or if the suspension of a license*
38 *is canceled, based on the licensee entering into an installment*
39 *payment agreement as described in Section 6832, and the licensee*
40 *fails to comply with the terms of the installment payment*

1 agreement, that license shall be suspended as of the date that is
2 30 days after the date of termination of that installment payment
3 agreement. If a license is suspended pursuant to this paragraph,
4 the board shall provide notice of suspension to the applicable state
5 governmental licensing entity and mail a notice of suspension to
6 the licensee.

7 (6) State governmental licensing entities shall provide to the
8 board the information required by this subdivision at a time that
9 the board may require.

10 (b) (1) The board may defer or cancel any suspension
11 authorized by this section if a licensee is unable to pay the liability
12 due to a current financial hardship. The board shall, if requested
13 by the licensee in writing, provide for an administrative hearing
14 to determine if the licensee is unable to pay the liability due to a
15 current financial hardship.

16 (2) The request for a hearing specified in paragraph (1) shall
17 be made in writing within 30 days from the mailing date of the
18 preliminary notice described in subdivision (a).

19 (3) The board shall conduct a hearing within 30 days after
20 receipt of a request pursuant to paragraph (1), unless the board
21 postpones the hearing, upon a showing of good cause by the
22 licensee, in which case a suspension pursuant to subdivision (a)
23 shall be deferred until the hearing has been completed.

24 (4) A licensee seeking relief under this subdivision shall only
25 be entitled to relief described in paragraph (1) if the licensee
26 provides the board with financial documents that substantiate a
27 financial hardship, and agrees to an acceptable payment
28 arrangement.

29 (5) If the deferral of a suspension of a license under this
30 subdivision is no longer operative, that license shall be suspended
31 as of the date that is 30 days after the date the deferral is no longer
32 operative. If a license is suspended pursuant to this paragraph,
33 the board shall provide notice of suspension to the applicable state
34 governmental licensing entity and mail a notice of suspension to
35 the licensee.

36 (c) For purposes of this section and Section 7057, the following
37 definitions shall apply:

38 (1) "Financial hardship" means financial hardship, as
39 determined by the board, where the licensee is financially unable
40 to pay any part of the amount described in subdivision (a). In order

1 *to establish the existence of a financial hardship, the licensee shall*
2 *submit any information, including information related to*
3 *reasonable business and personal expenses, requested by the board*
4 *for the purpose of making that determination.*

5 (2) *“License” includes a certificate, registration, or any other*
6 *authorization to engage in a profession or occupation issued by*
7 *a state governmental licensing entity. “License” includes a driver’s*
8 *license issued pursuant to Chapter 1 (commencing with Section*
9 *12500) of Division 6 of the Vehicle Code.*

10 (3) *“Licensee” means an individual authorized by a license to*
11 *drive a motor vehicle or authorized by a license, certificate,*
12 *registration, or other authorization to engage in a profession or*
13 *occupation issued by a state governmental licensing entity.*

14 (4) *“State governmental licensing entity” means any entity listed*
15 *in Section 101, 1000, or 19420 of the Business and Professions*
16 *Code, the office of the Attorney General, the Department of*
17 *Insurance, the Department of Motor Vehicles, the Department of*
18 *Real Estate, and any other state agency, board, or commission*
19 *that issues a license, certificate, or registration authorizing an*
20 *individual to engage in a profession or occupation, including any*
21 *certificate, business or occupational license, or permit or license*
22 *issued by the Department of Motor Vehicles or the Department of*
23 *the California Highway Patrol. “State governmental licensing*
24 *entity” shall not include the Department of Alcoholic Beverage*
25 *Control or the State Bar of California.*

26 (d) *Notwithstanding any other law, a state governmental*
27 *licensing entity may, with the approval of the appropriate*
28 *department director or governing body, impose a fee on licensees*
29 *whose license has been suspended as described in subdivision (a).*
30 *The fee shall not exceed the amount necessary for the state*
31 *governmental licensing entity to cover its costs in carrying out the*
32 *provisions of this section. Fees imposed pursuant to this section*
33 *shall be deposited in the fund in which other fees imposed by the*
34 *state governmental licensing entity are deposited and shall be*
35 *available to that entity upon appropriation in the annual Budget*
36 *Act.*

37 (e) *The process described in subdivision (b) shall constitute the*
38 *sole administrative remedy for contesting the suspension of a*
39 *license under this section. The procedures in the administrative*
40 *adjudication provisions of the Administrative Procedure Act*

1 (Chapter 4.5 (commencing with Section 11400) and Chapter 5
2 (commencing with Section 11500) of Part 1 of Division 3 of Title
3 2 of the Government Code) shall not apply to the suspension of a
4 license pursuant to this section.

5 (f) This section shall apply to any licensee whose name appears
6 on a list of the 500 largest tax delinquencies pursuant to Section
7 7063 on or after January 1, 2012.

8 SEC. 8. Section 6835 is added to the Revenue and Taxation
9 Code, to read:

10 6835. (a) The board may enter into an agreement with the
11 Internal Revenue Service or any other state imposing a sales and
12 use tax, or a similar tax, for the purpose of collecting delinquent
13 tax debts with respect to amounts assessed or imposed under this
14 part, provided the agreements do not cause the net displacement
15 of civil service employees. The agreement may provide, at the
16 discretion of the board, the rate of payment and the manner in
17 which compensation for services shall be paid.

18 (b) At the discretion of the board, the Internal Revenue Service
19 or the other state collecting the tax debt pursuant to subdivision
20 (a) may, as part of the collection process, refer the tax debt for
21 litigation by its legal representatives in the name of the board.

22 (c) For purposes of this section, "displacement" includes layoff,
23 demotion, involuntary transfer to a new class, involuntary transfer
24 to a new location requiring a change of residence, and time base
25 reductions. "Displacement" does not include changes in shifts or
26 days off, nor does it include reassignment to any other position
27 within the same class and general location.

28 SEC. 9. Article 9 (commencing with Section 6850) is added to
29 Chapter 6 of Part 1 of Division 2 of the Revenue and Taxation
30 Code, to read:

31
32 Article 9. Collection of Tax Debts Due to the Internal Revenue
33 Services or Other States
34

35 6850. (a) The board may enter into an agreement to collect
36 any delinquent tax debt due to the Internal Revenue Service or any
37 other state imposing a sales and use tax, or similar tax, if, pursuant
38 to Section 6851, the Internal Revenue Service or such a state has
39 entered into an agreement to collect delinquent tax debts due to
40 the board.

1 (b) Upon written notice to the debtor from the board, any
2 amount referred to the board under subdivision (a) shall be treated
3 as final and due and payable to the State of California, and shall
4 be collected from the debtor by the board in any manner authorized
5 under the law for collection of a delinquent sales and use tax
6 liability, including, but not limited to, the recording of a notice of
7 state tax lien under Article 2 (commencing with Section 7170) of
8 Chapter 14 of Division 7 of Title 1 of the Government Code, and
9 the issuance of an order and levy under Article 4 (commencing
10 with Section 706.070) of Chapter 5 of Division 2 of Title 9 of Part
11 2 of the Code of Civil Procedure in the manner provided for
12 earnings withholding orders for taxes.

13 (c) This part shall apply to amounts referred under this section
14 in the same manner and with the same force and effect and to the
15 full extent as if the language of those laws had been incorporated
16 in full into this section, except to the extent that any provision is
17 either inconsistent with this section or is not relevant to this section.

18 (d) The activities required to implement and administer this
19 section shall not interfere with the primary mission of the board
20 to administer this part.

21 (e) In no event shall a collection under this section be construed
22 as a payment of sales and use taxes imposed under this part, or in
23 accordance with Part 1.5 or Part 1.6.

24 SEC. 10. Section 7057 is added to the Revenue and Taxation
25 Code, to read:

26 7057. (a) The board may disclose to state governmental
27 licensing entities information regarding suspension of a license
28 pursuant to Section 6834 of this code or Section 494.5 or 7145.5
29 of the Business and Professions Code.

30 (b) Neither the state governmental licensing entity, nor any
31 officer, employee, or agent, or former officer, employee, or agent
32 of a state governmental licensing entity, may disclose or use any
33 information obtained from the board, pursuant to this section,
34 except to inform the public of the suspension of a license pursuant
35 to Section 6834 of this code or Section 494.5 or 7145.5 of the
36 Business and Professions Code.

37 (c) For purposes of this section, the definitions in Section 6834
38 shall apply.

39 SEC. 11. Section 7063 of the Revenue and Taxation Code is
40 amended to read:

1 7063. (a) Notwithstanding any other provision of law, the
2 board shall make available as a matter of public record each quarter
3 a list of the ~~250~~ 500 largest tax delinquencies in excess of one
4 hundred thousand dollars (\$100,000) under this part. For purposes
5 of compiling the list, a tax delinquency means an amount owed to
6 the board which is all of the following:

7 (1) Based on a determination made under Article 2 (commencing
8 with Section 6481) or Article 3 (commencing with Section 6511)
9 of Chapter 5 deemed final pursuant to Article 5 (commencing with
10 Section 6561) of Chapter 5, or that is “due and payable” under
11 Article 4 (commencing with Section 6536) of Chapter 5, or
12 self-assessed by the taxpayer.

13 (2) Recorded as a notice of state tax lien pursuant to Chapter
14 14 (commencing with Section 7150) of Division 7 of Title 1 of
15 the Government Code, in any county recorder’s office in this state.

16 (3) For an amount of tax delinquent for more than 90 days.

17 (b) For purposes of the list, a tax delinquency does not include
18 any of the following and may not be included on the list:

19 (1) A delinquency that is under litigation in a court of law.

20 (2) A delinquency for which payment arrangements have been
21 agreed to by both the taxpayer and the board and the taxpayer is
22 in compliance with the arrangement.

23 (3) A delinquency for which the taxpayer has filed for
24 bankruptcy protection pursuant to Title 11 of the United States
25 Code.

26 (c) Each quarterly list shall, with respect to each delinquency,
27 include all the following:

28 (1) The name of the person or persons liable for payment of the
29 tax and that person’s or persons’ last known address.

30 (2) The amount of tax delinquency as shown on the notice or
31 notices of state tax lien and any applicable interest or penalties,
32 less any amounts paid.

33 (3) The earliest date that a notice of state tax lien was filed.

34 (4) The type of tax that is delinquent.

35 (d) Prior to making a tax delinquency a matter of public record
36 as required by this section, the board shall provide a preliminary
37 written notice to the person or persons liable for the tax by certified
38 mail, return receipt requested. If within 30 days after issuance of
39 the notice, the person or persons do not remit the amount due or

1 make arrangements with the board for payment of the amount due,
2 the tax delinquency shall be included on the list.

3 (e) The quarterly list described in subdivision (a) shall include
4 the following:

5 (1) The telephone number and address of the board office to
6 contact if a person believes placement of his or her name on the
7 list is in error.

8 (2) The aggregate number of persons that have appeared on the
9 list who have satisfied their delinquencies in their entirety and the
10 dollar amounts, in the aggregate, that have been paid attributable
11 to those delinquencies.

12 (f) As promptly as feasible, but no later than 5 business days
13 from the occurrence of any of the following, the board shall remove
14 that taxpayer's name from the list of tax delinquencies:

15 (1) Tax delinquencies for which the person liable for the tax
16 has contacted the board and resolution of the delinquency has been
17 arranged.

18 (2) Tax delinquencies for which the board has verified that an
19 active bankruptcy proceeding has been initiated.

20 (3) Tax delinquencies for which the board has verified that a
21 bankruptcy proceeding has been completed and there are no assets
22 available with which to pay the delinquent amount or amounts.

23 (4) Tax delinquencies that the board has determined to be
24 uncollectible.

25 (g) A person whose delinquency appears on the quarterly list,
26 and who satisfies that delinquency in whole or in part, may request
27 the board to include in its quarterly list any payments that person
28 made to satisfy the delinquency. Upon receipt of that request, the
29 board shall include those payments on the list as promptly as
30 feasible.

31 (h) Notwithstanding subdivision (a), a person whose delinquency
32 appeared on the quarterly list and whose name has been removed
33 pursuant to paragraph (1) of subdivision (f) shall comply with the
34 terms of the arranged resolution. If a person fails to do so, the
35 board shall add that person's name to the list of delinquencies
36 without providing the prior written notice required by subdivision
37 (d).

38 ~~SEC. 7.~~

39 *SEC. 12.* Section 19195 of the Revenue and Taxation Code is
40 amended to read:

1 19195. (a) Notwithstanding any other provision of law,
2 including Section 6254.21 of the Government Code, the Franchise
3 Tax Board shall make available as a matter of public record at
4 least twice each calendar year a list of the ~~250~~ 500 largest tax
5 delinquencies in excess of one hundred thousand dollars (\$100,000)
6 under Part 10 and Part 11 of this division. For purposes of
7 compiling the list, a tax delinquency means the total amount owed
8 by a taxpayer to the State of California for which a notice of state
9 tax lien has been recorded in any county recorder's office in this
10 state, pursuant to Chapter 14 (commencing with Section 7150) of
11 Division 7 of Title 1 of the Government Code.

12 (b) For purposes of the list, a tax delinquency does not include
13 any of the following and may not be included on the list:

14 (1) A delinquency for which payment arrangements have been
15 agreed to by both the taxpayer and the Franchise Tax Board and
16 the taxpayer is in compliance with the arrangement.

17 (2) A delinquency for which the taxpayer has filed for
18 bankruptcy protection pursuant to Title 11 of the United States
19 Code.

20 (3) A delinquency for which the person or persons liable for the
21 tax have contacted the Franchise Tax Board and for which
22 resolution of the tax delinquency has been accepted by the
23 Franchise Tax Board.

24 (c) Each list shall, with respect to each delinquency, include all
25 the following:

26 (1) The name of the person or persons liable for payment of the
27 tax and that person's or persons' address.

28 (2) The amount of tax delinquency as shown on the notice or
29 notices of state tax lien and any applicable interest or penalties,
30 less any amounts paid.

31 (3) The earliest date that a notice of state tax lien was filed.

32 (4) The type of tax that is delinquent.

33 (5) The type, status, and license number of any occupational or
34 professional license held by the person or persons liable for
35 payment of the tax.

36 (6) The names and titles of the principal officers of the person
37 liable for payment of the tax if that person is a limited liability
38 company or corporation.

39 (d) Prior to making a tax delinquency a matter of public record
40 as required by this section, the Franchise Tax Board shall provide

1 a preliminary written notice to the person or persons liable for the
2 tax by certified mail, return receipt requested. If within 30 days
3 after issuance of the notice, the person or persons do not remit the
4 amount due or make arrangements with the Franchise Tax Board
5 for payment of the amount due, the tax delinquency shall be
6 included on the list.

7 (e) The list described in subdivision (a) shall include the
8 following:

9 (1) The telephone number and address of the Franchise Tax
10 Board office to contact if a person believes placement of his or
11 her name on the list is in error.

12 (2) The aggregate number of persons that have appeared on the
13 list who have satisfied their delinquencies in their entirety and the
14 dollar amounts, in the aggregate, that have been paid attributable
15 to those delinquencies.

16 (f) As promptly as feasible, but no later than five business days
17 from the occurrence of any of the following, the Franchise Tax
18 Board shall remove that taxpayer's name from the list of tax
19 delinquencies:

20 (1) Tax delinquencies for which the person liable for the tax
21 has contacted the Franchise Tax Board and resolution of the
22 delinquency has been arranged.

23 (2) Tax delinquencies for which the Franchise Tax Board has
24 verified that an active bankruptcy proceeding has been initiated.

25 (3) Tax delinquencies for which the Franchise Tax Board has
26 verified that a bankruptcy proceeding has been completed and
27 there are no assets available with which to pay the delinquent
28 amount or amounts.

29 (4) Tax delinquencies that the Franchise Tax Board has
30 determined to be uncollectible.

31 (g) A person whose delinquency appears on the list, and who
32 satisfies that delinquency in whole or in part, may request the
33 Franchise Tax Board to include in its list any payments that person
34 made to satisfy the delinquency. Upon receipt of that request, the
35 Franchise Tax Board shall include those payments on the list as
36 promptly as feasible.

37 (h) Notwithstanding subdivision (a), a person whose delinquency
38 appeared on the list and whose name has been removed pursuant
39 to paragraph (1) of subdivision (f) shall comply with the terms of
40 the arranged resolution. If the person fails to do so, the Franchise

1 Tax Board may add that person's name to the list of delinquencies
2 without providing the prior written notice otherwise required by
3 subdivision (d).

4 ~~SEC. 8.~~

5 *SEC. 13.* Section 19265 is added to the Revenue and Taxation
6 Code, to read:

7 19265. (a) (1) All state governmental licensing entities issuing
8 professional or occupational licenses, certificates, registrations, or
9 permits shall provide to the Franchise Tax Board the name and
10 social security number or federal taxpayer identification number,
11 as applicable, of each licensee of that state governmental licensing
12 entity.

13 (2) If any licensee appears on a list of the ~~250~~ 500 largest tax
14 delinquencies pursuant to Section 19195, and the license of that
15 licensee has not been suspended, revoked, or denied by the
16 applicable state governmental licensing entity pursuant to Section
17 494.5 of the Business and Professions Code, then the Franchise
18 Tax Board shall mail a preliminary notice of suspension to the
19 licensee indicating that the license will be suspended by a date
20 certain, which shall be at least 60 days after the mailing of the
21 preliminary notice, unless prior to the date certain the licensee
22 pays the unpaid taxes or enters into an installment payment
23 agreement, as described in Section 19008, to satisfy the unpaid
24 taxes. The preliminary notice shall also advise the licensee of the
25 opportunity to request deferral or cancellation of a suspension
26 pursuant to subdivision (b).

27 (3) If any licensee subject to paragraph (2) fails to pay the unpaid
28 taxes or to enter into an installment payment agreement, as
29 described in Section 19008, to satisfy the unpaid taxes prior to the
30 date certain listed in the preliminary notice of suspension, his or
31 her license shall be automatically suspended by operation of this
32 section, except as provided in subdivision (b), and the Franchise
33 Tax Board shall provide a notice of suspension to the applicable
34 state governmental licensing entity and shall mail a notice of
35 suspension to the licensee. The rights, powers, and privileges of
36 any licensee whose license to drive a motor vehicle, professional
37 or occupational license, certificate, registration, or permit has been
38 suspended pursuant to this section shall be subject to the same
39 prohibitions, limitations, and restrictions as if the license to drive
40 a motor vehicle, professional or occupational license, certificate,

1 registration, or permit were suspended by the state governmental
2 licensing entity that issued the professional or occupational license,
3 certificate, registration, or permit.

4 (4) (A) Upon compliance by the licensee with the tax obligation,
5 either by payment of the unpaid taxes or entry into an installment
6 payment agreement, as described in Section 19008, to satisfy the
7 unpaid taxes, a suspension pursuant to this subdivision shall be
8 canceled. The Franchise Tax Board shall, within 10 business days
9 of compliance by the licensee with the tax obligation, notify both
10 the state governmental licensing entity and the licensee that the
11 unpaid taxes have been paid or that an installment payment
12 agreement, as described in Section 19008, has been entered into
13 to satisfy the unpaid taxes and that the suspension has been
14 canceled.

15 (B) Whenever a suspension is canceled under this paragraph
16 and the applicable license or licenses have been suspended in error,
17 the Franchise Tax Board shall notify the state governmental
18 licensing entity to reinstate all applicable licenses back to the date
19 of suspension and expunge any notation of that suspension from
20 the licensee's record.

21 (5) If a license is not suspended, or if the suspension of a license
22 is canceled, based on the licensee entering into an installment
23 payment agreement as described in Section 19008, and the licensee
24 fails to comply with the terms of the installment payment
25 agreement, that license shall be suspended as of the date that is 30
26 days after the date of termination of that installment payment
27 agreement. If a license is suspended pursuant to this paragraph,
28 the Franchise Tax Board shall provide notice of suspension to the
29 applicable state governmental licensing entity and mail a notice
30 of suspension to the licensee.

31 (6) State governmental licensing entities shall provide to the
32 Franchise Tax Board the information required by this subdivision
33 at a time that the Franchise Tax Board may require.

34 (b) (1) The Franchise Tax Board may defer or cancel any
35 suspension authorized by this section if a licensee is unable to pay
36 the liability due to a current financial hardship. The Franchise Tax
37 Board shall, if requested by the licensee in writing, provide for an
38 administrative hearing to determine if the licensee is unable to pay
39 the liability due to a current financial hardship.

1 (2) The request for a hearing specified in paragraph (1) shall be
2 made in writing within 30 days from the mailing date of the
3 preliminary notice described in subdivision (a).

4 (3) The Franchise Tax Board shall conduct a hearing within 30
5 days after receipt of a request pursuant to paragraph (1), unless
6 the board postpones the hearing, upon a showing of good cause
7 by the licensee, in which case a suspension pursuant to subdivision
8 (a) shall be deferred until the hearing has been completed.

9 (4) A licensee seeking relief under this subdivision shall only
10 be entitled to relief described in paragraph (1) if the licensee
11 provides the Franchise Tax Board with financial documents that
12 substantiate a financial hardship, and agrees to an acceptable
13 payment arrangement.

14 (5) If the deferral of a suspension of a license under this
15 subdivision is no longer operative, that license shall be suspended
16 as of the date that is 30 days after the date the deferral is no longer
17 operative. If a license is suspended pursuant to this paragraph, the
18 Franchise Tax Board shall provide notice of suspension to the
19 applicable state governmental licensing entity and mail a notice
20 of suspension to the licensee.

21 (c) For purposes of this section and Section 19571, the following
22 definitions shall apply:

23 (1) "Financial hardship" means financial hardship within the
24 meaning of Section 19008, as determined by the Franchise Tax
25 Board, where the licensee is financially unable to pay any part of
26 the amount described in subdivision (a) and the licensee is unable
27 to qualify for an installment payment arrangement as provided for
28 by Section 19008. In order to establish the existence of a financial
29 hardship, the licensee shall submit any information, including
30 information related to reasonable business and personal expenses,
31 requested by the Franchise Tax Board for the purpose of making
32 that determination.

33 (2) "License" includes a certificate, registration, or any other
34 authorization to engage in a profession or occupation issued by a
35 state governmental licensing entity. "License" includes a driver's
36 license issued pursuant to Chapter 1 (commencing with Section
37 12500) of Division 6 of the Vehicle Code.

38 (3) "Licensee" means an individual authorized by a license to
39 drive a motor vehicle or authorized by a license, certificate,

1 registration, or other authorization to engage in a profession or
2 occupation issued by a state governmental licensing entity.

3 (4) “State governmental licensing entity” means any entity listed
4 in Section 101, 1000, or 19420 of the Business and Professions
5 Code, the office of the Attorney General, the Department of
6 Insurance, the Department of Motor Vehicles, the Department of
7 Real Estate, and any other state agency, board, or commission that
8 issues a license, certificate, or registration authorizing an individual
9 to engage in a profession or occupation, including any certificate,
10 business or occupational license, or permit or license issued by
11 the Department of Motor Vehicles or the Department of the
12 California Highway Patrol. “State governmental licensing entity”
13 shall not include the Department of Alcoholic Beverage Control
14 or the State Bar of California.

15 (d) Notwithstanding any other law, a state governmental
16 licensing entity may, with the approval of the appropriate
17 department director or governing body, impose a fee on licensees
18 whose license has been suspended as described in subdivision (a).
19 The fee shall not exceed the amount necessary for the state
20 governmental licensing entity to cover its costs in carrying out the
21 provisions of this section. Fees imposed pursuant to this section
22 shall be deposited in the fund in which other fees imposed by the
23 state governmental licensing entity are deposited and shall be
24 available to that entity upon appropriation in the annual Budget
25 Act.

26 (e) The process described in subdivision (b) shall constitute the
27 sole administrative remedy for contesting the suspension of a
28 license under this section. The procedures in the administrative
29 adjudication provisions of the Administrative Procedure Act
30 (Chapter 4.5 (commencing with Section 11400) and Chapter 5
31 (commencing with Section 11500) of Part 1 of Division 3 of Title
32 2 of the Government Code) shall not apply to the suspension of a
33 license pursuant to this section.

34 (f) This section shall apply to any licensee whose name appears
35 on a list of the ~~250~~ 500 largest tax delinquencies pursuant to
36 Section 19195 on or after January 1, 2012.

37 ~~SEC. 9.~~

38 *SEC. 14.* Article 7 (commencing with Section 19291) is added
39 to Chapter 5 of Part 10.2 of Division 2 of the Revenue and Taxation
40 Code, to read:

Article 7. Collection of Tax Debts Due to the Internal Revenue
Service or Other States

19291. (a) The Franchise Tax Board may enter into an agreement to collect any delinquent tax debt due to the Internal Revenue Service or any other state imposing an income tax or tax measured by income if, pursuant to Section 19377.5, the Internal Revenue Service or that state has entered into an agreement to collect delinquent tax debts due the Franchise Tax Board.

(b) Upon written notice to the debtor from the Franchise Tax Board, any amount referred to the Franchise Tax Board under subdivision (a) shall be treated as final and due and payable to the State of California, and shall be collected from the debtor by the Franchise Tax Board in any manner authorized under the law for collection of a delinquent income tax liability, including, but not limited to, the recording of a notice of state tax lien under Article 2 (commencing with Section 7170) of Chapter 14 of Division 7 of Title 1 of the Government Code, and the issuance of an order and levy under Article 4 (commencing with Section 706.070) of Chapter 5 of Division 2 of Title 9 of Part 2 of the Code of Civil Procedure in the manner provided for earnings withholding orders for taxes.

(c) Part 10 (commencing with Section 17001), this part, Part 10.7 (commencing with Section 21001), and Part 11 (commencing with Section 23001) shall apply to amounts referred under this section in the same manner and with the same force and effect and to the full extent as if the language of those laws had been incorporated in full into this section, except to the extent that any provision is either inconsistent with this section or is not relevant to this section.

(d) The activities required to implement and administer this section shall not interfere with the primary mission of the Franchise Tax Board to administer Part 10 (commencing with Section 17001) and Part 11 (commencing with Section 23001).

(e) In no event shall a collection under this section be construed as a payment of income taxes imposed under Part 10 (commencing with Section 17001) or Part 11 (commencing with Section 23001).

~~SEC. 10.~~

SEC. 15. Section 19377.5 is added to the Revenue and Taxation Code, to read:

1 19377.5. (a) The Franchise Tax Board may enter into an
2 agreement with the Internal Revenue Service or any other state
3 imposing an income tax or tax measured by income for the purpose
4 of collecting delinquent tax debts with respect to amounts assessed
5 or imposed under Part 10 (commencing with Section 17001), this
6 part, or Part 11 (commencing with Section 23001), provided the
7 agreements do not cause the net displacement of civil service
8 employees. The agreement may provide, at the discretion of the
9 Franchise Tax Board, the rate of payment and the manner in which
10 compensation for services shall be paid.

11 (b) At the discretion of the Franchise Tax Board, the Internal
12 Revenue Service or the other state collecting the tax debt pursuant
13 to subdivision (a) may, as part of the collection process, refer the
14 tax debt for litigation by its legal representatives in the name of
15 the Franchise Tax Board.

16 (c) For purposes of this section, “displacement” includes layoff,
17 demotion, involuntary transfer to a new class, involuntary transfer
18 to a new location requiring a change of residence, and time base
19 reductions. “Displacement” does not include changes in shifts or
20 days off, nor does it include reassignment to any other position
21 within the same class and general location.

22 ~~SEC. 11.~~

23 *SEC. 16.* Section 19571 is added to the Revenue and Taxation
24 Code, to read:

25 19571. (a) The Franchise Tax Board may disclose to state
26 governmental licensing entities information regarding suspension
27 of a license pursuant to Section 19265 of this code or Sections
28 494.5 or 7145.5 of the Business and Professions Code.

29 (b) Neither the state governmental licensing entity, nor any
30 officer, employee, or agent, or former officer, employee, or agent
31 of a state governmental licensing entity, may disclose or use any
32 information obtained from the Franchise Tax Board, pursuant to
33 this section, except to inform the public of the suspension of a
34 license pursuant to Section 19265 of this code or Sections 494.5
35 or 7145.5 of the Business and Professions Code.

36 (c) For purposes of this section, the definitions in Section 19265
37 shall apply.

38 *SEC. 17. Section 4.5 of this bill incorporates amendments to*
39 *Section 7145.5 of the Business and Professions Code proposed by*
40 *both this bill and A.B. 1307. It shall only become operative if (1)*

1 *both bills are enacted and become effective on or before January*
2 *1, 2012, (2) each bill amends Section 7145.5 of the Business and*
3 *Professions Code, and (3) this bill is enacted after A.B. 1307, in*
4 *which case Section 4 of this bill shall not become operative.*

5 ~~SEC. 12.~~

6 *SEC. 18.* No reimbursement is required by this act pursuant to
7 Section 6 of Article XIII B of the California Constitution because
8 a local agency or school district has the authority to levy service
9 charges, fees, or assessments sufficient to pay for the program or
10 level of service mandated by this act or because costs that may be
11 incurred by a local agency or school district will be incurred
12 because this act creates a new crime or infraction, eliminates a
13 crime or infraction, or changes the penalty for a crime or infraction,
14 within the meaning of Section 17556 of the Government Code, or
15 changes the definition of a crime within the meaning of Section 6
16 of Article XIII B of the California Constitution.

**CALIFORNIA STATE BOARD OF PHARMACY
BILL ANALYSIS**



BILL NUMBER: AB 1424

VERSION: As Amended July 12, 2011

AUTHOR: Perea

SPONSOR:

SUBJECT: Collection of Delinquent Tax Debt

Affected Sections:

Business and Professions Code (B&PC): Amend §§ 31, 476 and 7145.5; Add §494.5

Government Code: Add §12419.13

Public Contract Code: Add §10295.4

Revenue and Taxation Code: Amend §§ 7063 and 19195; Add §§ 6834, 6835, 7057, 19265, 19377.5, 19571, Article 9 (commencing with §6850), and Article 7 (commencing with § 19291)

CURRENT STATUS: Senate Appropriations Hearing scheduled for August 15, 2011.

OVERVIEW

This bill amends and adds a variety of provisions to the Revenue and Taxation Code, the Public Contract and Government Codes, as well as the Business and Professions Code to provide for the collection of unpaid tax debt.

In its current form, the board would be required to compare its licensee data with the certified list of “500 largest tax delinquencies” prepared by the Franchise Tax Board and the Board of Equalization. If an applicant is on that list, and is otherwise able to be licensed, the board could issue only a temporary license for 150 days and further deny the application if the person does not satisfy the tax obligation or otherwise enter into an agreement with the FTB or BOE to satisfy the debt. For an existing licensee, the board would be required to issue a temporary license for 150 days. The bill requires the board to provide notice to an applicant or licensee of the provisions; requires the board to include specified statements on its license and renewal applications; create forms; and ensure it does not contract with a person or entity on the “Top 500” list.

EXISTING LAW, as it relates to the Board:

1. Federal law mandates the Financial Institution Data Match (FIDM) for the collection of delinquent child support payments. The California Franchise Tax Board (FTB) is responsible for collecting child support debts in California. The Department of Consumer Affairs (DCA) Family Support Unit receives information on delinquent child support orders. Licensees found to be noncompliant with a child support order are issued a temporary license – this action is used as tool to bring a licensee into compliance with a child support order. A licensee who then

does not come into compliance with a child support order is subject to additional actions against their license.

AS AMENDED THIS BILL WOULD:

1. Amend B&PC §31 to specify that each licensee whose name appears on a list of the 500 largest tax delinquencies (as certified by the BOE and FTB) is subject to temporary suspension of their license until a tax obligation is satisfied or until the licensee enters into an agreement with the FTB or BOE to pay the obligation, as specified. This section further requires the board to include a statement on its initial and renewal applications regarding the BOE's and FTB's right to share taxpayer information, that the licensee is required to pay his or her tax obligation, and that his or her license may be suspended if the state tax obligation is not paid.
2. Add B&PC § 494.5 to do the following, effective January 1, 2012:
 - Add definitions (Certified list, license, licensee, state governmental licensing entity).
 - Provide an "opt-out" provision for a state governmental licensing entity and, upon election, requirements to notify the BOE and FTB in a manner specified by those agencies.
 - Require the BOE and FTB to provide the board with certified lists of the 500 largest tax delinquencies.
 - Require the board to collect SSN or FEIN numbers from all applicants, for the purpose of matching names against the BOE / FTB certified lists.
 - Authorize the board to withhold issuance or renewal of a license for an applicant on the BOE / FTB lists.
 - Require the board to provide notice to applicants or licensees on the "Top 500" list, to be sent via certified mail, and the content of those notices.
 - Require the board to create forms, notices, and include specific statements on its license and renewal applications.
 - Specify that the Administrative Procedure Act shall not apply to the denial, suspension or failure to issue or renew a license as specified in this section; and specify that information collected by the board pursuant to this section is subject to the Information Practices Act.
 - Authorize a state agency to assess a fee to cover its costs related to these provisions, and to enter into Interagency Agreements with the BOE and FTB.
 - Authorize the board to adopt emergency regulations for the purpose of adopting rules and regulations related to this section. Also, require the BOE and FTB to adopt regulations necessary to implement this section.
 - Specify that a suspension or revocation of a license under this section shall not be reported to the National Practitioner Data Bank.
 - Require the board to notify the BOE or FTB it has not suspended, revoked or denied a license following 90 days of mailing a preliminary notice; authorize

the BOE or FTB to suspend a license if the licensing entity has not done so or “opts out.”

- Specify that policies, practices and procedures used by the board shall be the same as those used by the licensing entity for the purpose of delinquent child support orders.
- Require a licensing entity, as specified, to provide the FTB with the name, SSN, FEIN of each licensee.
- Provide for the automatic suspension of a license if a person fails to pay unpaid taxes or fails to enter into an install payment agreement, as specified.
- Provide administrative remedies for the contesting of a suspension of a license; the process by which a suspension can be cancelled, as specified; provide definitions; and require the licensing entity to provide information to the FTB as required.

AUTHOR’S INTENT:

Staff has requested a Fact Sheet from the author’s office.

FISCAL IMPACT:

Board staff anticipates that the measure as amended July 12, 2011, would require a half-time AGPA to implement the provisions of the bill.

SUPPORT/OPPOSITION:

According to the Senate Committee Analysis (for the June 7, 2011 version):

Support

California Tax Reform Association; Western Center on Law and Poverty

Opposition

California Association of Realtors
California Chapter of the American Fence Association
California Fence Contractors Association
Engineering Contractors Association
California Landscape Contractors Association
Marin Builders Association
Flasher Barricade Association

HISTORY:

Date	Action
2011	
July 12	Read second time and amended. Re-referred to Com. on APPR.
July 11	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 6. Noes 3.) (July 6).
June 22	In committee: Hearing postponed by committee.
June 7	From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on

	GOV. & F.	
June 6	From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on GOV. & F.	<i>[gut & amend]</i>
June 2	Referred to Com. on GOV. & F.	
May 26	In Senate. Read first time. To Com. on RLS. for assignment.	
May 26	Read third time. Passed. Ordered to the Senate. (Ayes 75. Noes 0. Page 1566.)	
May 19	Read second time. Ordered to consent calendar.	
May 18	From committee: Do pass. To consent calendar. (Ayes 17. Noes 0.) (May 18).	
May 5	Re-referred to Com. on APPR.	
May 4	Read second time and amended.	
May 3	From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (May 2).	
May 2	In committee: Set, first hearing. Referred to REV. & TAX. suspense file.	
Mar. 31	Referred to Com. on REV. & TAX.	
Mar. 23	From printer. May be heard in committee April 22.	
Mar. 22	Read first time. To print.	

LEGISLATION AND REGULATION COMMITTEE

Goal 3: Advocate legislation and promulgate regulations that advance the vision and mission of the Board of Pharmacy.

Outcome: Improve the health and safety of Californians.

Objective 3.1	Annually identify and respond with legislative changes to keep pharmacy laws current and consistent with the board's mission.
Measure:	100 percent successful enactment of promoted legislative changes.
Tasks:	<p>1. Secure extension of board's sunset date.</p> <p><i>1st Qtr 06/07: Governor signs SB 1476 which delays the board's sunset date two years (until 2010), and requires the board's sunset report in 2008.</i></p> <p><i>4th Qtr 06/07: SB 963 (Ridley-Thomas) is amended to alter the sunset review process.</i></p> <p><i>1st Qtr 08/09: SB 963 (Ridley-Thomas) is amended to alter the sunset review process. Board staff attend a stakeholders meeting with committee staff to discuss amendments.</i></p> <p><i>Governor signs SB 963 (Chapter 385, Statutes of 2008)</i></p> <p><i>1st Qtr 09/10: Sunset extension amended into AB 1071. Bill enrolled and sent to Governor.</i></p> <p><i>2nd Qtr 09/10: Governor signs AB 1071 (Chapter 270, Statutes of 2009) to extend the board's sunset date to 2013.</i></p> <p><i>3rd Qtr 09/10: Sunset bills introduced</i></p> <p><i>AB 1659 (Huber) – State Government, Agency Repeals</i></p> <p><i>AB 2130 (Huber) – Joint Committee on Boards, Commissions and Consumer Protection</i></p> <p><i>SB 954 (Harmon) – Legislative Procedure, Committee Referrals</i></p> <p><i>SB 1171 (Negrete McLeod) – Regulatory Boards, Operations</i></p> <p><i>4th Qtr 09/10: SB 954 (Harmon) – Bill is dead (Failed deadline)</i></p> <p><i>SB 1171 (Negrete McLeod) – Bill is dead (Failed deadline)</i></p> <p><i>1st Qtr 10/11: Governor signs AB 1659 (Chapter 666, Statutes of 2010)</i></p> <p><i>Governor signs AB 2130 (Chapter 670, Statutes of 2010)</i></p>

2. Sponsor legislation to update pharmacy law.

Enacted - 1st Qtr. 08/09: SB 1048 (Chapter 588, Statutes 2007) containing board omnibus provisions

Oct. 2007: Board sponsors omnibus provisions for 2008. Four types of changes are discussed.

(1) Changes specific to the PIC and DRC requirements

- Section 4022.5 – Designated Representative; Designated Representative-in-Charge
- Section 4036.5 – Pharmacist-in-Charge
- Section 4161 – Nonresident wholesaler
- Section 4305 – Pharmacist-in-Charge; Notice to Board; Disciplinary Action
- Section 4329 – Nonpharmacists; Prohibited Acts
- Section 4330 – Proprietors; Prohibited Acts

(2) Changes to allow for the use of mobile pharmacies

- Section 4062 – Furnishing Dangerous Drugs During an Emergency.
- Section 4110 – License Required, Temporary Permit Upon Transfer of Ownership.

(3) General changes

- Section 4059.5 – Who May order Dangerous Drugs or Devices, Exceptions.
- Section 4081 – Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory
- Section 4126.5 – Furnishing Dangerous Drugs by Pharmacy.
- Section 4231 – Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New Licensee.
- H&SC 11165 – Controlled Substance Utilization Review and Evaluation System: Establishment; Operation; Funding; Reporting to Legislature.

(4) Changes based on recodification of Business and Professions

Code section 4052

- Section 733 – Dispensing Prescription Drugs and Devices
- Section 4027 – Skilled Nursing Facility – Intermediate Care Facility – Other Health Care Facilities
- Section 4040 – Prescription; Content Requirements
- Section 4051 – Conduct Limited to Pharmacist; Conduct Authorized by Pharmacist
- Section 4060 – Controlled Substance – Prescription Required, Exceptions
- Section 4076 – Prescription Container – Requirements for Labeling
- Section 4111 – Restrictions on Prescriber Ownership
- Section 4174 – Dispensing by Pharmacist Upon Order of Nurse Practitioner
- H&SC 11150 – Persons Authorized to Write or Issue a Prescription

	<p>Jan. 2008: <i>Staff provides language to Senate Business and Professions Committee for inclusion in omnibus bill SB 1779.</i></p> <p><i>Board approved language for omnibus bill.</i></p> <p>April 2008: <i>Some provisions of omnibus bill removed:</i></p> <ul style="list-style-type: none"> • <i>Section 4101 – Pharmacist-in-Charge; Designated Representative-in-Charge; Termination of Status; Duty to Notify the Board.</i> • <i>Section 4113 – Pharmacist-in-Charge; Approval; Responsibilities; Notifications</i> • <i>Section 4160 – Wholesaler Licenses</i> • <i>Section 4196 – Veterinary Food-Animal Drug Retailer Licenses; Persons Allowed in Areas Where Drugs are Stored, Possessed, or Repacked</i> • <i>Section 4362 – Entry Into Pharmacists Recovery Program.</i> <p>Oct. 2008: <i>Governor vetoes SB 1779</i></p> <p>1st Qtr 08/09: <i>Board seeks to pursue omnibus provisions (formerly contained in SB 1779). Four areas of change: (Included in SB 819)</i></p> <p><i>(1) Changes specific to the PIC and DRC requirements</i></p> <ul style="list-style-type: none"> • <i>Section 4022.5 – Designated Representative; Designated Representative-in-Charge</i> • <i>Section 4036.5 – Pharmacist-in-Charge</i> • <i>Section 4305 – Pharmacist-in-Charge; Notice to Board; Disciplinary Action</i> • <i>Section 4329 – Nonpharmacists; Prohibited Acts</i> • <i>Section 4330 – Proprietors; Prohibited Acts</i> <p><i>(2) Changes to allow for the use of mobile pharmacies</i></p> <ul style="list-style-type: none"> • <i>Section 4062 – Furnishing Dangerous Drugs During an Emergency.</i> • <i>Section 4110 – License Required, Temporary Permit Upon Transfer of Ownership.</i> <p><i>(3) General changes</i></p> <ul style="list-style-type: none"> • <i>Section 4059.5 – Who May order Dangerous Drugs or Devices, Exceptions.</i> • <i>Section 4081 – Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory</i> • <i>Section 4126.5 – Furnishing Dangerous Drugs by Pharmacy.</i> • <i>Section 4231 – Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New Licensee.</i> <p><i>H&SC 11165 – Controlled Substance Utilization Review and Evaluation System: Establishment; Operation; Funding; Reporting to Legislature.</i></p>
--	---

	<p>(4) <i>Changes based on recodification of Business and Professions Code section 4052</i></p> <ul style="list-style-type: none"> • <i>Section 733 – Dispensing Prescription Drugs and Devices</i> • <i>Section 4027 – Skilled Nursing Facility – Intermediate Care Facility – Other Health Care Facilities</i> • <i>Section 4040 – Prescription; Content Requirements</i> • <i>Section 4051 – Conduct Limited to Pharmacist; Conduct Authorized by Pharmacist</i> • <i>Section 4060 – Controlled Substance – Prescription Required, Exceptions</i> • <i>Section 4076 – Prescription Container – Requirements for Labeling</i> • <i>Section 4111 – Restrictions on Prescriber Ownership</i> • <i>Section 4174 – Dispensing by Pharmacist Upon Order of Nurse Practitioner</i> • <i>H&SC 11150 – Persons Authorized to Write or Issue a Prescription</i> <p>1st Qtr 08/09: <i>Board seeks to introduce additional changes: (Included in SB 821)</i></p> <ul style="list-style-type: none"> • <i>Section 4101 – Pharmacist-in-Charge; Designated Representative-in-Charge; Termination of Status; Duty to Notify the board.</i> • <i>Section 4113 – Pharmacist-in-Charge; Approval; Responsibilities; Notifications</i> • <i>Section 4160 – Wholesaler Licenses</i> • <i>Section 4196 – Veterinary Food-Animal Drug Retailer Licenses; Persons Allowed in Areas Where Drugs are Stored, Possessed, or Repacked</i> • <i>Section 4362 – Entry Into Pharmacists Recovery Program.</i> <p><i>New Provisions</i></p> <ul style="list-style-type: none"> • <i>4200.1 – Pharmacist Examination; Remedial Education</i> • <i>4112 – Non-resident Pharmacy: Registration Required</i> • <i>4146 – Return and Disposal of Sharps</i> • <i>4013 – Subscriber Alert</i> <p>3rd Qtr 08/09: <i>SB 821 introduced</i></p>
--	--

2nd Qtr 09/10: Governor signs SB 819 and SB 821, which contains all omnibus provisions with the exception of 4200.1 - Pharmacists Examination.

3rd Qtr 09/10: Staff provides language to Senate Business Professions and Economic Development Committee for inclusion in two omnibus bills.

Omnibus Proposal #1:

- (1) Amendments to update references to the California Department of Public Health (formerly known as Department of Health Services)
 - §4017 – Authorized Officers of the Law
 - §4027 – Skilled Nursing Facility – Intermediate Care Facility – Other Health Care Facilities
 - §4028 – Definition of Licensed Hospital
 - §4037 – Definition of Pharmacy
 - §4052.3 – Emergency Contraception Drug Therapy; Requirements and Limitations
 - §4072 – Oral or Electronic Transmission of Prescription – Health Care Facility
 - §4101 – Pharmacist-in-Charge, Designated Representative-in-Charge; Termination of Status; Duty to Notify the Board
Prescription: Exceptions.
 - §4119 – Furnish Prescription Drug to Licensed Health Care Facility – Secured Emergency Supplies
 - §4127.1 – License to Compound Injectable Sterile Drug Products Required
 - §4169 – Prohibited Acts (also, strike operative date of 2008)
 - §4181 – License Requirements; Policies and Procedures; Who May Dispense
 - §4191 – Compliance with California Department of Public Health Requirements; Who May dispense Drugs
- (2) Amendment to update a reference to the Physical Therapy Board of California (formerly known as the Physical Therapy Examining Committee of California)
 - §4059 – Furnishing Dangerous Drugs or Devices Prohibited Without Prescription: Exceptions
- (3) Amendments to update references to the State Department of Health Care Services (formerly known as the Department of Health Services)
 - §4425 – Pharmacy Participation in Medi-Cal Program; Conditions; Department of Health Care Services Utilization Review and Monitoring
 - §4426 – Department of Health Care Services to Study Reimbursement Rates

Omnibus Proposal #2

- (1) Amend §4196(e) – Veterinary Food-Animal Drug Retailer; Designated Representative-in-Charge
- (2) Amend §4200.1 – Retaking Examinations; Limits; Requirements (NAPLEX and CPJE 4x Failure)
- (3) Add §4362 – Pharmacists Recovery Program

3rd Qtr 09/10: SB 1489 introduced (Senate Business, Professions, and Economic Development Committee). Includes proposals #1 and #2, with the exception of §4362.

	<p>4th Qtr 09/10: Board establishes support position of SB 1489. SB 1489 is amended to modify §4013 – Subscriber Alert provisions for an owner of two or more pharmacies. SB 1489 is amended to modify §4076.5 – Patient-Centered Prescription Labels to authorize the board to exempt long-term health care facilities from regulations.</p> <p>1st Qtr 10/11: Governor signs SB 1489 (Chapter 653, Statutes of 2010).</p> <p>2nd Qtr 10/11: Board seeks to pursue omnibus provisions Section 4200 – Remove obsolete reference to prior pharmacist examination Staff provides language to Senate Committee on Business, Professions and Economic Development for inclusion in an omnibus bill.</p> <p>3rd Qtr 10/11: Staff provides language to Senate Business Professions and Economic Development for inclusion in Omnibus Bill. SB 943 is introduced. Contains amendments to section 4200.</p> <p>3. Advocate the board’s role and its positions regarding pharmacists’ care and dispensing of dangerous drugs and devices (AB 2408). Sep. 30, 2006: Governor signs AB 2408. Amendments taken in August remove provisions that would have described the professional services provided by pharmacists, and authorized pharmacists outside California to provide pharmacists’ care services to patients in California if licensed here or working within the framework of a nonresident pharmacy. Remaining provisions restructure pharmacist protocol provisions and several other changes.</p> <p>4. Secure statutory standards for pharmacies that compound medications (AB 595). Aug. 2006: Amendments made to remove opposition of DHS regarding pharmacy contracting with another pharmacy for compounded drugs triggers opposition from pharmacy organizations. Board drops AB 595, but will advance regulations developed for compounding pharmacies in the future. Aug. 2008: Regulatory effort initiated. (See Objective 3.2, Task 12) Oct. 2009: Board approves regulatory language for Initial Notice. Jan. 2010: Office of Administrative Law approves regulation. July 2010: Regulation effective.</p> <p>5. Secure implementation of e-pedigrees on prescription drugs dispensed in California. Sep. 2006: Governor signs SB 1476 which contains board amendments to delay implementation of the e-pedigree requirements until 2009, or upon board action, until 2011. Amendments also require interoperability, serialization, returned drug products to retain the initiating pedigree, require notice to the board of suspected or actual counterfeiting, and continuation of the pedigree through repackaging operations. Sep. 2008: Governor signs SB 1307 which delays implementation of e-pedigree.</p>
--	---

	<p>6. Advocate the board's position on pending legislation affecting pharmacy practice and/or the board's jurisdiction.</p> <p>Oct. 2007: Governor signs the following: <i>AB 110 (Chapter 707, Statutes of 2007) Drug Paraphernalia: Clean Needle and Syringe Exchange Projects.</i> <i>SB 472 (Chapter 470, Statutes of 2007) Prescription Drugs: Labeling Requirements.</i> <i>SB 966 (Chapter 542, Statutes of 2007) Pharmaceutical Drug Disposal.</i></p> <p> Governor vetoes the following: <i>AB 249 (Eng) Healing Arts: Settlement Agreements.</i> <i>AB 543 (Plescia) Ambulatory Surgical Centers: Licensure.</i> <i>AB 1025 (Bass) Professions and Vocations: Denial of Licensure.</i> <i>SB 615 (Oropeza) Pharmacy Technicians: Scholarship Fund.</i></p> <p>Oct. 2008: Governor signs the following: <i>AB 1394 (Chapter 431, Statutes of 2008) Counterfeit: Trademarks</i> <i>SB 963 (Chapter 385, Statutes of 2008) Regulatory Boards: Sunset Review</i></p> <p> Governor vetoes the following: <i>AB 501 (Swanson) Pharmaceutical Devices</i> <i>AB 865 (Davis) State Agencies</i> <i>AB1574 (Plescia) Surgical Clinics: Licensure</i></p> <p>Jan. 2009: <i>Legislation introduced affecting Pharmacy law:</i> (New Session) <i>AB 67 (Nava) Pharmacy Patient Protection Act of 2008. Dispensing of prescriptions, irrespective of a pharmacist's ethical, moral, or religious objections.</i> <i>SB 26 (Simitian) Home-generated pharmaceutical wastes and the disposal of devices.</i></p>
--	--

	<p>4th Qtr 08/09: AB 418 (Emmerson) Pharmacy Technicians – Education and CE Requirements AB 484 (Eng) Licensees Not in Compliance with Judgment or Order; Enforcement; Action on a License AB 718 (Emmerson) Prescription Drugs: Electronic Transmissions – Requirement to Electronically Transmit Data by January 2012 AB 830 (Cook) Drugs and Devices. References to US Pharmacopoeia; Compendia Recognized by the Centers of Medicare and Medicaid AB 877 (Emmerson) Healing Arts; DCA Committee Analysis; Scope of Healing Arts Practice AB 931 (Fletcher) Emergency Supplies – Doses Stored in an Emergency Supplies Container AB 1310 (Hernandez) Specifies Mandatory Fields for Initial and Renewal Application Forms (Various Healing Arts Boards). Annual Transmission of Data to Health Care Workforce Clearinghouse (OSHDPD) AB 1370 (Solorio) “Best Before” Date on a Prescription Label AB 1458 (Davis) Drugs: Adverse Effects Reporting SB 26 (Simitian) Home-Generated Pharmaceutical Waste SB 43 (Alquist) Cultural and Linguistic Competency SB 238 (Calderon) Medical Information SB 341 (DeSaulnier) California Department of Public Health to Contract with UC to Evaluate the Safety and Effectiveness of Prescription Drugs SB 389 (McLeod) – FBI and State Fingerprinting Requirements for DCA Boards and Bureaus SB 484 (Wright) Ephedrine Products to Schedule V SB 638 (Negrete McLeod) DCA Regulatory Boards -- Sunset Reviews SB 762 (Aanestad) Professions and Vocations; Healing Arts AB 718 (Emmerson) Prescription Drugs: Electronic Transmissions – Requirement to Electronically Transmit Data by January 2012 AB 830 (Cook) Drugs and Devices. References to US Pharmacopoeia; Compendia Recognized by the Centers of Medicare and Medicaid AB 931 (Fletcher) Emergency Supplies – Doses Stored in an Emergency Supplies Container AB 1310 (Hernandez) Specifies Mandatory Fields for Initial and Renewal Application Forms (Various Healing Arts Boards). Annual Transmission of Data to Health Care Workforce Clearinghouse (OSHDPD) SB 389 (McLeod) – FBI and State Fingerprinting Requirements for DCA Boards and Bureaus SB 484 (Wright) Ephedrine Products to Schedule V SB 638 (Negrete McLeod) DCA Regulatory Boards -- Sunset Reviews SB 762 (Aanestad) Professions and Vocations; Healing Arts</p> <p>1st Qtr 09/10: Governor signs SB 762 (Aanestad) Professions and Vocations; Healing Arts</p> <p>2nd Qtr 09/10: Governor signs SB 819 (Omnibus) Governor vetoes SB 820 (Omnibus) Governor signs SB 821 (Omnibus) Governor signs SB 470 (Corbett) - “Purpose” Governor signs AB 1071 (Emmerson) Pharmacy Fees; Sunset Governor signs AB 931 (Fletcher) - Emergency Supplies Container Governor signs AB 830 (Cook) Drugs and Devices; references to Compendia</p>
--	--

3rd Qtr 09/10: *Board considers new legislation*

1. *Board of Pharmacy*
 - AB 2104 (Hayashi) – California State Board of Pharmacy
 - SB 1390 (Corbett) – Prescription Container Labels
2. *Pharmacy Practice*
 - AB 1869 (Anderson) – Pharmacy (spot bill)
 - AB 1916 (Davis) – Pharmacies: Mandatory Reporting of Med Errors
3. *Sunset Review and Legislative Oversight Proposals*
 - AB 1659 (Huber) – State Government, Agency Repeals
 - AB 2130 (Huber) – Joint Committee on Boards, Commissions and Consumer Protection
 - SB 954 (Harmon) – Legislative Procedure, Committee Referrals
 - SB 1171 (Negrete McLeod) – Regulatory Boards, Operations
 - SB 1172 (Negrete McLeod) – Sunset of Diversion Program
4. *Regulation of Dangerous Drugs and Devices*
 - AB 1455 (Hill) -- Pseudoephedrine
 - AB 2548 (Block) – CURES – Prescription Drug Monitoring Program
 - SB 971 (Pavley) – Bleeding Disorders: Blood Clotting Products
 - SB 1071 (DeSaulnier) – CURES
 - SB 1106 (Yee) – Prescribers – Dispensing of Samples
5. *Pharmacy Licensing Issues*
 - AB 2077 (Solorio) – Centralized Hospital Packaging Pharmacies
 - AB 2292 (Lowenthal) – Pharmacy: Clinics
 - AB 2551 (Hernandez) – Pharmacy Technician: Scholarship and Loan Repayment Program
6. *Distribution of Needles and Syringes*
 - AB 1701 (Chesbro) – Hypodermic Needles and Syringes
 - AB 1858 (Blumenfield) – Hypodermic Needles and Syringes: Exchange Services
 - AB 2139 (Chesbro) – Solid Waste: Product Stewardship
 - SB 1029 (Yee) -- Hypodermic Needles and Syringes
7. *General / Other*
 - AB 2112 (Monning) – Prescription Record Privacy Act

	<p>4th Qtr 09/10: Board considers additional legislation AB 1939 (Fletcher) Sharps Waste SB1111 (Negrete McLeod) DCA Enforcement Model</p> <p>Apr. 2010: Board takes positions on legislative measures: AB 1701 (Chesbro) Support AB 2104 (Hayashi) Oppose AB 2292 (Lowenthal) Support SB 1106 (Yee) Support if Amended AB 1916 (Davis) Bill is dead (failed deadline) AB 2112 (Monning) Bill is dead (failed deadline) SB 1111 (Negrete McLeod) Bill is dead (failed deadline)</p> <p>May 2010: AB 1869 (Anderson) Bill is dead (failed deadline) AB 1939 (Fletcher) Bill is dead (failed deadline)</p> <p>June 2010: SB 1390 (Corbett) Fails passage in policy committee SB 954 (Harman) Bill is dead (failed deadline) SB 1171 (Negrete McLeod) Bill is dead (failed deadline) AB 2139 (Chesbro) Bill is dead (failed deadline) AB 2292 (Lowenthal) Bill is dead (failed deadline) AB 2548 (Block) Bill is dead (Failed deadline)</p> <p>Apr./May 2010: AB 2104 (Hayashi) Amended twice</p> <p>June 2010: AB 2104 (Hayashi) Amended to authorize Board appointment of Executive Officer with approval of DCA Director.</p> <p>July 2010: AB 2077 (Solorio – Centralized Hospital Packaging Pharmacies. Board establishes Support position.</p>
--	---

1st Qtr 10/11: Governor signs the following legislation:

AB 2104 (Hayashi) – Requires DCA Director approval of the Board's appointment of Executive Officer (Chapter 374, Statutes of 2010)

AB 1659 (Huber) – State Government, Agency Repeals (Chapter 666, Statutes of 2010)

AB 2130 (Huber) – Joint Committee on Boards, Commissions and Consumer Protection (Chapter 670, Statutes of 2010)

SB 1172 (Negrete McLeod) – Diversion Programs (Chapter 517, Statutes of 2010)

AB 1071 (Chesbro) – Hypodermic Needles and Syringes (Chapter 667, Statutes of 2010)

SB 1414 (Hill) – Apomorphine: Unscheduled (Chapter 76, Statutes of 2010)

AB 2699 (Bass) – Licensure Exemption: State of Emergency (Chapter 270, Statutes of 2010)

Governor vetoes the following legislation:

AB 1858 (Blumenfield) – Hypodermic Needles and Syringes

SB 1029 (Yee) – Hypodermic Needles and Syringes

AB 2077 (Solorio) – Centralized Hospital Packaging Pharmacies

SB 971 (Pavley) – Bleeding Disorders: Blood Clotting Products

AB 2747 (Lowenthal) – Prisons: Pharmacy Services

The following legislation fails passage:

AB 1455 (Hill) – Pseudoephedrine

SB 1071 (DeSaulnier) – CURES

SB 1106 (Yee) – Prescribers Dispensing of Samples

AB 2551 (Hernandez) – Pharmacy Technician Scholarship & Loan Repayment Program

AB 1310 (Hernandez) – Healing Arts Database

2nd Qtr 10/11: SB 41 (Yee) Introduced – Hypodermic Needles and Syringes

AB 36 (Hill) Introduced – Ephedrine: Retail Sale

Board approves provisions for sponsorship in 2011/2012 Session:

(1) Pharmacists Recovery Program

- Section 4362 – Amend to require that a participant in the pharmacists recovery program be responsible to pay an administrative co-pay each month to cover a portion of the administrative costs borne by the board; provision to allow the board to waive or defer the requirement based on a demonstrated financial hardship.*

3rd Qtr 10/11: Board advised changes to 4362 will not be sought this year.

1. Board-Sponsored Legislation

SB 431 (Emmerson) Pharmacies: regulation

- Sections 4040.5, 4081 and 4126.5 – Proposal Regarding Return of Medicine to Reverse Distributors
- Sections 4104, 4105 and 4112 – Enforcement Enhancements

2. Legislation Impacting the Practice of Pharmacy or the Board's Jurisdiction

a. Board of Pharmacy/Licensing

- AB 377 (Solorio) Pharmacy: Centralized hospital packaging
- AB 399 (Lowenthal, Bonnie) Corrections: offender pharmacies
- AB 847 (Lowenthal, Bonnie) Pharmacy: clinics
- SB 100 (Price) Healing arts
- SB 632 (Emmerson) Pharmacy

b. Controlled Substances/Marijuana

- AB 507 (Hayashi) Pain management
- SB 847 (Correa) Medical Cannabis Licensing Act
- SB 786 (Dutton) Controlled substances

c. Reporting Requirements/Records

- SB 260 (Cannella) Controlled substances
- SB 315 (Wright) Ephedrine and pseudoephedrine
- SB 360 (DeSaulnier) Controlled Substance Utilization Review and Evaluation System

d. Healing Arts/DCA

- AB 675 (Hagman) Continuing education
- AB 958 (Berryhill) Regulatory boards: limitation periods
- AB 1003 (Smyth) Professional and vocational licenses
- AB 1328 (Pan) Professions and vocations
- SB 231 (Emmerson) Regulatory boards: healing arts
- SB 227 (Wyland) Business and professions: licensure (corrected)
- SB 538 (Price) Healing arts
- SB 544 (Price) Healing arts
- SB 667 (Wyland) Healing arts

e. Other

- AB 389 (Mitchell) Bleeding disorders: blood clotting products
- AB 604 (Skinner) Needle exchange programs
- SB 41 (Yee) Hypodermic Needles and Syringes
- SB 514 (Simitian) Dextromethorphan: sale to minors prohibited
- SB 850 (Leno) Medical records: confidential information

4th Qtr 10/11: Board considers and establishes positions on the following legislation

- a. Board of Pharmacy/Licensing
 - AB 377 (Solorio) Pharmacy: Centralized hospital packaging - Support if amended
 - AB 399 (Lowenthal, Bonnie) Corrections: offender pharmacies -Support
- b. Controlled Substances/Marijuana
 - AB 507 (Hayashi) Pain management - Oppose
- c. Reporting Requirements/Records
 - SB 315 (Wright) Ephedrine and pseudoephedrine - Support
 - SB 360 (DeSaulnier) Controlled Substance Utilization Review and Evaluation System - Watch
 - AB 1280 (Hill) Ephedrine Sales - Watch
- d. Healing Arts/DCA
 - SB 541 (Price) Extromethorphan: sale to minors prohibited - Support
- e. Other
 - AB 389 (Mitchell) Bleeding disorders: blood clotting products - Watch
 - AB 604 (Skinner) Needle exchange programs - Support
 - SB 41 (Yee) Hypodermic Needles and Syringes - Support if amended
 - SB 514 (Simitian) Dextromethorphan: sale to minors prohibited - Support

	<p>7. Expand the conditions under which a pharmacist may administer an immunization independent of physician protocol.</p> <p>March 2007: <i>Licensing Committee considers and approves concept. More work is required.</i></p> <p>June 2007: <i>Licensing Committee considers draft language and requests additional refinements to proposal for consideration at September 2007 committee meeting.</i></p> <p>Sept. 2007: <i>Licensing Committee forwards to full board legislative proposal.</i></p> <p>Oct. 2007: <i>Board approved draft legislation.</i></p> <p>Nov. 2007: <i>Staff meeting with stakeholders to elicit support for the proposal.</i></p> <p>Dec. 2007: <i>Staff develop fact sheets and work with experts in immunizations.</i></p> <p>Feb. 2009: <i>Assembly Member Skinner authors AB 977, to allow pharmacists to initiate and administer immunizations pursuant to the Centers for Disease Control's guidelines for the adult and adolescent immunizations schedules.</i></p> <p>April 2009: <i>Bill amended to allow pharmacists to initiate and administer pneumonococcal and influenza vaccines.</i></p> <p>May 2009: <i>Bill amended to intent language requesting the California Pharmacists Association to provide information to legislative Committees on the status of immunization protocols. (2-year bill)</i></p> <p>Jan. 2010: <i>Bill amended (removing opposition) to allow pharmacists to administer influenza vaccinations pursuant to protocol and to require specified documentation and reporting.</i></p> <p>Jan. 2010: <i>AB 977 passes out of Assembly Health Committee Board reaffirms "support" position.</i></p> <p>April 2010: <i>Board changes position from "sponsor" to "support".</i></p> <p>June 2010: <i>AB 977 amended to apply only to a pharmacist associated with an independent community pharmacy. Bill died in committee.</i></p>
--	---

	<p>8. Advocate the board's role as an advocate for consumers by redesigning prescription label for all medicines dispensed to California patients.</p> <p><i>Oct. 2007: Governor signs SB 472 (Chapter 470, Statutes of 2007) Prescription Drugs: Labeling Requirements.</i></p> <p><i>Apr. 2008: First public forum held in Fremont.</i></p> <p><i>May 2008: Staff develop survey form to distribute to consumers to solicit input</i> <i>Staff attend Senior Seminar, interview attendees about prescription label and distribute surveys.</i></p> <p><i>June 2008: Staff attends community events, interview attendees about prescription label and distribute surveys.</i></p> <p><i>July 2008: Staff attends community events, interview attendees about prescription label and distribute surveys.</i></p> <p><i>Oct. 2008: Staff continues to attend community events, interview attendees about prescription label and distribute surveys.</i> <i>Public Education Committee updated on the status of survey results.</i></p> <p><i>Feb. 2009: Senator Corbett authors SB 470, to allow the purpose for which a medicine is prescribed to be included in the prescription and prescription label.</i></p> <p><i>May 2009: Bill passes out of the Senate</i></p> <p><i>Oct. 2009: Governor signs SB 470 (Chapter 590, Statutes of 2009).</i></p> <p><i>Oct. 2009: Board approves regulatory language for notice.</i></p> <p><i>Nov. 2009: Regulatory effort initiated.</i></p> <p><i>June 2010: Board adopts final text (See Objective 3.2, Task 16).</i></p> <p><i>Nov. 2010: Office of Administrative Law approves regulation.</i></p> <p><i>Jan. 2011: Regulation takes effect.</i></p> <p>9. Secure statutory fee increase to ensure sufficient funding to fulfill all of the boards statutory obligations as a consumer protection agency.</p> <p><i>Dec. 2008: Board receives findings of independent fee audit.</i></p> <p><i>Jan. 2009: Board votes to pursue fee increase.</i></p> <p><i>Feb. 2009: Assembly Member Emmerson authors AB 1071 which establishes new application and renewal fees.</i></p> <p><i>June 2009: Bill passes out of the Assembly.</i></p> <p><i>Sept. 2009: Bill is enrolled and sent to the Governor.</i></p> <p><i>Sept. 2009: Bill enrolled, then pulled back and amended to include sunset provisions for the board. Amendments pass Senate and Assembly concurs. The bill is re-enrolled.</i></p> <p><i>Oct. 2009: Governor signs AB 1071 (Chapter 270, Statutes of 2009)</i></p> <p><i>Jan. 2010: Statutory fee schedule implemented (supersedes 16 CCR 1749)</i></p>
--	--

10. Advocate legislation to enhance the board's enforcement activities.

Jan. 2010: Staff working to include in department-wide enforcement legislation the following enhancements to the board's enforcement activities (board approved Oct 2009):

Section 4081 - Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory.

Section 4104 - Licensed Employee, Theft or Impairment, Pharmacy Procedures.

Section 4112 - Nonresident Pharmacy; Registration; Provision of information to Board; Maintaining Records; Patient Consultation

2nd Qtr 10/11: Board approves provisions for sponsorship in 2011/2012 Session.

(1) Enforcement Enhancements

- Section 4104 – Amend to clarify that a pharmacy shall provide to the board, within 14 days, evidence of a licensee's theft or impairment. Require the pharmacy to conduct an audit to determine the scope of loss, and to provide the board with a certified copy of the audit results.
- Section 4105 – Amend to specify a time period in which records shall be provided to the board when requested by an inspector or authorized representative of the board.
- Section 4112 - Nonresident Pharmacy; Registration; Provision of information to Board; Maintaining Records; Patient Consultation.

(2) Pharmaceutical Waste – Reverse Distributors

- Section 4040.5 – Amend to specify that a reverse distributor may not accept previously dispensed medicine and specify that previously dispensed medicine returned to a pharmacy can only be handled by a licensed integrated waste hauler.
- Section 4081 – Amend to specify what records must be maintained of drugs being returned to a wholesaler or reverse distributor; and specify information that is to be maintained for drugs that are returned via a licensed integrated waste hauler.
- Section 4126.5 – Amend to authorize a pharmacy to furnish drugs to a licensed integrated waste hauler for the sole purpose of disposing of pharmaceutical waste returned to a pharmacy.

3rd Qtr 10/11: SB 431 is introduced containing – amendments to 4104, 4105, and 4112.

4th Qtr 10/11: SB 431 amended to also contain changes to 4081, 4126.5, and 4126.7.

Objective 3.2	Annually identify and respond with regulatory changes to keep pharmacy regulations current and consistent with the board's mission.
Measure:	Percentage successful enactment of promoted regulatory changes.
Tasks:	<ol style="list-style-type: none"> <p>Authorize technicians to check technicians in inpatient pharmacies with clinical pharmacist programs (§ 1793.7-1793.8). <i>Jan. 2007: Office of Administrative Law approves rulemaking. Regulation takes effect.</i></p> <p>Authorize the use of prescription drop boxes and automated delivery machines for outpatient pharmacies (§ 1713 and 1717(e)). <i>Jan. 2007: Regulation takes effect following approval by the Office of Administrative Law.</i></p> <p>Make technical changes in pharmacy regulations to keep the code updated. <i>April 2007: Section 1775.4 – contested citations. DCA determines no regulation is needed to accomplish the requirement to allow 1 rescheduling of an office conference. This regulation is withdrawn.</i> <i>June 2007: Section 1706.2 – Criteria for abandonment of files, changes take effect following approval by the Office of Administrative Law.</i></p> <p>Repeal the requirement to post a notice regarding electronic files (§ 1717.2). <i>March 2007: Office of Administrative Law approves rulemaking. Regulation takes effect.</i></p> <p>Revise and update Disciplinary Guidelines (§ 1760). <i>Oct. 2007: Board approves regulation for 45-day comment period.</i> <i>May 2009: Regulation and revised Disciplinary Guidelines approved and takes effect.</i> <i>July 2011: Discussion to update Disciplinary Guidelines to also incorporate recommendations of the Substance Abuse Coordination Committee.</i></p> <p>Self-assessment of a wholesaler by the designated representative (§ 1784). <i>April 2007: Office of Administrative Law approves rulemaking. Regulation takes effect.</i> <i>March 2011: Board releases language for 45-day comment to update regulation text and update Self-Assessment Form 17M-26 (See Objective 3.2, Task 24)</i> <i>Board notices regulation for 45-day comment period.</i> <i>May 2011: Board adopts regulation.</i> <i>June 2011: Rulemaking submitted to Department for review.</i></p> <p>Exempt the address of records of interns from display on the board's Website (§ 1727.1). <i>Sept. 2006: Office of Administrative Law approves rulemaking. Regulation takes effect October 2006.</i></p> <p>Modification of building standards for pharmacies – rulemaking by the California Building Standards Commission. <i>July 2006: Board notified that a new procedure now exists for adopting building standards. Staff will pursue these procedures in 2007.</i> <i>June 2007: Board staff submit rulemaking file to the California Building Standards Commission.</i></p> <p>Update Notice to Consumers Poster in conformance with AB 2583 (Chapter 487, Statutes 2006)(§ 1707.2). <i>Feb. 2007: Board notices regulation for 45 days comment period.</i> <i>Nov. 2007: Regulation changes takes effect.</i> <i>Jul. 2008: Board mails updated Notice to Consumers to all pharmacies in California.</i> <i>1st Qtr 10/11: Board discusses updates to Notices to Consumers (See Objective 3.2, Task 25)</i> <i>May 2011: Board approves language to revise Notice to Consumers (See Task 19.)</i></p>

	<p>10. Secure changes without regulatory effect (Section 100 changes) to pharmacy regulations to keep them accurate and current.</p> <p><i>Dec. 2007: Office of Administrative Law approves Section 100 Changes. Amend the following:</i> 1707 – Waiver of requirements for off-site storage of records 1709.1 – Designation of pharmacist-in-charge 1715 – Self-assessment of a pharmacy by the pharmacist-in-charge 1717 – Pharmacy practice 1746 – Emergency contraception 1780.1 – Minimum standards for veterinary food-animal drug retailers 1781 – Exemption certificate 1787 – Authorization to distribute dialysis drugs and devices 1790 – Assembling and packaging 1793.8 – Technician check technician Repeal section 1786 – Exemptions</p> <p><i>March 2009: Office of Administrative Law approves Section 100 Changes to update the self-assessment forms required in California Code of Regulations 1715 and 1784.</i></p> <p>11. Increase fees to keep the board's contingency fund solvent and maintain operations.</p> <p><i>Nov. 2007: Office of Administrative Law approves rulemaking.</i> <i>Nov. 2007: Staff complete necessary programming changes and begin advising licensees of the change.</i> <i>Jan. 1, 2008: New fees take effect.</i> <i>Oct. 2009: Governor signs AB 1071, new fee schedule.</i> <i>Jan. 2010: Statutory fee schedule becomes effective (supersedes 16 CCR §1749)</i></p> <p>12. Secure regulatory standards for pharmacies that compound. (§1735 et al)</p> <p><i>Nov. 2007: Board releases language for the 45-day comment period.</i> <i>Sep. 2008: Board releases (withdrawn) language for 45-day comment period.</i> <i>Oct. 2008: Regulation hearing</i> <i>Jan. 2010: Office of Administrative Law approves regulation.</i> <i>July 2010: Regulation and Self-Assessment Form 17M-39 is effective. Board staff developing fact sheet for pharmacies.</i></p> <p><i>March 2011: Board releases language for 45-day comment to update regulation text and update Self-Assessment Form 17M-39 (See Objective 3.2, Task 24) Board notices regulation for 45-day comment period to update § 1735.2 and § 1751 and to revise/update the Compounding Self-Assessment form (17M-39).</i></p> <p><i>May 2011: Board motions to adopt regulation.</i> <i>June 2011: Rulemaking submitted to the Department for review.</i></p> <p>13. Establish an ethics course (§1773 and §1773.5).</p> <p><i>Sep. 2008: Board notices regulation for 45-day comment period.</i> <i>Sep. 2009: Regulation takes effect.</i></p> <p>14. Pharmacist Renewal Requirements (§1702).</p> <p><i>Dec. 2009: Board notices regulation for 45-day comment period.</i> <i>Feb. 2010: Board adopts regulation.</i> <i>June 2010: Office of Administrative Law approves regulation.</i> <i>Dec. 2011: Regulation takes effect.</i></p>
--	---

	<p>15. Dishonest Conduct During Pharmacist Examination; Confidentiality of Exam Questions (§1721 and §1723.1).</p> <p><i>Oct. 2009: Board notices regulation for 45-day comment period.</i></p> <p><i>Jan. 2010: Board adoption of regulation as noticed.</i></p> <p><i>July 2010: Rulemaking submitted to the Office of Administrative Law for review.</i></p> <p><i>Aug. 2010: Office of Administrative Law approves regulation.</i></p> <p><i>Sep. 2010: Regulation takes effect.</i></p> <p>16. Standardized, Patient-Centered Prescription Labels (§1707.5)</p> <p><i>Nov. 2009: Board notices regulation for 45-day comment period.</i></p> <p><i>Jan. 2010: Regulation hearing.</i></p> <p><i>Feb. 2010: Board modifies text of regulation.</i></p> <p><i>Board notices modified text for 1st 15-day comment period.</i></p> <p><i>Apr. 2010: Board modifies text of regulation.</i></p> <p><i>Board notices modified text for 2nd 15-day comment period.</i></p> <p><i>June 2010: Board adopts regulation language noticed on April 28.</i></p> <p><i>July 2010: Rulemaking submitted to Department for review.</i></p> <p><i>Oct. 2010: Rulemaking submitted to the Office of Administrative Law for review.</i></p> <p><i>Nov. 2010: Office of Administrative Law approves rulemaking.</i></p> <p><i>Jan. 2011: Regulation takes effect.</i></p> <p>17. Update Protocol for Pharmacists Furnishing Emergency Contraception (EC) (§1746)</p> <p><i>Jan. 2010: Board approves language to initiate rulemaking to correct a typographical error in the Emergency Contraception Protocol regulation.</i></p> <p><i>July 2010: Board begins working with Medical Board to update the EC Protocol.</i></p> <p><i>May-June 2011: Executive Officer works with Medical Board (MBC) and others to revise the protocol. The MBC will discuss at its July 2011 meeting. Pharmacy will discuss update of board regulation after MBC approval. The board will also need to update the Patient Information Fact Sheet on EC Protocol.</i></p> <p>18. Board Issued Continuing Education (CE) Credit (§1732.2)</p> <p><i>Feb. 2010: Board votes to amend section 1732.2 defining board-issued CE and notice regulation for 45-day comment period.</i></p> <p><i>Oct. 2010: Board notices regulation for 45-day comment period.</i></p> <p><i>Feb. 2011: Board issues modified text for 15-day comment period.</i></p>
--	---

19. Notice to Consumers re: Patient-Centered Prescription Labels

Apr. 2010: Board directs staff to bring regulatory language to the July 2010 meeting re: increased font size, and language services.

July 2010: Board discusses possible language for Notice to Consumers.

Oct. 2010: Board discusses possible language for Notices to Consumers. Votes to modify and move existing Consumer Notices from §1707.2 to a new section at 16 CCR §1707.6, to include language for increased font size and oral interpretive services, and other changes.

1st - 3rd Qtr 10/11: Board discusses updates to the Notices to Consumers to incorporate Patient-Centered Requirements.

March 2011: Board approves language and directs staff to initiate a formal rulemaking to amend 16 CCR 1707.2 and to add 16 CCR §1707.6; directs staff to issue language for a 45 day public comment period; and to schedule a public hearing for the proposed regulation.
Board approves language for 45-day comment period and schedules regulation hearing for July 2011.

May 2011: Board notices regulation for 45-day comment period and notices regulation hearing for July 27, 2011.

20. Update references to USP Standards (§1780)

1st Qtr 07/08: Board considers review of USP references.

2nd Qtr 07/08: Subcommittee established to conduct full review of USP updates needed.

21. Veterinarian Food-Animal Drug Retailer Self-Assessment (§1785)

1st Qtr 07/08: Board approves regulation for notice.

2nd Qtr 07/08: Work on rulemaking stopped to allow for comprehensive review of Veterinary Food-Animal Drug Retailer Program.

22. Accreditation Agencies for Pharmacies that Compound (§1751.x)

1st Qtr 07/08: Board approves regulation text for notice (upon additional review by counsel, modification of language is necessary prior to notice of proposed text)

23. Pharmacist and Intern Pharmacist Applicants to submit a Self-Query from the National Practitioner Data Bank-Healthcare Integrity & Protection Data Bank (NPDB-HIPDB) (§ 1727.2, 1728)

1st Qtr 10/11: Board approves additional modifications to the Pharmacy Technician Application (Form 17A 5) and directs that the language approved in October 2010 and the application approved February 2011 be issued for a 45-day public comment period.

2nd Qtr 10/11: Board votes to require applicants to submit a Self-Query from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB), and to amend/update the Pharmacy Technician application:

- Section 1728 – Amend to require an applicant for the pharmacist examination to submit a Self-Query Report from NPDB-HIPDB.
- Section 1727.2. – Add new section to require an applicant for an Intern Pharmacist license to submit a Self-Query Report from NPDB-HIPDB.
- Section 1793.5. – Amend to require a Pharmacy Technician applicant to submit a Self-Query Report from NPDB-HIPDB; and to modify the Pharmacist Technician Application (17A-5), incorporated by reference.

April 2011: Proposed Text to Amend §1793.5 and modify Form 17A-5 issued for 45 day public comment.

Oct. 2011: Board votes to require applicants to submit a Self-Query from the NPDB HIPDB.

May 2011: Board notices regulation for 45-day comment period.

	<p>24. Pharmacy Technician Applicants to submit a Self-Query from the National Practitioner Data Bank-Healthcare Integrity & Protection Data Bank (NPDB-HIPDB) and Revise Pharmacy Technician Application (§ 1793.5)</p> <p><i>Oct. 2011: Board votes to require applicants to submit a Self-Query from the NPDB HIPDB and to amend/update the Pharmacy Technician Application (17A-5)</i></p> <p><i>Feb. 2011: Board approves additional modifications to TCH application.</i></p> <p><i>April 2011: Board notices regulation for 45-day comment period.</i></p> <p><i>June 2011: Regulation adopted.</i></p> <p><i>Rulemaking submitted to the Department for review.</i></p> <p>25. Update of Self-Assessment Forms</p> <p><i>March 2011: Board notices regulation for 45-day public comment period to update 16 CCR §1715, §1735.2, §1751 and §1784 and the self assessment forms incorporated by reference:</i></p> <p><i>17M-13 Community Pharmacy & Hospital Outpatient Pharmacy Self-Assessment</i></p> <p><i>17M-14 Hospital Pharmacy Self-Assessment</i></p> <p><i>17M-26 Wholesaler Dangerous Drugs & Dangerous Devices Self-Assessment</i></p> <p><i>17M-39 Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment</i></p> <p><i>May 2011: Board approves rulemaking.</i></p> <p><i>June 2011: Rulemaking submitted to the Department for review.</i></p>
--	--

Objective 3.3	Review five areas of pharmacy law for relevancy, currency and value for consumer protection by June 30, 2011.
Measure:	Number of areas of pharmacy law reviewed.
Tasks:	<p>1. Initiate review of the pharmacist-in-charge requirement.</p> <p><i>Aug. 2007:</i> Staff and counsel review pharmacist-in-charge and designated representative-in-charge statutes and regulations for reporting requirements and make recommendations to amend various statutes and regulations.</p> <p><i>Oct. 2007:</i> Legislation and Regulation Committee reviews draft language to be incorporated into omnibus bill.</p> <p><i>Jan. 2008:</i> Board approves omnibus language recommended by Legislation and Regulation Committee.</p> <ul style="list-style-type: none"> • Section 4022.5 – Designated Representative; Designated Representative-in-Charge • Section 4036.5 – Pharmacist-in-Charge • Section 4101 – Pharmacist-in-Charge; Designation Representative-in-Charge; Termination of Status; Duty to Notify the board. • Section 4113 – Pharmacist-in-Charge; Approval; Responsibilities; Notifications • Section 4160 – Wholesaler Licenses • Section 4196 – Veterinary Food-Animal Drug Retailer Licenses; Persons Allowed in Areas Where Drugs are Stored, Possessed, or Repacked • Section 4305 – Pharmacist-in-Charge; Notice to Board; Disciplinary Action • Section 4329 – Nonpharmacists; Prohibited Acts • Section 4330 – Proprietors; Prohibited Acts <p><i>April 2008:</i> The following provisions are not incorporated into omnibus bill.</p> <ul style="list-style-type: none"> • Section 4101 – Pharmacist-in-Charge; Designation Representative-in-Charge; Termination of Status; Duty to Notify the board. • Section 4113 – Pharmacist-in-Charge; Approval; Responsibilities; Notifications • Section 4160 – Wholesaler Licenses • Section 4196 – Veterinary Food-Animal Drug Retailer Licenses; Persons Allowed in Areas Where Drugs are Stored, Possessed, or Repacked <p><i>Sept. 2008:</i> Governor vetoes SB 1779.</p> <p><i>Jan. 2009:</i> Board seeks to reintroduce provisions contained in SB 1779 via omnibus bill. Provisions contained in SB 819 and SB 821. Senate BP & ED introduce Omnibus bills containing previously-approved / Pharmacist-in-Charge provisions.</p> <p><i>Sept. 2009:</i> SB 819 and SB 821 enrolled and sent to the Governor.</p> <p><i>Oct. 2009:</i> Governor signs SB 819 and SB 821. Provisions go into effect January 2010.</p> <p>2. Update Protocol for Pharmacists Furnishing Emergency Contraception (EC) (§1746)</p> <p><i>July 2010:</i> Board begins working with the Medical Board to update the EC Protocol.</p> <p>3. Initiate review of Pharmacist-in-Charge Requirements.</p> <p>4. Review of Continuing Education for Pharmacists in Specific Areas.</p> <p><i>1st Qtr 10/11:</i> Board moves to pursue implementation of CE for specific content areas.</p>